<SEC-DOCUMENT>0001104659-21-065584.txt : 20210513
<SEC-HEADER>0001104659-21-065584.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513091859
ACCESSION NUMBER:		0001104659-21-065584
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vallon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		21917558

	BUSINESS ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 207-3606

	MAIL ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vlon-20210331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/13/2021 1:11:44 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 27d97d41-b0ee-4445-9e9d-a92b15b84a7d -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:vlon="http://www.vallon-pharma.com/20210331" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" xs:nil="true" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_P25TTKWMT0aDw_BLDRvhDA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" xs:nil="true" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_zLOhcgS3BEO0VwososrwsA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" xs:nil="true" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" name="us-gaap:CommonStockValue" id="Hidden_Ti0IkjqKSEKs4zAInh32pw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" xs:nil="true" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" name="us-gaap:CommonStockValue" id="Hidden_T-rObeu-Lki245go8h12lw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityCentralIndexKey" id="Tc_I2h-mLIGz0uwd9mC636Yuw_2_1">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:CurrentFiscalYearEndDate" id="Tc_zy-Xn_jauEWkhm9bXl4XcQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentFiscalYearFocus" id="Tc_YypSIi1krUSUDd48T0Xixg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentFiscalPeriodFocus" id="Tc_NXxYsx_kZEmW9YKCWKtgIg_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:AmendmentFlag" id="Tc_dhi-b6u950GmxPt4zfx18w_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="vlon:TransitionReport" id="Tc_gNg6eLzqKUW59BG0ckeYRA_7_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityFilerCategory" id="Hidden_Rq87e8JKNE-RMNcIucaQOw">Non-accelerated Filer</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_RklKRiOmx06CoYYk0dhHnA">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_fHabEzam7kSC2KAlZ7HipA">6812836</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_zhrL4uj6rEKeY6WwziGRXQ">4506216</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_UIe2lbAF2kGKY5HDdycYJA">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_4Tffo4GuN0upl1nqEV12yw">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_jYgxiwEGF0KBpwAlJddKng">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_0cNKILO9WUW0kb65wvotjw">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_GeFOrwbLYkGAn3rmDzx4rw">0.025</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vlon-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_Tn38B5U-o02QABujfpad0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_OL8f_qfInEqpi_l0fTWnWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_6_2020_To_1_6_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vlon_MediceMember_NGprOuJ5l06TJqQZC_V8ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vlon:MediceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-06</xbrli:startDate><xbrli:endDate>2020-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_V2G_e2BzqUubv1rniE3q0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_SnkKNVvge0SVtghw5VA0qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_z-8EZMohVECdXJnLeqPxEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_lVQgaSqrRkK1DTlNgKvOrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2017_To_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_x-NQaVFMxUeZ4r1E-Nssgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-15</xbrli:startDate><xbrli:endDate>2017-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_cEy2Na7LTU6FHcLHdGkVLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_oUpLJpG1TEeUwluvcA56wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_OuHcg0aKu02Um5Wx4JT5vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9XvhFD3qEa4bDRHE-FeXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-15</xbrli:startDate><xbrli:endDate>2017-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_m_qpi2gNQ0Wm0F6HLx90lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VHEsqmgG7USeE3ti9qwcPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YznYzH3KBkyRhT1RG6mKBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fP7EG2hq1EeBSkVm4cUR3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xI19aMkKEkOTzmxGM0CaWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k1qRx4AD7Eit_zIYQsN9dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_25rnvO6dwkG_mYmCNm0M6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0cBdsHpQmE-cbvFcUq6nLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VWR0Rpxvjkq1cR6FDhHjRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WEsJPxIMW0ChK4dWlfgkZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJHTQwM9RESCtO731QNz6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SILDvqDH2kSgzCliI_rumQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6atNCI43bk-OY4mxZ0xDeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_p-WkrdawjkKSVhflMIYJmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_QRMywzI2uUq-75VZaFoA9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_JqpFDEggRkesYrNF0Z7d7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_lmsSk0l7KkWPJE-KMU2SDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_WGepaRPim0eFAsLrWHF3XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Nu0HlaQrV0STf4cE6gIghA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7RrpN30090e56LLSpDLmkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vlon_AdairStudyVal104Member_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_6XKRebR7BEWBtoFWLvbicQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vlon:AdairStudyVal104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_6vvh1yU2_0mn3PPDkIvZWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_PiKPhnXIVEe3otXkFQJSbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_kkrPw5KwQkynmgre4Q1gJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_AY-YYGiTG0q7QQrpwLwsHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_PeCqNyG65U-s5WHXh9lz0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_hOnNiNgctkydAp6WTPWNzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-07</xbrli:startDate><xbrli:endDate>2018-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-11</xbrli:startDate><xbrli:endDate>2018-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_11_2021_To_1_11_2021_8qOoRPKb30yKP4fdaCxr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-15</xbrli:startDate><xbrli:endDate>2017-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qzAzmG1G90-0EOTjcIpcRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_IzAODsPw3UW6_K3qX2og7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_aj1ck67-3kCcwaJeJiWVrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_BbC8XV5qlU2ceMNKytn5Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lCH-zADik0qKO3X2XzUZjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_nW_at-qhE0qwfYklAFP-Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vlon:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wj8fFhgfhkWVHez-hovm0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A4zr9qZIIkWi15ZK_wyfzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ba48kdCZkEG4MpU_eSZ57w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_vFarWyLSi0W_Rq5eAXJa0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnFirstAnniversaryOfStartDateMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_XJA5MW80TUen-MTCbD2nKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnFirstAnniversaryOfStartDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XY59mQ4yF0SnWeexPPyTCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GnqWo_CEXEeAcNENJ-Sk8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qHpeFWSKRU6tDNBCRoCPWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_99MbGdLZZ06ZDQEAKCqSSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:IfTerminationNotInConnectionWithChangeInControlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_K8OayvzVWk6w7L3GnwtAdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-10</xbrli:startDate><xbrli:endDate>2021-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember__uYmvO-NoEutzv5BKZjj-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_4CwAuiXkbUCOtvE65Xtb-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_ei25kWe8EU-JCt2bw1gHyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vlon:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vlon:UnderwritersWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_11_2021_B-c7BO4RP0aNIhbXZvMJhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vlon:AdairProductRightsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_nE5tkt9jPU267_p8BkBEfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vlon:AdairProductRightsAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TSib4yEdAUSlHbmW78scuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kYeoxmIIaUemiecYpa-T4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_peYk7ghKTU-3tzbPPE3XKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vlon:UnderwritersWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_Eo3ZEOdgO0WpIVlN7GsV9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_0sfEPIqYxkSB2d_NNWmuCg"><xbrli:measure>vlon:item</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_FGbZdoNwW02Av2IEwUE_aA_3_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__GHEDaYiVUGmBBtF5kMWvw_3_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2" toRefs="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1671aeb3_6263_414c_a792_65594d0ed47d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, DC 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentType" id="Narr_NQo7i6eYAE6HgNsO54eb1w"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentQuarterlyReport" id="Narr_vcyFHRI4qkK7l8Ss8xToSg"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;"> </b><b style="font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">For the quarterly period ended </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentPeriodEndDate" id="Narr_iwe7HM-uQk-hh_NWgxz-bw"><b style="font-size:9pt;font-weight:bold;">March&#160;31,&#160;2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:DocumentTransitionReport" id="Narr_OUoD7YYUPEC0GBSmJftyhg"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;"> </b><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">For the transition period from</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">to</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number:&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityFileNumber" id="Narr_-uZP4TlEtUeOlxAR0j-skw"><b style="font-size:9pt;font-weight:bold;">001-40034</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_c724a0df_2da6_4532_a06b_c409462fe0f5"></a><a id="Tc_A0lQN--hN0yS5ZQIA82tqA_2_0"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityRegistrantName" id="Tc_-nx9Rqd71Uq9Za0dXa5AiQ_1_0"><b style="font-weight:bold;">VALLON PHARMACEUTICALS, INC.</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:5pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_075a2d9a_ec10_4142_a811_685677457c37"></a><a id="Tc_-yiWcNsleEOWXt5J3I-2Og_1_0"></a><a id="Tc_8oOY-5689EGCisIcergxfg_1_2"></a><a id="Tc_Y6kdrCilhUC4A7H5buFZmw_3_0"></a><a id="Tc_1OFp8yG3g02U-yaHGnZT-Q_3_2"></a><a id="Tc_nUnugn9Epkum9zwcAets3g_4_0"></a><a id="Tc_bmmoT5G3TkqgPrdmI-H0wQ_4_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityIncorporationStateCountryCode" id="Tc_qartT2Y6d02lqst_5OJ6-w_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityTaxIdentificationNumber" id="Tc_u8uoAhIMA02uQ94k7MryEg_0_2"><b style="font-size:9pt;font-weight:bold;">82-4369909</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityAddressAddressLine1" id="Narr_gzEMeR0ayEeGuGSM8PxzXA"><b style="font-size:9pt;font-weight:bold;">100 N. 18</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:9pt;font-weight:bold;"> Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityAddressAddressLine2" id="Narr_BeiZRf64tUOKo4YXbd7nKA"><b style="font-size:9pt;font-weight:bold;">Suite 300</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityAddressCityOrTown" id="Narr_cmZAoke-_UuZCDSwPA4EDw"><b style="font-size:9pt;font-weight:bold;">Philadelphia</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityAddressStateOrProvince" id="Narr_CjUM9jzPfE6-CT2nwbW1-Q"><b style="font-size:9pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityAddressPostalZipCode" id="Narr_REheZaXisESSyNB6DktKqg"><b style="font-size:9pt;font-weight:bold;">19103</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:CityAreaCode" id="Narr_pjCz-tKtdEiNx5YYqO3vmA"><b style="font-size:9pt;font-weight:bold;">267</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:LocalPhoneNumber" id="Narr_YkbdNm1DqkOpw-eT_rWW2w"><b style="font-size:9pt;font-weight:bold;">207-3606 </b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_739a8fce_69bb_43fb_aa87_497fbba6603c"></a><a id="Tc_v3e9Xzr3ik6yKJRpomrHGQ_1_0"></a><a id="Tc_N3lyBnHno0O9bWF0y_tWrA_1_2"></a><a id="Tc_WYpwWoaHj0q6rOejzEyq1Q_1_4"></a><a id="Tc_9V6hW6h-lE6dBZyjX4Pq8A_2_4"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:31.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:middle;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:Security12bTitle" id="Tc_TLdW1uGZYEmbVEu4cNsJhg_2_0">Common Stock, par value $0.0001<br />per share</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:TradingSymbol" id="Tc_4NDWNtd5y0O8_qL2ARyrRA_2_2">VLON</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:SecurityExchangeName" id="Narr_mfrjRxH5WE6y7RPyZvKyGA">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityCurrentReportingStatus" id="Narr_w3vpEcS9yEuEPhc5UPHn_A"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityInteractiveDataCurrent" id="Narr_RrOZmw_g4UOVNkygag0Lsg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:41.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:39.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:41.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:39.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Rq87e8JKNE-RMNcIucaQOw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Non-accelerated filer</span></span></p></td><td style="vertical-align:top;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntitySmallBusiness" id="Narr_X16td8OLw0aALjNBifEH1g"><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:39.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityEmergingGrowthCompany" id="Narr_7Fssf0IiREyJAKqPlODndA"><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityExTransitionPeriod" id="Narr_3C9YKbCFhUy-Nsfx91J2Zg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="dei:EntityShellCompany" id="Narr_Tct1JK0BDUmgKI0JjO9Pdw"><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:36pt;margin:0pt;">As of May 13, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_13_2021_Eo3ZEOdgO0WpIVlN7GsV9Q" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_09pmckz8hkS4xzfb8e4mYw">6,812,836</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_60f47614_0093_4f5b_a96a_00427af086ce"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.67%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.67%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PART_IFINANCIAL_INFORMATION"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;I. </b></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PART_IFINANCIAL_INFORMATION"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets_353448"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Balance Sheets at March 31, 2021 (unaudited) and December 31, 2020</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations_892729"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Statements of Operations (unaudited) for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:13.7pt;text-indent:-13.7pt;margin:0pt;"><a href="#StatementsofStockholdersEquityDeficit_83"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Statements of Stockholders&#8217; Equity (Deficit) (unaudited) for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_628228"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Statements of Cash Flows (unaudited) for the three months ended March 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_731522"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Unaudited Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_714742"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_714742"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_180828"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;II. </b></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_180828"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_857108"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_857108"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_712957"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_712957"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_543697"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_543697"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_801779"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_801779"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_198066"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_198066"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_259311"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_259311"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_79392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_e42fd440_6b3b_4f79_87fd_3f5f5d18cbb3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;Part I&#8212;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Quarterly Report contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the likelihood of our clinical trials and non-clinical studies demonstrating safety and efficacy of our product candidates, and other positive results;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the size of the market opportunity for our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the success of competing therapies that are or may become available;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our estimates of the number of patients in the United States who suffer from ADHD or narcolepsy and the number of patients that will enroll in our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the beneficial characteristics, safety and efficacy of our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing or likelihood of regulatory filings and approval for our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain and maintain regulatory approval of our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our plans relating to the further development and manufacturing of our product candidates, including ADMIR;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the expected potential benefits of strategic collaborations with third parties, including MEDICE Arzneimittel Putter GmbH &amp;amp; Co. KG (&#8220;Medice&#8221;), which is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">existing regulations and regulatory developments in the United States, the European Union, and other geographic territories;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the need to hire additional personnel, and our ability to attract and retain such personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our financial performance;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the impacts of the COVID-19 pandemic on our operations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to maintain the listing of our common stock on The Nasdaq Capital Market.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should refer to the &#8220;Risk Factors&#8221; section of this Quarterly Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. If the forward-looking statements prove to be inaccurate; the inaccuracy may be material. In light of the significant uncertainties in these forward- looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represents our views as of the date of this Quarterly Report. We anticipate that subsequent events and developments will cause our views to change, however, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Quarterly Report includes trademarks and registered trademarks of Vallon Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Quarterly Report may be trademarks or registered trademarks of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As used in this Quarterly Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Vallon Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 22.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9cb162ad_74b7_40d2_a0a1_49011c900567"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PART_IFINANCIAL_INFORMATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART I&#8212;FINANCIAL INFORMATION</p><a id="ITEM_1_FINANCIAL_STATEMENTS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Item 1. Financi</b><b style="font-weight:bold;">al Statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vallon Pharmaceuticals, Inc.</b></p><a id="BalanceSheets_353448"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3c68b537_3aa2_4ee9_85d8_a5869547635c"></a><a id="Tc_JLrC8bq2sUmdK8Mn7BmsLg_1_2"></a><a id="Tc_QlKxwxU2zUyicyGWOeDwdg_1_5"></a><a id="Tc_KnV1-bESEEWuX7R2QTjJiw_2_0"></a><a id="Tc_Idr5YAgy2kqtZgnDaJSNSg_2_2"></a><a id="Tc_3FJ27U6vsU2PNcjo3zx6rw_3_0"></a><a id="Tc_-ZxJOnO_TkSFc2KmkzSzrg_4_0"></a><a id="Tc_WlcUqoimnUyCi04RWcRbCA_4_2"></a><a id="Tc_GsALGg9oE0uFMUA_8u216w_4_5"></a><a id="Tc_UwxRi23h6027juOgWk9pQA_5_0"></a><a id="Tc_r7pPRavCfkuVCK7f0RNBlA_6_0"></a><a id="Tc_HnQbejgMFUOa8cXGybIPXQ_8_0"></a><a id="Tc_EeOTY_FNukm-I0hgf6FGtg_9_0"></a><a id="Tc_B0JkBUKzZk-wqhK4uwVhNQ_10_0"></a><a id="Tc_RU_ns7CfskuPHdGjVDJ4bw_10_2"></a><a id="Tc_OA-gopGFTUOTsXN_n6m1uw_10_5"></a><a id="Tc_mqxT7VjftUSkdHPwkIM_lA_12_0"></a><a id="Tc_iHRRYQA3KkOy44vdFCI7Xw_13_0"></a><a id="Tc_uFrOYgNUUU6_Aslup9JAAQ_14_0"></a><a id="Tc_ZuZ19aj7Lkq8apqfCC6KAQ_14_2"></a><a id="Tc_izA9UK3ewEyA2K2m9mBRPQ_14_5"></a><a id="Tc_z-2Jy2_qjUusmw14goSvJg_15_0"></a><a id="Tc_kwjnyQVLkUeaVQ6Q9BROVQ_16_0"></a><a id="Tc_bK7nhvKx1E2M_f1mVIOPOA_16_3"></a><a id="Tc_iqr5kJbMREazNRec_cY4gg_17_0"></a><a id="Tc_OPyRx9e2BUmV6tP0hc5eKw_18_0"></a><a id="Tc_52VJWVD100atNRx77-AoTQ_19_0"></a><a id="Tc_cFaRIYDEiU62Wum4YSATWA_19_3"></a><a id="Tc_S1BlVgmOD02IBLh5MPhi7g_20_0"></a><a id="Tc_OVAjk_zIaUqL00XZSnCaJA_21_0"></a><a id="Tc_Z6IC2zikbUSoJS8NrPxxOg_23_0"></a><a id="Tc_eVBbrBWpkEi7AaMikEIt8A_25_0"></a><a id="Tc_8E4GzutIWkuOpBGqODdP6w_26_0"></a><a id="_a8f901b0_a2f0_40d9_b0c8_5e5afaa5cbe0"></a><a id="_a8f901b0_a2f0_40d9_b0c8_5e5afaa5cbe0_2"></a><a id="_a8f901b0_a2f0_40d9_b0c8_5e5afaa5cbe0_3"></a><a id="Tc_Ho0yFPKmQUmkv2ETnEm92Q_27_0"></a><a id="Tc_rwlyzcbBo0ea22Ny0J9U2g_28_0"></a><a id="Tc_1ql0OejJ20u3HEIVqMy_4g_29_0"></a><a id="Tc_Uqz5hU0-6U6QWVOwI6JB-A_30_0"></a><a id="Tc_DtBCoM97c0KM6VgJVJxObg_30_2"></a><a id="Tc_haE8ELr6UUuxpJgmPIIfpA_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_hiyhfJpmMkqVQmMCr8-COQ_4_3">12,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_XD79KIwPcEmeh5QsLzRxJA_4_6">109</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_IVXxVUFkKEa5oT6_ZUNC6g_5_3">1,358</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_vjHea_Tm4UCzsaSnLweSpA_5_6">565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Zl1JUNUqqkCkpFqjE02OeQ_6_3">14,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_7M1FFRGZgU-w1QdAV8f3vg_6_6">674</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_L0CArE5LgEyI4_7IhO7oqA_8_3">261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_8CEXtqHha0ifNNj8_u_iWA_8_6">279</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_k_h8XVZ7o0Kocf1vihjB7g_9_3">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_C2ddvJVE7kqxvup2Eh-D_A_9_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_VPS2pfb01kGl54v1kC9CWA_10_3">14,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_tNV17967fUm3oWRlJsZwUw_10_6">955</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Liabilities and Stockholders&#39;  Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_PypEAs5Ld06QMbDbiFzekw_14_3">1,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_nQI6rtSpyUiMNVacG1QJbw_14_6">1,226</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_BhooP5euGECwPBx88M3KpQ_15_3">985</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_sEI0jvfObUqoH1QK-Oit_A_15_6">847</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Note payable, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_UJpYb2RJ4EOUM3AYvE12Fg_16_6">47</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease liability, current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_ToyYXxbIWEOfgXlrf3mmaw_17_3">95</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_cYS3We3ACEORSGx9g6h1WQ_17_6">105</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_0UbBKs3DvUSmqt7KW7QnQg_18_3">2,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_8toWDGlrAE2Lt1IbtXzebw_18_6">2,225</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Note payable, non-current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_x8q1bJBtkEiKKpTCZSGHhw_19_6">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_yCoC9HFK50GR2cLzLlvlxw_20_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_JYd0mAhXxUiPQZPhni5s3A_20_6">170</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_0WeBNC2PPkOxEYBJYKrJyw_21_3">2,573</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_VeJ1OUFeM0uZi3O2Pb6xfg_21_6">2,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; equity (deficit):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_XS1YnS9en0W2Jl8Lm39RaQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_I8G2pGPav0OSwM-tVH42MQ">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_uLzXI2__x0q_jvZCdopMyQ"><ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_T0Pr1pj9jEyaBKL5U4qZHA">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_vXEiHIzIB063QxUYwd_F4w">6,812,836</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_pyzw6UY1yEm4GDuGiMyzFw">4,506,216</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_fHabEzam7kSC2KAlZ7HipA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_zhrL4uj6rEKeY6WwziGRXQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of March 31, 2021 and December 31, 2020, respectively, which gives retroactive effect to the one-for-40 reverse stock split. See Note 1 to these financial statements.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ti0IkjqKSEKs4zAInh32pw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_T-rObeu-Lki245go8h12lw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in-capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_qYHIq-ztSki5ftjjltpkOg_27_3">27,264</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_JaPICGWO8Ei3Gi7rSrYcFg_27_6">11,145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_gcsRgDoafU2XjpOm-fdp1g_28_3">15,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_y5jsdtBQIEKL_N3LEo8YeQ_28_6">12,599</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9aXvZ6BN1E-iiMIkGeeF0A_29_3">12,027</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_w2SDiG1oeEWTcSKAofixhA_29_6">1,454</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities and stockholders&#39; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_V1MBJ9GApk68_tzoc9-cQA_30_3">14,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_uJlEqZpqYkOIrA778fTtXg_30_6">955</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1ceae892_db13_44e8_964a_aa705bee309a"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Vallon Pharmaceuticals, Inc.</p><a id="StatementsofOperations_892729"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_67b8a6da_1fea_48e6_9f59_6e4ff13d6ba0"></a><a id="Tc_U2NxSUaLCUKyslfNQjvYLw_1_2"></a><a id="Tc_IeXmnzUPDE2mEvu2aI81lw_1_5"></a><a id="Tc__fnqrBxV0EWwjDOTMiyiXQ_2_2"></a><a id="Tc_G3c30FSivk-PwOMu8_HgQw_2_5"></a><a id="Tc_gtHfND_UO02iyrKK1r9O4g_3_2"></a><a id="Tc_KGnXcvGGGkSe9_F6l8qFPQ_3_5"></a><a id="Tc_7aWYFS8Zx0ycBcg2EMz4VQ_4_2"></a><a id="Tc_PntEnxszR0qz8eOrzcr6gg_4_5"></a><a id="Tc_SR4yhwuE30e5hcQAcDe0PQ_5_0"></a><a id="Tc_HLTVqLA260Ot2qY3uTkosw_5_2"></a><a id="Tc_tIuLnrBVq0S4hUrw1znAGg_5_3"></a><a id="Tc_UHYyntbfK0-pO8hq0UYKQg_5_5"></a><a id="Tc_HFk54dAU8kCRIvtjLwy7PQ_6_0"></a><a id="Tc_370Vvb1tLkScItFNgqC0eg_7_0"></a><a id="Tc_c6GrmoeBuEiQpptmwT9Ygw_8_0"></a><a id="Tc_pOjXwvc6lUiQZmLIJyqW6A_9_0"></a><a id="Tc_R9Dawa9yjUOiJgT-06N-CA_10_0"></a><a id="Tc_Q83zczwkb06JvlqOv0RymQ_11_0"></a><a id="Tc_OrS4BYCAKkGwVZEqo4ewBA_11_6"></a><a id="Tc_gn6LlVOrh0qb9-H29yXfkQ_12_0"></a><a id="Tc_DVoH4ONib0aG2kRBV2LLTw_12_6"></a><a id="Tc_Lu2_U2l8qEe6yijM03Az-g_13_0"></a><a id="Tc_EFoRFnU6y0iZ7FxFKSuTTQ_14_0"></a><a id="Tc_aUDO_eQR1U2w-0Z4p2HLbg_14_2"></a><a id="Tc_0TlHksy8r0GTQ25epfUa3g_14_5"></a><a id="Tc_BtCRuZ3j002UxPfPquDDtA_15_0"></a><a id="Tc_vkq8wPtO1E2GExZqUFGyzg_15_2"></a><a id="Tc_jha5aRKMPUixX83ZQrM70Q_15_5"></a><a id="Tc_KUU8GOKHeUWBxeXi9R1xMQ_16_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License revenue-related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_HvX9i1dNTkqfFInIexJg9g_5_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_yRZCHGhD60WiTJTm8SoR7w_7_3">1,772</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_J0R3Dy3cHk6GioXa2ZUIPQ_7_6">883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_O6GSAQ61-UKG9kOlEnTgEw_8_3">830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_-Av0GmvIEEOFadiZXtuL8w_8_6">375</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_KlVX4jWT7kqVeX4f0GyTRg_9_3">2,602</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_6vYK6KO0W0uiR3T14kKGEA_9_6">1,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_4GtSO28sFUmdzsgkDmZGcw_10_3">2,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-_TKactfy0yDfAeEm41_lw_10_6">1,158</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_k1O2EFgzckWEGEkWh3kG7Q_11_3">61</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revaluation of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Tc_TKqbQu9SZ0G4mtxFaoTW4A_12_3">89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_wjo7EQW8E0y3F0FexzMocA_13_3">8</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" sign="-" scale="3" id="Tc_VmStL362EEqN1MHwHuxu7g_13_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PbSJ-pjiQkmBUef5uUCuTw_14_3">2,638</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1DRmuswnS0mdms5zORiNPA_14_6">1,160</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_YDQIojs5zEyf1Xt30fRqSQ_15_3">0.46</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_iNo-_TOAlU-Wx4zFQsayPA_15_6">0.26</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_dwVhPDr1zUSVHwYI0xUFmw_16_3">5,710,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_eQ2uK1b0BEat8qLpsXlr7A_16_6">4,506,216</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cf656c46_7e21_40d7_af2f_1a556b1f73a8"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Vallon Pharmaceuticals, Inc.</p><a id="StatementsofStockholdersEquityDeficit_83"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statements of Stockholders&#8217; Equity (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except shares)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8a49166c_8d21_4757_a95b_7501d61ad02d"></a><a id="Tc_NiQd-LhZsE6uZdc9GcTs4Q_1_2"></a><a id="Tc_J8AL1mgT8kqbXXWLn1-_mg_1_7"></a><a id="Tc_1wrpCgrGNUe7LhGj3fUQUg_1_10"></a><a id="Tc_8SQbqv9_lEKKe_BRPf_PCQ_1_13"></a><a id="Tc_3mHLWtwkbE6fYj1BisZL8Q_2_2"></a><a id="Tc_v1ZW_No9zU2zp7LvZGduzw_2_4"></a><a id="Tc_-v9XIp_1AE6mP8QUgUCESQ_2_7"></a><a id="Tc_TrFw5GrMRUSe-pNM_PxppA_2_10"></a><a id="Tc_iiU0ddrB9UmXhpDCDOIMeQ_2_13"></a><a id="Tc_holp6dHNlU-IXOtBGPYutQ_3_0"></a><a id="Tc_uptGJq7Y8UGhM7D5Wr2I5A_3_4"></a><a id="Tc_lgphbskYb0GKxFX67UNjBw_3_5"></a><a id="Tc_2k7EEGG4oEmM7qJ4gvYz1A_3_7"></a><a id="Tc_c7sh_1jqBEa3HA0ZQjkBYQ_3_10"></a><a id="Tc_Kp0TJpuFXkShkH3WUCL-Hw_3_13"></a><a id="Tc_VXwxe_GNsEq4wDTw1dUvWA_4_0"></a><a id="Tc_nT3n3mYYz0SD6mZSYlrDAQ_4_2"></a><a id="Tc_H38NJC1fY0e2lm-qJfClmQ_4_5"></a><a id="Tc_UFElzqKBZkSse7bYRJ8_hw_5_0"></a><a id="Tc_TZ-6MWmaQ0qQjm_RElpPjQ_5_2"></a><a id="Tc_cL3F8X3pTUyQmvYDF_stZA_5_5"></a><a id="Tc_MpaAJspAgEODKXlIKdd6KA_6_0"></a><a id="Tc_znrDKlVuNUiErNH1ngk_-g_6_4"></a><a id="Tc_3NpghC88dEaoHNm_X1FHGQ_6_5"></a><a id="Tc_3qf-72ANqEGz6Pr6y1hc0g_6_7"></a><a id="Tc_ar8LG5VxAE2PHzAGtAMfJg_6_10"></a><a id="Tc_U2ZBQQBZGE-YVzRR16gJhg_6_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6atNCI43bk-OY4mxZ0xDeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_FGbZdoNwW02Av2IEwUE_aA_3_2">4,506,216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wqFbS2wI_UOv94hlHnM3Jw_3_8">10,991</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0cBdsHpQmE-cbvFcUq6nLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DFpGMoQwRkq3rNrHegq_4Q_3_11">7,777</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NRji_b780kunq9Moll2v4A_3_14">3,214</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3-MED-jfqUCR3yc30utlug_4_8">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_GUINFvT9mU-F_1gEGdiZgA_4_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_xVui0gBRyE-d-MwSddtmwg_4_14">35</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_--lWavcSO0-lcI6vsKjcoA_5_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wlkPX5OYpUS4YXNoRKJ4mw_5_11">1,160</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4QKjjvXRMUSRuQGBQjsGrQ_5_14">1,160</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, March&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SILDvqDH2kSgzCliI_rumQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2">4,506,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_25rnvO6dwkG_mYmCNm0M6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UtuC2xhq-kudNVSGGt2TQw_6_8">11,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k1qRx4AD7Eit_zIYQsN9dQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__BbZKZOM2k-FAqBDlJme3A_6_11">8,937</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__OKincFIjEiC_m4TFBCGYg_6_14">2,089</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c768b61d_48cc_4595_af09_69477bb19748"></a><a id="Tc_t68qlOfvlkiIlMDurWhuGw_1_2"></a><a id="Tc_2OYhMDHmekq0yehlbOWOWA_1_7"></a><a id="Tc_df0SZYpb_kmcKSu2foFQeg_1_10"></a><a id="Tc_3R5SFDzqiU6uDHcHVPXGOA_1_13"></a><a id="Tc_Ig2kK4uSPE--l3Fzi3fohg_2_2"></a><a id="Tc_uk4zuD1u8Uu9V4jQQz3o-g_2_4"></a><a id="Tc_skVQ7oqLI0Cx1n_iBXalTQ_2_7"></a><a id="Tc_aNoNvlm5GESmf00GbrNcyA_2_10"></a><a id="Tc_UGVYZSPUXU-jFnvT-vqfHQ_2_13"></a><a id="Tc_XnRLr0rL6E699qfm0Vxmlg_3_0"></a><a id="Tc_436re-pEmE2qS5TgGFaVqQ_3_4"></a><a id="Tc_3U84gtyMYE2Z46iN3wtKZA_3_5"></a><a id="Tc_MiILsl4n5kWnlD0A4JsEXA_3_7"></a><a id="Tc_vDb8hrZoLESQABDwp915jg_3_10"></a><a id="Tc_iJU1TVWqmEaw_WfxhUdA1w_3_13"></a><a id="Tc_YJ4USFr9a0G62HB8RmTnUA_4_0"></a><a id="Tc_D5OHpvzvukSSj3RwStmI1w_4_5"></a><a id="Tc_EvL5IbMFt0qs15F9AKfBWQ_4_11"></a><a id="Tc_7TCMPKj880izEObhuLOglw_5_0"></a><a id="Tc_WeMvneU5mUikVLXeuuvYZw_5_5"></a><a id="Tc_GR8OvWKmJEWLxCs8v0BfMA_5_11"></a><a id="Tc_BqUQpKfQsk-wgKxgx94NWA_6_0"></a><a id="Tc_Dh1GMCiTSky95PA3DkbCrw_6_5"></a><a id="Tc_djxDEJLiAUuygCq4X0jY9g_6_11"></a><a id="Tc_3rZx63tphUuvSs0ymTQsAA_7_0"></a><a id="Tc_bp63Q3s17kCUWgXN8lSLzA_7_2"></a><a id="Tc_UCKsc2HJykqKg03sSyV8lA_7_5"></a><a id="Tc_5vBS6-RA_0ysSuH_BC6YJw_7_11"></a><a id="Tc_huiSZXvgdE6Rk2q5ujxOng_8_0"></a><a id="Tc_Q4UKy5RVckmVRL9XOhqfyQ_8_2"></a><a id="Tc_vPsevQZPrkGW9A_yuN4Hlw_8_5"></a><a id="Tc_gsTEOWpsd0e-1prZaCRbBA_8_11"></a><a id="Tc_Ykn03AG3Mkm-3S-knRQUAA_9_0"></a><a id="Tc_TBvg0X9WckSOIbhLEc-Ubw_9_2"></a><a id="Tc_Ym0ZIFKciUuUJ-1Ad6pWAg_9_5"></a><a id="Tc_jZhkWg-Fl0iUG5oCKcBFEA_9_8"></a><a id="Tc_3gg7mDuApk6Ozsg_IHWOdw_10_0"></a><a id="Tc_Svi_yUqNC0CKpBZh-a5PoQ_10_4"></a><a id="Tc_cs3V_Xa9GkOVWI_KfvPJMw_10_5"></a><a id="Tc_SMzgUo1zIUOWZZOsskTFHA_10_7"></a><a id="Tc_iJWt-Xoov06nUfn9chPh5Q_10_10"></a><a id="Tc_dMxWSLHztEWFeChYmkDwVw_10_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance,&#160;December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJHTQwM9RESCtO731QNz6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc__GHEDaYiVUGmBBtF5kMWvw_3_2">4,506,216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xI19aMkKEkOTzmxGM0CaWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0Pf8zyJUW0q9rHTkdMMxxg_3_8">11,145</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fP7EG2hq1EeBSkVm4cUR3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_181ASgZ7tUCIBHK0ZOXQ3g_3_11">12,599</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dMpCsTu77UCHXlpnEraYIA_3_14">1,454</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock for convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2">54,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_xtPbXS518kWSTQbooMseqw_4_8">439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_m9aXEu5UZEGXhcRDrfBXMg_4_14">439</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock for IPO, net of issuance expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2">2,250,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_0mO0JaWL7kSqsxfzukhT4A_5_8">15,104</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_plqhYlVjakqozVJUNJcitQ_5_14">15,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock for services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2">1,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_OdGl0IU9TEO3P9rmJhLC4g_6_8">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_AzV0UOjKf0msbnQpDiK5ZQ_6_14">9</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of Underwriters Warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_NStlordgeEiRqPCeXZmizQ_7_8">399</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_hbG48_SZNEy_jes3xyswFw_7_14">399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wpv-I44gI0ue6PI1usWZyQ_8_8">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BRRykJT_x0OlfMX9XgdWgA_8_14">168</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qzAzmG1G90-0EOTjcIpcRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CtBxPA-EHkSPvdgoT8z1GA_9_11">2,638</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FCmsY8V8G06HK9S4RZfI9g_9_14">2,638</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Balance, March&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WEsJPxIMW0ChK4dWlfgkZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2">6,812,836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YznYzH3KBkyRhT1RG6mKBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zr2mO_V7Q0GcgFu7sRkoag_10_8">27,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VHEsqmgG7USeE3ti9qwcPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EECvLgZkFESo8PDk6K8Miw_10_11">15,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FObEYR74OkOlcpYQiFBzzg_10_14">12,027</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f3864853_b87a_4b99_adc2_1dcdbf669426"></a><a id="_f3864853_b87a_4b99_adc2_1dcdbf669426_2"></a><a id="_f3864853_b87a_4b99_adc2_1dcdbf669426_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;">(1)&#160;&#160;&#160;</span><ix:footnote xml:lang="en-US" id="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"><span style="font-size:8pt;">The number of shares above give retroactive effect to the </span><span style="font-size:8pt;">one</span><span style="font-size:8pt;">-for-40 reverse stock split. See Note 1 to these financial statements.</span></ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these financial statements. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_26b2440b_1a9e_41cf_ab63_3851b86d6e85"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vallon Pharmaceuticals, Inc.</b></p><a id="StatementsofCashFlows_628228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_065ce1a5_62e3_42f9_a2d1_d9064e5b5e97"></a><a id="Tc_svtlB_6cTUqFMNm64QIy6g_1_2"></a><a id="Tc_MVXvHqOY5U2Qmd-RDt8GiQ_1_5"></a><a id="Tc_SAEGZBaCUkOXnRIM_Zqvfg_2_2"></a><a id="Tc_PH6eksWJ4U6TuoX3HTYklg_2_5"></a><a id="Tc_x00dNEbh3kyy8RSu5JoUKg_3_2"></a><a id="Tc_2sXft2JM2UylKzv_SqmB2w_3_5"></a><a id="Tc_ZnTstbHBIEq6XgM-5gyLBA_4_0"></a><a id="Tc_MRFGmn7IB06Q0KK9uZOtVg_5_0"></a><a id="Tc_EnanTQmK6UKJj6LTY-fpgA_5_2"></a><a id="Tc_iMJW1ZWQ10GWpTc0H1yCSA_5_5"></a><a id="Tc_yEChKOaZ5Eeyg-zSLDXkfw_6_0"></a><a id="Tc_ataVZmuAPUeScayMrNvK_g_7_0"></a><a id="Tc_DuZ0wc4gK0e-hGkqFnIIzg_8_0"></a><a id="Tc_2eqLPwgZX0GEKRqbZm-8wQ_9_0"></a><a id="Tc_IXfk607zWUOHLj1hueDf1g_9_6"></a><a id="Tc_ZO_hB6yhEk6di7hUVGhRmw_10_0"></a><a id="Tc_pkdz0yinZ0WLCa1koWLXcA_10_6"></a><a id="Tc_03JLCjvTbkS9dQNmyTnDEg_11_0"></a><a id="Tc_dpdESgrPTUCkTeDMtm-KMw_11_6"></a><a id="Tc_JSIU2wPwbkeUWiko4tYmOg_12_0"></a><a id="Tc_z5oKH8FW30GSBl87osH2KA_13_0"></a><a id="Tc_FTq3hbK8m0iytHkgfGpdDg_14_0"></a><a id="Tc_na8t0p9zdEGRLzts1rpyQQ_15_0"></a><a id="Tc_J-R4oaUifk694dIaDUb8lA_16_0"></a><a id="Tc_RpoYExa6jUerx9R5rQtpHQ_18_0"></a><a id="Tc_1x1J6KMKv0mtFH65a9hu2w_19_0"></a><a id="Tc_f6AaqPLpF0uigg420IWrEw_19_3"></a><a id="Tc_E6cdnekWTkee4Qe0T5phDg_20_0"></a><a id="Tc_rp8o-mJxdEaUqVYueqkVMQ_20_3"></a><a id="Tc_UlmO2F1qZUeuxv4DS7RTkQ_22_0"></a><a id="Tc_6DQo51VJB0aSE5lfOhxjqw_23_0"></a><a id="Tc_ErmQ2ID1cUCrSbE_amJ2eA_23_6"></a><a id="Tc_lfd3VIADekacPZ5NyRhdHA_24_0"></a><a id="Tc_l0iB0_ZPYkirWSve9I0sfg_24_6"></a><a id="Tc_HMdR1AI6t06WGcyJnYCQCw_25_0"></a><a id="Tc_lG-0aIGCAUeys2diE-Cr2w_26_0"></a><a id="Tc_YDTx-46cFE6LHXP-saGeEw_28_0"></a><a id="Tc_K-QpS3xBzEGg_SH70r7sVg_29_0"></a><a id="Tc_T7muzGmQBEiON9xpvswBtw_30_0"></a><a id="Tc_GKSqAS3Knki6rSG3Rv5iZQ_30_2"></a><a id="Tc_rKwdIE-uIk-2UJzXi-5hMw_30_5"></a><a id="Tc_wWD82EZNbESmlGXNKqZq1A_31_0"></a><a id="Tc_mLjtZpW6QUu2KYOpkurQ8w_32_0"></a><a id="Tc_vpXIfYrZ1UmstaahUtigkA_32_2"></a><a id="Tc_2ay7-ptGpku3icOPC0Xq1Q_32_3"></a><a id="Tc_rwuK4yB8fEOlYNghTrwI-A_32_5"></a><a id="Tc_KmLhzpBGEEejIBY0KTNscw_32_6"></a><a id="Tc_tI9AdhuVZ0awaViVgJ-5uw_33_0"></a><a id="Tc_ymJ25cL75kGug-bRBBG_MQ_34_0"></a><a id="Tc_d-Ul2lWrxkSxlMSY_jtsjw_34_2"></a><a id="Tc_-mWVMo7ZGkKcgPUJ63aWag_34_5"></a><a id="Tc_J45rYRaipEOXepneC1tyiQ_34_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Months&#160;Ended</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_qbHK-HTdAk6ZbCJLIqsI6A_5_3">2,638</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_HtI9BgZLEk2zeFNRuLJh8A_5_6">1,160</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of finance lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_lDOe87g-6kCdJueQLXOZ4Q_7_3">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_U8lkcsP4U0KBxLTnNp23TQ_7_6">18</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc__LfzMxFsSEiGvSN6xckloA_8_3">168</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_6dlGM8fG10eblg2z7ein_Q_8_6">35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Revaluation of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Tc_UmCdTcH1A0Kv4MDh6IJLeQ_9_3">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forgiveness of PPP note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_iXFW5jzwa0uIZNW8OZnAjA_10_3">61</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest, depreciation and other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="vlon:NonCashInterestDepreciationAndOtherExpense" scale="3" id="Tc_EBhonR9l3kC6intmkEbMlQ_11_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_7aMbqJzcWU2hcwR-ZErOzA_13_3">793</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_vbpX_706IECgzMQ0xW2WFg_13_6">87</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_7LWI_1gRvEGOutTUBJFKfw_14_3">121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_jDY6gL0eBkW9PZ1DCVkP_g_14_6">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_LLpqdHBj5U6jC-8oLKwVbQ_15_3">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_FlxSje1S40yTNPF6ew49ZA_15_6">226</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_QODsCD_qCU6afPG8Li4d8A_16_3">2,948</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_rreigemFjkS1C5koFC40iQ_16_6">766</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Rr3X0AVT6kuEhXlnFbpX5w_19_6">2</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_0pzGTNIBqk-VLCzaStpdOA_20_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from common stock, net of offering expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_YjLjyaQxOEy5tn9Pie_tRw_23_3">15,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from convertible notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Tc_1Nig52I62020CUG6zkVKww_24_3">350</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of finance lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_y3Z_WtFiH0aQNhxOa42yAw_25_3">34</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_7qyoilPrVE6dgqOjHE9EEw_25_6">29</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by (used in) financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_hgSdZQLQq0euMObhQT-vAQ_26_3">15,819</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_E72pb7qEtUqXVgEX2PrVOA_26_6">29</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) increase in cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_yxWL1SUL40GWoyFjiL0zng_28_3">12,871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_DDSnKdnYQUe3XVEoEn1qMQ_28_6">797</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YiW79IjUqk29BoTrvl-oSQ_29_3">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_c01XKo-ub0WssvjMoF6W_Q_29_6">3,821</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, at end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_WFM27ELN80iFhZu2VE3uTg_30_3">12,980</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5DYSJqXOxU-GlsaRcrb4LA_30_6">3,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental disclosure of cash flows information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncash financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Conversion of convertible notes to common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_aqJPGGTPmk-9OPxToH6P8Q_34_3">350</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_2f9048ee_5626_470f_80f9_3cf577beea07"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vallon Pharmaceuticals, Inc.</b></p><a id="NotestoFinancialStatements_731522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="NOTE_1_NATURE_OPERATIONS"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_Gcnrq1LNQ0CFw1hy-i_J1g" continuedAt="Tb_Gcnrq1LNQ0CFw1hy-i_J1g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 1</b><b style="font-weight:bold;"> &#8211; NATURE</b><b style="font-weight:bold;"> OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vallon Pharmaceuticals, Inc. (&#8220;Vallon&#8221; or the &#8220;Company&#8221;), a Delaware corporation, is a biopharmaceutical company based in Philadelphia, PA, which is focused on the development and commercialization of proprietary biopharmaceutical products. The Company&#8217;s only clinical-stage product currently under development is ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of Attention-deficit/hyperactivity disorder, or ADHD, and Narcolepsy. The Company plans to develop other abuse-deterrent products which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vallon Pharmaceuticals, Inc. was incorporated in Delaware on January 11, 2018, which is the date of inception. The Company&#8217;s fiscal-year ends on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immediately prior to the closing of the initial public offering of the Company&#8217;s common stock (the &#8220;IPO&#8221;) (Note 5), the Company effected a one-for-<span style="-sec-ix-hidden:Hidden_UIe2lbAF2kGKY5HDdycYJA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">40 </span></span>reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Formation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 15, 2017, before the Company&#8217;s formation, Amiservice Development Ltd., a BVI corporation (&#8220;Amiservice&#8221;) entered into an agreement for the purchase of the ADAIR product rights for a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_11_15_2017_To_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_x-NQaVFMxUeZ4r1E-Nssgw" decimals="0" format="ixt:numdotdecimal" name="vlon:AgreementPurchasePriceProductRightsPriorToBusinessFormation" scale="0" id="Narr_jqT2G_r8XEq_gT64f35zgQ">250,000</ix:nonFraction>. The Asset Purchase Agreement (&#8220;the APA&#8221;), by and between Amiservice and Arcturus Therapeutics Ltd. (&#8221;Arcturus&#8221;), was subject to several closing conditions. One of the key terms and conditions of the APA was that the purchasers provide funding of at least $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_V2G_e2BzqUubv1rniE3q0w" decimals="-4" format="ixt:numdotdecimal" name="vlon:MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" scale="6" id="Narr_L8btn0Aj7EuX_iWnhspdxw">2.75</ix:nonFraction> million towards the development of ADAIR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 11, 2018, Ofir Levi, Chairman of the newly formed Vallon, purchased <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_M-FbannLWkuCQLGnkHGiuA">196,875</ix:nonFraction> common shares from the Company at par value for $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_StEdGeeUw026FiS1fxT_gw">788</ix:nonFraction>. On June 7, 2018, Vallon entered into a stock purchase agreement with several investors pursuant to which Vallon issued <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cxVBSsafCk-sS86bQ5jI5w">1,771,881</ix:nonFraction> common shares for $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_j0-EXapfBkKDLcJVRMYuBw">3.0</ix:nonFraction> million (&#8220;Private Placement&#8221;). Subsequently, on June 22, 2018, the Company executed the amended APA, by and between Arcturus Therapeutics Ltd. Such APA was amended and restated from the initial agreement discussed above, dated as of November 15, 2017. In exchange for the ADAIR product rights, Vallon issued <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nVdl1LAka0qDq0eAxljJNw">843,750</ix:nonFraction> common shares to Arcturus, valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_rKR8t6ZhAUGtfDIlg3rSAA">1.4</ix:nonFraction> million based upon the price at which the common shares were issued and sold in the Private Placement, which comprised approximately <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ" decimals="2" format="ixt:numdotdecimal" name="vlon:PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" scale="-2" id="Narr_-7cyLGDx5EKCR0PX1Mkg1A">30</ix:nonFraction>% of the then-outstanding common stock of the Company, on a fully diluted basis. In addition, Amiservice signed a consent and release agreement to all rights to the APA in exchange for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9XvhFD3qEa4bDRHE-FeXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_yrP0m5XlaUCcGSbRftRWxg">562,000</ix:nonFraction> which represented a reimbursement for expenses Amiservice incurred on Vallon&#8217;s behalf in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg" decimals="0" format="ixt:numdotdecimal" name="vlon:AssetPurchaseAgreementReimbursementOfExpenses" scale="0" id="Narr_MDruRe14GEGIjsBhkmEUuQ">310,000</ix:nonFraction>, the repayment of <ix:nonFraction unitRef="Unit_Standard_item_0sfEPIqYxkSB2d_NNWmuCg" contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg" decimals="INF" format="ixt-sec:numwordsen" name="vlon:NumberOfPromissoryNotes" scale="0" id="Narr_kK6PdPHFxUGjz5AMxF-WvA">two</ix:nonFraction> promissory notes totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" scale="0" id="Narr_jOJiR5NiFkGI_QJp2OYbjw">192,000</ix:nonFraction> including interest, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherCostAndExpenseOperating" scale="0" id="Narr_U8w7rbrLgEy_keB3wk30Jw">60,000</ix:nonFraction> of other operating expenses incurred. The assets acquired in the ADAIR acquisition are classified as in-process research and development (&#8220;IPR&amp;D&#8221;). Accounting for IPR&amp;D assets in an asset acquisition follows the guidance in Accounting Standards Codifications (&#8220;ASC&#8221;) 730, <i style="font-style:italic;">Research and Development</i>, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and charged to expense at the acquisition date. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_WvWGat3RkE28bv-oe7Evjw">1.7</ix:nonFraction> million to research and development expense on June 22, 2018, the date of acquisition, which included $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_OmCENw6bT0OrEyThdmUHpg">1.4</ix:nonFraction> million of common shares issued for the acquisition, as well as, the original $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="0" id="Narr_ZY51Qx9KRkqq2-n4bmcpZQ">250,000</ix:nonFraction> exclusivity payment and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_nE5tkt9jPU267_p8BkBEfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" id="Narr_e2ZoVHXpEEW7WFkLlgk89w">60,000</ix:nonFraction> in transaction fees.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gcnrq1LNQ0CFw1hy-i_J1g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern and Liquidity:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception, and has incurred $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_sxNzBDgUFkqCX2-2uU4O6g">15.2</ix:nonFraction> million in accumulated deficit through March 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (&#8220;PPP&#8221;) promissory note, as described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 11, 2021, the Company completed a $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_11_2021_To_1_11_2021_8qOoRPKb30yKP4fdaCxr0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" id="Narr_SuXCxPEyE0y34qnVxgeomQ">350,000</ix:nonFraction> convertible note financing and on February 12, 2021, the Company completed the IPO, raising net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_-hHBgSrlhUW_ys1LB8Ltkw">15.5</ix:nonFraction> million, as described in Note 5. On March&#160;31, 2021, the Company had cash and cash equivalents totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_1_11_2021_B-c7BO4RP0aNIhbXZvMJhg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_Town7XVA90Gc0AP34yYNLw">13.0</ix:nonFraction> million which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove to be wrong, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that these financial statements are being issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#8217;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. Furthermore, the Company may not be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements. If the Company is unable to obtain sufficient cash resources to fund its operations, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Ze1tN77XY06WgjjKmg8kxw" continuedAt="Tb_Ze1tN77XY06WgjjKmg8kxw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s significant accounting policies are described in Note B, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 29, 2021. There have been no material changes to the significant accounting policies during the period ended March 31, 2021, except for items mentioned below.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="vlon:UnauditedInterimFinancialStatementsPolicyTextBlock" id="Tb_JaaBcm6R70K0QUmpHP_LmQ" continuedAt="Tb_JaaBcm6R70K0QUmpHP_LmQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[A]&#160;&#160;Unaudited Interim Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments necessary for a fair presentation of the Company&#8217;s financial position at March 31, 2021 and the results of operations, stockholders&#8217; equity (deficit) and cash flows for the three months ended March 31, 2021 and 2020. All such adjustments are of a normal and recurring nature. Interim financial statements are prepared on a basis consistent with the Company&#8217;s annual financial statements. Results of operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is to the Accounting Standards Codification issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For further information, refer to the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ze1tN77XY06WgjjKmg8kxw_cont1"><ix:continuation id="Tb_JaaBcm6R70K0QUmpHP_LmQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:UseOfEstimates" id="Tb_EY8Z06aDpUm0WWR2xmAcEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[B]&#160;&#160;Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_IoV3_5yaO0iC-N8wMWTF2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[C]&#160;&#160;Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <i style="font-style:italic;">Stock-Based Compensation</i>. ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company&#39;s control and depends upon a number of factors including the Company&#39;s market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised. The stock options granted, other than the <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_JqpFDEggRkesYrNF0Z7d7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_IYhkh1cbYkuqTnj6i8Yz0g">61,250</ix:nonFraction> granted to Mr. Baker described in Note 10[A], as of March 31, 2021 vest primarily upon specified performance milestones. As Mr. Baker&#8217;s stock option grant was pursuant to milestones associated with an underwritten public offering or a listing on a national stock exchange, management determined that no expense should be recognized for this grant until such time that the milestone becomes probable. The options vested on February 12, 2021, concurrent with the closing of the IPO and thus the expense for such options was recognized in the three months ended March 31, 2021. The Company elected to use the expected term, rather than the contractual term, for both employee and consultant options issued.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_-nhjxK8UCEG1DBWmFA9uTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[D]&#160;&#160;Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all Accounting Standards Updates (&#8220;ASUs&#8221;). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d0f70d73_74fe_450f_b797_d6cc11b7d224"></a><a id="Tc_11Hvs5qcx0qaA5vlLRXz-A_1_2"></a><a id="Tc_NQszSOX2jUaceRCynpWn4Q_1_5"></a><a id="Tc_32VAhcouxECcenNHCJOpJA_2_2"></a><a id="Tc_7YHY81QQlUyUsLvZGwrhvg_2_5"></a><a id="Tc_yw2scHIzlEWbyks_VyXJ9w_3_0"></a><a id="Tc_yVWGXj0ahUqL733NB6keVg_3_2"></a><a id="Tc_rlvHttuhmkGWYc-5ZpCjuQ_3_5"></a><a id="Tc_aTGfVKJKnku4AKSAZVHBaw_4_0"></a><a id="Tc_f7E8tvG7b0eLyqMTkTgArg_5_0"></a><a id="Tc_VkeLQNuME0WD0zdzXv8PeQ_6_0"></a><a id="Tc_DaCkGHQzrkytJmyVlgVOSQ_6_3"></a><a id="Tc_6UFKz586g0Wy5iYWnMmnBQ_7_0"></a><a id="Tc_9Ja95ZsK1kG2v3dv_cYpjg_8_0"></a><a id="Tc_u1_vNb-h50uMjgWCcl5vxg_9_0"></a><a id="Tc_w_BCFCIVlkOPHaX9eL1UIQ_9_2"></a><a id="Tc_qQ-_n3ieTUKrKcg6xANnzA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_Ic5PsTMnZkyQb2tasTlnUw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3 &#8211; ACCRUED EXPENSES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_fv6-0KuphEqlbd2sI-maWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_edhe74gHmE6pgWQTTGDmeg_3_3">176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_49MONCDGN0-Tem5FaYLS5g_3_6">342</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and preclinical trial and regulatory related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" scale="3" id="Tc_0IxeVm44dU6RwLVTSQoAwA_4_3">490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" scale="3" id="Tc_zGbz6zEnDUuxg0cbwjBq2g_4_6">137</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chemistry and manufacturing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedChemistryAndManufacturingExpensesCurrent" scale="3" id="Tc_iaxSqN3dbkKLNcV8YJZbHg_5_3">154</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedChemistryAndManufacturingExpensesCurrent" scale="3" id="Tc_J2H6ba5OckSQMcP8f-Lhsw_5_6">117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_MANStX-wpEm4d4sJIBcjaw_6_6">97</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Licensing related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedLicensingFeesCurrent" scale="3" id="Tc_mMYd7Nd2E0KQriO2iu5qiw_7_3">76</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="vlon:AccruedLicensingFeesCurrent" scale="3" id="Tc_S7KmqxdxaECPZLlRoK8j9w_7_6">81</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_AVfURmAQvkS1q-BfQRVTyg_8_3">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_RZimvOb_3U2xfPBnpCWPbg_8_6">73</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_OdhcrH7fp0SutKPYo0j67g_9_3">985</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_-v50OyGPj0el7e4WXIUEPg_9_6">847</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_AKHYBwKYW0WvVlR1wwF-2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4 &#8211; PPP NOTE AND CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company issued a promissory note under the PPP totaling $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_5_31_2020_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_ei25kWe8EU-JCt2bw1gHyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_1Wrl_73sz0qZ_oeN1g-WcQ">61,000</ix:nonFraction>. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_nW_at-qhE0qwfYklAFP-Yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Narr_nHQKjbYL_0GgNexsrfXMLg">61,000</ix:nonFraction> included in other income on the accompanying Statements of Operations. The Company had accounted for the note under ASC 470. The note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a 1.5-year period beginning November 1, 2020 unless forgiven. The Company did not impute interest on the note as the rate was determined to be a below-market rate due to the scope exception in ASC 835-30-15-3(e) for government-mandated interest rates. Amounts due under the next twelve months are presented as notes payable &#8211; current on the Company&#8217;s balance sheet as of December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (&#8220;Salmon Pharma&#8221;), an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the &#8220;2021 Convertible Notes&#8221;), for cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" id="Narr_sEzCS3tXpUiffsuhnC8zxA">350,000</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_4CwAuiXkbUCOtvE65Xtb-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_XAQcpLGfoUWf2RBvtrr8Kg">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_hsfpIlRkLUGC_vfDby0-qw">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="vlon:EquityFinancingDisclosureTextBlock" id="Tb_nphj7rv2IUuHkejxfaTvcA" continuedAt="Tb_nphj7rv2IUuHkejxfaTvcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;5 &#8211; EQUITY FINANCING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February&#160;12, 2021, the Company completed the IPO of <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_m_qpi2gNQ0Wm0F6HLx90lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_NajJosQPYESJo8OWf7x3wg">2,250,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VWR0Rpxvjkq1cR6FDhHjRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Auva2gOjEkawGeaFfEWulg">8.00</ix:nonFraction> per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA" decimals="-5" format="ixt:numdotdecimal" name="vlon:GrossProceedsFromInitialPublicOffering" scale="6" id="Narr_MIwEslV7DEiZ-fwx7t2rew">18.0</ix:nonFraction> million. Underwriting discounts and expenses totaled $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA" decimals="-5" format="ixt:numdotdecimal" name="vlon:SaleOfStockUnderwritingDiscountsAndOtherExpenses" scale="6" id="Narr_Qi8usb7B1kGaiUUO0x01QQ">1.6</ix:nonFraction> million and the Company incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA" decimals="0" format="ixt:numdotdecimal" name="vlon:SaleOfStockOtherOfferingCosts" scale="0" id="Narr_7yscHPjJg0K_69wf8uXr4g">905,000</ix:nonFraction> of additional expenses related to completing the IPO, of which $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_OL8f_qfInEqpi_l0fTWnWw" decimals="0" format="ixt:numdotdecimal" name="vlon:SaleOfStockOtherOfferingCosts" scale="0" id="Narr_daqLt9DcO0K5Lmh4HA6CWw">494,000</ix:nonFraction> were incurred as of December 31, 2020 and included prepaids and other current assets on the Company&#8217;s balance sheet; thus aggregate net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_GfkSJnOr40CMGKSZYzhfNQ">15.5</ix:nonFraction> million. Immediately prior to the closing of the IPO, the Company effected a one-for-<span style="-sec-ix-hidden:Hidden_RklKRiOmx06CoYYk0dhHnA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">40</span></span> reverse stock split of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_HjPd_SxIakSY4C9Ef75PYw_1_0"></a><a id="Tc_aXSDhdcTokWx1wH9YIGaIQ_1_4"></a><a id="Tc_TBHqECjLA0i8obH66wVNYA_2_0"></a><a id="Tc_uL-73XtiYk-_TD7Csmbxuw_3_0"></a><a id="Tc_jP-Eaw68Z0GQFKaj5rNtAQ_3_4"></a><a id="Tc_whyh8yARv0O2X3zqfmaGyA_4_0"></a><a id="Tc_AEcrd_6hK0GIiHRNaSJehg_4_4"></a><ix:continuation id="Tb_nphj7rv2IUuHkejxfaTvcA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the IPO, the Company granted the underwriters warrants (the &#8220;Underwriters&#39; Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_mp4DINXbDUGfII7GoJ2Ntg">112,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_f00YQBYZd0aPyycuSJ5JXQ">10.00</ix:nonFraction> per share, which is <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg" decimals="2" format="ixt:numdotdecimal" name="vlon:PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" scale="-2" id="Narr_DIeMgFyDnEedFSkjsvEy6w">125</ix:nonFraction>% of the initial public offering price. The Underwriters&#8217; Warrants have a <ix:nonNumeric contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_KGMA0EZQhE2vboUkHwrJBg">five-year</ix:nonNumeric> term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding at March 31, 2021. According to ASC 480-10-25-8 and ASC 480-10-25-14, a warrant is classified as a liability if the warrant obligates the issuer to repurchase its shares by transferring an asset. A warrant can also be classified as a liability if it (conditionally or unconditionally) obligates the issuer to settle the warrant by issuing a variable number of shares if the monetary value of the obligation is based on a predetermined fixed amount, variation in something other than the issuers stock price, or variations inversely related to the issuers stock price. Any other warrant would be classified as equity. Given that these warrants do not meet the criteria of debt classification, these warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Narr_dfhyoIK8rE6XI4kW7COA-g">399,000</ix:nonFraction> is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_9IMiHaFMVECXeDEyxfhfLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_3T_YOj8HYkuyIghH89HkUQ_1_3">85.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_oUpLJpG1TEeUwluvcA56wQ" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_WMpWQYbtdU2UCOLjqacrtg_2_3">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_OuHcg0aKu02Um5Wx4JT5vw" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_unBrGkU0ok-uHXS0soFFVA_3_3">0.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_cEy2Na7LTU6FHcLHdGkVLA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_gHYclDrBGk2IY6idVXsL5Q_4_3">0.155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2503dbdc_a4c7_417f_a721_8fac3d8010f8"></a><a id="Tc_IL4K__Arhk6vzWFOxv0Jfg_1_2"></a><a id="Tc_-kj6kbs9K0a_fkEsccr-Gg_2_2"></a><a id="Tc_EU1jvG_YlEKS_29VR2RA-w_2_5"></a><a id="Tc_LfRYzGRTOEm17vPbRiT7GQ_3_0"></a><a id="Tc_njYRFBscPUy9to2V5ASacw_3_2"></a><a id="Tc_X07oQ21zTkKn3QGcXCnc2Q_3_5"></a><a id="Tc_mbmHL_ixN0iw1Ypwa-OLmA_4_0"></a><a id="Tc_7p_T4-fHgU-t1gznWeWLKA_4_6"></a><a id="Tc_2X8fpAwg9EK13k-vSm1SJw_5_0"></a><a id="Tc_ryNRC7Ueo0SJKJiBp8vqLw_5_2"></a><a id="Tc_9BuURBsF2kiMWJGW7obL6Q_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Aas1er-3hECMjmKgJbeHeA" continuedAt="Tb_Aas1er-3hECMjmKgJbeHeA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6&#8211; STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Equity Incentive Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. We have also granted certain stock options outside of the 2018 Equity Incentive Plan. As of March 31, 2021, all equity awards granted from the 2018 Equity Incentive Plan were in the form of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures equity-based awards granted to employees, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards the Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes stock option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the stock option, the risk-free interest rate for a period that approximates the expected term of the stock option, and the Company&#8217;s expected dividend yield. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics to it with historical share price information that approximates the expected term of the equity-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of its stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_8OA-jaYsMk6s3_YAaLYWFQ" continuedAt="Tb_8OA-jaYsMk6s3_YAaLYWFQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TSib4yEdAUSlHbmW78scuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_S5TL72MHCUeuNNwwU3ap-g_3_3">20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_peYk7ghKTU-3tzbPPE3XKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_WQ5Jy5YQAUeJ_DxBCUJSAA_3_6">35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kYeoxmIIaUemiecYpa-T4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_G1xlqcxoNES3yyZ6RyuESA_4_3">148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_s1apAlCoZUWLip1_d-sNGA_5_3">168</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iFTSa8h7kkyYwDJ44T60_g_5_6">35</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_953219b7_0af7_4c4b_a22e_c9ce59343525"></a><a id="Tc_rQFqx33flkejGjgS6Cls5w_1_2"></a><a id="Tc_8fuYfkttkkaTCburJNdtiQ_2_2"></a><a id="Tc_GPckg3JKnkqwJnXd2hUNJg_2_5"></a><a id="Tc_NMLBA4j77EyGv2RKVdGooA_3_0"></a><a id="Tc_A-xF6Nq3AkeZ38H5ZtCThw_3_4"></a><a id="Tc_A_8R101SMkuT9b23h20Dgg_3_7"></a><a id="Tc_Dr9l-3akG0mGBeMqSm8DEA_4_0"></a><a id="Tc_F9UwJNHOl0OgUk8_mONeZA_4_3"></a><a id="Tc_gGDQUVCuvEik2M-xyZn-kw_5_0"></a><a id="Tc_0_imdA1zHUOt0xG3uDa3eg_5_4"></a><a id="Tc_ui_gxXws40Km_3XdfSg_Uw_5_7"></a><a id="Tc_eo8ft2g2kUW2XhQo8B36uQ_6_0"></a><a id="Tc_aXKILK-O2EiFWH0B8Os20A_6_3"></a><a id="Tc_717hzLWBnEeA9hdXbcVt6Q_6_4"></a><a id="Tc_9eMs_jqDG0CiKElzT0t5qA_6_7"></a><a id="Tc_nsDlUyiBuk-M8wG8m5_rmg_7_0"></a><a id="Tc_V8JX2NYf3UqF9VdP0v4YoQ_7_2"></a><a id="Tc_bvYRXyunBEK6yqDL-_7tHA_7_3"></a><a id="Tc_kMjAB_lFb0q2sXS8BxLN3g_7_5"></a><a id="_5a02cf40_f1d8_47a0_aa18_4c271776d3d3"></a><a id="Tc_E7AwNkyBMEqGxugCIPy7lw_1_2"></a><a id="Tc_rKV-nQJakE268edCWz0-YQ_2_8"></a><a id="Tc_a7CLmVqY40Oo81iQ6d8BWA_3_8"></a><a id="Tc_BJ94gncVAkafy1c_VCcQSQ_3_11"></a><a id="Tc_zJfdN6jU2km8Ef_33URhqA_4_5"></a><a id="Tc_dzrtAnkSx0yD3mQQhnCxYQ_4_8"></a><a id="Tc_V8nnPm2_9kqQufHcLbqsVA_4_11"></a><a id="Tc_syOCcd6diUevlchSqVhefw_5_2"></a><a id="Tc_5Xy80KTP-USUC28t_blYWA_5_5"></a><a id="Tc_3M3rTZYwTUWijLYD4snpCQ_5_8"></a><a id="Tc_WYwGIyVrpU-WY0xScUm6hw_5_11"></a><a id="Tc_ZqfH-paVW0qTgXO2tliazg_6_2"></a><a id="Tc_68IvSLmhCU258oiedT1uxA_6_5"></a><a id="Tc_JMHQwKGpb0uNR1gkZYq7bA_6_8"></a><a id="Tc_2PNUfB515Uq4MYNBntJNvA_6_11"></a><a id="Tc_Rg3auYcYMkeh6_FMR8dNrA_7_0"></a><a id="Tc_e-1bcWpi6U2l8beMjP7VuQ_7_5"></a><a id="Tc_WcJIgosDKUWNOOSNM147HA_7_11"></a><a id="Tc_oC6RgvUisk6qUncwuo5vwg_8_0"></a><a id="Tc_c2U0CoyLrkataUiymYF2dQ_8_9"></a><a id="Tc_OTS4Blu-mUuB7PqkTRhOGg_8_12"></a><a id="Tc_MggrJmTeOUy7JyprB_Ev0w_9_0"></a><a id="Tc_6jYWlkSpqEiDK4C7FjgiAw_9_5"></a><a id="Tc_d-XJKfSesUybIBc5lErzSw_9_11"></a><a id="Tc_tOOP4mJuJEynB94rc5HOGQ_10_0"></a><a id="Tc_kwVSerSbqkC0Y8ww-h8kEg_10_5"></a><a id="Tc_8h1jjyrzrEiifvT1iM7cqQ_10_11"></a><ix:continuation id="Tb_Aas1er-3hECMjmKgJbeHeA_cont1"><ix:continuation id="Tb_8OA-jaYsMk6s3_YAaLYWFQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_Aqy7aKMMyEqzkbFocIvuCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of the options granted during the three months ended March 31, 2021 and 2020 was estimated by utilizing the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_6AP9XH5CXEq8h9BNnMD0CQ_3_3">80.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ivGur_zP-0WFjE_cadpA4Q_3_6">85.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_d6P1EaoKk0mhAT_yEHaCng">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_hkRAoTNKTkm4VxbhVrI2Og">5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_rwk_GPxfAUW44pSPKsA1LQ_4_6"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_BLoQRRX6UUu0oVUfk8K8qQ_5_3">0.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_dDT9WxoVHEmqbvOJecxqsA_5_6">0.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_J9BeA8Kx30CyYiOYjRVmkA">0.63</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_taewhfNYrE6n01LW3ZAbnA">0.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_FxLKxyLFkUaaNckjOQw1UA_6_6">2.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of option on grant date</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_p-WkrdawjkKSVhflMIYJmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_hdIc8zVBlUK69Hz4qDFGpQ">4.08</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_QRMywzI2uUq-75VZaFoA9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_BSzRCJu19kak2sup4oFQqA">5.31</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_OSqEfg60bk-OxELzLZmIMQ_7_6">3.24</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Do458bbwdEyqbY-vMnv_1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below represents the activity of stock options granted to employees and consultants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from December 31, 2020 through March 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">terms</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">000)</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ZrN0HwwxAkuPP_dv5fFsmw_7_3">266,250</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yPJqIRKe9kuODOkC6XDPWw_7_6">2.94</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_3oTw1yMDg0imluvlL_IRbw_7_9"> 4.109</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_fhElnFsS8UyskJbWwTPtXA_7_12">474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_l1Xb8CuMsk2Nn_1QIKNHCg_8_3">22,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_xF4BahWKuUyCesy1exBZmg_8_6">7.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ee44-MgibU2jp4NihDIr1g_9_3">289,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_7aYXcXg2Pk-6gZTWIovUmQ_9_6">3.29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_vA4jzHDujkGBu1QsTEXhEQ_9_9"> 4.060</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_uyYfIkqFTk-gcnwIbq8WXg_9_12">460</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_CQn1lQZeAkaUW-RHS_mVGQ_10_3">135,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_iu5rn_wv_0iwEYj4IgaqLQ_10_6">2.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_bBxdPL_1w0aUHWBC3g9sNg_10_9"> 3.770</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_fkLKO3EQIkujiHiF-knhhw_10_12">320</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the deemed fair value of the Company&#8217;s common stock for those shares that had exercise prices lower than the deemed fair value of the Company&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2021, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_vFarWyLSi0W_Rq5eAXJa0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_pdDLejIk106g7PjDDm_1xg">105,000</ix:nonFraction> of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to employees which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A4zr9qZIIkWi15ZK_wyfzA" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_qXy7DPZBKEylDrcLeTFQJA">one year</ix:nonNumeric>. As of March 31, 2021, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ba48kdCZkEG4MpU_eSZ57w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_knSEtf4XV0euIIdgjnoomA">118,000</ix:nonFraction> of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to non-employees. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wj8fFhgfhkWVHez-hovm0Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_2mP1xqcM1USY6nMSODtoBQ">0.7</ix:nonNumeric> years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_VyVtcsSLfEe8nQCUtfk04Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; INCOME TAXES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended March 31, 2021 and 2020, respectively, <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_Zarqf9S8ck25Ds22i-S4jA"><ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_iR5exADq20OXvqBnHIjnxQ">no</ix:nonFraction></ix:nonFraction> income tax expense or benefit was recognized. The Company&#8217;s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_IVOmPOp0d0KFNko0xrf-Zw" continuedAt="Tb_IVOmPOp0d0KFNko0xrf-Zw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8 - RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 6, 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_6_2020_To_1_6_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vlon_MediceMember_NGprOuJ5l06TJqQZC_V8ig" decimals="0" format="ixt:numdotdecimal" name="vlon:RelatedPartyTransactionUpfrontPayment" scale="0" id="Narr_JnQ9_gncHE6y8y3Hq3pO4w">100,000</ix:nonFraction> upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IVOmPOp0d0KFNko0xrf-Zw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" id="Narr_Fr9C5Wp_S0ugaX6yMpMrng">350,000</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember__uYmvO-NoEutzv5BKZjj-g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_87HizcI-BUayant54YKjnA">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_w-BjMeWCnkO08hRk-vHoqQ">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1a3dd9a2_10b2_4d5e_b2d1_4401e6e56467"></a><a id="Tc_Xagh-6rZa0qEI-P6KTgS8w_1_2"></a><a id="Tc_ZIrrxC2X-0K7DTDpwQFT1Q_1_5"></a><a id="Tc_KIz6s1pmqkGNpsKYsgP96A_2_0"></a><a id="Tc_yBgIIGblSkiH6e4Q0lrAZQ_2_2"></a><a id="Tc_LcIoqG1YUk2eBHkOH60BbA_2_5"></a><a id="Tc_vKN3WvCx0kOSzuS_0fvjvQ_3_0"></a><a id="Tc_iglWdx2Sg0i008mffdsMaA_3_2"></a><a id="Tc_ApXOYhOy7Ua9en8f51u8sw_3_5"></a><a id="Tc_g2Ueq9c__EyALde4Yp2nvw_4_0"></a><a id="Tc_07_9kK50XkWGr5Mn6S-i1A_5_0"></a><a id="Tc_BYw8Wjr64k-IWvw2imDQPA_5_4"></a><a id="Tc_oDpVQX3v9UCunJ-r_QMY0w_5_7"></a><a id="_3f572f6f_98ba_4c5a_8a76_388a010b5746"></a><a id="Tc_wbdkZfDHjkaxt6wRpwwtdA_1_2"></a><a id="Tc_ahcVlhZlEUmB9yGDgCn8wA_2_2"></a><a id="Tc_LEpUP3ncq0mOrlf4lvICaQ_2_5"></a><a id="Tc_7JygVU_M8kCQpHDwJjKIgQ_3_0"></a><a id="Tc_67AeutUdzkydNVfIUnvHBw_3_2"></a><a id="Tc_qTuU-cqg9UmAV8pY81x-HQ_3_5"></a><a id="Tc_tLk3q_DDs0C4bqybMylE8g_4_0"></a><a id="Tc_8yyxTPvUdUya5r6qaEthhA_4_2"></a><a id="Tc__f7EH05DS0-B04n60UJu3w_4_5"></a><a id="_a7591322_2efc_463b_8191_b6958ab47170"></a><a id="Tc_p9G6Ttswy0SGl3mT9QHsXQ_1_0"></a><a id="Tc_0-AnQwfPIkaQwsdK6LCRmA_1_2"></a><a id="Tc_IlUDzXS3y0uN-IMKAOXQuw_2_0"></a><a id="Tc_covcEkDi_0ea1zPV7E4ZEg_3_0"></a><a id="Tc_p0tlgBytvUCFJPkZ2ehd3w_4_0"></a><a id="Tc_JP24liDBfECjMGK1RxENug_5_0"></a><a id="Tc_TaDGLmr1UkOVoRvMzYsXYg_6_0"></a><a id="Tc_9JqrXy8z2ESHf0pkzn23Ig_6_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:LesseeFinanceLeasesTextBlock" id="Tb_7mIpZyXgdk-OSA9EU7P37A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9 - FINANCE LEASE</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:LeaseCostTableTextBlock" id="Tb_vdr1b3ZJ-EqxH6NTdQ3_pA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a finance lease in October 2019 in relation to equipment utilized in the commercial scale manufacturing of ADAIR ($ in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial lease right-of-use asset </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="Tc_UjHtOm-npkyfs-EgnkaHew_2_3">368</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="Tc_kxFe-qSY0kK_jZWPD-v3Pg_2_6">368</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_IqnuxUrtYEW0_SZjBtKe1w_3_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_H_qrvBa2_0iJtkyAHB7IXQ_3_6">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - finance lease (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_2T_tY441n0WUZUkpNLXDfg_4_3"> 2.50</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc__2rHPZujDECx0zS3EGhwGQ_4_6"> 2.75</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_n-hNp8yYsEOGztDe5645Uw_5_3">13.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_VsqfCdHV3EO40m4N70ZTCw_5_6">13.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from finance lease amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_6ruH5zRSlk6zFR2g26XzPQ_3_3">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_byttA8vdzEuaqxavHzRJnQ_3_6">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash flows from finance lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_waXUh2tHUkSFZiN84cqu5w_4_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_NYFwosuZyEya628hrvfMtA_4_6">29</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_t1kDe8VGjEihGNbc0SL3RA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The maturities of the finance lease liability as of March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_HvfZEPLfNUOY91lUBpIxZw_1_3">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_-MV30wFL70O_ZKVEicE_Mw_2_3">114</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_1i5u8y3k_EKWYnvBfe-YEA_3_3">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_qGbdf_O0Rki_APkp-6meFA_4_3">285</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_0Kq2VCaKckW4ZjqGMIcaFA_5_3">44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_Kuxla10tt0qHSd5wVyeJeQ_6_3">241</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_y6e2vxRVi0a8UfyyiD_7QA" continuedAt="Tb_y6e2vxRVi0a8UfyyiD_7QA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;10 &#8211; COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A)&#160;Employment Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 15, 2019, the Company entered into an employment agreement with David Baker, to serve as its President and Chief Executive Officer, which was subsequently superseded by a new employment agreement, effective as of April 20, 2021 (the &#8220;Baker Agreement&#8221;). The Baker Agreement provides for a base salary of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" scale="0" id="Narr_oHrZ9OVs0kyv9jpFA4mcOQ">400,000</ix:nonFraction> per year, effective as of April 20, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Baker Agreement, in the event of an involuntary termination by the Company or termination by Mr. Baker for good reason, Mr. Baker will receive:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continued base salary for a period of </span><ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" id="Narr_JbVDBeRIRUSmX4YSaP5w6Q"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least </span><ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" id="Narr_8i5y-1DM3E69Pt9o87Xn-w"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">six months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> during that year; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ" format="ixt-sec:durwordsen" name="vlon:CobraHealthInsuranceCoveragePeriod" id="Narr_2FL1iGOyjkybrW49evdvdg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_y6e2vxRVi0a8UfyyiD_7QA_cont1" continuedAt="Tb_y6e2vxRVi0a8UfyyiD_7QA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of a termination within 12 months after the occurrence of a change in control transaction, the President and Chief Executive Officer will receive:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continued base salary for a period of </span><ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" id="Narr__y_j571jY0iuFsgeKPE04Q"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18 months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, plus a lump sum payment equal to <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_VhmnJep2JkO1qViW7_X-HQ">150</ix:nonFraction>% of his target bonus, without proration, for the fiscal year of termination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><ix:nonNumeric contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA" format="ixt-sec:durwordsen" name="vlon:CobraHealthInsuranceCoveragePeriod" id="Narr_5Xz4m0FtOkWtC6QMvS-uSw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18 months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In exchange for the severance benefits described above, Mr. Baker must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company. The description of the terms above are qualified in their entirety by reference to the Baker Agreement, a copy of which is filed by the Company as Exhibit 10.1 to this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(B)&#160;Clinical Trial Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2020, the Company entered into a service agreement, amended August 2020 and further amended January 2021, with a clinical research organization to provide clinical trial management services to the Company to assist the Company in its pivotal human abuse liability clinical trial of ADAIR, Study VAL-104. The agreement may be terminated by either party upon <ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_Tn38B5U-o02QABujfpad0A" format="ixt-sec:durwordsen" name="vlon:TerminationPeriodUponPriorWrittenNotice" id="Narr_XeiRZ_zEMUy5U_t0fy6TuA">thirty days</ix:nonNumeric> prior written notice. The total clinical trial cost is expected to be $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_lVQgaSqrRkK1DTlNgKvOrA" decimals="-5" format="ixt:numdotdecimal" name="vlon:ClinicalTrialCostExpectedAmount" scale="6" id="Narr_xDoRgWmEyUyJOo7BZQ6mWg">3.1</ix:nonFraction> million of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_PiKPhnXIVEe3otXkFQJSbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_B92eaWS5g0yD1c2_dYDX6g">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_AY-YYGiTG0q7QQrpwLwsHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_pibCa7L6NUml21y09SBQag">49,000</ix:nonFraction> was expensed during the three months ended March 31, 2021 and 2020, respectively. The Company has expensed $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vlon_AdairStudyVal104Member_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_6XKRebR7BEWBtoFWLvbicQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_YxIBoP6bTUaGoPefq-lhmQ">1.9</ix:nonFraction> million cumulative from contract inception through the three months ended March 31, 2021 for Study VAL-104 and expects topline results from the study by the end of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(C)&#160;Consulting Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective April 2, 2018, the Company entered into a consulting agreement with a consultant to serve as the Chief Medical Officer for the Company. Pursuant to the consulting agreement, the consultant is paid $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A" decimals="0" format="ixt:numdotdecimal" name="vlon:ProfessionalFeesPaidPerMonth" scale="0" id="Narr_1EELvVin0EiL9jPJ8IkguQ">10,000</ix:nonFraction> per month for his services. In October 2018 and May 2020, the Company granted the consultant <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_WGepaRPim0eFAsLrWHF3XQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_mmqqdg6ym06xAuh-xXO7Dg">15,625</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_lmsSk0l7KkWPJE-KMU2SDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_YC2-StoH20ab3fEB6QHcvQ">6,250</ix:nonFraction> options, respectively. For the three months ended March 31, 2021 and 2020, the Company has incurred consulting fees in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_PeCqNyG65U-s5WHXh9lz0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="0" id="Narr_VxSvQvZ_60-MU93jYh1mgg">30,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_hOnNiNgctkydAp6WTPWNzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="0" id="Narr_qnj4To1KzEWzNOgDBVxzhw">30,000</ix:nonFraction>, respectively, under the agreement. The agreement may be terminated by either party with <ix:nonNumeric contextRef="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A" format="ixt-sec:durwordsen" name="vlon:TerminationPeriodUponPriorWrittenNotice" id="Narr_zwYviDB9UUKTpyTOAa-v9Q">30 days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(D)&#160;Manufacturing Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company entered into an agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR. The total contract is estimated at $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g" decimals="-5" format="ixt:numdotdecimal" name="vlon:EstimatedContractCosts" scale="6" id="Narr_XjlQkwFwOUqjGrB-nwllZQ">1.6</ix:nonFraction> million of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_aj1ck67-3kCcwaJeJiWVrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManufacturingCosts" scale="0" id="Narr_Ugekvilo90WqtUu15WpLVg">79,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lCH-zADik0qKO3X2XzUZjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManufacturingCosts" scale="0" id="Narr_THGRVrSKAUm4K8EL6TOdtQ">79,000</ix:nonFraction> was expensed under the agreement during the three months ended March 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered into an agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin&#174;). The total contract is estimated at $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_z-8EZMohVECdXJnLeqPxEw" decimals="0" format="ixt:numdotdecimal" name="vlon:EstimatedContractCosts" scale="0" id="Narr_dDttVJmYrUqfq75xnKmNQQ">232,000</ix:nonFraction>, of which $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_IzAODsPw3UW6_K3qX2og7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManufacturingCosts" scale="0" id="Narr_MQJZlaqsEUuca_xUL6vKGw">6,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_BbC8XV5qlU2ceMNKytn5Qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManufacturingCosts" scale="0" id="Narr_yhDAMmAra0qh4YTOrG_-ag">83,000</ix:nonFraction> was expensed during the three months ended March 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(E)&#160;Pre-Clinical Agreement (included in research and development expense)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company entered into an agreement with a clinical research organization for pre-clinical services. The total contract currently authorized is estimated at $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_11_30_2019_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_SnkKNVvge0SVtghw5VA0qw" decimals="-5" format="ixt:numdotdecimal" name="vlon:EstimatedContractCosts" scale="6" id="Narr_7-qJnMQaVUWXN2xPHlVpOA">1.5</ix:nonFraction> million of which $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_6vvh1yU2_0mn3PPDkIvZWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_1Rj7M0oYL0qZHvleSDa5_g">245,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_kkrPw5KwQkynmgre4Q1gJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_aFQUtK-HpkG8j5EM4NCRhA">175,000</ix:nonFraction> was expensed during the three months ended March 31, 2021 and 2020, respectively. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_y6e2vxRVi0a8UfyyiD_7QA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(F)&#160;COVID-19 Impact</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The global COVID-19 pandemic continues to rapidly evolve, and the Company continues to monitor the COVID-19 situation closely, including the worldwide vaccine rollout and the recent outbreaks of various strains of the virus. the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its future impact on the Company&#8217;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom it does business, as well as its impact on regulatory authorities and the Company&#8217;s key scientific and management personnel. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with many of its employees and consultants working remotely. The Company will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom the Company does business.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a04d5059_727e_42d0_b205_eb8e35af553e"></a><a id="Tc_3W4NI16Ye0-ud_g7AQt9iA_1_0"></a><a id="Tc_hcLt8QKYmESvO0a3Ar5M0Q_1_2"></a><a id="Tc_3SpeOhU-WUG6bbqw2ZcTiA_1_3"></a><a id="Tc_zAZfIHscvUG52Fr-tgFtTA_2_0"></a><a id="Tc_TvPll6c0hkyA2tpJgMYhhw_3_0"></a><a id="Tc_rSADLfnsPUaaATImgMUZfg_4_0"></a><a id="Tc_eS2KZmEFLke5oHOVPDhJ-g_4_2"></a><a id="Tc_jtESEeTOH022KoTwVorjjw_4_3"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_z9PSXDPdPEGKwG_KeIS6eQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;11: FAIR VALUE MEASUREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA" contextRef="As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_6rIYtBDvXkWwMbdZz0ya6A">8</ix:nonFraction> per share upon closing of the IPO. As such, an expense of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="Narr_jr9JRiK3Q06ncNR3voONwg">89,000</ix:nonFraction> was recorded in the first quarter of 2021.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_BKq6xbIm-0iKkn7-yr7X7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the three months ended March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance at January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions during the quarter ended March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_QFgD0fWl90Gi6-5_j7HNaQ_2_3">89</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer out of Level 3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" scale="3" id="Tc_gFgBG1bd7k2RORxOEk-2GA_3_3">89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_7XGkMaXjh0KiYEqadqccNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 12: SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 10, 2021, the Company appointed Leanne M. Kelly to serve as its Chief Financial Officer, and principal financial and accounting officer. In connection with Ms. Kelly&#8217;s appointment, the Company entered into an employment agreement with Ms. Kelly (the &#8220;Kelly Agreement&#8221;), which provides for an initial base annual salary of $<ix:nonFraction unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" scale="0" id="Narr_hBkuDYTmeUKD2YM8Ddts3Q">275,000</ix:nonFraction> and a target bonus opportunity equal to <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_K8OayvzVWk6w7L3GnwtAdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_vaVbToZ7eEK4igaud0CtLQ">35</ix:nonFraction>%<span style="white-space:pre-wrap;"> of her base salary.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Kelly Agreement also provides that the Company will recommend that the Board approve a stock option grant covering <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_99MbGdLZZ06ZDQEAKCqSSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" id="Narr_yn-8_tLI80GqfhM6mPYKHg">100,000</ix:nonFraction><span style="white-space:pre-wrap;"> common shares of the Company (the &#8220;Stock Option&#8221;).  The Stock Option shall have an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant and shall vest in installments and become exercisable as follows: (i) </span><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7RrpN30090e56LLSpDLmkw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_fqhacwp0TEyRbsg8Gj4rMA">70</ix:nonFraction>% of the shares underlying the Stock Option shall vest as follows: (x) <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnFirstAnniversaryOfStartDateMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_XJA5MW80TUen-MTCbD2nKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" id="Narr_WbxtFkbTkEmxNvyZ0jvrQg">17,500</ix:nonFraction> option shares on the first anniversary of her start date, and (y) the remaining <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qHpeFWSKRU6tDNBCRoCPWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" id="Narr_vN4w1RKSsEGPkaveAdUfTA">52,500</ix:nonFraction> option shares in equal installments on a quarterly basis for the next three years, in each case subject to continued employment, and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Nu0HlaQrV0STf4cE6gIghA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_hvqUdhQL8kaB6vKzbbsOZg">30</ix:nonFraction>% of the shares underlying the Stock Option shall vest as follows: (x) <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GnqWo_CEXEeAcNENJ-Sk8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" id="Narr_Foimo3ERKkOO7rO3VttvDA">15,000</ix:nonFraction> option shares on the date the Company submits a New Drug Application (&#8220;NDA&#8221;) filing for ADAIR with the U.S. Food &amp; Drug Administration, and (y) <ix:nonFraction unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg" contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XY59mQ4yF0SnWeexPPyTCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" id="Narr_zelhPukZik6mbHwxVfvHPA">15,000</ix:nonFraction> option shares on the date when the U.S. Food &amp; Drug Administration approves the NDA, provided that she is employed by the Company at the time the applicable performance objective is achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Kelly Agreement provides that if she is terminated by the Company other than for cause, or she resigns for good reason, in either case not in connection with a change in control, she will receive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">continued base salary for a period of </span><ix:nonNumeric contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw" format="ixt-sec:durmonth" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" id="Narr_x3oJfwgU_UOjPcfJoUNk3A"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">9</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided she was employed for at least </span><ix:nonNumeric contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" id="Narr_ks_fxv6tx0uUQk4WY8h7Mg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">six months</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> during that year; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><ix:nonNumeric contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw" format="ixt-sec:durmonth" name="vlon:CobraHealthInsuranceCoveragePeriod" id="Narr_e48YLbQIQUKNkiSKqzHrmg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">9</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If she is terminated by the Company other than for cause, or she resigns for good reason, in either case within the one-year period commencing on a change in control, she will receive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">continued base salary for a period of </span><ix:nonNumeric contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q" format="ixt-sec:durmonth" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" id="Narr_BAsEqfSXSEyRCm_yxucMnw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">12</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months, plus a lump sum payment equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g" contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_01brJRbFo0iAtrB0lf6StQ">100</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> of her target bonus, without proration, for the fiscal year of termination;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><ix:nonNumeric contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q" format="ixt-sec:durmonth" name="vlon:CobraHealthInsuranceCoveragePeriod" id="Narr_FSfC6HPeXkyLlBrmi90Exg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">12</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.  </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In exchange for the severance benefits described above, Ms. Kelly must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company.  The description of the terms above are qualified in their entirety by reference to the Kelly Agreement, a copy of which is filed by the Company as Exhibit&#160;10.2 to this Quarterly Report on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See description of the Baker Agreement under Note 10 &#8211; Employment Agreements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2d29da71_9891_44f2_a610_5c69c02c404f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial statements (and notes thereto), and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December 31, 2020, included in our Annual Report on Form 10-K that was filed with the SEC on March 29, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. Our only clinical-stage product currently under development is ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of Attention-deficit/hyperactivity disorder (&#8220;<i style="font-style:italic;">ADHD</i>&#8221;), and Narcolepsy. In the future, we plan to develop other abuse-deterrent products that have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which we are conducting formulation development work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ADAIR assets were acquired by us on June&#160;22, 2018 pursuant to the terms and conditions of the Amended and Restated Asset Purchase Agreement with Arcturus Therapeutics, Inc. (the successor to Arcturus Therapeutics Ltd.), referred to herein collectively as Arcturus, and Amiservice Development Ltd., dated as of June&#160;22, 2018 (the &#8220;<i style="font-style:italic;">Asset Purchase Agreement</i>&#8221;). In exchange for the ADAIR assets, we issued 843,750 shares of our common stock to Arcturus (valued at approximately $1.4&#160;million based upon the price at which the common stock was issued and sold in the June 2018 private placement of our common stock) which comprised 30% of our then-outstanding common stock on a fully diluted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to develop ADAIR for registration through the Section&#160;505(b)(2) approval pathway. We filed our Investigational New Drug (&#8220;<i style="font-style:italic;">IND</i>&#8221;), application for ADAIR in June&#160;2018 and the IND was cleared in July&#160;2018. Subsequently, we have successfully completed a Phase&#160;1 pivotal bioequivalence study of ADAIR and a Phase&#160;1 food effect study. In 2019, we conducted a Phase&#160;1 proof-of-concept intranasal human abuse potential study designed to compare ADAIR when insufflated (snorted) to the reference comparator, crushed immediate release dextroamphetamine sulfate tablets. We began enrollment of subjects in a pivotal intranasal abuse study during the fourth quarter of 2020 and expect to have topline results for the study by the end of 2021. We are also currently conducting a 13-week preclinical toxicology study on the final formulation of ADAIR and have begun planning additional non-clinical safety studies during 2021. We also plan to conduct additional preclinical studies of unintended routes of administration such as IV and intranasal administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to develop other abuse-deterrent products that have potential for abuse in their current forms, beginning with the development of an abuse deterrent formulation of Ritalin (&#8220;<i style="font-style:italic;">ADMIR</i>&#8221;), for which we are conducting formulation development work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January&#160;6, 2020, we entered into a license agreement with Medice, who is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice currently markets several ADHD products in Europe and is the ADHD market leader in Europe based on branded prescription market share. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid us a minimal upfront payment and will pay milestone payments of up to $6.3&#160;million in the aggregate upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five&#160;years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our objective is to develop and commercialize proprietary biopharmaceutical products. To this effect, we intend to develop and seek marketing approvals from the FDA and other worldwide regulatory bodies for ADAIR, and any other products we opt to pursue in the future, such as ADMIR. To achieve these objectives, we plan to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">seek the necessary regulatory approvals to complete the clinical development of ADAIR for the treatment of ADHD and, if successful, file for marketing approval in the United States and other territories;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">prepare to commercialize ADAIR by establishing independent distribution capabilities or in conjunction with other biopharmaceutical companies in the United States and other key markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">commence development of other abuse-deterrent products such as ADMIR; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">continue our business development activities and seek partnering, licensing, merger and acquisition opportunities or other transactions to further develop our pipeline and drug-development capabilities and take advantage of our financial resources for the benefit of increasing stockholder value.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221; For as long as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation, and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation in the assessment of our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). We will remain an emerging growth company until the earliest of (i)&#160;the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the end of the second fiscal quarter, (ii)&#160;the end of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more during such fiscal year, (iii)&#160;the date on which we issue more than $1&#160;billion in non-convertible debt in a three-year period, or (iv)&#160;the end of the fiscal year following the fifth anniversary of the date of the first sale of our Common Stock pursuant to an effective registration statement filed under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The global COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely, including the worldwide vaccine rollout and the recent outbreaks of various strains of the virus. The full impact of the COVID-19 pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its future impact on our clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 10, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware, which effected a one-for-40 reverse stock split (the &#8220;<i style="font-style:italic;">reverse split</i>&#8221;) of its issued and outstanding shares of common stock at 11:59 PM Eastern Time on that date. As a result of the reverse split, every 40 shares of common stock issued and outstanding were reclassified into one share of common stock. No fractional shares were issued in connection with the reverse split and any fractional shares were rounded up to the nearest whole share.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The reverse split did not change the par value of the common stock or the authorized number of shares of common stock. The reverse split affected all stockholders uniformly and did not alter any stockholder&#8217;s percentage interest in equity. All outstanding options and other securities entitling their holders to purchase or otherwise receive shares of common stock have been adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company&#8217;s 2018 Equity Incentive Plan have also been appropriately adjusted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All share and per share amounts, excluding the number of authorized shares and par value, contained in this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering (&#8220;IPO&#8221;); Underwriting Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As previously disclosed, on February 12, 2021, we consummated the initial public offering of our common stock through which we sold 2,250,000 shares of our common stock for total gross proceeds of $18.0 million, resulting in net proceeds of approximately $15.5 million after deducting $1.6 million in underwriter&#8217;s discounts, expenses and commissions, and $905,000 of other expenses incurred in connection with the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the closing of the IPO, we also issued warrants to purchase an aggregate of 112,500 shares of common stock to certain of the underwriter&#8217;s affiliates. Such warrants may be exercised beginning on August 11, 2021 (180 days from the commencement of sales of the IPO) until February 12, 2026 (five years after the commencement of sales in the IPO).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2021 Convertible Note Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 11, 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (&#8220;Salmon Pharma&#8221;), an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the &#8220;2021 Convertible Notes&#8221;) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a &#8220;Qualified Financing&#8221;), and were convertible at a twenty percent (20%) discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the initial public offering of our common stock, consummated on February 12, 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Operations Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any significant revenue, and we do not expect to generate any revenue from the sale of any products unless or until we obtain regulatory approval of and commercialize ADAIR. The only revenue we have generated was the $100,000 license fee from the Medice license agreement recognized in the three months ended March 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our incorporation, our operations have primarily been limited to building our management and corporate team, acquiring the ADAIR assets from Arcturus and conducting our clinical program for ADAIR. Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our research and development expenses have consisted primarily of in-process research and development expenses which consisted of non-cash costs acquiring the ADAIR assets of $1.7&#160;million, costs incurred in preparing for and conducting the development program for ADAIR, working on commercial manufacturing of ADAIR and developing formulations for ADMIR. We expect to significantly increase our research and development efforts by conducting the remaining studies necessary for the development and approval of ADAIR and for preparing for commercial supplies of the product. Future research and development expenses may include:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">employee -related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, share-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">expenses incurred under agreements with contract research organizations (<span style="font-family:'Symbol';">&#8220;</span>CROs<span style="font-family:'Symbol';">&#8221;</span>), as well as consultants that support the implementation of the clinical and non-clinical studies described above;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">formulation, research and development expenses related to ADMIR; and other products we may choose to develop; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">costs for sponsored research.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development activities will continue to be central to our business model. Products in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to be significant over the next several&#160;years as we increase personnel and compensation costs and conduct the studies described above, and prepare to seek regulatory approval for ADAIR and any other future product, such as ADMIR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The duration, costs and timing of clinical trials of ADAIR and any other future product, such as ADMIR, will depend on a variety of factors that include, but are not limited to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of trials required for approval;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the per patient trial costs;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of patients that participate in the trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of sites included in the trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the countries in which the trial is conducted;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the length of time required to enroll eligible patients;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of doses that patients receive;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the drop-out or discontinuation rates of patients;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the potential additional safety monitoring or other studies requested by regulatory agencies;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the duration of patient follow-up;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the timing and receipt of regulatory approvals; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the efficacy and safety profile of our product candidates.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the probability of success for ADAIR and any other future products, such as ADMIR, will depend on numerous factors, including competition, manufacturing capability and commercial viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to our formation and corporate matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of personnel, including compensation and employee-related expenses, including stock-based compensation, and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs. In addition, if ADAIR obtains regulatory approval for marketing, we expect that we would incur expenses associated with building a commercialization team if we have not sold or licensed the rights to commercialize ADAIR to a third party in territories not under the license agreement with Medice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Expense and Revaluation of Derivative Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement pursuant to which we issued $350,000 in 2021 Convertible Notes The 2021 Convertible Notes automatically converted into 54,906 shares of our common stock concurrently with the closing of the IPO. We identified the mandatory conversion into shares our common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. We evaluated the fair value of the derivative liability at issuance. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s critical accounting policies are described in Note B, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 29, 2021. There have been no material changes to the significant accounting policies during the period ended March 31, 2021, except for items mentioned in Note 2 of the financial statements in this Quarterly Report on Form 10-Q.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the three months ended March&#160;31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the results of our operations for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change $</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License revenue-from related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,772</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 883</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 889</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 830</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 455</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,602</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,258</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,344</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,602)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,158)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,444</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revaluation of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (89)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (89)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,638)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,160)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,478</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Revenue &#8211; From Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We determined there is a single performance obligation with respect to our involvement in the joint development committee in regards to the Medice license agreement and thus the entire $100,000 allocable consideration was assigned to that accounting unit and recognized in the first quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by approximately $889,000 to $1.8 million from $883,000 for the three months ended March 31, 2020 to the three months ended March 31, 2021. The increase in research and development expenses was primarily due to increases of: $1.0 million primarily related to the registration development program of ADAIR offset by decreases of&#160;$77,000 related to the formulation work for ADMIR. In the three months ended March 31, 2020 we had expensed $60,000 for the estimate of costs to complete the services related to the Medice license agreement and the amortization of that in the first quarter of 2021 was $3,000, thus resulting in a decrease in research and development expense of $57,000 for the three months ended March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by approximately $455,000 to $830,000 from $375,000 the three months ended March 31, 2020 to the three months ended March 31, 2021. The increase was primarily related to increased costs for directors and officers insurance of $200,000, non-cash stock compensation of $148,000, consultant related expenses of $51,000 and brand development of $25,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the note along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revaluation of Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2021, pursuant to ASC-815, we revalued the embedded derivative liability associated with the Convertible Notes, resulting in $89,000 in the fair value of the derivative liability associated with the Convertible Notes.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2021 and 2020, respectively, no income tax expense or benefit was recognized. Our deferred tax assets are comprised primarily of net operating loss carryforwards. We maintain a full valuation allowance on our deferred tax assets since we have not yet achieved sustained profitable operations. As a result, we have not recorded any income tax benefit since our inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recorded $2.6 million in net loss for the three months ended March 31, 2021, as compared to $1.2 million in net loss during the three months ended March 31, 2020. The increase in net loss was primarily due to increases of $889,000 in research and development expenses and $445,000 in general and administrative expenses and a decrease in licensing revenue of $100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the period from January&#160;11, 2018 (inception) through March 31, 2021, we have an accumulated deficit of $15.2 million and we do not expect to have positive cash flow from operations for the foreseeable future. As of March 31, 2021, we had cash and cash equivalents of $13.0 million which management expects will provide funding for our ongoing business activities into the third quarter of 2022; however, we have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect therefore there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for, and successfully commercialize ADAIR, or any other future products, including ADMIR. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of planned clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">conduct clinical trials and non-clinical studies;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">scale up manufacturing capabilities with third-party contract manufacturer(s);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">conduct ongoing stability studies of ADAIR;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">seek to identify, acquire, develop and commercialize additional products, such as ADMIR;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">integrate acquired technologies into a comprehensive regulatory and product development strategy;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">maintain, expand and protect our intellectual property portfolio;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">hire scientific, clinical, quality control and administrative personnel;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">seek regulatory approvals for any products that successfully complete clinical trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates for which we may obtain regulatory approval, including through the license agreement with Medice; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">operate as a public company.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,948)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (766)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,819</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,871</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (797)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March&#160;31, 2021 and 2020, $2.9 million and $766,000 were used in operating activities, respectively. The $2.2 million increase was primarily due to the $1.5 million increase in our net loss offset by a $793,000 increase in prepaid expenses and increased accounts payable and accrued expenses of $259,000. The net loss for the three months ended March 31, 2021 included non-cash expenses of $168,000 in non-cash stock compensation, $89,000 in revaluation of derivative liability and $18,000 amortization of finance lease right-of-use asset offset by $61,000 of other income from the forgiveness of the PPP note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $0 for the three months ended March 31, 2021 and $2,000 for the three months ended March 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $15.8 million during the three months ended March 31, 2021 related to the net proceeds from our IPO and 2021 Convertible Notes financings compared to $29,000 used in financing activities during the three months ended March 31, 2020 related to our finance lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contractual Obligations and Other Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2021, there have been no changes to our contractual obligations and commitments since December&#160;31, 2020. For a discussion of our contractual obligations, see &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report on Form 10K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">reduced disclosure about our executive compensation arrangements;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the our IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c0c95628_e5ea_4e9e_aee8_b3b12b2c6b24"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable to a smaller reporting company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_061cbef1_c6c1_4053_b6f8_0f88b2ad006e"></a><a id="Item4ControlsandProcedures_714742"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. Controls and Procedures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Chief Executive Officer evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2021. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the evaluation of our disclosure controls and procedures as of March 31, 2021, our Chief Executive Officer has concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are taking actions to remediate the material weaknesses relating to our internal controls over financial reporting as described in our Annual Report on Form 10-K. Except as otherwise disclosed herein, there have been no changes in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ccbfb9cd_3773_4104_9647_411735e0bca3"></a><a id="PARTIIOTHERINFORMATION_180828"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II&#8212;OTHER INFORMATION</b></p><a id="Item1LegalProceedings_857108"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1. Legal Proceedings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us because of defense and settlement costs, diversion of management resources, and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_dd92f180_d92e_4482_b48c_e09b0e747051"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item1ARiskFactors_712957"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, except as set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. The COVID-19 pandemic continues affect the U.S. and global economies and may affect our operations and certain other third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical trials. Moreover, the COVID-19 pandemic may adversely affect the operations of the FDA and other health authorities, resulting in delays of reviews and approvals with respect to our product candidates. While the potential economic impact brought by, and the duration of the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the loss of any of our employees as a result of COVID-19, or another pandemic, may adversely affect our operations. The ultimate impact of the COVID-19 pandemic is highly uncertain, and we do not yet know the full extent of potential delays or impacts that COVID-19 may have on our business, financing or clinical trial activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Some examples of potential disruptions that may result from the COVID-19 pandemic, include, but are not limited to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">delays or difficulties in enrolling patients in our clinical trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors, including any delays caused by the COVID-19 outbreak;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The COVID-19 global pandemic continues to rapidly evolve. The extent to which the outbreak may affect our clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States, and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, and the ongoing worldwide vaccine rollout. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_5f457873_5db6_4982_8f4b_6a62521c6f14"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d2c355f9_814a_45c1_bc30_f8237d3528c6"></a><a id="Item3DefaultsUponSeniorSecurities_543697"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3. Defaults Upon Senior Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_175788fa_8da3_474c_969e_464bf5f351a2"></a><a id="Item4MineSafetyDisclosures_801779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. Mine Safety Disclosures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c088cc5b_9ab6_462a_b316_1dc87f6c781e"></a><a id="Item5OtherInformation_198066"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5. Other Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0f63fa20_aa31_41c4_ba63_fed63dfe9b2e"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Item6Exhibits_259311"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 6. Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d3fa2f3d_1a10_45a5_ba68_7c0c5a4418a2"></a><a id="_d37f33ec_4ed2_442c_877a_0f23a6157e5a"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></td><td style="vertical-align:bottom;width:2.29%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:89.52%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1#</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement, dated as of April 20, 2021, by and between the Company and David Baker</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2#</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement, dated as of May 10, 2021, by and between the Company and Leanne M. Kelly</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="vlon-20210331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 2pt 0pt;">Unless otherwise indicated, exhibits are filed herewith.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;">Indicates a management contract or any compensatory plan, contract or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_48eae8e4_3230_4141_b78a_de9d4f510923"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:27.35pt;min-height:8.65pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_79392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VALLON PHARMACEUTICALS, INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2021</p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Baker</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: David Baker</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>vlon-20210331xex10d1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This EMPLOYMENT AGREEMENT (this &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:12pt;">&#8221;) is made as of the 20th day of April, 2021 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date</u><font style="font-size:12pt;">&#8221;), between Vallon Pharmaceuticals, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;) and David Baker (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive</u><font style="font-size:12pt;">&#8221;). &#160;In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Employment Term</b><font style="font-size:12pt;">. The Company shall continue to employ Executive, and Executive accepts continued employment with the Company, upon the terms and subject to the conditions set forth in this Agreement, for the period beginning on the Effective Date and ending on the Date of Termination (as defined in Section 4(e) of this Agreement) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Term</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Terms of Employment</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Position and Duties</u><font style="font-size:12pt;">. During the Term, Executive shall be employed by the Company as President and Chief Executive Officer and shall have such duties, responsibilities and authorities as are customarily associated with his position (including, but not limited to, the general management of the affairs of the Company) and such additional duties and responsibilities consistent with his positions as may, from time to time, be properly and lawfully assigned to him. &#160;Executive shall report directly to the Board of Directors of the Company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Board</u><font style="font-size:12pt;">&#8221;). &#160;Executive shall act at all times in compliance in all respects with the policies, rules and decisions adopted from time to time by the Company and perform all of the duties and obligations required of him by this Agreement in a loyal and conscientious manner.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Board Service</u><font style="font-size:12pt;">. During the Term, the Company shall cause the Nominating and Corporate Governance Committee of the Board or its equivalent (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Nominating Committee</u><font style="font-size:12pt;">&#8221;) to nominate Executive to serve as a member of the Board each year Executive&#8217;s term of Board service is to be slated for reelection to the Board. If, during the Term, the Company&#8217;s stockholders vote in favor of the Nominating Committee&#8217;s nomination of Executive to serve as a member of the Board, Executive agrees to serve in such capacity and also agrees that any such Board service shall be without additional compensation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Engaging in Other Activities</u><font style="font-size:12pt;">. During the Term, Executive shall devote his full time and attention to the Company and its affiliates and shall not be employed by or provide services to any other person or entity, except that Executive shall be permitted to provide services to any person or entity with permission of the Board or its Chairperson. During the Term, it shall not be a violation of this Agreement for Executive, subject to the requirements of Section 8 hereof, to (i) serve on civic, charitable or religious boards or engage in other activities for such organizations, (ii) with the consent of the Board, which consent shall not be unreasonably withheld, serve on up to two corporate boards unrelated to the Company (and retain all compensation in whatever form for such service), and (iii) manage personal investments, so long as such activities (individually or in the aggregate) do not interfere with the performance of Executive&#8217;s responsibilities as set forth in Sections 2(a) or 2(b) of this Agreement or Executive&#8217;s fiduciary duties to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Location</u><font style="font-size:12pt;">. Executive shall perform his duties and responsibilities hereunder principally at the Company&#8217;s corporate headquarters; provided that Executive may be required under reasonable business circumstances to travel outside of such location in connection with performing his duties under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Affiliates</u><font style="font-size:12pt;">. Executive agrees to serve, without additional compensation, as an officer and director of each of the other members of the Company&#8217;s affiliates, as determined by the Company. &#160;As used in this Agreement, the term &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">affiliate</u><font style="font-size:12pt;">&#8221; shall mean any entity controlled by, controlling, or under common control with, the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;"> </font><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3. </b></font><b style="font-size:12pt;font-weight:bold;">Compensation and Benefits</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Base Salary</u><font style="font-size:12pt;">. During the Term, the Company shall pay Executive an annualized base salary (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Annual Base Salary</u><font style="font-size:12pt;">&#8221;) of $400,000, payable in regular installments in accordance with the Company&#8217;s normal payroll practices. &#160;During the Term, the Annual Base Salary shall be reviewed by the Board or a committee thereof at such time as the salaries of other senior executives of the Company are reviewed generally, but no less frequently than once a year. &#160;The Annual Base Salary shall not be reduced other than in connection with an across-the-board salary reduction which applies in a comparable manner to other senior executives of the Company. &#160;If so increased or reduced, then such adjusted salary will thereafter be the Annual Base Salary for all purposes under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Annual Incentives</u><font style="font-size:12pt;">. For each fiscal year during the Term, Executive shall be eligible to participate in an annual bonus plan under terms and conditions no less favorable than other senior executives of the Company; provided that Executive&#8217;s target annual bonus opportunity shall be 50% of his Annual Base Salary (or such higher amount as determined by the Board or a committee thereof from time to time) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Target Annual Incentive</u><font style="font-size:12pt;">&#8221;). &#160;Executive&#8217;s payment under the annual bonus plan shall be based on the extent to which the performance objectives established by the Board or a committee thereof have been achieved; such objectives shall be established in consultation with Executive and communicated to him by the end of January of the applicable year. &#160;Unless a different payment date is established in the bonus plan by the Company, the bonus payment shall be made in a single lump sum within two and one-half months following the end of the Company&#8217;s fiscal year. &#160;Except as set forth in Section 5(b) or 5(c) below, Executive must be employed on the last day of the fiscal year to receive payment of any annual bonus earned for that fiscal year. &#160;Nothing contained in this Section 3(b) will guarantee Executive any specific amount of bonus compensation or prevent the Company from establishing performance goals and targets applicable only to Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">PTO</u><font style="font-size:12pt;">. During the Term, Executive shall be eligible for at least four (4) weeks paid time off (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">PTO</u><font style="font-size:12pt;">&#8221;) per year in accordance with the Company&#8217;s policies in effect from time to time for its senior vice presidents generally. &#160;Executive may carry over up to one (1) week of unused PTO into the next following year only.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Expense Reimbursement</u><font style="font-size:12pt;">. Executive shall be reimbursed for all reasonable travel and other out-of-pocket expenses actually and properly incurred by Executive prior to and during the Term in connection with carrying out his duties hereunder in accordance with the Company&#8217;s policies in effect from time to time for its senior executives generally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Benefits</u><font style="font-size:12pt;">. During the Term, and except as otherwise provided in this Agreement, Executive shall be eligible to participate in all welfare, perquisite, fringe benefit, insurance, retirement and other benefit plans, practices, policies and programs, maintained by the Company and its affiliates applicable to senior executives of the Company generally, in each case as amended from time to time, including a car allowance of $500 per month, a life insurance benefit equal to two times his Annual Base Salary, timely replacement of, and reimbursement of monthly charges related to, telephone and computer equipment reasonably required by Executive to perform his duties hereunder, and membership in one airline club. &#160;In addition, during the Term, to the extent the Company maintains a Simple IRA or a 401(k) plan, it shall match Executive&#8217;s elective deferrals thereunder on a dollar-for-dollar basis (i.e., one dollar matched by the Company for each dollar of elective deferral by Executive) up to 3% of Executive&#8217;s Annual Base Salary, subject to applicable IRS limits. &#160;The Company shall also purchase short and long term disability coverage for Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Termination of Employment</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Death and Disability</u><font style="font-size:12pt;">. Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death. &#160;If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Term, it may give to Executive written notice in accordance with Section 11 of this Agreement of its intention to terminate Executive&#8217;s employment; provided that (i) such notice is provided no later than 150 calendar days following the determination of Executive&#8217;s Disability, and (ii) Executive has not returned to full-time employment during the period between such determination and the giving of such notice. &#160;In such event, Executive&#8217;s employment shall terminate effective on the 30th calendar day after receipt of such notice by Executive (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disability Effective Date</u><font style="font-size:12pt;">&#8221;), provided that, within the 30 calendar days after such receipt, Executive shall not have returned to full-time performance of Executive&#8217;s duties. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disability</u><font style="font-size:12pt;">&#8221; shall mean the inability of Executive to perform the essential duties of the position held by Executive by reason of any medically determined physical or mental impairment that is reasonably expected to result in death or lasts for 120 calendar days in any one-year period, all as determined by an independent licensed physician mutually acceptable to the Company and Executive or Executive&#8217;s legal representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cause</u><font style="font-size:12pt;">. Executive&#8217;s employment with the Company may be terminated by the Company with or without Cause. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cause</u><font style="font-size:12pt;">&#8221; shall mean: &#160;(i) the continued failure of Executive to perform Executive&#8217;s duties as set forth in Section 2 hereof or Executive&#8217;s material disregard of the reasonable and lawful directives of the Company (in each case other than any such failure resulting from any medically determined physical or mental impairment) that is not cured by Executive within 20 calendar days after a written demand for performance is delivered to Executive by the Company which specifically identifies the manner in which the Company believes that Executive has not performed Executive&#8217;s duties or disregarded a directive of the Board; (ii) Executive&#8217;s commission of any material act of fraud, misappropriation or embezzlement against or in connection with the Company or any of its affiliates or their respective businesses or operations; (iii) Executive&#8217;s commission of, or indictment for or otherwise being formally charged with, any crime involving dishonesty or for any felony; (iv) the engaging by Executive in misconduct that is materially detrimental to the financial condition or business reputation of the Company or any of its affiliates, including due to any adverse publicity; or (v) a material breach by Executive of his obligations under Section 8,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">or his representations under Section 9, of this Agreement. In addition to the notice and opportunity to cure set forth in subsection (i) above, to the extent that any of the grounds set forth in subsections (ii), (iv) or (v) above is capable of being cured, the Company shall not have Cause unless it has furnished Executive with written notice specifically identifying the conduct &#160;allegedly giving rise to Cause, and he has failed to cure such ground within 20 days of the delivery of such notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason</u><font style="font-size:12pt;">. Executive&#8217;s employment with the Company may be terminated by Executive with or without Good Reason. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason</u><font style="font-size:12pt;">&#8221; shall mean the occurrence of any of the following without Executive&#8217;s consent: (i) a material reduction by the Company of Executive&#8217;s title, duties, responsibilities, authority or reporting relationship set forth in Section 2(a); provided that the loss of the title of &#8220;President&#8221;, or the loss of the responsibility of &#8220;principal financial officer&#8221; (either individually or in the aggregate) will not, in and of itself, constitute Good Reason if the individual who is appointed to the position of President, or who assumes the responsibility of &#8220;principal financial officer&#8221;, reports directly or indirectly to Executive; (ii) a material reduction by the Company of Executive&#8217;s Annual Base Salary (other than as provided in Section 3(a) of this Agreement); (iii) a material breach of the Company of this Agreement or of any other agreement between Executive and the Company; or (iv) a material change in geographic location at which Executive must principally perform services under this Agreement from the Company&#8217;s offices at which Executive was principally employed (the Company has determined that a relocation of more than 25 miles would constitute such a material change). &#160;A termination of Executive&#8217;s employment by Executive under Sections 4(c)(i), (ii),(iii) or (iv) shall not be deemed to be for Good Reason unless (x) Executive gives notice to the Company of the existence of the event or condition constituting Good Reason within 30 calendar days after becoming aware of the initial occurrence or existence of such event or condition, and (y) the Company fails to cure such event or condition within 30 calendar days after receiving such notice. &#160;Additionally, Executive must terminate his employment within 90 calendar days after the initial occurrence of the circumstance constituting Good Reason for such termination to be &#8220;Good Reason&#8221; hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:12pt;">. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party in accordance with Section 11. &#160;For purposes of this Agreement, a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:12pt;">&#8221; means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Termination</u><font style="font-size:12pt;">. &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Termination</u><font style="font-size:12pt;">&#8221; means, as applicable, the date of Executive&#8217;s death, the Disability Effective Date, or the date on which the termination of Executive&#8217;s employment by the Company for Cause or without Cause or by Executive for Good Reason or without Good Reason is effective.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Resignation from All Positions</u><font style="font-size:12pt;">. Notwithstanding any other provision of this Agreement, upon the termination of Executive&#8217;s employment for any reason, unless otherwise requested by the Board, Executive shall immediately resign from all positions that he holds or has</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ever held with the Company and its affiliates, including the Board and the boards of directors or committees of the Company&#8217;s affiliates. &#160;Executive hereby agrees to execute any and all documentation to effectuate such resignations upon request by the Company, but he shall be treated for all purposes as having so resigned upon termination of his employment, regardless of when or whether he executes any such documentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Severance Payments</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Any Termination of Employment</u><font style="font-size:12pt;">. If, during or at the expiration of the Term, Executive&#8217;s employment with the Company and its affiliates shall terminate for any reason or no reason, then:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accrued Benefits</u><font style="font-size:12pt;">. The Company shall pay, or cause to be paid, to Executive the sum of: &#160;(A) the portion of Executive&#8217;s Annual Base Salary earned through the Date of Termination, to the extent not previously paid, (B) the amount of any annual bonus that has been earned by Executive for a completed fiscal year or other measuring period preceding the Date of Termination, but has not yet been paid to Executive, and (C) any unreimbursed business expenses to the extent reimbursable in accordance with the Company&#8217;s reimbursement policies (the sum of the amounts described in clauses (A) through and including (C) shall be referred to as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accrued Benefits</u><font style="font-size:12pt;">&#8221;). The Accrued Benefits shall be paid to Executive in a single lump sum within 30 calendar days after the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Benefits</u><font style="font-size:12pt;">. To the extent not previously paid or provided, the Company shall pay or provide, or cause to be paid or provided, to Executive (or his estate) any other amounts or benefits (including, as applicable, any payment of long-term incentive awards) required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company, including any benefits to which Executive is entitled under the Consolidated Omnibus Budget Reconciliation Act (such other amounts and benefits described in this Section 5(a)(ii) shall be hereinafter referred to as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Benefits</u><font style="font-size:12pt;">&#8221;) in accordance with the terms and normal procedures of each such plan, program, policy or practice or contract or agreement, based on accrued and vested benefits through the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason, Other than for Cause (not During the Change in Control Protection Period)</u><font style="font-size:12pt;">. If, during the Term (other than during the Change in Control Protection Period, as defined below), the Company shall terminate Executive&#8217;s employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the following amounts and benefits to Executive:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severance</u><font style="font-size:12pt;">. The Company shall continue to pay to Executive the Annual Base Salary, as of the Date of Termination, for the period beginning on the Date of Termination and ending 12 months thereafter (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severance Period</u><font style="font-size:12pt;">&#8221;), which shall be payable over the Severance Period in regular installments in accordance with the Company&#8217;s normal payroll practices as they may exist from time to time, with the installments that otherwise would be paid prior to the first payroll date following the date the Release described in Section 6 becomes</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">effective and irrevocable in accordance with its terms (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release Effective Date</u><font style="font-size:12pt;">&#8221;) being paid (without interest) on such payroll date in a lump sum and the remaining installments being paid as otherwise scheduled assuming payments had begun immediately after the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Continued Health Insurance</u><font style="font-size:12pt;">. If Executive elects COBRA coverage under the applicable medical and dental plans of the Company, the Company will subsidize a portion of the applicable monthly COBRA premium during the Severance Period, so that Executive will only be required to pay the premiums applicable to continuing employees during that time; provided that such subsidy shall cease on the date on which Executive becomes eligible for medical and dental coverage from a third party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Pro-Rated Annual Incentive</u><font style="font-size:12pt;">. Executive will be eligible to receive an annual incentive under the annual bonus plan for the fiscal year during which the Date of Termination occurs, based on actual performance results during the entire fiscal year and without regard to any discretionary adjustments that have the effect of reducing the amount of the annual incentive (other than discretionary adjustments applicable to all senior executives who did not terminate employment), pro-rated based on the number of days in the Company&#8217;s fiscal year through (and including) the Date of Termination (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Pro-Rated Annual Incentive</u><font style="font-size:12pt;">&#8221;), which, if earned, shall be payable in a single lump sum at the same time that payments are made to other participants in the annual bonus plan for that fiscal year; provided, however, that Executive shall be entitled to such a Pro-Rated Annual Incentive only if Executive was employed by the Company for at least six months during the fiscal year in which the Date of Termination occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason, Other than for Cause During the Change in Control Protection Period</u><font style="font-size:12pt;">. If, during the Term and during the period beginning upon the occurrence of a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change in Control</u><font style="font-size:12pt;">&#8221; (as defined in the Company&#8217;s 2018 Equity Incentive Plan) and ending on the first anniversary of the occurrence of the Change in Control (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change in Control Protection Period</u><font style="font-size:12pt;">&#8221;), the Company shall terminate Executive&#8217;s employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the following amounts and benefits to Executive:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Enhancements</u><font style="font-size:12pt;">. The Company shall pay or provide, or cause to be paid or provided, to Executive the payments and benefits set forth in Section 5(b)(i) and (ii) above (but not Section 5(b)(iii) above), provided that when applying those provisions, the Severance Period shall mean the period beginning on the Date of Termination and ending 18 months thereafter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Target Annual Incentive</u><font style="font-size:12pt;">. In lieu of (and not in duplication of) the Pro-Rated Annual Incentive set forth in Section 5(b)(iii) above, Executive shall be entitled to receive an amount equal to the product of (x) 1.50 and (y) his Target Annual Incentive for the fiscal year in which the Date of Termination occurs, without pro-ration (and even if the Date of Termination occurs within the first 6 months of the fiscal year), which amount shall be paid to Executive within 15 business days after the Release Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Equity</u><font style="font-size:12pt;">. Notwithstanding anything contained in the applicable Company equity plan and award agreements to the contrary, all outstanding and unvested equity awards of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the Company granted to Executive shall become immediately vested and exercisable; provided that any such awards the vesting of which depends upon the achievement of performance objectives shall vest at the &#8220;target&#8221; achievement level for each performance objective. In addition, all outstanding and vested Company stock options (including those that vest pursuant to the operation of the immediately preceding sentence) will remain exercisable for the full duration of their term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 280G</u><font style="font-size:12pt;">. Notwithstanding anything in this Agreement to the contrary, in the event it shall be determined that any accrual, acceleration, payment, benefit or distribution by the Company or any of its affiliated companies to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Payment</u><font style="font-size:12pt;">&#8221;) would be an excess parachute payment within the meaning of section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Code</u><font style="font-size:12pt;">&#8221;) (such excess only, an &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Excess Payment</u><font style="font-size:12pt;">&#8221;), then Executive shall forfeit all Excess Payments if the after-tax value to Executive of the Payments, as reduced by such forfeiture, would be greater than the after-tax value to Executive of the Payments absent such forfeiture. The forfeiture of Excess Payments, if applicable, shall be applied to the severance described in Section 5(c) hereof, then to cancellation of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), then to cancellation of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and then to any other Payments on a pro-rata basis. &#160;All determinations required to be made under this Section 5(d), including whether and when a Payment is subject to section 280G of the Code, and the value of a Payment for purposes of section 280G of the Code, and the assumptions to be utilized in arriving at such determination, shall be made by an accounting firm with expertise in such matters designated by the Company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accounting Firm</u><font style="font-size:12pt;">&#8221;). &#160;The Company will direct the Accounting Firm to provide its determination and detailed supporting calculations both to the Company and Executive within 15 business days after the date of the event giving rise to the Payment or such other time as is requested by the Company. &#160;Any determination by the Accounting Firm shall be binding upon the Company and Executive. &#160;All fees and expenses of the Accounting Firm for services performed pursuant to this Section 5(d) shall be borne solely by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Release</b><font style="font-size:12pt;">. Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to make any payment or provide any benefit under Sections 5(b) or 5(c) hereof unless: (a) Executive or Executive&#8217;s legal representative first executes within 21 calendar days after the Date of Termination (or such longer period as required by applicable law) a release of claims agreement in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;">, with such changes as the Company, after consulting with Executive or Executive&#8217;s legal representative, may determine to be required or reasonably advisable in order to make the release enforceable and otherwise compliant with applicable law (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release</u><font style="font-size:12pt;">&#8221;); (b) Executive does not revoke the Release; and (c) the Release becomes effective and irrevocable in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Full Settlement</b><font style="font-size:12pt;">. The Company&#8217;s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company or any of its affiliates may have against Executive or others, except as otherwise may be provided in Section 8 hereof. &#160;In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Executive&#8217;s Covenants</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:12pt;">. During the Term and thereafter, Executive agrees to keep secret and confidential, and not to use or disclose to any third parties, except as directly required for Executive to perform Executive&#8217;s responsibilities for the Company under this Agreement, any of the Company&#8217;s Confidential Information (as defined in paragraph (k) below) acquired by Executive during the course of, or in connection with, Executive&#8217;s employment with the Company. &#160; Executive acknowledges that the Confidential Information is the exclusive property of the Company. &#160;Upon termination of Executive&#8217;s employment with the Company, for any reason, or at the request of the Company at any time, Executive shall promptly return to the Company all property then in Executive&#8217;s possession, custody or control belonging to the Company, including all Confidential Information. &#160;Executive shall not retain any copies of correspondence, memoranda, reports, notebooks, drawings, photographs or other documents in any form whatsoever (including information contained in computer or other electronic memory or on any computer or electronic storage device) relating in any way to the affairs of the Company and which were entrusted to Executive or obtained by Executive at any time during the Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assignment of Rights</u><font style="font-size:12pt;">. Executive shall promptly disclose to the Company and hereby assigns and transfers to the Company all of Executive&#8217;s right, title and interest in and to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:12pt;">any and all patents, inventions, discoveries, concepts, processes, methods, formulas, techniques, trade secrets, know-how, and related rights, whether or not patentable; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:12pt;">any and all copyrights and works of authorship, whether or not copyrightable,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">if and only to the extent that such intellectual property was conceived, created or reduced to tangible form by Executive in the course of performing his duties for the Company, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">and</u><font style="font-size:12pt;"> &#160;either relates to the business of the Company, or was conceived, created or reduced to tangible form &#160;with the use or assistance of the Company&#8217;s facilities, materials or personnel. Without limiting the generality of the foregoing, this assignment requirement applies to applications for U.S. or foreign letters patent and copyright registration granted upon such inventions, discoveries, and works of authorship and similar items as hereinabove set forth.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Executive shall deliver to the Company any and all instruments necessary to confirm complete ownership by the Company of any and all rights as described above, and upon the failure of Executive to furnish such documents, this Agreement shall constitute such documentation for all purposes. Executive further agrees during and after Executive&#8217;s employment by the Company, to cooperate fully, including giving testimony in support of Executive&#8217;s inventorship, as may be necessary in the opinion of the Company to obtain and/or maintain letters patent and to vest the entire ownership of such letters patent with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Competition</u><font style="font-size:12pt;">. Executive and the Company agree that Executive is being employed in an important fiduciary capacity with the Company, that the Company is engaged in a highly competitive business and that Executive will have access to the Company&#8217;s Confidential</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Information. &#160;Executive and the Company further agree that it is appropriate to place reasonable limits as set forth herein on Executive&#8217;s ability to compete with the Company to protect and preserve the legitimate business interests and goodwill of the Company. &#160;Executive agrees that, during the Term and thereafter during the Protection Period (as defined in paragraph (k) below), Executive will not, directly or indirectly (in a business capacity where Executive could use specialized knowledge, training, skill or expertise, Confidential Information, or customer contacts obtained from the Company to the detriment of the Company), own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, employee, partner, principal, agent, representative, or consultant to any business or activity that is Competitive with the Company (as defined in paragraph (k) below). &#160;After the end of the Term, the covenant in this Section 8(c) shall restrict Executive&#8217;s conduct within the Restricted Area (as defined in paragraph (k) below). &#160;Executive agrees that in his position, it is expected that Executive will receive Confidential Information related to the Restricted Area and if Executive was permitted to engage in competition with the Company within the Restricted Area, it would lead to unfair competition and it would be a significant disadvantage to the Company that would likely cause irreparable harm. &#160;Notwithstanding the foregoing, the ownership of not more than two percent (2%) of the outstanding securities of any company listed on any public exchange or regularly traded in the over-the-counter market, assuming Executive&#8217;s involvement with any such company is solely that of a security holder, shall not constitute a violation of this Section 8(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Customer Non-Solicitation</u><font style="font-size:12pt;">. Executive agrees that, during the Term and thereafter during the Protection Period, Executive will not, directly or indirectly (in a capacity where Executive could use specialized knowledge, training, skill or expertise, Confidential Information, or customer contacts or information obtained from the Company to the detriment of the Company): (i) on behalf of a business that is Competitive with the Company, solicit, attempt to solicit, call on, or accept business from any Customer (as defined in paragraph (k) below); or (ii) in any manner cause or attempt to cause any Customer to divert, terminate, limit, modify or fail to enter into any existing or potential business relationship with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Employee Non-Solicitation</u><font style="font-size:12pt;">. Executive agrees that, during the Term and thereafter during the Protection Period, Executive will not directly or indirectly engage, solicit, hire, attempt to hire, or encourage any current employee or former employee (limited to former employees whose employment has been terminated or concluded for less than 6 months) of the Company to leave or terminate his or her employment relationship with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Disparagement</u><font style="font-size:12pt;">. Executive agrees that he will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the marketplace of the Company or any of its affiliates, employees, officers, directors, stockholders, members, principals or assigns. &#160;Subject to Executive&#8217;s continuing obligations to comply with Section 8(a) (Confidential Information) hereof, nothing in this Section 8(f) shall preclude Executive from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding, provided that, to the extent permitted by law and Section 8(i) hereof, Executive promptly informs the Company of any such obligation prior to participating in any such proceedings. &#160;The Company, defined for purposes of this Section 8(f) as the Board and its individual members, agrees in turn that it will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the marketplace of Executive,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">provided that nothing in this Section 8(f) shall prevent the Company from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Divisible Provisions</u><font style="font-size:12pt;">. The individual terms and provisions of this Section 8 are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Section 8 shall thereby be affected. &#160;It is the intention of Executive and the Company that the potential restrictions on Executive&#8217;s solicitation and future employment imposed by this Section 8 be reasonable in both duration and geographic scope and in all other respects. &#160;If for any reason any court of competent jurisdiction shall find any provisions of this Section 8 unreasonable in duration or geographic scope or otherwise, Executive and the Company agree that the restrictions and prohibitions contained herein may be modified by a court of competent jurisdiction and shall be effective to the fullest extent allowed under applicable law in such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Injunctive Relief and Remedies</u><font style="font-size:12pt;">. &#160;In event of a breach or threatened breach of any of Executive&#8217;s duties and obligations under this Section 8, the Company shall be entitled, in addition to any other legal or equitable remedies it may have in connection therewith (including any right to damages it may suffer), to (i) seek temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach, (ii) cease making payments or providing benefits under Section 5 of this Agreement (other than paragraph 5(a) thereof), and (iii) seek any other relief obtainable through statutory or common law means (including, but not limited to, applicable trade secrets law). &#160;Executive hereby expressly acknowledges that the harm that might result to the Company&#8217;s business as a result of any noncompliance by Executive with the provisions of this Section 8 may be largely irreparable. &#160;The restrictions stated in this Section 8 are in addition to and not in lieu of protections afforded to trade secrets and confidential information under applicable law. &#160;Nothing in this Section 8 is intended to or shall be interpreted as diminishing or otherwise limiting the Company&#8217;s right under applicable law to protect its trade secrets and confidential information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Protected Activity</u><font style="font-size:12pt;">. &#160;Nothing contained in this Agreement, or any other agreement, policy, practice, procedure, directive or instruction maintained by the Company shall prohibit Executive from reporting possible violations of federal, state or local laws or regulations to any federal, state or local governmental agency or commission (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Government Agency</u><font style="font-size:12pt;">&#8221;) or from making other disclosures that are protected under the whistleblower provisions of federal, state or local laws or regulations. &#160;Executive does not need prior authorization of any kind to make any such reports or disclosures to any Government Agency and Executive is not required to notify the Company that Executive has made such reports or disclosures. &#160;Nothing in this Agreement limits any right Executive may have to receive a whistleblower award or bounty for information provided to any Government Agency. &#160;Executive hereby acknowledges that the Company has informed Executive, in accordance with 18 U.S.C. &#167; 1833(b), that Executive may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret where the disclosure: (i) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notification/Survival</u><font style="font-size:12pt;">. To enable the Company to monitor Executive&#8217;s compliance with the obligations imposed by this Section 8, Executive agrees to inform the Company during the Protection Period, of the identity of any subsequent employer and Executive&#8217;s new job title. &#160;Executive agrees that he will disclose the existence of this Section 8 to any subsequent employer. &#160;Following the expiration of the Term or this Agreement, this Section 8 shall survive and be of full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:12pt;">. As used in this Section 8, the following definitions shall apply</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221; means the Company and its subsidiaries and affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Competitive with the Company</u><font style="font-size:12pt;">&#8221; means a person, entity, business or activity that focuses on the development and commercialization of abuse deterrent biopharmaceutical products for the treatment of Attention-deficit/hyperactivity disorder, or ADHD, or any other proprietary biopharmaceutical products in development by the Company during Executive&#8217;s employment hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidential Information</u><font style="font-size:12pt;">&#8221; means information pertaining to the business of the Company that is generally not known to or readily ascertainable to the industry in which the Company competes, and that gives or tends to give the Company a competitive advantage over persons who do not possess such information or the secrecy of which is otherwise of value to the Company in the conduct of its business regardless of when and by whom such information &#160;was &#160;developed &#160;or &#160;acquired, &#160;and &#160;regardless &#160;of &#160;whether any &#160;of these &#160;are described in writing, copyrightable or considered copyrightable, patentable or considered patentable. &#160;Confidential Information includes, but is not limited to, the Company&#8217;s trade secrets, financial information or plans, pricing and profit information, sales and marketing information or plans, business or strategic plans, information concerning methods of operation, proprietary systems or software, legal or regulatory information, cost and pricing information or policies, information concerning new or potential products or markets, clinical data, medical or other data relating to participants in clinical trials, or research and/or analysis, information related to present and potential customers, vendors and suppliers (including, but not limited to, lists, contact information, requirements, contract terms, and pricing), methods of operations, research and development, product information, business technical information, including technical data, techniques, solutions, test methods, quality control systems, processes, design specifications, technical formulas, procedures and information, all agreements, schematics, manuals, studies, reports, and statistical information relating to the Company, all formulations, database files, information technology, strategic alliances, products, services, programs and processes used or sold, and all software licensed or developed by the Company, computer programs, systems and/or software, ideas, inventions, business information, know-how, improvements, designs, redesigns, creations, discoveries and developments of the Company. &#160;Confidential Information includes all forms of the information, whether oral, written or contained in electronic or any other format.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Customer</u><font style="font-size:12pt;">&#8221; means any actual or potential customer or client of the Company that (i) Executive knows to have been engaged as a customer or client of the Company during the 1 year period prior to the Date of Termination, (ii) Executive knows to have been contacted by the Company during the 1 year period prior to the Date of Termination or (iii) about which Executive</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">had been provided or had access to Confidential Information during his employment with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Protection Period</u><font style="font-size:12pt;">&#8221; means the applicable Severance Period; provided, however, that such period shall be extended for an additional period of time equal to the time that elapses from the commencement of a breach of the covenants contained in this Section 8 until the termination of such breach.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Restricted Area</u><font style="font-size:12pt;">&#8221; means the geographic area or areas where Executive conducted activities on behalf of the Company (including its Affiliates). &#160;It is intended as of the Effective Date that the Restricted Area will include the entire United States, as Executive is engaged to provide services and has duties related to this entire geographic area.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Representations. </b><font style="font-size:12pt;">Executive hereby represents and warrants to the Company that Executive is not party to any contract, understanding, agreement or policy, whether or not written, with his current employer (or any other previous employer) or otherwise, that would be breached by Executive&#8217;s entering into, or performing services under, this Agreement. &#160;Executive further represents that he has disclosed to the Company in writing all material threatened, pending, or actual claims against Executive that are unresolved and still outstanding as of the Effective Date, in each case of which he is aware, resulting or arising from his service with his current employer (or any other previous employer) or his membership on any boards of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Cooperation</b><font style="font-size:12pt;">. During the Term and thereafter, Executive shall cooperate with the Company and its affiliates, without additional consideration, in any internal investigation or administrative, regulatory, or judicial proceeding as reasonably requested by the Company including, without limitation, Executive&#8217;s being available to the Company and its affiliates upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information, and turning over to the Company all relevant documents that are or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments and otherwise taking into account Executive&#8217;s reasonable business obligations. Executive shall be reimbursed for the reasonable expenses Executive incurs in connection with any such cooperation and/or assistance and shall receive from the Company hourly compensation equal to the Annual Base Salary immediately prior to the Date of Termination divided by 2,200 hours, in each case in connection with any assistance or cooperation that occurs after the Date of Termination. &#160;Any such reimbursements or per diem compensation shall be paid to Executive no later than the 15th day of the month immediately following the month in which such expenses were incurred or such cooperation and/or assistance was provided (subject to Executive&#8217;s timely submission to the Company of proper documentation with respect thereto).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Notices</b><font style="font-size:12pt;">. Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by electronic mail, or sent by reputable overnight carrier, in each case with proof of receipt, to the recipient. &#160;Notices to Executive shall be sent to the address of Executive most recently provided to the Company. &#160;Notices to the Company should be sent to Vallon Pharmaceuticals, Inc., at the address of its corporate headquarters, Attention: &#160;Ofir Levi.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Any notice under this Agreement will be deemed to have been given when so delivered, sent or mailed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">12.</b></font><b style="font-size:12pt;font-weight:bold;">Severability</b><font style="font-size:12pt;">. The invalidity or unenforceability of any particular provision in this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if the invalid or unenforceable provision were omitted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">13.</b></font><b style="font-size:12pt;font-weight:bold;">Complete Agreement</b><font style="font-size:12pt;">. This Agreement, along with the Indemnity Agreement between Executive and the Company dated as of the Effective Date, embodies the complete agreement and understanding between the parties with respect to the subject matter hereof and effective as of its date supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way, including the employment agreement between Executive and the Company dated as of January 15, 2019, which agreement shall be considered null and void as of the Effective Date without any further action or notice; provided, however, that no provision in this Agreement shall be construed to adversely affect any of Executive&#8217;s rights to compensation, expense reimbursement or benefits (including equity compensation) payable in accordance with the terms of Executive&#8217;s prior employment agreements with the Company (and applicable equity award agreements) or any of Executive&#8217;s rights to indemnification with respect to Executive&#8217;s service under Executive&#8217;s prior employment agreements with the Company, all of which are expressly agreed to survive the execution of this Agreement. The payments and benefits provided under Section 5 shall be in full satisfaction of the Company&#8217;s obligations to Executive upon his termination of employment. &#160;Notwithstanding the foregoing, the Company and Executive agree that Executive shall be entitled to earn $100,000 upon achievement of Milestone #2 as defined in the consulting agreement between Executive and the Company dated as of January 15, 2018 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Consulting Agreement</u><font style="font-size:12pt;">&#8221;) (for the avoidance of doubt, notwithstanding the second paragraph of Section 2 of the Consulting Agreement, Consultant shall be paid 100% of the bonus upon achievement of the Milestone #2, despite the termination of the Consulting Agreement and regardless of how long after such termination Milestone #2 is achieved). Executive must be employed by the Company on the date Milestone #2 is achieved, except that (i) if Executive&#8217;s employment is terminated by the Company for any reason within two months prior to successful completion of Milestone #2, then 100% of the associated cash bonus shall be paid to Consultant upon achievement of the milestone, and (ii) if Company terminates Executive&#8217;s employment for any reason between two and four months prior to successful completion of Milestone #2, then 50% of the associated cash bonus shall be paid to Consultant upon achievement of the milestone.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">14.</b></font><b style="font-size:12pt;font-weight:bold;">Withholding of Taxes</b><font style="font-size:12pt;">. The Company and its affiliates may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company and its affiliates are required to withhold pursuant to any law or government regulation or ruling.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.</b></font><b style="font-size:12pt;font-weight:bold;">Successors and Assigns</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">This Agreement is personal to Executive, and, without the prior written consent of the Company, shall not be assignable by Executive other than by will or the laws of descent and distribution. &#160;This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. &#160;Except as provided in Section 15(c), without the prior written consent of Executive this Agreement shall not be assignable by the Company, except to an affiliate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. &#160;&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221; means the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid that assumes and agrees to perform this Agreement by operation of law or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">16.</b></font><b style="font-size:12pt;font-weight:bold;">Choice of Law</b><font style="font-size:12pt;">. This Agreement shall be governed, construed, interpreted and enforced in accordance with the substantive laws of the Commonwealth of Pennsylvania , without regard to conflicts of law principles. &#160;The parties hereto irrevocably agree to submit to the jurisdiction and venue of the federal and state courts located in Philadelphia, Pennsylvania in any court action or proceeding brought with respect to or in connection with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">17.</b></font><b style="font-size:12pt;font-weight:bold;">Amendment and Waiver</b><font style="font-size:12pt;">. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">18.</b></font><b style="font-size:12pt;font-weight:bold;">Section 409A Compliance</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">In General</u><font style="font-size:12pt;">. The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 409A</u><font style="font-size:12pt;">&#8221;) or are exempt therefrom and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered so as to be in compliance therewith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation from Service</u><font style="font-size:12pt;">. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A, and for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service&#8221; within the meaning of Section 409A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Reimbursements or In-Kind Benefits</u><font style="font-size:12pt;">. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred, or such earlier date as required hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Six Month Delay</u><font style="font-size:12pt;">. Notwithstanding anything contained in this Agreement to the contrary, if Executive is a &#8220;specified employee,&#8221; as determined under the Company&#8217;s policy for identifying specified employees on the Date of Termination, then to the extent required in order to comply with Section 409A, all payments, benefits or reimbursements paid or provided under this Agreement that constitute a &#8220;deferral of compensation&#8221; within the meaning of Section 409A, that are provided as a result of a &#8220;separation from service&#8221; within the meaning of Section 409A and that would otherwise be paid or provided during the first six months following such Date of Termination shall be accumulated through and paid or provided (without interest), within 20 calendar days after the first business day that is more than six months after the date of his separation from service (or, if Executive dies during such six-month period, within 20 calendar days after Executive&#8217;s death).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Payment Dates</u><font style="font-size:12pt;">. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><i style="font-size:12pt;font-style:italic;">e.g.,</i><font style="font-size:12pt;"> &#8220;within 20 calendar days after the Release described in Section 6 becomes effective and irrevocable&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company. &#160;In the event the payment period under this Agreement for any nonqualified deferred compensation commences in one calendar year and ends in a second calendar year, the payments shall not be paid (or installments commenced) until the later of the first payroll date of the second calendar year, or the date that such Release becomes effective and irrevocable, to the extent necessary to comply with Section 409A. &#160;For purposes of Section 409A, Executive&#8217;s right to receive any &#8220;installment&#8221; payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">19.</b></font><b style="font-size:12pt;font-weight:bold;">Counterparts</b><font style="font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by electronic mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VALLON PHARMACEUTICALS, INC.</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Ofir Levi</font></p></td><td style="vertical-align:bottom;width:24.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: Ofir Levi PhD</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: Chairman</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">EXECUTIVE</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ David Baker</font></p></td><td style="vertical-align:bottom;width:24.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">David Baker</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">15</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GENERAL RELEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This General Release (this &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release</u><font style="font-size:12pt;">&#8221;) is made and entered into as of this [</font><font style="font-family:'Times New Roman';font-size:12pt;">&#9679;</font><font style="font-size:12pt;">] day of [</font><font style="font-family:'Times New Roman';font-size:12pt;">&#9679;</font><font style="font-size:12pt;">], 20[</font><font style="font-family:'Times New Roman';font-size:12pt;">&#9679;</font><font style="font-size:12pt;">], by and between Vallon Pharmaceuticals, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;) and David Baker (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Employment Status</b><font style="font-size:12pt;">. Executive&#8217;s employment with the Company and its affiliates terminated effective as of [</font><font style="font-family:'Times New Roman';font-size:12pt;">&#9679;</font><font style="font-size:12pt;">], 20[</font><font style="font-family:'Times New Roman';font-size:12pt;">&#9679;</font><font style="font-size:12pt;">] (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation Date</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Payments and Benefits</b><font style="font-size:12pt;">. Upon the effectiveness of the terms set forth herein, the Company shall provide Executive with the benefits set forth in Section 5(b) of the Employment Agreement between Executive and the Company dated as of April 20, 2021 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Employment Agreement</u><font style="font-size:12pt;">&#8221;), upon the terms, and subject to the conditions, of the Employment Agreement. &#160;Executive agrees that Executive is not entitled to receive any additional payments as wages, vacation or bonuses except as otherwise provided under Section 5(b)/5(c) of the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-size:12pt;font-weight:bold;">No Liability</b><font style="font-size:12pt;">. This Release does not constitute an admission by the Company, or any of its parents, subsidiaries, affiliates, divisions, officers, directors, partners, agents, or employees, or by Executive, of any unlawful acts or of any violation of federal, state or local laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Release</b><font style="font-size:12pt;">. In consideration of the payments and benefits set forth in Section 2 above, Executive for himself, his heirs, administrators, representatives, executors, successors and assigns does hereby irrevocably and unconditionally release, acquit and forever discharge the Company and each of its parents, subsidiaries, affiliates, divisions, successors, assigns, officers, directors, partners, agents, attorneys, and former and current employees, including without limitation all persons acting by, through, under or in concert with any of them (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Releasees</u><font style="font-size:12pt;">&#8221;), and each of them, from any and all claims, demands, actions, causes of action, costs, attorney fees, and all liability whatsoever, whether known or unknown, fixed or contingent, which Executive has, had, or may ever have against the Releasees relating to or arising out of Executive&#8217;s employment or separation from employment with the Company, from the beginning of time and up to and including the date Executive executes this Release. This Release includes, without limitation, (i) law or equity claims; (ii) contract (express or implied) or tort claims; (iii) claims for wrongful discharge, retaliatory discharge, whistle blowing, libel, slander, defamation, unpaid compensation, intentional infliction of emotional distress, fraud, public policy, contract or tort, and implied covenant of good faith and fair dealing; (iv) claims arising under any federal, state, or local laws of any jurisdiction that prohibit age, sex, race, national origin, color, disability, religion, veteran, military status, sexual orientation, or any other form of discrimination, harassment, or retaliation (including without limitation under the Age Discrimination in Employment Act of 1967 as amended by the Older Workers Benefit Protection Act (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">ADEA</u><font style="font-size:12pt;">&#8221;), the National Labor Relations Act, Executive Order 11246, the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act, Title VII of the Civil Rights Act of 1964 as amended by the Civil Rights Act of 1991, Section 1981 of the Civil Rights Act of 1966, the Equal Pay Act of 1962, the Americans with Disabilities Act of 1990, the Rehabilitation Act of 1973, the Family and Medical Leave Act of 1993, the Consolidated Omnibus Budget Reconciliation Act (COBRA), the Genetic Information Non-discrimination Act, the Sarbanes-Oxley Act, the Employee</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Polygraph Protection Act, the Uniformed Services Employment and Reemployment Rights Act of 1994, the Equal Pay Act, the Lilly Ledbetter Fair Pay Act, the Post-Civil War Civil Rights Act (42 U.S.C. &#167;&#167;1981-1988), or any other foreign, federal, state or local law or judicial decision), (v) claims arising under the Employee Retirement Income Security Act (excluding claims for amounts that are vested benefits or that Executive is otherwise entitled to receive under any employee benefit plan of the Company or any of its affiliates in accordance with the terms of such plan and applicable law), and (vi) any other statutory or common law claims related to Executive&#8217;s employment with the Company or the separation of Executive&#8217;s employment with the Company; provided, however, that nothing herein shall release any obligation of the Company under the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Protected Activity</b><font style="font-size:12pt;">. Nothing contained in this Release limits Executive&#8217;s ability to file a charge or complaint with any federal, state or local governmental agency or commission (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Government Agency</u><font style="font-size:12pt;">&#8221;). &#160;In addition, nothing in this Release or any other Company agreement, policy, practice, procedure, directive or instruction shall prohibit Executive from reporting possible violations of federal, state or local laws or regulations to any Government Agency or making other disclosures that are protected under the whistleblower provisions of federal, state or local laws or regulations. &#160;Executive does not need prior authorization of any kind to make any such reports or disclosures and Executive is not required to notify the Company that Executive has made such reports or disclosures. &#160;If Executive files any charge or complaint with any Government Agency, and if the Government Agency pursues any claim on Executive&#8217;s behalf, or if any other third party pursues any claim on Executive&#8217;s behalf, Executive waives any right to monetary or other individualized relief (either individually, or as part of any collective or class action) that arises out of alleged facts or circumstances on or before the effective date of this Release; provided that nothing in this Release limits any right Executive may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission or other Government Agency.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Bar</b><font style="font-size:12pt;">. Executive and the Company acknowledge and agree that if he or it should hereafter make any claim or demand or commence or threaten to commence any action, claim or proceeding against the other party with respect to any cause, matter or thing which is the subject of the releases under Section 4 of this Release, this Release may be raised as a complete bar to any such action, claim or proceeding, and the applicable Releasee may recover from the other party all costs incurred in connection with such action, claim or proceeding, including attorneys&#8217; fees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Governing Law</b><font style="font-size:12pt;">. This Release shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to conflicts of laws principles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Acknowledgment</b><font style="font-size:12pt;">. Executive has read this Release, understands it, and voluntarily accepts its terms, and Executive acknowledges that he has been advised by the Company to seek the advice of legal counsel before entering into this Release, and has been provided with a period of at least twenty-one (21) days in which to consider entering into this Release. &#160;Executive acknowledges and agrees that the payments and benefits provided under Section 2 of this Release represent substantial value over and above that to which Executive would otherwise be entitled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Revocation</b><font style="font-size:12pt;">. Executive has a period of seven (7) days following the execution of this Release during which Executive may revoke this Release by delivering written notice to the Company, and this Release shall not become effective or enforceable until such revocation period has expired. &#160;Executive understands that if he revokes this Release, it will be null and void in its entirety, and he will not be entitled to any payments or benefits provided in this Release, including without limitation those under Section 2 above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Miscellaneous</b><font style="font-size:12pt;">. This Release is the complete understanding between Executive and the Company in respect of the subject matter of this Release and supersedes all prior agreements relating to the same subject matter. Executive has not relied upon any representations, promises or agreements of any kind except those set forth herein in signing this Release. In the event that any provision of this Release should be held to be invalid or unenforceable, each and all of the other provisions of this Release shall remain in full force and effect. If any provision of this Release is found to be invalid or unenforceable, such provision shall be modified as necessary to permit this Release to be upheld and enforced to the maximum extent permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Counterparts</b><font style="font-size:12pt;">. This Release may be executed by the parties hereto in counterparts, which taken together shall be deemed one original.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">VALLON PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">[Form of release &#8211; Do not sign]</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: </font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXECUTIVE</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">[Form of release &#8211; Do not sign]</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">David Baker</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>vlon-20210331xex10d2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This EMPLOYMENT AGREEMENT (this &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:12pt;">&#8221;) is made as of the 11th day of May 2021, between Vallon Pharmaceuticals, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;) and Leanne M. Kelly (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive</u><font style="font-size:12pt;">&#8221;). &#160;In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Employment Term</b><font style="font-size:12pt;">. &#160;The Company shall employ Executive, and Executive accepts employment with the Company, upon the terms and subject to the conditions set forth in this Agreement, for the period beginning on May 10, 2021 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date</u><font style="font-size:12pt;">&#8221;) and ending on the Date of Termination (as defined in Section 4(e) of this Agreement) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Term</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Terms of Employment</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Position and Duties</u><font style="font-size:12pt;">. &#160;During the Term, Executive shall be employed by the Company as Chief Financial Officer and shall have such duties, responsibilities and authorities as are customarily associated with her position and such additional duties and responsibilities consistent with her position as may, from time to time, be properly and lawfully assigned to her. &#160;Executive shall report directly to the Chief Executive Officer. &#160;Executive shall act at all times in compliance in all respects with the policies, rules and decisions adopted from time to time by the Company and perform all of the duties and obligations required of her by this Agreement in a loyal and conscientious manner.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Engaging in Other Activities</u><font style="font-size:12pt;">. &#160;During the Term, Executive shall devote her full time and attention to the Company and its affiliates and shall not be employed by or provide services to any other person or entity. &#160;During the Term, it shall not be a violation of this Agreement for Executive, subject to the requirements of Section 8 hereof, to (i) serve on civic, charitable or religious boards or engage in other activities for such organizations, (ii) with the consent of the Board of Directors of the Company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Board</u><font style="font-size:12pt;">&#8221;), which consent shall not be unreasonably withheld, serve on up to one corporate board unrelated to the Company (and retain all compensation in whatever form for such service), and (iii) manage personal investments, so long as such activities (individually or in the aggregate) do not interfere with the performance of Executive&#8217;s responsibilities as set forth in Sections 2(a) or 2(b) of this Agreement or Executive&#8217;s fiduciary duties to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Location</u><font style="font-size:12pt;">. &#160;Initially, Executive shall be permitted to perform her duties and responsibilities hereunder principally at her personal residence. &#160;Once the Company establishes a physical corporate headquarters, and subject to applicable remote work or work-at-home policies or requirements, Executive shall perform her duties and responsibilities hereunder principally at those corporate headquarters. &#160;In any event, Executive may be required under reasonable business circumstances to travel outside of her principal work location in connection with performing her duties under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Affiliates</u><font style="font-size:12pt;">. &#160;Executive agrees to serve, without additional compensation, as an officer and director of each of the other members of the Company&#8217;s affiliates, as determined by</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the Company. &#160;As used in this Agreement, the term &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">affiliate</u><font style="font-size:12pt;">&#8221; shall mean any entity controlled by, controlling, or under common control with, the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3. </b></font><b style="font-size:12pt;font-weight:bold;">Compensation and Benefits</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Base Salary</u><font style="font-size:12pt;">. &#160;During the Term, the Company shall pay Executive an annualized base salary (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Annual Base Salary</u><font style="font-size:12pt;">&#8221;) of $275,000, payable in regular installments in accordance with the Company&#8217;s normal payroll practices. &#160;During the Term, the Annual Base Salary shall be reviewed by the Board or a committee thereof at such time as the salaries of other senior executives of the Company are reviewed generally, but no less frequently than once a year. &#160;The Annual Base Salary shall not be reduced other than in connection with an across-the-board salary reduction which applies in a comparable manner to other senior executives of the Company. &#160;If so increased or reduced, then such adjusted salary will thereafter be the Annual Base Salary for all purposes under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Annual Incentives</u><font style="font-size:12pt;">. For each fiscal year during the Term, Executive shall be eligible to participate in an annual bonus plan under terms and conditions no less favorable than other senior executives of the Company; provided that Executive&#8217;s target annual bonus opportunity shall be 35% of her Annual Base Salary (or such higher amount as determined by the Board or a committee thereof from time to time) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Target Annual Incentive</u><font style="font-size:12pt;">&#8221;) and pro-rated for the 2021 fiscal year. &#160;Executive&#8217;s payment under the annual bonus plan shall be based on the extent to which the performance objectives established by the Board or a committee thereof have been achieved. &#160;Unless a different payment date is established in the bonus plan by the Company, the bonus payment shall be made in a single lump sum within two and one-half months following the end of the Company&#8217;s fiscal year. &#160;Except as set forth in Section 5(b) or 5(c) below, Executive must be employed on the last day of the fiscal year to receive payment of any annual bonus earned for that fiscal year. &#160;Nothing contained in this Section 3(b) will guarantee Executive any specific amount of bonus compensation or prevent the Company from establishing performance goals and targets applicable only to Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Stock Option</u><font style="font-size:12pt;">. &#160;Within 30 calendar days after the Effective Date, the Company shall recommend to the Board or a committee thereof to grant Executive an option to purchase up to 100,000 common shares of the Company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Stock Option</u><font style="font-size:12pt;">&#8221;) under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Equity Plan</u><font style="font-size:12pt;">&#8221;). &#160;The Stock Option shall have an exercise price per share equal to the &#8220;Fair Market Value&#8221; (as defined in the Equity Plan) of a share of the Company&#8217;s common stock on the date of grant. &#160;The Stock Option shall vest in installments and become exercisable as follows: (i) 70% of the shares underlying the Stock Option shall vest as follows: (x) 17,500 option shares on the first anniversary of the Effective Date, and (y) the remaining 52,500 option shares in equal installments on a quarterly basis for the next three years, in each case subject to Executive&#8217;s continued employment, and (ii) 30% of the shares underlying the Stock Option shall vest as follows: (x) 15,000 option shares on the date the Company submits a New Drug Application (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">NDA</u><font style="font-size:12pt;">&#8221;) filing for ADAIR with the U.S. Food &amp; Drug Administration, and (y) 15,000 option shares on the date when the U.S. Food &amp; Drug Administration approves the NDA, provided that Executive is employed by the Company at the time the applicable performance objective is achieved. Except as specifically provided in this Section 3(c), the Stock Option shall be granted upon the terms, and subject to the conditions, of the Equity Plan and the award agreement evidencing the grant of the Stock Option, as provided</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">to senior executives of the Company generally. &#160;During the Term, the Company may, but shall have no obligation to, grant additional equity compensation awards to Executive under this Agreement or under the Equity Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">PTO</u><font style="font-size:12pt;">. &#160;During the Term, Executive shall be eligible for at least four (4) weeks paid time off (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">PTO</u><font style="font-size:12pt;">&#8221;) per year in accordance with the Company&#8217;s policies in effect from time to time for its senior vice presidents generally. &#160;Executive may carry over up to one (1) week of unused PTO into the next following year only.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Expense Reimbursement</u><font style="font-size:12pt;">. &#160;Executive shall be reimbursed for all reasonable travel and other out-of-pocket expenses actually and properly incurred by Executive prior to and during the Term in connection with carrying out her duties hereunder in accordance with the Company&#8217;s policies in effect from time to time for its senior executives generally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Benefits</u><font style="font-size:12pt;">. &#160;During the Term, and except as otherwise provided in this Agreement, Executive shall be eligible to participate in all welfare, perquisite, fringe benefit, insurance, retirement and other benefit plans, practices, policies and programs, maintained by the Company and its affiliates applicable to senior executives of the Company generally, in each case as amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Termination of Employment</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Death and Disability</u><font style="font-size:12pt;">. Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death. &#160;If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Term, it may give to Executive written notice in accordance with Section 11 of this Agreement of its intention to terminate Executive&#8217;s employment; provided that (i) such notice is provided no later than 150 calendar days following the determination of Executive&#8217;s Disability, and (ii) Executive has not returned to full-time employment during the period between such determination and the giving of such notice. &#160;In such event, Executive&#8217;s employment shall terminate effective on the 30th calendar day after receipt of such notice by Executive (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disability Effective Date</u><font style="font-size:12pt;">&#8221;), provided that, within the 30 calendar days after such receipt, Executive shall not have returned to full-time performance of Executive&#8217;s duties. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disability</u><font style="font-size:12pt;">&#8221; shall mean the inability of Executive to perform the essential duties of the position held by Executive by reason of any medically determined physical or mental impairment that is reasonably expected to result in death or lasts for 120 calendar days in any one-year period, all as determined by an independent licensed physician mutually acceptable to the Company and Executive or Executive&#8217;s legal representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cause</u><font style="font-size:12pt;">. &#160;Executive&#8217;s employment with the Company may be terminated by the Company with or without Cause. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cause</u><font style="font-size:12pt;">&#8221; shall mean: &#160;(i) the continued failure of Executive to perform Executive&#8217;s duties as set forth in Section 2 hereof or Executive&#8217;s material disregard of the reasonable and lawful directives of the Company (in each case other than any such failure resulting from any medically determined physical or mental impairment) that is not cured by Executive within 20 calendar days after a written demand for performance is delivered to Executive by the Company which specifically identifies the manner in which the Company believes that Executive has not performed Executive&#8217;s duties or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">disregarded a directive of the Board; (ii) Executive&#8217;s commission of any material act of fraud, misappropriation or embezzlement against or in connection with the Company or any of its affiliates or their respective businesses or operations; (iii) Executive&#8217;s commission of, or indictment for or otherwise being formally charged with, any crime involving dishonesty or for any felony; (iv) the engaging by Executive in misconduct that is materially detrimental to the financial condition or business reputation of the Company or any of its affiliates, including due to any adverse publicity; or (v) a material breach by Executive of her obligations under Section 8, or her representations under Section 9, of this Agreement. &#160;In addition to the notice and opportunity to cure set forth in subsection (i) above, to the extent that any of the grounds set forth in subsections (ii), (iv) or (v) above is capable of being cured, the Company shall not have Cause unless it has furnished Executive with written notice specifically identifying the conduct &#160;allegedly giving rise to Cause, and she has failed to cure such ground within 20 days of the delivery of such notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason</u><font style="font-size:12pt;">. &#160;Executive&#8217;s employment with the Company may be terminated by Executive with or without Good Reason. &#160;For purposes of this Agreement, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason</u><font style="font-size:12pt;">&#8221; shall mean the occurrence of any of the following without Executive&#8217;s consent: (i) a material reduction by the Company of Executive&#8217;s title, duties, responsibilities, authority or reporting relationship set forth in Section 2(a); (ii) a material reduction by the Company of Executive&#8217;s Annual Base Salary (other than as provided in Section 3(a) of this Agreement); (iii) a material breach of the Company of this Agreement or of any other agreement between Executive and the Company; or (iv) a material change in geographic location at which Executive must principally perform services under this Agreement from the location at which Executive was principally employed (the Company has determined that a relocation of more than 50 miles would constitute such a material change). A termination of Executive&#8217;s employment by Executive under Sections 4(c)(i), (ii),(iii) or (iv) shall not be deemed to be for Good Reason unless (x) Executive gives notice to the Company of the existence of the event or condition constituting Good Reason within 30 calendar days after becoming aware of the initial occurrence or existence of such event or condition, and (y) the Company fails to cure such event or condition within 30 calendar days after receiving such notice. &#160;Additionally, Executive must terminate her employment within 90 calendar days after the initial occurrence of the circumstance constituting Good Reason for such termination to be &#8220;Good Reason&#8221; hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:12pt;">. &#160;Any termination by the Company for Cause, or by &#160;Executive for Good Reason, shall be communicated by Notice of Termination to the other party in accordance with Section 11. &#160;For purposes of this Agreement, a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Termination</u><font style="font-size:12pt;">&#8221; means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Termination</u><font style="font-size:12pt;">. &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Termination</u><font style="font-size:12pt;">&#8221; means, as applicable, the date of Executive&#8217;s death, the Disability Effective Date, or the date on which the termination of Executive&#8217;s employment by the Company for Cause or without Cause or by Executive for Good Reason or without Good Reason is effective.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Resignation from All Positions</u><font style="font-size:12pt;">. &#160;Notwithstanding any other provision of this Agreement, upon the termination of Executive&#8217;s employment for any reason, unless otherwise requested by the Board, Executive shall immediately resign from all positions that she holds or has ever held with the Company and its affiliates, including the boards of directors or committees of the Company&#8217;s affiliates. &#160;Executive hereby agrees to execute any and all documentation to effectuate such resignations upon request by the Company, but she shall be treated for all purposes as having so resigned upon termination of her employment, regardless of when or whether she executes any such documentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Severance Payments</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Any Termination of Employment</u><font style="font-size:12pt;">. &#160;If, during or at the expiration of the Term, Executive&#8217;s employment with the Company and its affiliates shall terminate for any reason or no reason, then:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accrued Benefits</u><font style="font-size:12pt;">. &#160;The Company shall pay, or cause to be paid, to Executive the sum of: &#160;(A) the portion of Executive&#8217;s Annual Base Salary earned through the Date of Termination, to the extent not previously paid, (B) the amount of any annual bonus that has been earned by Executive for a completed fiscal year or other measuring period preceding the Date of Termination, but has not yet been paid to Executive, and (C) any unreimbursed business expenses to the extent reimbursable in accordance with the Company&#8217;s reimbursement policies (the sum of the amounts described in clauses (A) through and including (C) shall be referred to as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accrued Benefits</u><font style="font-size:12pt;">&#8221;). The Accrued Benefits shall be paid to Executive in a single lump sum within 30 calendar days after the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Benefits</u><font style="font-size:12pt;">. &#160;To the extent not previously paid or provided, the Company shall pay or provide, or cause to be paid or provided, to Executive (or her estate) any other amounts or benefits (including, as applicable, any payment of long-term incentive awards) required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company, including any benefits to which Executive is entitled under the Consolidated Omnibus Budget Reconciliation Act (such other amounts and benefits described in this Section 5(a)(ii) shall be hereinafter referred to as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Benefits</u><font style="font-size:12pt;">&#8221;) in accordance with the terms and normal procedures of each such plan, program, policy or practice or contract or agreement, based on accrued and vested benefits through the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason, Other than for Cause (not During the Change in Control Protection Period)</u><font style="font-size:12pt;">. &#160;If, during the Term (other than during the Change in Control Protection Period, as defined below), the Company shall terminate Executive&#8217;s employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the following amounts and benefits to Executive:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severance</u><font style="font-size:12pt;">. &#160;The Company shall continue to pay to Executive the Annual Base Salary, as of the Date of Termination, for the period beginning on the Date of Termination and ending 9 months thereafter (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severance Period</u><font style="font-size:12pt;">&#8221;), which shall be payable over the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Severance Period in regular installments in accordance with the Company&#8217;s normal payroll practices as they may exist from time to time, with the installments that otherwise would be paid prior to the first payroll date following the date the Release described in Section 6 becomes effective and irrevocable in accordance with its terms (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release Effective Date</u><font style="font-size:12pt;">&#8221;) being paid (without interest) on such payroll date in a lump sum and the remaining installments being paid as otherwise scheduled assuming payments had begun immediately after the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Continued Health Insurance</u><font style="font-size:12pt;">. &#160;If Executive elects COBRA coverage under the applicable medical and dental plans of the Company, the Company will subsidize a portion of the applicable monthly COBRA premium during the Severance Period, so that Executive will only be required to pay the premiums applicable to continuing employees during that time; provided that such subsidy shall cease on the date on which Executive becomes eligible for medical and dental coverage from a third party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Pro-Rated Annual Incentive</u><font style="font-size:12pt;">. &#160;Executive will be eligible to receive an annual incentive under the annual bonus plan for the fiscal year during which the Date of Termination occurs, based on actual performance results during the entire fiscal year and without regard to any discretionary adjustments that have the effect of reducing the amount of the annual incentive (other than discretionary adjustments applicable to all senior executives who did not terminate employment), pro-rated based on the number of days in the Company&#8217;s fiscal year through (and including) the Date of Termination (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Pro-Rated Annual Incentive</u><font style="font-size:12pt;">&#8221;), which, if earned, shall be payable in a single lump sum at the same time that payments are made to other participants in the annual bonus plan for that fiscal year; provided, however, that Executive shall be entitled to such a Pro-Rated Annual Incentive only if Executive was employed by the Company for at least six months during the fiscal year in which the Date of Termination occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Good Reason, Other than for Cause During the Change in Control Protection Period</u><font style="font-size:12pt;">. &#160;If, during the Term and during the period beginning upon the occurrence of a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change in Control</u><font style="font-size:12pt;">&#8221; (as defined in the Equity Plan) and ending on the first anniversary of the occurrence of the Change in Control (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change in Control Protection Period</u><font style="font-size:12pt;">&#8221;), the Company shall terminate Executive&#8217;s employment other than for Disability or Cause, or if Executive shall terminate employment for Good Reason, then, in addition to providing the Accrued Benefits and Other Benefits, as set forth in Section 5(a) above, and subject to Sections 6 and 8(f) below, the Company shall pay or provide the following amounts and benefits to Executive:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Enhancements</u><font style="font-size:12pt;">. &#160;The Company shall pay or provide, or cause to be paid or provided, to Executive the payments and benefits set forth in Section 5(b)(i) and (ii) above (but not Section 5(b)(iii) above), provided that when applying those provisions, the Severance Period shall mean the period beginning on the Date of Termination and ending on the first anniversary thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Target Annual Incentive</u><font style="font-size:12pt;">. &#160;In lieu of (and not in duplication of) the Pro-Rated Annual Incentive set forth in Section 5(b)(iii) above, Executive shall be entitled to receive her Target Annual Incentive for the fiscal year in which the Date of Termination occurs, without pro-ration (and even if the Date of Termination occurs within the first 6 months of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">fiscal year), which amount shall be paid to Executive within 15 business days after the Release Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(iii)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Equity</u><font style="font-size:12pt;">. &#160;Notwithstanding anything contained in the applicable Company equity plan and award agreements to the contrary, all outstanding and unvested equity awards of the Company granted to Executive shall become immediately vested and exercisable; provided that any such awards the vesting of which depends upon the achievement of performance objectives shall vest at the &#8220;target&#8221; achievement level for each performance objective. In addition, all outstanding and vested Company stock options (including those that vest pursuant to the operation of the immediately preceding sentence) will remain exercisable for the full duration of their term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 280G</u><font style="font-size:12pt;">. &#160;Notwithstanding anything in this Agreement to the contrary, in the event it shall be determined that any accrual, acceleration, payment, benefit or distribution by the Company or any of its affiliated companies to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Payment</u><font style="font-size:12pt;">&#8221;) would be an excess parachute payment within the meaning of section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Code</u><font style="font-size:12pt;">&#8221;) (such excess only, an &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Excess Payment</u><font style="font-size:12pt;">&#8221;), then Executive shall forfeit all Excess Payments if the after-tax value to Executive of the Payments, as reduced by such forfeiture, would be greater than the after-tax value to Executive of the Payments absent such forfeiture. The forfeiture of Excess Payments, if applicable, shall be applied to the severance described in Section 5(c) hereof, then to cancellation of accelerated vesting of performance-based equity awards (based on the reverse order of the date of grant), then to cancellation of accelerated vesting of other equity awards (based on the reverse order of the date of grant), and then to any other Payments on a pro-rata basis. &#160;All determinations required to be made under this Section 5(d), including whether and when a Payment is subject to section 280G of the Code, and the value of a Payment for purposes of section 280G of the Code, and the assumptions to be utilized in arriving at such determination, shall be made by an accounting firm with expertise in such matters designated by the Company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accounting Firm</u><font style="font-size:12pt;">&#8221;). &#160;The Company will direct the Accounting Firm to provide its determination and detailed supporting calculations both to the Company and Executive within 15 business days after the date of the event giving rise to the Payment or such other time as is requested by the Company. &#160;Any determination by the Accounting Firm shall be binding upon the Company and Executive. &#160;All fees and expenses of the Accounting Firm for services performed pursuant to this Section 5(d) shall be borne solely by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Release</b><font style="font-size:12pt;">. Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to make any payment or provide any benefit under Section 5(b) or 5(c) hereof unless: (a) Executive or Executive&#8217;s legal representative first executes within 21 calendar days after the Date of Termination (or such longer period as required by applicable law) a release of claims agreement in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;">, with such changes as the Company, after consulting with Executive or Executive&#8217;s legal representative, may determine to be required or reasonably advisable in order to make the release enforceable and otherwise compliant with applicable law (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release</u><font style="font-size:12pt;">&#8221;); (b) Executive does not revoke the Release; and (c) the Release becomes effective and irrevocable in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Full Settlement</b><font style="font-size:12pt;">. &#160;The Company&#8217;s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company or any of its affiliates may have against Executive or others, except as otherwise may be provided in Section 8 hereof. &#160;In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Executive&#8217;s Covenants</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:12pt;">. &#160; During the Term and thereafter, Executive agrees to keep secret and confidential, and not to use or disclose to any third parties, except as directly required for Executive to perform Executive&#8217;s responsibilities for the Company under this Agreement, any of the Company&#8217;s Confidential Information (as defined in paragraph (k) below) acquired by Executive during the course of, or in connection with, Executive&#8217;s employment with the Company. &#160; Executive acknowledges that the Confidential Information is the exclusive property of the Company. &#160;Upon termination of Executive&#8217;s employment with the Company, for any reason, or at the request of the Company at any time, Executive shall promptly return to the Company all property then in Executive&#8217;s possession, custody or control belonging to the Company, including all Confidential Information. &#160;Executive shall not retain any copies of correspondence, memoranda, reports, notebooks, drawings, photographs or other documents in any form whatsoever (including information contained in computer or other electronic memory or on any computer or electronic storage device) relating in any way to the affairs of the Company and which were entrusted to Executive or obtained by Executive at any time during the Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assignment of Rights</u><font style="font-size:12pt;">. Executive shall promptly disclose to the Company and hereby assigns and transfers to the Company all of Executive&#8217;s right, title and interest in and to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:12pt;">any and all patents, inventions, discoveries, concepts, processes, methods, formulas, techniques, trade secrets, know-how, and related rights, whether or not patentable; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:12pt;">any and all copyrights and works of authorship, whether or not copyrightable,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">if and only to the extent that such intellectual property was conceived, created or reduced to tangible form by Executive in the course of performing her duties for the Company, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">and</u><font style="font-size:12pt;"> &#160;either relates to the business of the Company, or was conceived, created or reduced to tangible form &#160;with the use or assistance of the Company&#8217;s facilities, materials or personnel. Without limiting the generality of the foregoing, this assignment requirement applies to applications for U.S. or foreign letters patent and copyright registration granted upon such inventions, discoveries, and works of authorship and similar items as hereinabove set forth.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Executive shall deliver to the Company any and all instruments necessary to confirm complete ownership by the Company of any and all rights as described above, and upon the failure of Executive to furnish such documents, this Agreement shall constitute such documentation for all</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">purposes. Executive further agrees during and after Executive&#8217;s employment by the Company, to cooperate fully, including giving testimony in support of Executive&#8217;s inventorship, as may be necessary in the opinion of the Company to obtain and/or maintain letters patent and to vest the entire ownership of such letters patent with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Competition</u><font style="font-size:12pt;">. &#160; Executive and the Company agree that Executive is being employed in an important fiduciary capacity with the Company, that the Company is engaged in a highly competitive business and that Executive will have access to the Company&#8217;s Confidential Information. &#160;Executive and the Company further agree that it is appropriate to place reasonable limits as set forth herein on Executive&#8217;s ability to compete with the Company to protect and preserve the legitimate business interests and goodwill of the Company. &#160;Executive agrees that, during the Term and thereafter during the Protection Period (as defined in paragraph (k) below), Executive will not, directly or indirectly (in a business capacity where Executive could use specialized knowledge, training, skill or expertise, Confidential Information, or customer contacts obtained from the Company to the detriment of the Company), own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, employee, partner, principal, agent, representative, or consultant to any business or activity that is Competitive with the Company (as defined in paragraph (k) below). &#160;After the end of the Term, the covenant in this Section 8(c) shall restrict Executive&#8217;s conduct within the Restricted Area (as defined in paragraph (k) below). &#160;Executive agrees that in her position, it is expected that Executive will receive Confidential Information related to the Restricted Area and if Executive was permitted to engage in competition with the Company within the Restricted Area, it would lead to unfair competition and it would be a significant disadvantage to the Company that would likely cause irreparable harm. &#160;Notwithstanding the foregoing, the ownership of not more than two percent (2%) of the outstanding securities of any company listed on any public exchange or regularly traded in the over-the-counter market, assuming Executive&#8217;s involvement with any such company is solely that of a security holder, shall not constitute a violation of this Section 8(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Customer Non-Solicitation</u><font style="font-size:12pt;">. &#160;Executive agrees that, during the Term and thereafter during the Protection Period, Executive will not, directly or indirectly (in a capacity where Executive could use specialized knowledge, training, skill or expertise, Confidential Information, or customer contacts or information obtained from the Company to the detriment of the Company): (i) on behalf of a business that is Competitive with the Company, solicit, attempt to solicit, call on, or accept business from any Customer (as defined in paragraph (k) below); or (ii) in any manner cause or attempt to cause any Customer to divert, terminate, limit, modify or fail to enter into any existing or potential business relationship with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Employee Non-Solicitation</u><font style="font-size:12pt;">. &#160;Executive agrees that, during the Term and thereafter during the Protection Period, Executive will not directly or indirectly engage, solicit, hire, attempt to hire, or encourage any current employee or former employee (limited to former employees whose employment has been terminated or concluded for less than 6 months) of the Company to leave or terminate his or her employment relationship with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Disparagement</u><font style="font-size:12pt;">. &#160;Executive agrees that she will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the marketplace of the Company or any of its affiliates, employees, officers, directors, stockholders,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">members, principals or assigns. &#160;Subject to Executive&#8217;s continuing obligations to comply with Section 8(a) (Confidential Information) hereof, nothing in this Section 8(f) shall preclude Executive from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding, provided that, to the extent permitted by law and Section 8(i) hereof, Executive promptly informs the Company of any such obligation prior to participating in any such proceedings. &#160;The Company, defined for purposes of this Section 8(f) as the Board and its individual members, agrees in turn that it will not do or say anything that could reasonably be expected to disparage or impact negatively the name or reputation in the marketplace of Executive, provided that nothing in this Section 8(f) shall prevent the Company from responding truthfully to any legal process or truthfully testifying in a legal or regulatory proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Divisible Provisions</u><font style="font-size:12pt;">. The individual terms and provisions of this Section 8 are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Section 8 shall thereby be affected. &#160;It is the intention of Executive and the Company that the potential restrictions on Executive&#8217;s solicitation and future employment imposed by this Section 8 be reasonable in both duration and geographic scope and in all other respects. &#160;If for any reason any court of competent jurisdiction shall find any provisions of this Section 8 unreasonable in duration or geographic scope or otherwise, Executive and the Company agree that the restrictions and prohibitions contained herein may be modified by a court of competent jurisdiction and shall be effective to the fullest extent allowed under applicable law in such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Injunctive Relief and Remedies</u><font style="font-size:12pt;">. &#160;In event of a breach or threatened breach of any of Executive&#8217;s duties and obligations under this Section 8, the Company shall be entitled, in addition to any other legal or equitable remedies it may have in connection therewith (including any right to damages it may suffer), to (i) seek temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach, (ii) cease making payments or providing benefits under Section 5 of this Agreement (other than paragraph 5(a) thereof), and (iii) seek any other relief obtainable through statutory or common law means (including, but not limited to, applicable trade secrets law). &#160;Executive hereby expressly acknowledges that the harm that might result to the Company&#8217;s business as a result of any noncompliance by Executive with the provisions of this Section 8 may be largely irreparable. &#160;The restrictions stated in this Section 8 are in addition to and not in lieu of protections afforded to trade secrets and confidential information under applicable law. &#160;Nothing in this Section 8 is intended to or shall be interpreted as diminishing or otherwise limiting the Company&#8217;s right under applicable law to protect its trade secrets and confidential information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Protected Activity</u><font style="font-size:12pt;">. &#160;Nothing contained in this Agreement, or any other agreement, policy, practice, procedure, directive or instruction maintained by the Company shall prohibit Executive from reporting possible violations of federal, state or local laws or regulations to any federal, state or local governmental agency or commission (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Government Agency</u><font style="font-size:12pt;">&#8221;) or from making other disclosures that are protected under the whistleblower provisions of federal, state or local laws or regulations. &#160;Executive does not need prior authorization of any kind to make any such reports or disclosures to any Government Agency and Executive is not required to notify the Company that Executive has made such reports or disclosures. &#160;Nothing in this Agreement limits any right Executive may have to receive a whistleblower award or bounty for</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">information provided to any Government Agency. &#160;Executive hereby acknowledges that the Company has informed Executive, in accordance with 18 U.S.C. &#167; 1833(b), that Executive may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret where the disclosure: (i) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notification/Survival</u><font style="font-size:12pt;">. To enable the Company to monitor Executive&#8217;s compliance with the obligations imposed by this Section 8, Executive agrees to inform the Company during the Protection Period, of the identity of any subsequent employer and Executive&#8217;s new job title. &#160;Executive agrees that she will disclose the existence of this Section 8 to any subsequent employer. &#160;Following the expiration of the Term or this Agreement, this Section 8 shall survive and be of full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:12pt;">. &#160;As used in this Section 8, the following definitions shall apply</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221; means the Company and its subsidiaries and affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Competitive with the Company</u><font style="font-size:12pt;">&#8221; means a person, entity, business or activity that focuses on the development and commercialization of abuse deterrent biopharmaceutical products for the treatment of Attention-deficit/hyperactivity disorder, or ADHD, or any other proprietary biopharmaceutical products in development by the Company during Executive&#8217;s employment hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidential Information</u><font style="font-size:12pt;">&#8221; means information pertaining to the business of the Company that is generally not known to or readily ascertainable to the industry in which the Company competes, and that gives or tends to give the Company a competitive advantage over persons who do not possess such information or the secrecy of which is otherwise of value to the Company in the conduct of its business regardless of when and by whom such information &#160;was &#160;developed &#160;or &#160;acquired, &#160;and &#160;regardless &#160;of &#160;whether any &#160;of these &#160;are described in writing, copyrightable or considered copyrightable, patentable or considered patentable. &#160;Confidential Information includes, but is not limited to, the Company&#8217;s trade secrets, financial information or plans, pricing and profit information, sales and marketing information or plans, business or strategic plans, information concerning methods of operation, proprietary systems or software, legal or regulatory information, cost and pricing information or policies, information concerning new or potential products or markets, clinical data, medical or other data relating to participants in clinical trials, or research and/or analysis, information related to present and potential customers, vendors and suppliers (including, but not limited to, lists, contact information, requirements, contract terms, and pricing), methods of operations, research and development, product information, business technical information, including technical data, techniques, solutions, test methods, quality control systems, processes, design specifications, technical formulas, procedures and information, all agreements, schematics, manuals, studies, reports, and statistical information relating to the Company, all formulations, database files, information technology, strategic alliances, products, services, programs and processes used or sold, and all software licensed or developed by the Company, computer programs, systems and/or software, ideas, inventions, business information, know-how, improvements, designs, redesigns, creations,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">discoveries and developments of the Company. &#160;Confidential Information includes all forms of the information, whether oral, written or contained in electronic or any other format.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Customer</u><font style="font-size:12pt;">&#8221; means any actual or potential customer or client of the Company that (i) Executive knows to have been engaged as a customer or client of the Company during the 1 year period prior to the Date of Termination, (ii) Executive knows to have been contacted by the Company during the 1 year period prior to the Date of Termination or (iii) about which Executive had been provided or had access to Confidential Information during her employment with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Protection Period</u><font style="font-size:12pt;">&#8221; means the applicable Severance Period; provided, however, that such period shall be extended for an additional period of time equal to the time that elapses from the commencement of a breach of the covenants contained in this Section 8 until the termination of such breach.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Restricted Area</u><font style="font-size:12pt;">&#8221; means the geographic area or areas where Executive conducted activities on behalf of the Company (including its Affiliates). &#160;It is intended as of the Effective Date that the Restricted Area will include the entire United States, as Executive is engaged to provide services and has duties related to this entire geographic area.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Representations. &#160;</b><font style="font-size:12pt;">Executive hereby represents and warrants to the Company that Executive is not party to any contract, understanding, agreement or policy, whether or not written, with her current employer (or any other previous employer) or otherwise, that would be breached by Executive&#8217;s entering into, or performing services under, this Agreement. &#160;Executive further represents that she has disclosed to the Company in writing all material threatened, pending, or actual claims against Executive that are unresolved and still outstanding as of the Effective Date, in each case of which she is aware, resulting or arising from her service with her current employer (or any other previous employer) or her membership on any boards of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Cooperation</b><font style="font-size:12pt;">. &#160; During the Term and thereafter, Executive shall cooperate with the Company and its affiliates, without additional consideration, in any internal investigation or administrative, regulatory, or judicial proceeding as reasonably requested by the Company including, without limitation, Executive&#8217;s being available to the Company and its affiliates upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information, and turning over to the Company all relevant documents that are or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments and otherwise taking into account Executive&#8217;s reasonable business obligations. Executive shall be reimbursed for the reasonable expenses Executive incurs in connection with any such cooperation and/or assistance and shall receive from the Company hourly compensation equal to the Annual Base Salary immediately prior to the Date of Termination divided by 2,200 hours, in each case in connection with any assistance or cooperation that occurs after the Date of Termination. &#160;Any such reimbursements or per diem compensation shall be paid to Executive no later than the 15th day of the month immediately following the month in which such</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">expenses were incurred or such cooperation and/or assistance was provided (subject to Executive&#8217;s timely submission to the Company of proper documentation with respect thereto).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Notices</b><font style="font-size:12pt;">. &#160; Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by electronic mail, or sent by reputable overnight carrier, in each case with proof of receipt, to the recipient. &#160;Notices to Executive shall be sent to the address of Executive most recently provided to the Company. &#160;Notices to the Company should be sent to Vallon Pharmaceuticals, Inc., 100 N. 18th Street, Suite 300, Philadelphia, PA 19103, Attention: &#160;Chief Executive Officer. &#160;Any notice under this Agreement will be deemed to have been given when so delivered, sent or mailed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">12.</b></font><b style="font-size:12pt;font-weight:bold;">Severability</b><font style="font-size:12pt;">. The invalidity or unenforceability of any particular provision in this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if the invalid or unenforceable provision were omitted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">13.</b></font><b style="font-size:12pt;font-weight:bold;">Complete Agreement</b><font style="font-size:12pt;">. This Agreement, along with the Indemnity Agreement between Executive and the Company dated as of the Effective Date, embodies the complete agreement and understanding between the parties with respect to the subject matter hereof and effective as of its date supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject matter hereof in any way.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">14.</b></font><b style="font-size:12pt;font-weight:bold;">Withholding of Taxes</b><font style="font-size:12pt;">. &#160;The Company and its affiliates may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as the Company and its affiliates are required to withhold pursuant to any law or government regulation or ruling.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">15.</b></font><b style="font-size:12pt;font-weight:bold;">Successors and Assigns</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">This Agreement is personal to Executive, and, without the prior written consent of the Company, shall not be assignable by Executive other than by will or the laws of descent and distribution. &#160;This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. &#160;Except as provided in Section 15(c), without the prior written consent of Executive this Agreement shall not be assignable by the Company, except to an affiliate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. &#160;&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221; means the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid that assumes and agrees to perform this Agreement by operation of law or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">16.</b></font><b style="font-size:12pt;font-weight:bold;">Choice of Law</b><font style="font-size:12pt;">. This Agreement shall be governed, construed, interpreted and enforced in accordance with the substantive laws of the Commonwealth of Pennsylvania,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">without regard to conflicts of law principles. &#160;The parties hereto irrevocably agree to submit to the jurisdiction and venue of the federal and state courts located in Philadelphia, Pennsylvania in any court action or proceeding brought with respect to or in connection with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">17.</b></font><b style="font-size:12pt;font-weight:bold;">Amendment and Waiver</b><font style="font-size:12pt;">. &#160;The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">18.</b></font><b style="font-size:12pt;font-weight:bold;">Section 409A Compliance</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">In General</u><font style="font-size:12pt;">. &#160;The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 409A</u><font style="font-size:12pt;">&#8221;) or are exempt therefrom and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered so as to be in compliance therewith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation from Service</u><font style="font-size:12pt;">. &#160;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A, and for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service&#8221; within the meaning of Section 409A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Reimbursements or In-Kind Benefits</u><font style="font-size:12pt;">. &#160;With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred, or such earlier date as required hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Six Month Delay</u><font style="font-size:12pt;">. &#160;Notwithstanding anything contained in this Agreement to the contrary, if Executive is a &#8220;specified employee,&#8221; as determined under the Company&#8217;s policy for identifying specified employees on the Date of Termination, then to the extent required in order to comply with Section 409A, all payments, benefits or reimbursements paid or provided under this Agreement that constitute a &#8220;deferral of compensation&#8221; within the meaning of Section 409A, that are provided as a result of a &#8220;separation from service&#8221; within the meaning of Section 409A and that would otherwise be paid or provided during the first six months following such Date of Termination shall be accumulated through and paid or provided (without interest), within 20 calendar days after the first business day that is more than six months after the date of her separation from service (or, if Executive dies during such six-month period, within 20 calendar days after Executive&#8217;s death).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Payment Dates</u><font style="font-size:12pt;">. &#160;Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><i style="font-size:12pt;font-style:italic;">e.g.,</i><font style="font-size:12pt;"> &#8220;within 20 calendar days after the Release described in Section 6 becomes effective and irrevocable&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company. &#160;In the event the payment period under this Agreement for any nonqualified deferred compensation commences in one calendar year and ends in a second calendar year, the payments shall not be paid (or installments commenced) until the later of the first payroll date of the second calendar year, or the date that such Release becomes effective and irrevocable, to the extent necessary to comply with Section 409A. &#160;For purposes of Section 409A, Executive&#8217;s right to receive any &#8220;installment&#8221; payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">19.</b></font><b style="font-size:12pt;font-weight:bold;">Counterparts</b><font style="font-size:12pt;">. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by electronic mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VALLON PHARMACEUTICALS, INC.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ David Baker</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: David Baker</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Its:  President and Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">EXECUTIVE</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Leanne M. Kelly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Leanne M. Kelly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">15</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GENERAL RELEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This General Release (this &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Release</u><font style="font-size:12pt;">&#8221;) is made and entered into as of this [</font><font style="font-family:'Times New Roman';">&#9679;</font><font style="font-size:12pt;">] day of [</font><font style="font-family:'Times New Roman';">&#9679;</font><font style="font-size:12pt;">], 20[</font><font style="font-family:'Times New Roman';">&#9679;</font><font style="font-size:12pt;">], by and between Vallon Pharmaceuticals, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;) and Leanne M. Kelly (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Employment Status</b><font style="font-size:12pt;">. Executive&#8217;s employment with the Company and its affiliates terminated effective as of [</font><font style="font-family:'Times New Roman';">&#9679;</font><font style="font-size:12pt;">], 20[</font><font style="font-family:'Times New Roman';">&#9679;</font><font style="font-size:12pt;">] (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation Date</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Payments and Benefits</b><font style="font-size:12pt;">. &#160;Upon the effectiveness of the terms set forth herein, the Company shall provide Executive with the benefits set forth in Section 5(b)/(c) of the Employment Agreement between Executive and the Company dated as of May ___, 2021 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Employment Agreement</u><font style="font-size:12pt;">&#8221;), upon the terms, and subject to the conditions, of the Employment Agreement. &#160;Executive agrees that Executive is not entitled to receive any additional payments as wages, vacation or bonuses except as otherwise provided under Section 5(b)/(c) of the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-size:12pt;font-weight:bold;">No Liability</b><font style="font-size:12pt;">. This Release does not constitute an admission by the Company, or any of its parents, subsidiaries, affiliates, divisions, officers, directors, partners, agents, or employees, or by Executive, of any unlawful acts or of any violation of federal, state or local laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Release</b><font style="font-size:12pt;">. &#160;In consideration of the payments and benefits set forth in Section 2 above, Executive for herself, her heirs, administrators, representatives, executors, successors and assigns does hereby irrevocably and unconditionally release, acquit and forever discharge the Company and each of its parents, subsidiaries, affiliates, divisions, successors, assigns, officers, directors, partners, agents, attorneys, and former and current employees, including without limitation all persons acting by, through, under or in concert with any of them (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Releasees</u><font style="font-size:12pt;">&#8221;), and each of them, from any and all claims, demands, actions, causes of action, costs, attorney fees, and all liability whatsoever, whether known or unknown, fixed or contingent, which Executive has, had, or may ever have against the Releasees relating to or arising out of Executive&#8217;s employment or separation from employment with the Company, from the beginning of time and up to and including the date Executive executes this Release. This Release includes, without limitation, (i) law or equity claims; (ii) contract (express or implied) or tort claims; (iii) claims for wrongful discharge, retaliatory discharge, whistle blowing, libel, slander, defamation, unpaid compensation, intentional infliction of emotional distress, fraud, public policy, contract or tort, and implied covenant of good faith and fair dealing; (iv) claims arising under any federal, state, or local laws of any jurisdiction that prohibit age, sex, race, national origin, color, disability, religion, veteran, military status, sexual orientation, or any other form of discrimination, harassment, or retaliation (including without limitation under the Age Discrimination in Employment Act of 1967 as amended by the Older Workers Benefit Protection Act (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">ADEA</u><font style="font-size:12pt;">&#8221;), the National Labor Relations Act, Executive Order 11246, the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act, Title VII of the Civil Rights Act of 1964 as amended by the Civil Rights Act of 1991, Section 1981 of the Civil Rights Act of 1966, the Equal Pay Act of 1962, the Americans with Disabilities Act of 1990, the Rehabilitation Act of 1973, the Family and Medical Leave Act of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1993, the Consolidated Omnibus Budget Reconciliation Act (COBRA), the Genetic Information Non-discrimination Act, the Sarbanes-Oxley Act, the Employee Polygraph Protection Act, the Uniformed Services Employment and Reemployment Rights Act of 1994, the Equal Pay Act, the Lilly Ledbetter Fair Pay Act, the Post-Civil War Civil Rights Act (42 U.S.C. &#167;&#167;1981-1988), or any other foreign, federal, state or local law or judicial decision), (v) claims arising under the Employee Retirement Income Security Act (excluding claims for amounts that are vested benefits or that Executive is otherwise entitled to receive under any employee benefit plan of the Company or any of its affiliates in accordance with the terms of such plan and applicable law), and (vi) any other statutory or common law claims related to Executive&#8217;s employment with the Company or the separation of Executive&#8217;s employment with the Company; provided, however, that nothing herein shall release any obligation of the Company under the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Protected Activity</b><font style="font-size:12pt;">. &#160;Nothing contained in this Release limits Executive&#8217;s ability to file a charge or complaint with any federal, state or local governmental agency or commission (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Government Agency</u><font style="font-size:12pt;">&#8221;). &#160;In addition, nothing in this Release or any other Company agreement, policy, practice, procedure, directive or instruction shall prohibit Executive from reporting possible violations of federal, state or local laws or regulations to any Government Agency or making other disclosures that are protected under the whistleblower provisions of federal, state or local laws or regulations. &#160;Executive does not need prior authorization of any kind to make any such reports or disclosures and Executive is not required to notify the Company that Executive has made such reports or disclosures. &#160;If Executive files any charge or complaint with any Government Agency, and if the Government Agency pursues any claim on Executive&#8217;s behalf, or if any other third party pursues any claim on Executive&#8217;s behalf, Executive waives any right to monetary or other individualized relief (either individually, or as part of any collective or class action) that arises out of alleged facts or circumstances on or before the effective date of this Release; provided that nothing in this Release limits any right Executive may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission or other Government Agency.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Bar</b><font style="font-size:12pt;">. Executive and the Company acknowledge and agree that if she or it should hereafter make any claim or demand or commence or threaten to commence any action, claim or proceeding against the other party with respect to any cause, matter or thing which is the subject of the releases under Section 4 of this Release, this Release may be raised as a complete bar to any such action, claim or proceeding, and the applicable Releasee may recover from the other party all costs incurred in connection with such action, claim or proceeding, including attorneys&#8217; fees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Governing Law</b><font style="font-size:12pt;">. This Release shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to conflicts of laws principles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Acknowledgment</b><font style="font-size:12pt;">. Executive has read this Release, understands it, and voluntarily accepts its terms, and Executive acknowledges that she has been advised by the Company to seek the advice of legal counsel before entering into this Release, and has been provided with a period of at least twenty-one (21) days in which to consider entering into this Release. &#160;Executive acknowledges and agrees that the payments and benefits provided under</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Section 2 of this Release represent substantial value over and above that to which Executive would otherwise be entitled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Revocation</b><font style="font-size:12pt;">. Executive has a period of seven (7) days following the execution of this Release during which Executive may revoke this Release by delivering written notice to the Company, and this Release shall not become effective or enforceable until such revocation period has expired. &#160;Executive understands that if she revokes this Release, it will be null and void in its entirety, and she will not be entitled to any payments or benefits provided in this Release, including without limitation those under Section 2 above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Miscellaneous</b><font style="font-size:12pt;">. This Release is the complete understanding between Executive and the Company in respect of the subject matter of this Release and supersedes all prior agreements relating to the same subject matter. Executive has not relied upon any representations, promises or agreements of any kind except those set forth herein in signing this Release. In the event that any provision of this Release should be held to be invalid or unenforceable, each and all of the other provisions of this Release shall remain in full force and effect. If any provision of this Release is found to be invalid or unenforceable, such provision shall be modified as necessary to permit this Release to be upheld and enforced to the maximum extent permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Counterparts</b><font style="font-size:12pt;">. This Release may be executed by the parties hereto in counterparts, which taken together shall be deemed one original.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">VALLON PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">[Form of release &#8211; Do not sign]</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXECUTIVE</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">[Form of release &#8211; Do not sign]</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Leanne M. Kelly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">A-</font><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>vlon-20210331xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, David Baker, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2021</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Baker</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Baker</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>vlon-20210331xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Leanne M. Kelly, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2021</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leanne M Kelly</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leanne M. Kelly</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:40.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>vlon-20210331xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the &#8220;<i style="font-style:italic;">Company</i>&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the &#8220;<i style="font-style:italic;">Quarterly Report</i>&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2021</p></td><td style="vertical-align:top;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Baker</p></td></tr><tr><td style="vertical-align:top;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Baker</p></td></tr><tr><td style="vertical-align:top;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>vlon-20210331xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/13/2021 01:11:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Leanne M. Kelly, Chief Financial Officer of Vallon Pharmaceuticals, Inc. (the &#8220;<i style="font-style:italic;">Company</i>&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021 (the &#8220;<i style="font-style:italic;">Quarterly Report</i>&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 13, 2021</p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.17%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leanne M. Kelly</p></td></tr><tr><td style="vertical-align:top;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leanne M. Kelly</p></td></tr><tr><td style="vertical-align:top;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:41.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:41.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vlon-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2021 1:11:52 PM-->
<!--Modified on: 5/13/2021 1:11:52 PM-->
<xsd:schema targetNamespace="http://www.vallon-pharma.com/20210331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:vlon="http://www.vallon-pharma.com/20210331">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementBalanceSheet" id="StatementBalanceSheet">
        <link:definition>00100 - Statement - Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40301 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" id="DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails">
        <link:definition>40902 - Disclosure - FINANCE LEASE - Maturities of finance lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit" id="StatementStatementsOfStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" id="DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails">
        <link:definition>40101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails" id="DisclosurePppNoteAndConvertibleNotesDetails">
        <link:definition>40401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails" id="DisclosureEquityFinancingDetails">
        <link:definition>40501 - Disclosure - EQUITY FINANCING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" id="DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails">
        <link:definition>40502 - Disclosure - EQUITY FINANCING - Estimate the fair value of the warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>40601 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" id="DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails">
        <link:definition>40602 - Disclosure - STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" id="DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails">
        <link:definition>40603 - Disclosure - STOCK-BASED COMPENSATION - Activity of stock options granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" id="DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails">
        <link:definition>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" id="DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails">
        <link:definition>41002 - Disclosure - COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" id="DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails">
        <link:definition>41003 - Disclosure - COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" id="DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails">
        <link:definition>41004 - Disclosure - COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" id="DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails">
        <link:definition>41005 - Disclosure - COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical" id="StatementBalanceSheetParenthetical">
        <link:definition>00105 - Statement - Balance Sheet (parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical" id="StatementStatementsOfStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity" id="DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10301 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes" id="DisclosurePppNoteAndConvertibleNotes">
        <link:definition>10401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancing" id="DisclosureEquityFinancing">
        <link:definition>10501 - Disclosure - EQUITY FINANCING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10601 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10701 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10801 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLease" id="DisclosureFinanceLease">
        <link:definition>10901 - Disclosure - FINANCE LEASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11101 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables" id="DisclosureEquityFinancingTables">
        <link:definition>30503 - Disclosure - EQUITY FINANCING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30603 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables" id="DisclosureFinanceLeaseTables">
        <link:definition>30903 - Disclosure - FINANCE LEASE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31103 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>40701 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails" id="DisclosureFinanceLeaseDetails">
        <link:definition>40901 - Disclosure - FINANCE LEASE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>41101 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="vlon-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vlon-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vlon-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vlon-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_TransitionReport" name="TransitionReport" nillable="true" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_NonCashInterestDepreciationAndOtherExpense" name="NonCashInterestDepreciationAndOtherExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_MediceMember" name="MediceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_RelatedPartyTransactionUpfrontPayment" name="RelatedPartyTransactionUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" name="AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AccruedChemistryAndManufacturingExpensesCurrent" name="AccruedChemistryAndManufacturingExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AccruedLicensingFeesCurrent" name="AccruedLicensingFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock" name="UnauditedInterimFinancialStatementsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_EquityFinancingAbstract" name="EquityFinancingAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_UnderwritersWarrantsMember" name="UnderwritersWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" name="SaleOfStockUnderwritingDiscountsAndOtherExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_SaleOfStockOtherOfferingCosts" name="SaleOfStockOtherOfferingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" name="PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_EquityFinancingDisclosureTextBlock" name="EquityFinancingDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AmiserviceDevelopmentLtdMember" name="AmiserviceDevelopmentLtdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ArcturusTherapeuticsLtdMember" name="ArcturusTherapeuticsLtdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AdairProductRightsAcquisitionMember" name="AdairProductRightsAcquisitionMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" name="AgreementPurchasePriceProductRightsPriorToBusinessFormation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" name="MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" name="PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AssetPurchaseAgreementReimbursementOfExpenses" name="AssetPurchaseAgreementReimbursementOfExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_NumberOfPromissoryNotes" name="NumberOfPromissoryNotes" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_WeightedAverageRemainingContractualTermAbstract" name="WeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_EmploymentAgreementWithLeanneM.KellyMember" name="EmploymentAgreementWithLeanneM.KellyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_VestOnFirstAnniversaryOfStartDateMember" name="VestOnFirstAnniversaryOfStartDateMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" name="VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" name="VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" name="VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_IfTerminationNotInConnectionWithChangeInControlMember" name="IfTerminationNotInConnectionWithChangeInControlMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" name="IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_CobraHealthInsuranceCoveragePeriod" name="CobraHealthInsuranceCoveragePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_NewEmploymentAgreementWithDavidBakerMember" name="NewEmploymentAgreementWithDavidBakerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" name="InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" name="InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ClinicalTrialAgreementsMember" name="ClinicalTrialAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_AdairStudyVal104Member" name="AdairStudyVal104Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_TerminationPeriodUponPriorWrittenNotice" name="TerminationPeriodUponPriorWrittenNotice" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ClinicalTrialCostExpectedAmount" name="ClinicalTrialCostExpectedAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ProfessionalFeesPaidPerMonth" name="ProfessionalFeesPaidPerMonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ManufacturingAgreementsMember" name="ManufacturingAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" name="ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" name="ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_EstimatedContractCosts" name="EstimatedContractCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" name="PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>vlon-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2021 1:11:52 PM-->
<!--Modified on: 5/13/2021 1:11:52 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementBalanceSheet" roleURI="http://www.vallon-pharma.com/role/StatementBalanceSheet" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfOperations" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" />
  <calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementBalanceSheet" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637565083113437192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637565083113437192" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083113447194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565083113437192" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083113447194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637565083113447194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637565083113437192" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637565083113447194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637565083113447194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637565083113447194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637565083113457227" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637565083113457227" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637565083113457227" xlink:to="us-gaap_LiabilitiesCurrent_637565083113457227" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565083113457227" xlink:to="us-gaap_AccountsPayableCurrent_637565083113457227" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565083113457227" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637565083113457227" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565083113457227" xlink:to="us-gaap_NotesPayableCurrent_637565083113457227" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637565083113457227" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637565083113457227" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637565083113457227" xlink:to="us-gaap_LongTermNotesPayable_637565083113457227" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637565083113457227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637565083113457227" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637565083113457227" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637565083113467195" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637565083113467195" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637565083113467195" xlink:to="us-gaap_AdditionalPaidInCapital_637565083113467195" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637565083113467195" xlink:to="us-gaap_CommonStockValue_637565083113467195" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637565083113467195" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637565083113467195" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637565083113467195" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637565083113467195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565083113467195" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637565083113467195" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637565083113467195" xlink:to="us-gaap_OperatingExpenses_637565083113477194" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637565083113477194" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565083113477194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637565083113477194" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637565083113477194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncome_637565083113477194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637565083113477194" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet_637565083113477194" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_ProfitLoss_637565083113477194" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083113477194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083113477194" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_ShareBasedCompensation_637565083113487196" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637565083113487196" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083113487196" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NonCashInterestDepreciationAndOtherExpense" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="vlon_NonCashInterestDepreciationAndOtherExpense_637565083113487196" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637565083113487196" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637565083113487196" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083113477194" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637565083113487196" order="9" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565083113487196" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565083113487196" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565083113487196" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083113487196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083113487196" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083113487196" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083113497195" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083113487196" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637565083113497195" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083113487196" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637565083113497195" order="3" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCRUED EXPENSES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedChemistryAndManufacturingExpensesCurrent" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vlon_AccruedChemistryAndManufacturingExpensesCurrent_637565083113497195" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_637565083113497195" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedLicensingFeesCurrent" xlink:label="vlon_AccruedLicensingFeesCurrent_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vlon_AccruedLicensingFeesCurrent_637565083113497195" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637565083113497195" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637565083113497195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent_637565083113497195" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637565083113507196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637565083113507196" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - FINANCE LEASE - Maturities of finance lease liability (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_637565083113507196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_637565083113507196" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637565083113507196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637565083113507196" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637565083113507196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637565083113507196" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>vlon-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2021 1:11:52 PM-->
<!--Modified on: 5/13/2021 1:11:52 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosurePppNoteAndConvertibleNotesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancingDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565083113607219" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637565083113607219" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637565083113637204" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637565083113637204" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ArcturusTherapeuticsLtdMember" xlink:label="vlon_ArcturusTherapeuticsLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="vlon_ArcturusTherapeuticsLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083113637204" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083113637204" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637565083113637204" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637565083113637204" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AmiserviceDevelopmentLtdMember" xlink:label="vlon_AmiserviceDevelopmentLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vlon_AmiserviceDevelopmentLtdMember" priority="1" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vlon_ArcturusTherapeuticsLtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637565083113647201" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637565083113647201" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637565083113659729" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637565083113659729" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairProductRightsAcquisitionMember" xlink:label="vlon_AdairProductRightsAcquisitionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vlon_AdairProductRightsAcquisitionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AssetPurchaseAgreementReimbursementOfExpenses" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="vlon_AssetPurchaseAgreementReimbursementOfExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NumberOfPromissoryNotes" xlink:label="vlon_NumberOfPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="vlon_NumberOfPromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCostAndExpenseOperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637565083113707225" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_637565083113707225" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565083113707225" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637565083113707225" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PaycheckProtectionProgramLoanMember" xlink:label="vlon_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vlon_PaycheckProtectionProgramLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails" xlink:type="extended" xlink:title="40501 - Disclosure - EQUITY FINANCING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637565083113727214" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637565083113727214" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637565083113727214" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637565083113727214" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_UnderwritersWarrantsMember" xlink:label="vlon_UnderwritersWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="vlon_UnderwritersWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_GrossProceedsFromInitialPublicOffering" xlink:label="vlon_GrossProceedsFromInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vlon_GrossProceedsFromInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockOtherOfferingCosts" xlink:label="vlon_SaleOfStockOtherOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vlon_SaleOfStockOtherOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - EQUITY FINANCING - Estimate the fair value of the warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637565083113757272" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637565083113757272" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637565083113767224" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637565083113767224" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40602 - Disclosure - STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637565083113777216" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637565083113777216" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" xlink:type="extended" xlink:title="40603 - Disclosure - STOCK-BASED COMPENSATION - Activity of stock options granted (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637565083113787216" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_637565083113787216" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_WeightedAverageRemainingContractualTermAbstract" xlink:label="vlon_WeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vlon_WeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vlon_WeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vlon_WeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AggregateIntrinsicValueAbstract" xlink:label="vlon_AggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vlon_AggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vlon_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vlon_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vlon_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vlon_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637565083113817230" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637565083113817230" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MediceMember" xlink:label="vlon_MediceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vlon_MediceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_RelatedPartyTransactionUpfrontPayment" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="vlon_RelatedPartyTransactionUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083113827219" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083113827219" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NewEmploymentAgreementWithDavidBakerMember" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_NewEmploymentAgreementWithDavidBakerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637565083113837219" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637565083113837219" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_CobraHealthInsuranceCoveragePeriod" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_CobraHealthInsuranceCoveragePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637565083113847219" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637565083113847219" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairStudyVal104Member" xlink:label="vlon_AdairStudyVal104Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="vlon_AdairStudyVal104Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialAgreementsMember" xlink:label="vlon_ClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_ClinicalTrialAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TerminationPeriodUponPriorWrittenNotice" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_TerminationPeriodUponPriorWrittenNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialCostExpectedAmount" xlink:label="vlon_ClinicalTrialCostExpectedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_ClinicalTrialCostExpectedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ConsultingAgreementsMember" xlink:label="vlon_ConsultingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_ConsultingAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ProfessionalFeesPaidPerMonth" xlink:label="vlon_ProfessionalFeesPaidPerMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_ProfessionalFeesPaidPerMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TerminationPeriodUponPriorWrittenNotice" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_TerminationPeriodUponPriorWrittenNotice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementsMember" xlink:label="vlon_ManufacturingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_ManufacturingAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="vlon_ManufacturingAgreementsMember" xlink:to="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vlon_ManufacturingAgreementsMember" xlink:to="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EstimatedContractCosts" xlink:label="vlon_EstimatedContractCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_EstimatedContractCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingCosts" xlink:label="us-gaap_ManufacturingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ManufacturingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EstimatedContractCosts" xlink:label="vlon_EstimatedContractCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vlon_EstimatedContractCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EmploymentAgreementWithLeanneM.KellyMember" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vlon_EmploymentAgreementWithLeanneM.KellyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637565083113897220" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637565083113897220" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637565083113907221" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637565083113907221" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637565083113907221" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637565083113907221" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_637565083113917228" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_637565083113917228" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnFirstAnniversaryOfStartDateMember" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="vlon_VestOnFirstAnniversaryOfStartDateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AwardDateDomain" xlink:to="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AwardDateDomain" xlink:to="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationNotInConnectionWithChangeInControlMember" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vlon_IfTerminationNotInConnectionWithChangeInControlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_CobraHealthInsuranceCoveragePeriod" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vlon_CobraHealthInsuranceCoveragePeriod" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>vlon-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2021 1:11:52 PM-->
<!--Modified on: 5/13/2021 1:11:52 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TransitionReport" xlink:label="vlon_TransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_TransitionReport" xlink:to="vlon_TransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_TransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boolean flag that is true when the company has a shorter operating period because the period of inception of the company is later than the start of the reporting period, therefore, the Fiscal Period Focus is longer than the actual period of operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_TransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transition Report</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash held outside the Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use asset, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note payable, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liability, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note payable, non-current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 10)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 6,812,836 and 4,506,216 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively, which gives retroactive effect to the one-for-40 reverse stock split. See Note 1 to these financial statements.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenue-related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation of derivative liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for convertible notes (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for IPO, net of issuance expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for IPO, net of issuance expenses (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for services (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Underwriters Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants classified as additional paid in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of finance lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from finance lease amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forgiveness of PPP note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from extinguishment of loan</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NonCashInterestDepreciationAndOtherExpense" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_NonCashInterestDepreciationAndOtherExpense" xlink:to="vlon_NonCashInterestDepreciationAndOtherExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash interest, depreciation and other income (expense) included in net income that results in no cash inflow (outflow).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Interest, Depreciation And Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest, depreciation and other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from common stock, net of offering expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of finance lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing cash flows from finance lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible notes to common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PPP NOTE AND CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PPP NOTE AND CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingAbstract" xlink:label="vlon_EquityFinancingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_EquityFinancingAbstract" xlink:to="vlon_EquityFinancingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_EquityFinancingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_EquityFinancingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY FINANCING</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingDisclosureTextBlock" xlink:label="vlon_EquityFinancingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_EquityFinancingDisclosureTextBlock" xlink:to="vlon_EquityFinancingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_EquityFinancingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of equity financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_EquityFinancingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Financing Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_EquityFinancingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY FINANCING</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCE LEASE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCE LEASE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for unaudited interim financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Statements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimates used for fair value of the warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used to estimate fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity of stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of finance lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of liability measured at estimated fair value using unobservable inputs</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" xlink:to="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount agreed for the purchase of product rights prior to business formation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Purchase Price, Product Rights, Prior to Business Formation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" xlink:to="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount agreed under the asset purchase agreement for funding the development of product, as per the key terms and conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Amount Agreed, Asset Purchase Agreement, Prior to Business Formation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum funds for product development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" xlink:to="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares then outstanding at the issuance on a diluted basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Shares of Outstanding at Issuance, on a Diluted Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares held on fully-diluted basis</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AssetPurchaseAgreementReimbursementOfExpenses" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AssetPurchaseAgreementReimbursementOfExpenses" xlink:to="vlon_AssetPurchaseAgreementReimbursementOfExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reimbursement of expenses incurred under the asset purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Purchase Agreement, Reimbursement of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement for expenses</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NumberOfPromissoryNotes" xlink:label="vlon_NumberOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_NumberOfPromissoryNotes" xlink:to="vlon_NumberOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_NumberOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_NumberOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_NumberOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of promissory notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of Promissory notes due</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Cost and Expense, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Acquisition Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exclusivity payment fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted during the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" xlink:to="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for Clinical and preclinical trial and regulatory related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical and Preclinical Trial and Regulatory Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical and preclinical trial and regulatory related</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedChemistryAndManufacturingExpensesCurrent" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AccruedChemistryAndManufacturingExpensesCurrent" xlink:to="vlon_AccruedChemistryAndManufacturingExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for chemistry and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Chemistry and Manufacturing Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chemistry and manufacturing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing related</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedLicensingFeesCurrent" xlink:label="vlon_AccruedLicensingFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AccruedLicensingFeesCurrent" xlink:to="vlon_AccruedLicensingFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AccruedLicensingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for licensing related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AccruedLicensingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Licensing Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AccruedLicensingFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing related</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory note, principal amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares converted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price, per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_GrossProceedsFromInitialPublicOffering" xlink:label="vlon_GrossProceedsFromInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_GrossProceedsFromInitialPublicOffering" xlink:to="vlon_GrossProceedsFromInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_GrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gross proceeds from initial public offering during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_GrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Proceeds from Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_GrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" xlink:to="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of underwriting discounts and other expenses incurred and paid for underwriters to the public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Underwriting Discounts and Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts and expenses</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockOtherOfferingCosts" xlink:label="vlon_SaleOfStockOtherOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_SaleOfStockOtherOfferingCosts" xlink:to="vlon_SaleOfStockOtherOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other offering costs incurred in connection with the initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Other Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants to purchase shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" xlink:to="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares on initial public offering price for warrants exercisable by underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Shares on Initial Public Offering Price Upon Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of public offering price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions to estimate the fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term in years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of option on grant date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted during the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_WeightedAverageRemainingContractualTermAbstract" xlink:label="vlon_WeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_WeightedAverageRemainingContractualTermAbstract" xlink:to="vlon_WeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_WeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_WeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual terms (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding balance of period (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (years)</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AggregateIntrinsicValueAbstract" xlink:label="vlon_AggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AggregateIntrinsicValueAbstract" xlink:to="vlon_AggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average period expected to be recognized (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_RelatedPartyTransactionUpfrontPayment" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_RelatedPartyTransactionUpfrontPayment" xlink:to="vlon_RelatedPartyTransactionUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payment on milestone payments under the agreement with a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term - finance lease (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate - finance lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of finance lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial base annual salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base salary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Maximum Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base salary period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum employment period</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_CobraHealthInsuranceCoveragePeriod" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_CobraHealthInsuranceCoveragePeriod" xlink:to="vlon_CobraHealthInsuranceCoveragePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of COBRA health insurance coverage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COBRA, Health Insurance Coverage Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COBRA coverage period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of base salary</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TerminationPeriodUponPriorWrittenNotice" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_TerminationPeriodUponPriorWrittenNotice" xlink:to="vlon_TerminationPeriodUponPriorWrittenNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of termination upon prior written notice.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination Period Upon Prior Written Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination period upon prior notice</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialCostExpectedAmount" xlink:label="vlon_ClinicalTrialCostExpectedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ClinicalTrialCostExpectedAmount" xlink:to="vlon_ClinicalTrialCostExpectedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ClinicalTrialCostExpectedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of clinical trial cost expected.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ClinicalTrialCostExpectedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Cost, Expected Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ClinicalTrialCostExpectedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total expected clinical trial cost</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ProfessionalFeesPaidPerMonth" xlink:label="vlon_ProfessionalFeesPaidPerMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ProfessionalFeesPaidPerMonth" xlink:to="vlon_ProfessionalFeesPaidPerMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ProfessionalFeesPaidPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of professional fees paid per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ProfessionalFeesPaidPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fees, Paid per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ProfessionalFeesPaidPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting fees paid per month</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting fees incurred</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EstimatedContractCosts" xlink:label="vlon_EstimatedContractCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_EstimatedContractCosts" xlink:to="vlon_EstimatedContractCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_EstimatedContractCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of estimated contract costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_EstimatedContractCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Contract Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_EstimatedContractCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated contract costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingCosts" xlink:label="us-gaap_ManufacturingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingCosts" xlink:to="us-gaap_ManufacturingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense recognized on embedded derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability measured at estimated fair value using unobservable inputs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions during the quarter ended March 31, 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer out of Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option to be granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ArcturusTherapeuticsLtdMember" xlink:label="vlon_ArcturusTherapeuticsLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ArcturusTherapeuticsLtdMember" xlink:to="vlon_ArcturusTherapeuticsLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ArcturusTherapeuticsLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amiservice Development Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ArcturusTherapeuticsLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arcturus Therapeutics Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ArcturusTherapeuticsLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arcturus Therapeutics Ltd</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board Of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ofir Levi, Chairman</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AmiserviceDevelopmentLtdMember" xlink:label="vlon_AmiserviceDevelopmentLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AmiserviceDevelopmentLtdMember" xlink:to="vlon_AmiserviceDevelopmentLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AmiserviceDevelopmentLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Amiservice Development Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AmiserviceDevelopmentLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amiservice Development Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AmiserviceDevelopmentLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amiservice Development Ltd</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairProductRightsAcquisitionMember" xlink:label="vlon_AdairProductRightsAcquisitionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AdairProductRightsAcquisitionMember" xlink:to="vlon_AdairProductRightsAcquisitionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AdairProductRightsAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to ADAIR product rights acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AdairProductRightsAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adair Product Rights Acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AdairProductRightsAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADAIR acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">David Baker</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PaycheckProtectionProgramLoanMember" xlink:label="vlon_PaycheckProtectionProgramLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_PaycheckProtectionProgramLoanMember" xlink:to="vlon_PaycheckProtectionProgramLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to paycheck protection program loan (PPP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paycheck Protection Program Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses And Other Current Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_UnderwritersWarrantsMember" xlink:label="vlon_UnderwritersWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_UnderwritersWarrantsMember" xlink:to="vlon_UnderwritersWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to underwriters' warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_UnderwritersWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-employee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MediceMember" xlink:label="vlon_MediceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_MediceMember" xlink:to="vlon_MediceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_MediceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Medice, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_MediceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medice [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_MediceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medice</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affiliated Entity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salmon Pharma</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NewEmploymentAgreementWithDavidBakerMember" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_NewEmploymentAgreementWithDavidBakerMember" xlink:to="vlon_NewEmploymentAgreementWithDavidBakerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to New employment agreement with David Baker.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Employment Agreement With David Baker [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baker Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" xlink:to="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of an involuntary termination by the Company or termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Event Of Involuntary Termination By Entity Or Termination For Good Reason [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of an involuntary termination by the Company or termination</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" xlink:to="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of a termination within 12 months after the occurrence of a change in control transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Event Of Termination Within12 Months After Occurrence Of Change In Control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of a termination within 12 months after the occurrence of a change in control transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairStudyVal104Member" xlink:label="vlon_AdairStudyVal104Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_AdairStudyVal104Member" xlink:to="vlon_AdairStudyVal104Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_AdairStudyVal104Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to ADAIR, Study VAL-104.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_AdairStudyVal104Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adair Study Val104 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_AdairStudyVal104Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Study VAL-104</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialAgreementsMember" xlink:label="vlon_ClinicalTrialAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ClinicalTrialAgreementsMember" xlink:to="vlon_ClinicalTrialAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Clinical Trial Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Agreements</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ConsultingAgreementsMember" xlink:label="vlon_ConsultingAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ConsultingAgreementsMember" xlink:to="vlon_ConsultingAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ConsultingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to consulting agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ConsultingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ConsultingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreements</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementsMember" xlink:label="vlon_ManufacturingAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ManufacturingAgreementsMember" xlink:to="vlon_ManufacturingAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ManufacturingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to manufacturing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ManufacturingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ManufacturingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" xlink:to="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Agreement With Contract Manufacturer For Commercial Scale Up And Registration Batches For Adair [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" xlink:to="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Agreement With Formulation Development Company For Formulation And Development For Abuse Deterrent Formulation Of Methylphenidate Ritalin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin)</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" xlink:to="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to pre-clinical agreement (included in research and development expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Clinical Agreement Included In Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Clinical Agreement (included in research and development expense)</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EmploymentAgreementWithLeanneM.KellyMember" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_EmploymentAgreementWithLeanneM.KellyMember" xlink:to="vlon_EmploymentAgreementWithLeanneM.KellyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to employment agreement with Leanne M. Kelly.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement With Leanne M. Kelly [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kelly Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leanne M. Kelly</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche, one</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche, two</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnFirstAnniversaryOfStartDateMember" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_VestOnFirstAnniversaryOfStartDateMember" xlink:to="vlon_VestOnFirstAnniversaryOfStartDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on First Anniversary of Start Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest On First Anniversary Of Start Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on First Anniversary of Start Date</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" xlink:to="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest in Equal Installments on Quarterly Basis for Next Three Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest In Equal Installments On Quarterly Basis For Next Three Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest in Equal Installments on Quarterly Basis for Next Three Years</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" xlink:to="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on Date the Entity Submits New Drug Application ("NDA") Filing for ADAIR with U.S. Food &amp; Drug Administration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest On Date Entity Submits New Drug Application Nda Filing For Adair With U.s. Food Drug Administration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on Date the Entity Submits New Drug Application ("NDA") Filing for ADAIR with U.S. Food &amp; Drug Administration</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" xlink:to="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on Date When U.S. Food &amp; Food Administration Approves New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest On Date When U.s. Food Food Administration Approves New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vest on Date When U.S. Food &amp; Food Administration Approves New Drug Application</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationNotInConnectionWithChangeInControlMember" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_IfTerminationNotInConnectionWithChangeInControlMember" xlink:to="vlon_IfTerminationNotInConnectionWithChangeInControlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination not in Connection with change in Control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination Not In Connection With Change In Control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination not in Connection with change in Control</label>
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" xlink:to="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination within One Year Period Commencing on Change in Control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination Within One Year Period Commencing On Change In Control [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">If Termination within One Year Period Commencing on Change in Control</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>vlon-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/13/2021 1:11:52 PM-->
<!--Modified on: 5/13/2021 1:11:52 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementBalanceSheet" roleURI="http://www.vallon-pharma.com/role/StatementBalanceSheet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementBalanceSheetParenthetical" roleURI="http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfOperations" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#StatementStatementsOfCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity" roleURI="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureAccruedExpenses" roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosurePppNoteAndConvertibleNotes" roleURI="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancing" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensation" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureIncomeTaxes" roleURI="http://www.vallon-pharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFinanceLease" roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLease" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSubsequentEvents" roleURI="http://www.vallon-pharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancingTables" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFinanceLeaseTables" roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosurePppNoteAndConvertibleNotesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancingDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFinanceLeaseDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="vlon-20210331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637565083113977262" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637565083113977262" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_637565083113977262" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637565083113977262" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637565083113977262" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637565083113977262" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637565083113977262" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637565083113977262" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637565083113977262" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637565083113977262" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637565083113977262" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637565083113977262" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637565083113977262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637565083113977262" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637565083113987260" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637565083113987260" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637565083113987260" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637565083113987260" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637565083113987260" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637565083113987260" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637565083113987260" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_637565083113987260" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_637565083113987260" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637565083113987260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637565083113987260" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637565083113997250" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_637565083113997250" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637565083113997250" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637565083113997250" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637565083113997250" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637565083113997250" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637565083113997250" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637565083113997250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637565083113997250" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TransitionReport" xlink:label="vlon_TransitionReport_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="vlon_TransitionReport_637565083114007262" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementBalanceSheet" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheet" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637565083114007262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565083114007262" xlink:to="us-gaap_AssetsCurrentAbstract_637565083114007262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565083114007262" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083114007262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565083114007262" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637565083114007262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637565083114007262" xlink:to="us-gaap_AssetsCurrent_637565083114007262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565083114007262" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637565083114007262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637565083114007262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565083114007262" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637565083114007262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637565083114007262" xlink:to="us-gaap_Assets_637565083114017264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" xlink:to="us-gaap_AccountsPayableCurrent_637565083114017264" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637565083114017264" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" xlink:to="us-gaap_NotesPayableCurrent_637565083114017264" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637565083114017264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637565083114017264" xlink:to="us-gaap_LiabilitiesCurrent_637565083114017264" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_LongTermNotesPayable_637565083114017264" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637565083114017264" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_Liabilities_637565083114017264" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637565083114017264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_CommitmentsAndContingencies_637565083114017264" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_StockholdersEquityAbstract_637565083114027243" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637565083114027243" xlink:to="us-gaap_CommonStockValue_637565083114027243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637565083114027243" xlink:to="us-gaap_AdditionalPaidInCapital_637565083114027243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637565083114027243" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637565083114027243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637565083114027243" xlink:to="us-gaap_StockholdersEquity_637565083114027243" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637565083114027243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637565083114017264" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637565083114027243" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheet (parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637565083114037263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637565083114037263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637565083114037263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637565083114037263" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114037263" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637565083114037263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637565083114037263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637565083114037263" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565083114037263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637565083114037263" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637565083114037263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637565083114037263" xlink:to="us-gaap_OperatingExpenses_637565083114037263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637565083114037263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome_637565083114037263" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637565083114037263" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_637565083114037263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet_637565083114037263" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637565083114047258" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637565083114047258" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637565083114047258" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637565083114047258" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114047258" xlink:to="us-gaap_StatementEquityComponentsAxis_637565083114047258" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114047258" xlink:to="us-gaap_CommonStockMember_637565083114047258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114047258" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637565083114047258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114047258" xlink:to="us-gaap_RetainedEarningsMember_637565083114047258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114047258" xlink:to="us-gaap_EquityComponentDomain_637565083114047258" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565083114047258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114047258" xlink:to="us-gaap_StatementLineItems_637565083114047258" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114047258" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565083114057277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockholdersEquity_637565083114057277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637565083114057277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_SharesIssued_637565083114057277" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637565083114057277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637565083114057277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637565083114137442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637565083114137442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565083114137442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565083114137442" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114137442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114137442" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637565083114137442" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637565083114137442" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637565083114147322" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637565083114147322" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637565083114147322" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_NetIncomeLoss_637565083114147322" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_StockholdersEquity_637565083114147322" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637565083114057277" xlink:to="us-gaap_SharesIssued_637565083114147322" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Stockholders' Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114147322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114147322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_ProfitLoss_637565083114157263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083114157263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_ShareBasedCompensation_637565083114157263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637565083114157263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083114157263" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NonCashInterestDepreciationAndOtherExpense" xlink:label="vlon_NonCashInterestDepreciationAndOtherExpense_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="vlon_NonCashInterestDepreciationAndOtherExpense_637565083114157263" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637565083114157263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637565083114157263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637565083114157263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637565083114157263" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637565083114157263" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565083114157263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565083114157263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637565083114167268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637565083114157263" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637565083114167268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114167268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637565083114167268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637565083114167268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637565083114167268" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637565083114167268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637565083114167268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637565083114167268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637565083114167268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375650831141672681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375650831141672681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637565083114177249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637565083114177249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_637565083114177249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637565083114177249" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_637565083114177249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637565083114177249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637565083114177249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637565083114177249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637565083114177249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10301 - Disclosure - ACCRUED EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637565083114177249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637565083114177249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes" xlink:type="extended" xlink:title="10401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637565083114187276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637565083114187276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancing" xlink:type="extended" xlink:title="10501 - Disclosure - EQUITY FINANCING" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingAbstract" xlink:label="vlon_EquityFinancingAbstract" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingDisclosureTextBlock" xlink:label="vlon_EquityFinancingDisclosureTextBlock_637565083114187276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_EquityFinancingAbstract" xlink:to="vlon_EquityFinancingDisclosureTextBlock_637565083114187276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10601 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637565083114187276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637565083114187276" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10701 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637565083114187276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637565083114187276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10801 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637565083114187276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637565083114187276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFinanceLease" xlink:type="extended" xlink:title="10901 - Disclosure - FINANCE LEASE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_637565083114197269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_637565083114197269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637565083114197269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637565083114197269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11101 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637565083114197269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637565083114197269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637565083114197269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637565083114197269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_637565083114197269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vlon_UnauditedInterimFinancialStatementsPolicyTextBlock_637565083114197269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637565083114207251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637565083114207251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637565083114207251" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30303 - Disclosure - ACCRUED EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637565083114207251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables" xlink:type="extended" xlink:title="30503 - Disclosure - EQUITY FINANCING (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingAbstract" xlink:label="vlon_EquityFinancingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_EquityFinancingAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637565083114207251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30603 - Disclosure - STOCK-BASED COMPENSATION - (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637565083114207251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637565083114207251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637565083114207251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637565083114207251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables" xlink:type="extended" xlink:title="30903 - Disclosure - FINANCE LEASE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637565083114217273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_637565083114217273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31103 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637565083114217273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_637565083114217273" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="dei_LegalEntityAxis_637565083114217273" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637565083114217273" xlink:to="dei_EntityDomain_637565083114217273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ArcturusTherapeuticsLtdMember" xlink:label="vlon_ArcturusTherapeuticsLtdMember_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637565083114217273" xlink:to="vlon_ArcturusTherapeuticsLtdMember_637565083114217273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="srt_TitleOfIndividualAxis_637565083114217273" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114217273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637565083114217273" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114217273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114217273" xlink:to="srt_BoardOfDirectorsChairmanMember_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="srt_CounterpartyNameAxis_637565083114227251" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637565083114227251" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AmiserviceDevelopmentLtdMember" xlink:label="vlon_AmiserviceDevelopmentLtdMember_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637565083114227251" xlink:to="vlon_AmiserviceDevelopmentLtdMember_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ArcturusTherapeuticsLtdMember" xlink:label="vlon_ArcturusTherapeuticsLtdMember_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637565083114227251" xlink:to="vlon_ArcturusTherapeuticsLtdMember_637565083114227251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="us-gaap_StatementEquityComponentsAxis_637565083114227251" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114227251" xlink:to="us-gaap_EquityComponentDomain_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637565083114227251" xlink:to="us-gaap_CommonStockMember_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637565083114227251" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637565083114227251" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114227251" xlink:to="us-gaap_PrivatePlacementMember_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="us-gaap_BusinessAcquisitionAxis_637565083114227251" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637565083114227251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637565083114227251" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637565083114227251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairProductRightsAcquisitionMember" xlink:label="vlon_AdairProductRightsAcquisitionMember_637565083114237272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637565083114227251" xlink:to="vlon_AdairProductRightsAcquisitionMember_637565083114237272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637565083114237272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637565083114217273" xlink:to="us-gaap_StatementLineItems_637565083114237272" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114237272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114237272" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation" xlink:label="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_637565083114237272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation_637565083114237272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation" xlink:label="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_637565083114237272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation_637565083114237272" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114247272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114247272" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565083114247272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637565083114247272" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637565083114247272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637565083114247272" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637565083114247272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637565083114247272" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis" xlink:label="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis_637565083114258075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AssetPurchaseAgreementReimbursementOfExpenses" xlink:label="vlon_AssetPurchaseAgreementReimbursementOfExpenses_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="vlon_AssetPurchaseAgreementReimbursementOfExpenses_637565083114258075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NumberOfPromissoryNotes" xlink:label="vlon_NumberOfPromissoryNotes_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="vlon_NumberOfPromissoryNotes_637565083114258075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637565083114258075" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_OtherCostAndExpenseOperating_637565083114258075" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565083114258075" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637565083114258075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637565083114258075" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_637565083114267276" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637565083114267276" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637565083114267276" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114267276" order="18" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637565083114237272" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637565083114267276" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114267276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114267276" xlink:to="srt_TitleOfIndividualAxis_637565083114267276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637565083114267276" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114267276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114267276" xlink:to="srt_ChiefExecutiveOfficerMember_637565083114267276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114267276" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114267276" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114267276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114267276" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114267276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent_637565083114281373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent" xlink:label="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent_637565083114281373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedChemistryAndManufacturingExpensesCurrent" xlink:label="vlon_AccruedChemistryAndManufacturingExpensesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vlon_AccruedChemistryAndManufacturingExpensesCurrent_637565083114281373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent_637565083114281373" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AccruedLicensingFeesCurrent" xlink:label="vlon_AccruedLicensingFeesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="vlon_AccruedLicensingFeesCurrent_637565083114281373" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637565083114281373" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637565083114281373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637565083114281373" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637565083114287284" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637565083114287284" xlink:to="us-gaap_ShortTermDebtTypeAxis_637565083114287284" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637565083114287284" xlink:to="us-gaap_ShortTermDebtTypeDomain_637565083114287284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637565083114287284" xlink:to="us-gaap_ConvertibleNotesPayableMember_637565083114287284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637565083114287284" xlink:to="us-gaap_DebtInstrumentAxis_637565083114287284" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637565083114287284" xlink:to="us-gaap_DebtInstrumentNameDomain_637565083114287284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PaycheckProtectionProgramLoanMember" xlink:label="vlon_PaycheckProtectionProgramLoanMember_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637565083114287284" xlink:to="vlon_PaycheckProtectionProgramLoanMember_637565083114287284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637565083114287284" xlink:to="us-gaap_DebtInstrumentLineItems_637565083114287284" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637565083114287284" xlink:to="us-gaap_DebtInstrumentFaceAmount_637565083114287284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637565083114287284" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637565083114287284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637565083114287284" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637565083114287284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637565083114287284" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565083114287284" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637565083114287284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637565083114287284" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637565083114287284" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails" xlink:type="extended" xlink:title="40501 - Disclosure - EQUITY FINANCING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingAbstract" xlink:label="vlon_EquityFinancingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_EquityFinancingAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" xlink:to="us-gaap_StatementEquityComponentsAxis_637565083114297259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637565083114297259" xlink:to="us-gaap_EquityComponentDomain_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637565083114297259" xlink:to="us-gaap_CommonStockMember_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" xlink:to="us-gaap_BalanceSheetLocationAxis_637565083114297259" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637565083114297259" xlink:to="us-gaap_BalanceSheetLocationDomain_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637565083114297259" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637565083114297259" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637565083114297259" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_UnderwritersWarrantsMember" xlink:label="vlon_UnderwritersWarrantsMember_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637565083114297259" xlink:to="vlon_UnderwritersWarrantsMember_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637565083114297259" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637565083114297259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637565083114297259" xlink:to="us-gaap_IPOMember_637565083114297259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637565083114297259" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637565083114307269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_SharesIssuedPricePerShare_637565083114307269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_GrossProceedsFromInitialPublicOffering" xlink:label="vlon_GrossProceedsFromInitialPublicOffering_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="vlon_GrossProceedsFromInitialPublicOffering_637565083114307269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses" xlink:label="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses_637565083114307269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_SaleOfStockOtherOfferingCosts" xlink:label="vlon_SaleOfStockOtherOfferingCosts_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="vlon_SaleOfStockOtherOfferingCosts_637565083114307269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637565083114307269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637565083114307269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637565083114307269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637565083114307269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable" xlink:label="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_637565083114307269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable_637565083114307269" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637565083114317275" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637565083114297259" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637565083114317275" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - EQUITY FINANCING - Estimate the fair value of the warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EquityFinancingAbstract" xlink:label="vlon_EquityFinancingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_EquityFinancingAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565083114317275" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565083114317275" xlink:to="us-gaap_MeasurementInputTypeAxis_637565083114317275" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637565083114317275" xlink:to="us-gaap_MeasurementInputTypeDomain_637565083114317275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565083114317275" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637565083114317275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565083114317275" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637565083114317275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565083114317275" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637565083114317275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637565083114317275" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637565083114317275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637565083114317275" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637565083114317275" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637565083114317275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637565083114317275" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637565083114317275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637565083114327259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637565083114327259" xlink:to="us-gaap_IncomeStatementLocationAxis_637565083114327259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637565083114327259" xlink:to="us-gaap_IncomeStatementLocationDomain_637565083114327259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637565083114327259" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637565083114327259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637565083114327259" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637565083114327259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637565083114327259" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565083114327259" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637565083114327259" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637565083114327259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails" xlink:type="extended" xlink:title="40602 - Disclosure - STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114327259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114327259" xlink:to="srt_RangeAxis_637565083114327259" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637565083114327259" xlink:to="srt_RangeMember_637565083114327259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637565083114327259" xlink:to="srt_MinimumMember_637565083114327259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637565083114327259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637565083114327259" xlink:to="srt_MaximumMember_637565083114327259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114327259" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637565083114337279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637565083114337279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637565083114337279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637565083114337279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_SharePrice_637565083114337279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails" xlink:type="extended" xlink:title="40603 - Disclosure - STOCK-BASED COMPENSATION - Activity of stock options granted (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114337279" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114337279" xlink:to="us-gaap_GranteeStatusAxis_637565083114337279" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637565083114337279" xlink:to="us-gaap_GranteeStatusDomain_637565083114337279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637565083114337279" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637565083114337279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637565083114337279" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637565083114337279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637565083114347278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114347278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375650831143472781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375650831143472781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637565083114347278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637565083114347278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637565083114347278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375650831143472781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375650831143472781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637565083114347278" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637565083114347278" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_WeightedAverageRemainingContractualTermAbstract" xlink:label="vlon_WeightedAverageRemainingContractualTermAbstract_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="vlon_WeightedAverageRemainingContractualTermAbstract_637565083114347278" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637565083114347278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_WeightedAverageRemainingContractualTermAbstract_637565083114347278" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637565083114347278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_WeightedAverageRemainingContractualTermAbstract_637565083114347278" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637565083114357285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AggregateIntrinsicValueAbstract" xlink:label="vlon_AggregateIntrinsicValueAbstract_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637565083114337279" xlink:to="vlon_AggregateIntrinsicValueAbstract_637565083114357285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_AggregateIntrinsicValueAbstract_637565083114357285" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637565083114357285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6375650831143572851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_AggregateIntrinsicValueAbstract_637565083114357285" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6375650831143572851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_AggregateIntrinsicValueAbstract_637565083114357285" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637565083114357285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_AggregateIntrinsicValueAbstract_637565083114357285" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637565083114357285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637565083114357285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_AggregateIntrinsicValueAbstract_637565083114357285" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637565083114357285" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" xlink:to="us-gaap_ShortTermDebtTypeAxis_637565083114367266" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637565083114367266" xlink:to="us-gaap_ShortTermDebtTypeDomain_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637565083114367266" xlink:to="us-gaap_ConvertibleNotesPayableMember_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" xlink:to="srt_TitleOfIndividualAxis_637565083114367266" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637565083114367266" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114367266" xlink:to="srt_ChiefExecutiveOfficerMember_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637565083114367266" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637565083114367266" xlink:to="us-gaap_RelatedPartyDomain_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_MediceMember" xlink:label="vlon_MediceMember_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637565083114367266" xlink:to="vlon_MediceMember_637565083114367266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember_637565083114367266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637565083114367266" xlink:to="srt_AffiliatedEntityMember_637565083114367266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637565083114367266" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_RelatedPartyTransactionUpfrontPayment" xlink:label="vlon_RelatedPartyTransactionUpfrontPayment_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" xlink:to="vlon_RelatedPartyTransactionUpfrontPayment_637565083114377275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637565083114377275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637565083114377275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637565083114377275" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637565083114377275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails" xlink:type="extended" xlink:title="40901 - Disclosure - FINANCE LEASE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_637565083114377275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_637565083114377275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637565083114377275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637565083114377275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083114377275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637565083114377275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637565083114387273" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - FINANCE LEASE - Maturities of finance lease liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_637565083114387273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_637565083114387273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_637565083114387273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637565083114387273" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_637565083114387273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_637565083114387273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637565083114387273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability_637565083114387273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" xlink:to="srt_TitleOfIndividualAxis_637565083114397285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637565083114397285" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114397285" xlink:to="srt_ChiefExecutiveOfficerMember_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114397285" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114397285" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_NewEmploymentAgreementWithDavidBakerMember" xlink:label="vlon_NewEmploymentAgreementWithDavidBakerMember_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114397285" xlink:to="vlon_NewEmploymentAgreementWithDavidBakerMember_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" xlink:to="srt_StatementScenarioAxis_637565083114397285" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637565083114397285" xlink:to="srt_ScenarioUnspecifiedDomain_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember" xlink:label="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637565083114397285" xlink:to="vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_637565083114397285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember" xlink:label="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637565083114397285" xlink:to="vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_637565083114397285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114397285" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_637565083114407263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637565083114407263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_637565083114407263" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_CobraHealthInsuranceCoveragePeriod" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" xlink:to="vlon_CobraHealthInsuranceCoveragePeriod_637565083114407263" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114397285" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637565083114407263" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114407263" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114407263" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637565083114407263" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637565083114407263" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637565083114407263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_AdairStudyVal104Member" xlink:label="vlon_AdairStudyVal104Member_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637565083114407263" xlink:to="vlon_AdairStudyVal104Member_637565083114407263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114407263" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114407263" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114407263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114407263" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114407263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialAgreementsMember" xlink:label="vlon_ClinicalTrialAgreementsMember_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114407263" xlink:to="vlon_ClinicalTrialAgreementsMember_637565083114417282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114407263" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TerminationPeriodUponPriorWrittenNotice" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="vlon_TerminationPeriodUponPriorWrittenNotice_637565083114417282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ClinicalTrialCostExpectedAmount" xlink:label="vlon_ClinicalTrialCostExpectedAmount_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="vlon_ClinicalTrialCostExpectedAmount_637565083114417282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565083114417282" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114417282" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114417282" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114417282" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114417282" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114417282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ConsultingAgreementsMember" xlink:label="vlon_ConsultingAgreementsMember_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114417282" xlink:to="vlon_ConsultingAgreementsMember_637565083114417282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114417282" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ProfessionalFeesPaidPerMonth" xlink:label="vlon_ProfessionalFeesPaidPerMonth_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="vlon_ProfessionalFeesPaidPerMonth_637565083114417282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114417282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637565083114417282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="us-gaap_ProfessionalFees_637565083114427276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_TerminationPeriodUponPriorWrittenNotice" xlink:label="vlon_TerminationPeriodUponPriorWrittenNotice_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114417282" xlink:to="vlon_TerminationPeriodUponPriorWrittenNotice_637565083114427276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114427276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114427276" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114427276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114427276" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114427276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementsMember" xlink:label="vlon_ManufacturingAgreementsMember_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114427276" xlink:to="vlon_ManufacturingAgreementsMember_637565083114427276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember" xlink:label="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_ManufacturingAgreementsMember_637565083114427276" xlink:to="vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_637565083114427276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember" xlink:label="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vlon_ManufacturingAgreementsMember_637565083114427276" xlink:to="vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_637565083114427276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114427276" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114427276" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EstimatedContractCosts" xlink:label="vlon_EstimatedContractCosts_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114427276" xlink:to="vlon_EstimatedContractCosts_637565083114427276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingCosts" xlink:label="us-gaap_ManufacturingCosts_637565083114427276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114427276" xlink:to="us-gaap_ManufacturingCosts_637565083114427276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114437263" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114437263" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114437263" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114437263" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114437263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember" xlink:label="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114437263" xlink:to="vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_637565083114437263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637565083114437263" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114437263" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EstimatedContractCosts" xlink:label="vlon_EstimatedContractCosts_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114437263" xlink:to="vlon_EstimatedContractCosts_637565083114437263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637565083114437263" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637565083114437263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637565083114437263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_637565083114437263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637565083114437263" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637565083114437263" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_637565083114437263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637565083114437263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637565083114437263" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637565083114437263" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637565083114447274" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_TypeOfArrangementAxis_637565083114447274" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637565083114447274" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114447274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_EmploymentAgreementWithLeanneM.KellyMember" xlink:label="vlon_EmploymentAgreementWithLeanneM.KellyMember_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637565083114447274" xlink:to="vlon_EmploymentAgreementWithLeanneM.KellyMember_637565083114447274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_SubsequentEventTypeAxis_637565083114447274" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637565083114447274" xlink:to="us-gaap_SubsequentEventTypeDomain_637565083114447274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637565083114447274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637565083114447274" xlink:to="us-gaap_SubsequentEventMember_637565083114447274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="srt_TitleOfIndividualAxis_637565083114459141" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637565083114459141" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637565083114459141" xlink:to="srt_ChiefFinancialOfficerMember_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_AwardTypeAxis_637565083114459141" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637565083114459141" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637565083114459141" xlink:to="us-gaap_EmployeeStockOptionMember_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_VestingAxis_637565083114459141" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637565083114459141" xlink:to="us-gaap_VestingDomain_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637565083114459141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637565083114459141" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637565083114459141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637565083114459141" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637565083114467295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_AwardDateAxis_637565083114467295" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_637565083114467295" xlink:to="us-gaap_AwardDateDomain_637565083114467295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnFirstAnniversaryOfStartDateMember" xlink:label="vlon_VestOnFirstAnniversaryOfStartDateMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637565083114467295" xlink:to="vlon_VestOnFirstAnniversaryOfStartDateMember_637565083114467295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember" xlink:label="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637565083114467295" xlink:to="vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_637565083114467295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember" xlink:label="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637565083114467295" xlink:to="vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_637565083114467295" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember" xlink:label="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_637565083114467295" xlink:to="vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_637565083114467295" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="srt_StatementScenarioAxis_637565083114467295" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637565083114467295" xlink:to="srt_ScenarioUnspecifiedDomain_637565083114467295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationNotInConnectionWithChangeInControlMember" xlink:label="vlon_IfTerminationNotInConnectionWithChangeInControlMember_637565083114467295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637565083114467295" xlink:to="vlon_IfTerminationNotInConnectionWithChangeInControlMember_637565083114467295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember" xlink:label="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637565083114467295" xlink:to="vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_637565083114477261" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637565083114447274" xlink:to="us-gaap_SubsequentEventLineItems_637565083114477261" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_637565083114477261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637565083114477261" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_637565083114477261" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637565083114477261" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637565083114477261" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_637565083114477261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_637565083114477261" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="vlon-20210331.xsd#vlon_CobraHealthInsuranceCoveragePeriod" xlink:label="vlon_CobraHealthInsuranceCoveragePeriod_637565083114487255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637565083114477261" xlink:to="vlon_CobraHealthInsuranceCoveragePeriod_637565083114487255" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>vlon-20210331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:vlon="http://www.vallon-pharma.com/20210331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vlon-20210331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_Tn38B5U-o02QABujfpad0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_OL8f_qfInEqpi_l0fTWnWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_6_2020_To_1_6_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vlon_MediceMember_NGprOuJ5l06TJqQZC_V8ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vlon:MediceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-06</endDate>
        </period>
    </context>
    <context id="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="As_Of_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_V2G_e2BzqUubv1rniE3q0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-15</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_SnkKNVvge0SVtghw5VA0qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_z-8EZMohVECdXJnLeqPxEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_lVQgaSqrRkK1DTlNgKvOrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="Duration_11_15_2017_To_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_x-NQaVFMxUeZ4r1E-Nssgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-15</startDate>
            <endDate>2017-11-15</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_cEy2Na7LTU6FHcLHdGkVLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_oUpLJpG1TEeUwluvcA56wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_OuHcg0aKu02Um5Wx4JT5vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9XvhFD3qEa4bDRHE-FeXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-15</startDate>
            <endDate>2017-11-15</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_m_qpi2gNQ0Wm0F6HLx90lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VHEsqmgG7USeE3ti9qwcPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YznYzH3KBkyRhT1RG6mKBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fP7EG2hq1EeBSkVm4cUR3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xI19aMkKEkOTzmxGM0CaWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k1qRx4AD7Eit_zIYQsN9dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_25rnvO6dwkG_mYmCNm0M6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0cBdsHpQmE-cbvFcUq6nLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VWR0Rpxvjkq1cR6FDhHjRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WEsJPxIMW0ChK4dWlfgkZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJHTQwM9RESCtO731QNz6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SILDvqDH2kSgzCliI_rumQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6atNCI43bk-OY4mxZ0xDeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_p-WkrdawjkKSVhflMIYJmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_QRMywzI2uUq-75VZaFoA9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_JqpFDEggRkesYrNF0Z7d7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_lmsSk0l7KkWPJE-KMU2SDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_WGepaRPim0eFAsLrWHF3XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Nu0HlaQrV0STf4cE6gIghA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7RrpN30090e56LLSpDLmkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vlon_AdairStudyVal104Member_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_6XKRebR7BEWBtoFWLvbicQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vlon:AdairStudyVal104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_6vvh1yU2_0mn3PPDkIvZWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_PiKPhnXIVEe3otXkFQJSbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_kkrPw5KwQkynmgre4Q1gJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_AY-YYGiTG0q7QQrpwLwsHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_PeCqNyG65U-s5WHXh9lz0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_hOnNiNgctkydAp6WTPWNzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-07</startDate>
            <endDate>2018-06-07</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:ArcturusTherapeuticsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-11</startDate>
            <endDate>2018-02-11</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_1_11_2021_To_1_11_2021_8qOoRPKb30yKP4fdaCxr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vlon:AmiserviceDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-15</startDate>
            <endDate>2017-11-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qzAzmG1G90-0EOTjcIpcRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_IzAODsPw3UW6_K3qX2og7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_aj1ck67-3kCcwaJeJiWVrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_BbC8XV5qlU2ceMNKytn5Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lCH-zADik0qKO3X2XzUZjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_nW_at-qhE0qwfYklAFP-Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vlon:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wj8fFhgfhkWVHez-hovm0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A4zr9qZIIkWi15ZK_wyfzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ba48kdCZkEG4MpU_eSZ57w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_vFarWyLSi0W_Rq5eAXJa0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnFirstAnniversaryOfStartDateMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_XJA5MW80TUen-MTCbD2nKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnFirstAnniversaryOfStartDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XY59mQ4yF0SnWeexPPyTCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GnqWo_CEXEeAcNENJ-Sk8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qHpeFWSKRU6tDNBCRoCPWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">vlon:VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_99MbGdLZZ06ZDQEAKCqSSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:IfTerminationNotInConnectionWithChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <context id="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <context id="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_K8OayvzVWk6w7L3GnwtAdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-10</endDate>
        </period>
    </context>
    <context id="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">vlon:InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:EmploymentAgreementWithLeanneM.KellyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vlon:NewEmploymentAgreementWithDavidBakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="As_Of_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember__uYmvO-NoEutzv5BKZjj-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="As_Of_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_4CwAuiXkbUCOtvE65Xtb-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_ei25kWe8EU-JCt2bw1gHyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vlon:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vlon:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_11_2021_B-c7BO4RP0aNIhbXZvMJhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vlon:AdairProductRightsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="As_Of_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_nE5tkt9jPU267_p8BkBEfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vlon:AdairProductRightsAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-22</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TSib4yEdAUSlHbmW78scuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kYeoxmIIaUemiecYpa-T4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_peYk7ghKTU-3tzbPPE3XKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vlon:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2021_Eo3ZEOdgO0WpIVlN7GsV9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_0sfEPIqYxkSB2d_NNWmuCg">
        <measure>vlon:item</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      id="Hidden_P25TTKWMT0aDw_BLDRvhDA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      id="Hidden_zLOhcgS3BEO0VwososrwsA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      id="Hidden_Ti0IkjqKSEKs4zAInh32pw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      id="Hidden_T-rObeu-Lki245go8h12lw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_I2h-mLIGz0uwd9mC636Yuw_2_1">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_zy-Xn_jauEWkhm9bXl4XcQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_YypSIi1krUSUDd48T0Xixg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_NXxYsx_kZEmW9YKCWKtgIg_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_dhi-b6u950GmxPt4zfx18w_6_1">false</dei:AmendmentFlag>
    <vlon:TransitionReport
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_gNg6eLzqKUW59BG0ckeYRA_7_1">false</vlon:TransitionReport>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Hidden_Rq87e8JKNE-RMNcIucaQOw">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw"
      decimals="3"
      id="Hidden_RklKRiOmx06CoYYk0dhHnA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Hidden_fHabEzam7kSC2KAlZ7HipA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="INF"
      id="Hidden_zhrL4uj6rEKeY6WwziGRXQ"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="3"
      id="Hidden_UIe2lbAF2kGKY5HDdycYJA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="3"
      id="Hidden_4Tffo4GuN0upl1nqEV12yw"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g"
      decimals="3"
      id="Hidden_jYgxiwEGF0KBpwAlJddKng"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="3"
      id="Hidden_0cNKILO9WUW0kb65wvotjw"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g"
      decimals="3"
      id="Hidden_GeFOrwbLYkGAn3rmDzx4rw"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_NQo7i6eYAE6HgNsO54eb1w">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_vcyFHRI4qkK7l8Ss8xToSg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_iwe7HM-uQk-hh_NWgxz-bw">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_OUoD7YYUPEC0GBSmJftyhg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_-uZP4TlEtUeOlxAR0j-skw">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_-nx9Rqd71Uq9Za0dXa5AiQ_1_0">VALLON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_qartT2Y6d02lqst_5OJ6-w_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_u8uoAhIMA02uQ94k7MryEg_0_2">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_gzEMeR0ayEeGuGSM8PxzXA">100 N. 18th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_BeiZRf64tUOKo4YXbd7nKA">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_cmZAoke-_UuZCDSwPA4EDw">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_CjUM9jzPfE6-CT2nwbW1-Q">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_REheZaXisESSyNB6DktKqg">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_pjCz-tKtdEiNx5YYqO3vmA">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_YkbdNm1DqkOpw-eT_rWW2w">207-3606 </dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_TLdW1uGZYEmbVEu4cNsJhg_2_0">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_4NDWNtd5y0O8_qL2ARyrRA_2_2">VLON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_mfrjRxH5WE6y7RPyZvKyGA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_w3vpEcS9yEuEPhc5UPHn_A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_RrOZmw_g4UOVNkygag0Lsg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_X16td8OLw0aALjNBifEH1g">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_7Fssf0IiREyJAKqPlODndA">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_3C9YKbCFhUy-Nsfx91J2Zg">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Narr_Tct1JK0BDUmgKI0JjO9Pdw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_13_2021_Eo3ZEOdgO0WpIVlN7GsV9Q"
      decimals="INF"
      id="Narr_09pmckz8hkS4xzfb8e4mYw"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">6812836</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_hiyhfJpmMkqVQmMCr8-COQ_4_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">12980000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_XD79KIwPcEmeh5QsLzRxJA_4_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">109000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_IVXxVUFkKEa5oT6_ZUNC6g_5_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1358000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_vjHea_Tm4UCzsaSnLweSpA_5_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">565000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_Zl1JUNUqqkCkpFqjE02OeQ_6_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">14338000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_7M1FFRGZgU-w1QdAV8f3vg_6_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">674000</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_L0CArE5LgEyI4_7IhO7oqA_8_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">261000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_8CEXtqHha0ifNNj8_u_iWA_8_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">279000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_k_h8XVZ7o0Kocf1vihjB7g_9_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_C2ddvJVE7kqxvup2Eh-D_A_9_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_VPS2pfb01kGl54v1kC9CWA_10_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">14600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_tNV17967fUm3oWRlJsZwUw_10_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">955000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_PypEAs5Ld06QMbDbiFzekw_14_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1347000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_nQI6rtSpyUiMNVacG1QJbw_14_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1226000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_BhooP5euGECwPBx88M3KpQ_15_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_sEI0jvfObUqoH1QK-Oit_A_15_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_UJpYb2RJ4EOUM3AYvE12Fg_16_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">47000</us-gaap:NotesPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_ToyYXxbIWEOfgXlrf3mmaw_17_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">95000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_cYS3We3ACEORSGx9g6h1WQ_17_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">105000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_0UbBKs3DvUSmqt7KW7QnQg_18_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2427000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_8toWDGlrAE2Lt1IbtXzebw_18_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_x8q1bJBtkEiKKpTCZSGHhw_19_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">14000</us-gaap:LongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_yCoC9HFK50GR2cLzLlvlxw_20_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">146000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_JYd0mAhXxUiPQZPhni5s3A_20_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">170000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_0WeBNC2PPkOxEYBJYKrJyw_21_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2573000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_VeJ1OUFeM0uZi3O2Pb6xfg_21_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2409000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Narr_XS1YnS9en0W2Jl8Lm39RaQ"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="INF"
      id="Narr_I8G2pGPav0OSwM-tVH42MQ"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Narr_uLzXI2__x0q_jvZCdopMyQ"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="INF"
      id="Narr_T0Pr1pj9jEyaBKL5U4qZHA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Narr_vXEiHIzIB063QxUYwd_F4w"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="INF"
      id="Narr_pyzw6UY1yEm4GDuGiMyzFw"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_qYHIq-ztSki5ftjjltpkOg_27_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">27264000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_JaPICGWO8Ei3Gi7rSrYcFg_27_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">11145000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_gcsRgDoafU2XjpOm-fdp1g_28_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-15237000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_y5jsdtBQIEKL_N3LEo8YeQ_28_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-12599000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_9aXvZ6BN1E-iiMIkGeeF0A_29_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">12027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_w2SDiG1oeEWTcSKAofixhA_29_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_V1MBJ9GApk68_tzoc9-cQA_30_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">14600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_uJlEqZpqYkOIrA778fTtXg_30_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_HvX9i1dNTkqfFInIexJg9g_5_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_yRZCHGhD60WiTJTm8SoR7w_7_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1772000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_J0R3Dy3cHk6GioXa2ZUIPQ_7_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_O6GSAQ61-UKG9kOlEnTgEw_8_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">830000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_-Av0GmvIEEOFadiZXtuL8w_8_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">375000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_KlVX4jWT7kqVeX4f0GyTRg_9_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2602000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_6vYK6KO0W0uiR3T14kKGEA_9_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1258000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_4GtSO28sFUmdzsgkDmZGcw_10_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2602000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_-_TKactfy0yDfAeEm41_lw_10_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1158000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_k1O2EFgzckWEGEkWh3kG7Q_11_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">61000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_TKqbQu9SZ0G4mtxFaoTW4A_12_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-89000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_wjo7EQW8E0y3F0FexzMocA_13_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-8000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_VmStL362EEqN1MHwHuxu7g_13_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_PbSJ-pjiQkmBUef5uUCuTw_14_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_1DRmuswnS0mdms5zORiNPA_14_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1160000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="2"
      id="Tc_YDQIojs5zEyf1Xt30fRqSQ_15_3"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="2"
      id="Tc_iNo-_TOAlU-Wx4zFQsayPA_15_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="0"
      id="Tc_dwVhPDr1zUSVHwYI0xUFmw_16_3"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">5710270</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="0"
      id="Tc_eQ2uK1b0BEat8qLpsXlr7A_16_6"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6atNCI43bk-OY4mxZ0xDeQ"
      decimals="INF"
      id="Tc_FGbZdoNwW02Av2IEwUE_aA_3_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg"
      decimals="-3"
      id="Tc_wqFbS2wI_UOv94hlHnM3Jw_3_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">10991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0cBdsHpQmE-cbvFcUq6nLQ"
      decimals="-3"
      id="Tc_DFpGMoQwRkq3rNrHegq_4Q_3_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-7777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg"
      decimals="-3"
      id="Tc_NRji_b780kunq9Moll2v4A_3_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-3214000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA"
      decimals="-3"
      id="Tc_3-MED-jfqUCR3yc30utlug_4_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw"
      decimals="-3"
      id="Tc_GUINFvT9mU-F_1gEGdiZgA_4_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_xVui0gBRyE-d-MwSddtmwg_4_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_btATO1o-8ESmbxskmIiwxA"
      decimals="-3"
      id="Tc_--lWavcSO0-lcI6vsKjcoA_5_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3qPVXhZkq0mlDlfmbRjQJw"
      decimals="-3"
      id="Tc_wlkPX5OYpUS4YXNoRKJ4mw_5_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1160000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_4QKjjvXRMUSRuQGBQjsGrQ_5_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1160000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SILDvqDH2kSgzCliI_rumQ"
      decimals="INF"
      id="Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_25rnvO6dwkG_mYmCNm0M6g"
      decimals="-3"
      id="Tc_UtuC2xhq-kudNVSGGt2TQw_6_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">11026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k1qRx4AD7Eit_zIYQsN9dQ"
      decimals="-3"
      id="Tc__BbZKZOM2k-FAqBDlJme3A_6_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-8937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug"
      decimals="-3"
      id="Tc__OKincFIjEiC_m4TFBCGYg_6_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2089000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KJHTQwM9RESCtO731QNz6w"
      decimals="INF"
      id="Tc__GHEDaYiVUGmBBtF5kMWvw_3_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">4506216</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xI19aMkKEkOTzmxGM0CaWg"
      decimals="-3"
      id="Tc_0Pf8zyJUW0q9rHTkdMMxxg_3_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">11145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fP7EG2hq1EeBSkVm4cUR3g"
      decimals="-3"
      id="Tc_181ASgZ7tUCIBHK0ZOXQ3g_3_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-12599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_dMpCsTu77UCHXlpnEraYIA_3_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA"
      decimals="INF"
      id="Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">54906</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"
      decimals="-3"
      id="Tc_xtPbXS518kWSTQbooMseqw_4_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_m9aXEu5UZEGXhcRDrfBXMg_4_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA"
      decimals="INF"
      id="Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"
      decimals="-3"
      id="Tc_0mO0JaWL7kSqsxfzukhT4A_5_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_plqhYlVjakqozVJUNJcitQ_5_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2GLFeFSTfEibGZUbonPASA"
      decimals="INF"
      id="Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">1714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"
      decimals="-3"
      id="Tc_OdGl0IU9TEO3P9rmJhLC4g_6_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_AzV0UOjKf0msbnQpDiK5ZQ_6_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"
      decimals="-3"
      id="Tc_NStlordgeEiRqPCeXZmizQ_7_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_hbG48_SZNEy_jes3xyswFw_7_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wGpLIrZEoUKGdHXHqbHafw"
      decimals="-3"
      id="Tc_wpv-I44gI0ue6PI1usWZyQ_8_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_BRRykJT_x0OlfMX9XgdWgA_8_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qzAzmG1G90-0EOTjcIpcRA"
      decimals="-3"
      id="Tc_CtBxPA-EHkSPvdgoT8z1GA_9_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_FCmsY8V8G06HK9S4RZfI9g_9_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WEsJPxIMW0ChK4dWlfgkZQ"
      decimals="INF"
      id="Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">6812836</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YznYzH3KBkyRhT1RG6mKBw"
      decimals="-3"
      id="Tc_zr2mO_V7Q0GcgFu7sRkoag_10_8"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">27264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VHEsqmgG7USeE3ti9qwcPQ"
      decimals="-3"
      id="Tc_EECvLgZkFESo8PDk6K8Miw_10_11"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-15237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_FObEYR74OkOlcpYQiFBzzg_10_14"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">12027000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_qbHK-HTdAk6ZbCJLIqsI6A_5_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_HtI9BgZLEk2zeFNRuLJh8A_5_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-1160000</us-gaap:ProfitLoss>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_lDOe87g-6kCdJueQLXOZ4Q_7_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_U8lkcsP4U0KBxLTnNp23TQ_7_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc__LfzMxFsSEiGvSN6xckloA_8_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">168000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_6dlGM8fG10eblg2z7ein_Q_8_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">35000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_UmCdTcH1A0Kv4MDh6IJLeQ_9_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-89000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_iXFW5jzwa0uIZNW8OZnAjA_10_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">61000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vlon:NonCashInterestDepreciationAndOtherExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_EBhonR9l3kC6intmkEbMlQ_11_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">10000</vlon:NonCashInterestDepreciationAndOtherExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_7aMbqJzcWU2hcwR-ZErOzA_13_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">793000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_vbpX_706IECgzMQ0xW2WFg_13_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">87000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_7LWI_1gRvEGOutTUBJFKfw_14_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">121000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_jDY6gL0eBkW9PZ1DCVkP_g_14_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_LLpqdHBj5U6jC-8oLKwVbQ_15_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">138000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_FlxSje1S40yTNPF6ew49ZA_15_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">226000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_QODsCD_qCU6afPG8Li4d8A_16_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2948000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_rreigemFjkS1C5koFC40iQ_16_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-766000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_Rr3X0AVT6kuEhXlnFbpX5w_19_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_0pzGTNIBqk-VLCzaStpdOA_20_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_YjLjyaQxOEy5tn9Pie_tRw_23_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15503000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_1Nig52I62020CUG6zkVKww_24_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_y3Z_WtFiH0aQNhxOa42yAw_25_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">34000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_7qyoilPrVE6dgqOjHE9EEw_25_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">29000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_hgSdZQLQq0euMObhQT-vAQ_26_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15819000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_E72pb7qEtUqXVgEX2PrVOA_26_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-29000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_yxWL1SUL40GWoyFjiL0zng_28_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">12871000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_DDSnKdnYQUe3XVEoEn1qMQ_28_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-797000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_YiW79IjUqk29BoTrvl-oSQ_29_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_9aw5mHe0Dk-1X9CMm9SHJg"
      decimals="-3"
      id="Tc_c01XKo-ub0WssvjMoF6W_Q_29_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">3821000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_WFM27ELN80iFhZu2VE3uTg_30_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">12980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug"
      decimals="-3"
      id="Tc_5DYSJqXOxU-GlsaRcrb4LA_30_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">3024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_aqJPGGTPmk-9OPxToH6P8Q_34_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Gcnrq1LNQ0CFw1hy-i_J1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; &#x2013; NATURE&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Vallon Pharmaceuticals, Inc. (&#x201c;Vallon&#x201d; or the &#x201c;Company&#x201d;), a Delaware corporation, is a biopharmaceutical company based in Philadelphia, PA, which is focused on the development and commercialization of proprietary biopharmaceutical products. The Company&#x2019;s only clinical-stage product currently under development is ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of Attention-deficit/hyperactivity disorder, or ADHD, and Narcolepsy. The Company plans to develop other abuse-deterrent products which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Vallon Pharmaceuticals, Inc. was incorporated in Delaware on January 11, 2018, which is the date of inception. The Company&#x2019;s fiscal-year ends on December 31.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Immediately prior to the closing of the initial public offering of the Company&#x2019;s common stock (the &#x201c;IPO&#x201d;) (Note 5), the Company effected a one-for-&lt;span style="-sec-ix-hidden:Hidden_UIe2lbAF2kGKY5HDdycYJA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;40 &lt;/span&gt;&lt;/span&gt;reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business Formation:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 15, 2017, before the Company&#x2019;s formation, Amiservice Development Ltd., a BVI corporation (&#x201c;Amiservice&#x201d;) entered into an agreement for the purchase of the ADAIR product rights for a payment of $250,000. The Asset Purchase Agreement (&#x201c;the APA&#x201d;), by and between Amiservice and Arcturus Therapeutics Ltd. (&#x201d;Arcturus&#x201d;), was subject to several closing conditions. One of the key terms and conditions of the APA was that the purchasers provide funding of at least $2.75 million towards the development of ADAIR.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 11, 2018, Ofir Levi, Chairman of the newly formed Vallon, purchased 196,875 common shares from the Company at par value for $788. On June 7, 2018, Vallon entered into a stock purchase agreement with several investors pursuant to which Vallon issued 1,771,881 common shares for $3.0 million (&#x201c;Private Placement&#x201d;). Subsequently, on June 22, 2018, the Company executed the amended APA, by and between Arcturus Therapeutics Ltd. Such APA was amended and restated from the initial agreement discussed above, dated as of November 15, 2017. In exchange for the ADAIR product rights, Vallon issued 843,750 common shares to Arcturus, valued at approximately $1.4 million based upon the price at which the common shares were issued and sold in the Private Placement, which comprised approximately 30% of the then-outstanding common stock of the Company, on a fully diluted basis. In addition, Amiservice signed a consent and release agreement to all rights to the APA in exchange for approximately $562,000 which represented a reimbursement for expenses Amiservice incurred on Vallon&#x2019;s behalf in the amount of approximately $310,000, the repayment of two promissory notes totaling approximately $192,000 including interest, and approximately $60,000 of other operating expenses incurred. The assets acquired in the ADAIR acquisition are classified as in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accounting for IPR&amp;amp;D assets in an asset acquisition follows the guidance in Accounting Standards Codifications (&#x201c;ASC&#x201d;) 730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and charged to expense at the acquisition date. The Company recorded $1.7 million to research and development expense on June 22, 2018, the date of acquisition, which included $1.4 million of common shares issued for the acquisition, as well as, the original $250,000 exclusivity payment and approximately $60,000 in transaction fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Going Concern and Liquidity:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception, and has incurred $15.2 million in accumulated deficit through March 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (&#x201c;PPP&#x201d;) promissory note, as described in Note 4.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 11, 2021, the Company completed a $350,000 convertible note financing and on February 12, 2021, the Company completed the IPO, raising net proceeds of $15.5 million, as described in Note 5. On March&#160;31, 2021, the Company had cash and cash equivalents totaling approximately $13.0 million which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove to be wrong, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date that these financial statements are being issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#x2019;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. Furthermore, the Company may not be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements. If the Company is unable to obtain sufficient cash resources to fund its operations, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <vlon:AgreementPurchasePriceProductRightsPriorToBusinessFormation
      contextRef="Duration_11_15_2017_To_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_x-NQaVFMxUeZ4r1E-Nssgw"
      decimals="0"
      id="Narr_jqT2G_r8XEq_gT64f35zgQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">250000</vlon:AgreementPurchasePriceProductRightsPriorToBusinessFormation>
    <vlon:MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation
      contextRef="As_Of_11_15_2017_dei_LegalEntityAxis_vlon_ArcturusTherapeuticsLtdMember_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_V2G_e2BzqUubv1rniE3q0w"
      decimals="-4"
      id="Narr_L8btn0Aj7EuX_iWnhspdxw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">2750000</vlon:MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA"
      decimals="INF"
      id="Narr_M-FbannLWkuCQLGnkHGiuA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">196875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_11_2018_To_2_11_2018_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q4iAOlKtj0WTzABOb0CHBA"
      decimals="0"
      id="Narr_StEdGeeUw026FiS1fxT_gw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">788</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g"
      decimals="INF"
      id="Narr_cxVBSsafCk-sS86bQ5jI5w"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">1771881</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_6_7_2018_To_6_7_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LIT7mijFeEmSfqBwwdGA8g"
      decimals="-5"
      id="Narr_j0-EXapfBkKDLcJVRMYuBw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">3000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ"
      decimals="INF"
      id="Narr_nVdl1LAka0qDq0eAxljJNw"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">843750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ"
      decimals="-5"
      id="Narr_rKR8t6ZhAUGtfDIlg3rSAA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vlon:PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis
      contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ"
      decimals="2"
      id="Narr_-7cyLGDx5EKCR0PX1Mkg1A"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.30</vlon:PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e9XvhFD3qEa4bDRHE-FeXQ"
      decimals="0"
      id="Narr_yrP0m5XlaUCcGSbRftRWxg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">562000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vlon:AssetPurchaseAgreementReimbursementOfExpenses
      contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg"
      decimals="0"
      id="Narr_MDruRe14GEGIjsBhkmEUuQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">310000</vlon:AssetPurchaseAgreementReimbursementOfExpenses>
    <vlon:NumberOfPromissoryNotes
      contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg"
      decimals="INF"
      id="Narr_kK6PdPHFxUGjz5AMxF-WvA"
      unitRef="Unit_Standard_item_0sfEPIqYxkSB2d_NNWmuCg">2</vlon:NumberOfPromissoryNotes>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg"
      decimals="0"
      id="Narr_jOJiR5NiFkGI_QJp2OYbjw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">192000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="Duration_11_15_2017_To_11_15_2017_srt_CounterpartyNameAxis_vlon_AmiserviceDevelopmentLtdMember_vK8gXCOTZUSJrjZD5m5oLg"
      decimals="0"
      id="Narr_U8w7rbrLgEy_keB3wk30Jw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">60000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ"
      decimals="-5"
      id="Narr_WvWGat3RkE28bv-oe7Evjw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_22_2018_To_6_22_2018_srt_CounterpartyNameAxis_vlon_ArcturusTherapeuticsLtdMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f4gihH1gHEe8OuZKPPN_yQ"
      decimals="-5"
      id="Narr_OmCENw6bT0OrEyThdmUHpg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_6_22_2018_To_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_k-KjmXtk5kimmk4VBoIpKQ"
      decimals="0"
      id="Narr_ZY51Qx9KRkqq2-n4bmcpZQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">250000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="As_Of_6_22_2018_us-gaap_BusinessAcquisitionAxis_vlon_AdairProductRightsAcquisitionMember_nE5tkt9jPU267_p8BkBEfQ"
      decimals="0"
      id="Narr_e2ZoVHXpEEW7WFkLlgk89w"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">60000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-5"
      id="Narr_sxNzBDgUFkqCX2-2uU4O6g"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">-15200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_11_2021_To_1_11_2021_8qOoRPKb30yKP4fdaCxr0g"
      decimals="0"
      id="Narr_SuXCxPEyE0y34qnVxgeomQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw"
      decimals="-5"
      id="Narr_-hHBgSrlhUW_ys1LB8Ltkw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_1_11_2021_B-c7BO4RP0aNIhbXZvMJhg"
      decimals="-5"
      id="Narr_Town7XVA90Gc0AP34yYNLw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">13000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Ze1tN77XY06WgjjKmg8kxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s significant accounting policies are described in Note B, &#x201c;Summary of Significant Accounting Policies,&#x201d; in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 29, 2021. There have been no material changes to the significant accounting policies during the period ended March 31, 2021, except for items mentioned below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[A]&#160;&#160;Unaudited Interim Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments necessary for a fair presentation of the Company&#x2019;s financial position at March 31, 2021 and the results of operations, stockholders&#x2019; equity (deficit) and cash flows for the three months ended March 31, 2021 and 2020. All such adjustments are of a normal and recurring nature. Interim financial statements are prepared on a basis consistent with the Company&#x2019;s annual financial statements. Results of operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is to the Accounting Standards Codification issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For further information, refer to the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[B]&#160;&#160;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[C]&#160;&#160;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, &lt;i style="font-style:italic;"&gt;Stock-Based Compensation&lt;/i&gt;. ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised. The stock options granted, other than the 61,250 granted to Mr. Baker described in Note 10[A], as of March 31, 2021 vest primarily upon specified performance milestones. As Mr. Baker&#x2019;s stock option grant was pursuant to milestones associated with an underwritten public offering or a listing on a national stock exchange, management determined that no expense should be recognized for this grant until such time that the milestone becomes probable. The options vested on February 12, 2021, concurrent with the closing of the IPO and thus the expense for such options was recognized in the three months ended March 31, 2021. The Company elected to use the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[D]&#160;&#160;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all Accounting Standards Updates (&#x201c;ASUs&#x201d;). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <vlon:UnauditedInterimFinancialStatementsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_JaaBcm6R70K0QUmpHP_LmQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[A]&#160;&#160;Unaudited Interim Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments necessary for a fair presentation of the Company&#x2019;s financial position at March 31, 2021 and the results of operations, stockholders&#x2019; equity (deficit) and cash flows for the three months ended March 31, 2021 and 2020. All such adjustments are of a normal and recurring nature. Interim financial statements are prepared on a basis consistent with the Company&#x2019;s annual financial statements. Results of operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is to the Accounting Standards Codification issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For further information, refer to the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020.&lt;/p&gt;</vlon:UnauditedInterimFinancialStatementsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_EY8Z06aDpUm0WWR2xmAcEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[B]&#160;&#160;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_IoV3_5yaO0iC-N8wMWTF2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[C]&#160;&#160;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, &lt;i style="font-style:italic;"&gt;Stock-Based Compensation&lt;/i&gt;. ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised. The stock options granted, other than the 61,250 granted to Mr. Baker described in Note 10[A], as of March 31, 2021 vest primarily upon specified performance milestones. As Mr. Baker&#x2019;s stock option grant was pursuant to milestones associated with an underwritten public offering or a listing on a national stock exchange, management determined that no expense should be recognized for this grant until such time that the milestone becomes probable. The options vested on February 12, 2021, concurrent with the closing of the IPO and thus the expense for such options was recognized in the three months ended March 31, 2021. The Company elected to use the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_JqpFDEggRkesYrNF0Z7d7A"
      decimals="INF"
      id="Narr_IYhkh1cbYkuqTnj6i8Yz0g"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">61250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_-nhjxK8UCEG1DBWmFA9uTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;[D]&#160;&#160;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all Accounting Standards Updates (&#x201c;ASUs&#x201d;). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Ic5PsTMnZkyQb2tasTlnUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3 &#x2013; ACCRUED EXPENSES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical and preclinical trial and regulatory related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chemistry and manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Licensing related&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 985&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_fv6-0KuphEqlbd2sI-maWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical and preclinical trial and regulatory related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chemistry and manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Licensing related&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 985&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_edhe74gHmE6pgWQTTGDmeg_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">176000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_49MONCDGN0-Tem5FaYLS5g_3_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">342000</us-gaap:AccruedSalariesCurrent>
    <vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_0IxeVm44dU6RwLVTSQoAwA_4_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">490000</vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent>
    <vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_zGbz6zEnDUuxg0cbwjBq2g_4_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">137000</vlon:AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent>
    <vlon:AccruedChemistryAndManufacturingExpensesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_iaxSqN3dbkKLNcV8YJZbHg_5_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">154000</vlon:AccruedChemistryAndManufacturingExpensesCurrent>
    <vlon:AccruedChemistryAndManufacturingExpensesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_J2H6ba5OckSQMcP8f-Lhsw_5_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">117000</vlon:AccruedChemistryAndManufacturingExpensesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_MANStX-wpEm4d4sJIBcjaw_6_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">97000</us-gaap:InterestPayableCurrent>
    <vlon:AccruedLicensingFeesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_mMYd7Nd2E0KQriO2iu5qiw_7_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">76000</vlon:AccruedLicensingFeesCurrent>
    <vlon:AccruedLicensingFeesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_S7KmqxdxaECPZLlRoK8j9w_7_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">81000</vlon:AccruedLicensingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_AVfURmAQvkS1q-BfQRVTyg_8_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">89000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_RZimvOb_3U2xfPBnpCWPbg_8_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">73000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_OdhcrH7fp0SutKPYo0j67g_9_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_-v50OyGPj0el7e4WXIUEPg_9_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_AKHYBwKYW0WvVlR1wwF-2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4 &#x2013; PPP NOTE AND CONVERTIBLE NOTES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2020, the Company issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61,000 included in other income on the accompanying Statements of Operations. The Company had accounted for the note under ASC 470. The note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a 1.5-year period beginning November 1, 2020 unless forgiven. The Company did not impute interest on the note as the rate was determined to be a below-market rate due to the scope exception in ASC 835-30-15-3(e) for government-mandated interest rates. Amounts due under the next twelve months are presented as notes payable &#x2013; current on the Company&#x2019;s balance sheet as of December&#160;31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (&#x201c;Salmon Pharma&#x201d;), an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the &#x201c;2021 Convertible Notes&#x201d;), for cash proceeds of $350,000. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#x2019;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_31_2020_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_ei25kWe8EU-JCt2bw1gHyA"
      decimals="INF"
      id="Narr_1Wrl_73sz0qZ_oeN1g-WcQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">61000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_nW_at-qhE0qwfYklAFP-Yg"
      decimals="INF"
      id="Narr_nHQKjbYL_0GgNexsrfXMLg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">61000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA"
      decimals="0"
      id="Narr_sEzCS3tXpUiffsuhnC8zxA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_4CwAuiXkbUCOtvE65Xtb-g"
      decimals="INF"
      id="Narr_XAQcpLGfoUWf2RBvtrr8Kg"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_11_2021_To_1_11_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_gPOSwYrfFkeiDl0KnypBzA"
      decimals="INF"
      id="Narr_hsfpIlRkLUGC_vfDby0-qw"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <vlon:EquityFinancingDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_nphj7rv2IUuHkejxfaTvcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;5 &#x2013; EQUITY FINANCING&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;12, 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18.0 million. Underwriting discounts and expenses totaled $1.6 million and the Company incurred approximately $905,000 of additional expenses related to completing the IPO, of which $494,000 were incurred as of December 31, 2020 and included prepaids and other current assets on the Company&#x2019;s balance sheet; thus aggregate net proceeds were approximately $15.5 million. Immediately prior to the closing of the IPO, the Company effected a one-for-&lt;span style="-sec-ix-hidden:Hidden_RklKRiOmx06CoYYk0dhHnA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;40&lt;/span&gt;&lt;/span&gt; reverse stock split of its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In connection with the IPO, the Company granted the underwriters warrants (the &#x201c;Underwriters' Warrants&#x201d;) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share, which is 125% of the initial public offering price. The Underwriters&#x2019; Warrants have a five-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#x2019; Warrants were outstanding at March 31, 2021. According to ASC 480-10-25-8 and ASC 480-10-25-14, a warrant is classified as a liability if the warrant obligates the issuer to repurchase its shares by transferring an asset. A warrant can also be classified as a liability if it (conditionally or unconditionally) obligates the issuer to settle the warrant by issuing a variable number of shares if the monetary value of the obligation is based on a predetermined fixed amount, variation in something other than the issuers stock price, or variations inversely related to the issuers stock price. Any other warrant would be classified as equity. Given that these warrants do not meet the criteria of debt classification, these warrants were classified as equity and the fair value of $399,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</vlon:EquityFinancingDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_m_qpi2gNQ0Wm0F6HLx90lg"
      decimals="INF"
      id="Narr_NajJosQPYESJo8OWf7x3wg"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_12_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VWR0Rpxvjkq1cR6FDhHjRw"
      decimals="2"
      id="Narr_Auva2gOjEkawGeaFfEWulg"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">8.00</us-gaap:SharesIssuedPricePerShare>
    <vlon:GrossProceedsFromInitialPublicOffering
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA"
      decimals="-5"
      id="Narr_MIwEslV7DEiZ-fwx7t2rew"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">18000000.0</vlon:GrossProceedsFromInitialPublicOffering>
    <vlon:SaleOfStockUnderwritingDiscountsAndOtherExpenses
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA"
      decimals="-5"
      id="Narr_Qi8usb7B1kGaiUUO0x01QQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1600000</vlon:SaleOfStockUnderwritingDiscountsAndOtherExpenses>
    <vlon:SaleOfStockOtherOfferingCosts
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA"
      decimals="0"
      id="Narr_7yscHPjJg0K_69wf8uXr4g"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">905000</vlon:SaleOfStockOtherOfferingCosts>
    <vlon:SaleOfStockOtherOfferingCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_OL8f_qfInEqpi_l0fTWnWw"
      decimals="0"
      id="Narr_daqLt9DcO0K5Lmh4HA6CWw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">494000</vlon:SaleOfStockOtherOfferingCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA"
      decimals="-5"
      id="Narr_GfkSJnOr40CMGKSZYzhfNQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">15500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ"
      decimals="INF"
      id="Narr_mp4DINXbDUGfII7GoJ2Ntg"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">112500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ"
      decimals="2"
      id="Narr_f00YQBYZd0aPyycuSJ5JXQ"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vlon:PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg"
      decimals="2"
      id="Narr_DIeMgFyDnEedFSkjsvEy6w"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">1.25</vlon:PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_O-ovzlMuA0yCBbAuEJqQbQ"
      id="Narr_KGMA0EZQhE2vboUkHwrJBg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_ClassOfWarrantOrRightAxis_vlon_UnderwritersWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_a_2m79Ugn0ezIXxax-NPkg"
      decimals="0"
      id="Narr_dfhyoIK8rE6XI4kW7COA-g"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_9IMiHaFMVECXeDEyxfhfLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog"
      decimals="1"
      id="Tc_3T_YOj8HYkuyIghH89HkUQ_1_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">85.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_oUpLJpG1TEeUwluvcA56wQ"
      decimals="1"
      id="Tc_WMpWQYbtdU2UCOLjqacrtg_2_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_OuHcg0aKu02Um5Wx4JT5vw"
      decimals="1"
      id="Tc_unBrGkU0ok-uHXS0soFFVA_3_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_cEy2Na7LTU6FHcLHdGkVLA"
      decimals="3"
      id="Tc_gHYclDrBGk2IY6idVXsL5Q_4_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Aas1er-3hECMjmKgJbeHeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;6&#x2013; STOCK-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Equity Incentive Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. We have also granted certain stock options outside of the 2018 Equity Incentive Plan. As of March 31, 2021, all equity awards granted from the 2018 Equity Incentive Plan were in the form of stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures equity-based awards granted to employees, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards the Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes stock option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the stock option, the risk-free interest rate for a period that approximates the expected term of the stock option, and the Company&#x2019;s expected dividend yield. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics to it with historical share price information that approximates the expected term of the equity-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period that approximates the calculated expected term of its stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expense as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of the options granted during the three months ended March 31, 2021 and 2020 was estimated by utilizing the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.63-0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.08-5.31&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below represents the activity of stock options granted to employees and consultants:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period from December 31, 2020 through March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;terms&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;000)&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266,250&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.94&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.109&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.29&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.060&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the deemed fair value of the Company&#x2019;s common stock for those shares that had exercise prices lower than the deemed fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of March 31, 2021, there was approximately $105,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to employees which is expected to be recognized over a weighted-average period of one year. As of March 31, 2021, there was approximately $118,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to non-employees. That cost is expected to be recognized over a weighted-average period of 0.7 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_8OA-jaYsMk6s3_YAaLYWFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expense as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TSib4yEdAUSlHbmW78scuA"
      decimals="-3"
      id="Tc_S5TL72MHCUeuNNwwU3ap-g_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_peYk7ghKTU-3tzbPPE3XKQ"
      decimals="-3"
      id="Tc_WQ5Jy5YQAUeJ_DxBCUJSAA_3_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kYeoxmIIaUemiecYpa-T4w"
      decimals="-3"
      id="Tc_G1xlqcxoNES3yyZ6RyuESA_4_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_s1apAlCoZUWLip1_d-sNGA_5_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_iFTSa8h7kkyYwDJ44T60_g_5_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Aqy7aKMMyEqzkbFocIvuCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of the options granted during the three months ended March 31, 2021 and 2020 was estimated by utilizing the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.63-0.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.08-5.31&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="2"
      id="Tc_6AP9XH5CXEq8h9BNnMD0CQ_3_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="2"
      id="Tc_ivGur_zP-0WFjE_cadpA4Q_3_6"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA"
      id="Narr_d6P1EaoKk0mhAT_yEHaCng">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg"
      id="Narr_hkRAoTNKTkm4VxbhVrI2Og">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      id="Tc_rwk_GPxfAUW44pSPKsA1LQ_4_6">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="2"
      id="Tc_BLoQRRX6UUu0oVUfk8K8qQ_5_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="2"
      id="Tc_dDT9WxoVHEmqbvOJecxqsA_5_6"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MinimumMember__-6XP8PLyEWKF3M79AJUjA"
      decimals="4"
      id="Narr_J9BeA8Kx30CyYiOYjRVmkA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_RangeAxis_srt_MaximumMember_dFYBSNneMkuzHgNTBxXHLg"
      decimals="4"
      id="Narr_taewhfNYrE6n01LW3ZAbnA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="4"
      id="Tc_FxLKxyLFkUaaNckjOQw1UA_6_6"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.0220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MinimumMember_p-WkrdawjkKSVhflMIYJmA"
      decimals="2"
      id="Narr_hdIc8zVBlUK69Hz4qDFGpQ"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">4.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2021_srt_RangeAxis_srt_MaximumMember_QRMywzI2uUq-75VZaFoA9w"
      decimals="2"
      id="Narr_BSzRCJu19kak2sup4oFQqA"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">5.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2020_xPE79LlkVEK82dLwjettug"
      decimals="2"
      id="Tc_OSqEfg60bk-OxELzLZmIMQ_7_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">3.24</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_Do458bbwdEyqbY-vMnv_1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below represents the activity of stock options granted to employees and consultants:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period from December 31, 2020 through March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;terms&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;000)&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;(1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266,250&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.94&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.109&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.29&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.060&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the deemed fair value of the Company&#x2019;s common stock for those shares that had exercise prices lower than the deemed fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="INF"
      id="Tc_ZrN0HwwxAkuPP_dv5fFsmw_7_3"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">266250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="2"
      id="Tc_yPJqIRKe9kuODOkC6XDPWw_7_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_su5wP3O73kScJQ5b145b2g"
      id="Tc_3oTw1yMDg0imluvlL_IRbw_7_9">P4Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_fhElnFsS8UyskJbWwTPtXA_7_12"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">474000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="INF"
      id="Tc_l1Xb8CuMsk2Nn_1QIKNHCg_8_3"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">22750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="2"
      id="Tc_xF4BahWKuUyCesy1exBZmg_8_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">7.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Tc_ee44-MgibU2jp4NihDIr1g_9_3"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="2"
      id="Tc_7aYXcXg2Pk-6gZTWIovUmQ_9_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_vA4jzHDujkGBu1QsTEXhEQ_9_9">P4Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_uyYfIkqFTk-gcnwIbq8WXg_9_12"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="INF"
      id="Tc_CQn1lQZeAkaUW-RHS_mVGQ_10_3"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">135794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="2"
      id="Tc_iu5rn_wv_0iwEYj4IgaqLQ_10_6"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tc_bBxdPL_1w0aUHWBC3g9sNg_10_9">P3Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_fkLKO3EQIkujiHiF-knhhw_10_12"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">320000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_vFarWyLSi0W_Rq5eAXJa0A"
      decimals="0"
      id="Narr_pdDLejIk106g7PjDDm_1xg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">105000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A4zr9qZIIkWi15ZK_wyfzA"
      id="Narr_qXy7DPZBKEylDrcLeTFQJA">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ba48kdCZkEG4MpU_eSZ57w"
      decimals="0"
      id="Narr_knSEtf4XV0euIIdgjnoomA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">118000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wj8fFhgfhkWVHez-hovm0Q"
      id="Narr_2mP1xqcM1USY6nMSODtoBQ">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_VyVtcsSLfEe8nQCUtfk04Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the three months ended March 31, 2021 and 2020, respectively, no income tax expense or benefit was recognized. The Company&#x2019;s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="0"
      id="Narr_Zarqf9S8ck25Ds22i-S4jA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="0"
      id="Narr_iR5exADq20OXvqBnHIjnxQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_IVOmPOp0d0KFNko0xrf-Zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;8 - RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 6, 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100,000 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350,000. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <vlon:RelatedPartyTransactionUpfrontPayment
      contextRef="Duration_1_6_2020_To_1_6_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vlon_MediceMember_NGprOuJ5l06TJqQZC_V8ig"
      decimals="0"
      id="Narr_JnQ9_gncHE6y8y3Hq3pO4w"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">100000</vlon:RelatedPartyTransactionUpfrontPayment>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg"
      decimals="0"
      id="Narr_Fr9C5Wp_S0ugaX6yMpMrng"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember__uYmvO-NoEutzv5BKZjj-g"
      decimals="3"
      id="Narr_87HizcI-BUayant54YKjnA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_11_2021_To_1_11_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_ee2yptPV3kqe7YKsBz-VZg"
      decimals="INF"
      id="Narr_w-BjMeWCnkO08hRk-vHoqQ"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_7mIpZyXgdk-OSA9EU7P37A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;9 - FINANCE LEASE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into a finance lease in October 2019 in relation to equipment utilized in the commercial scale manufacturing of ADAIR ($ in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial lease right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term - finance lease (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from finance lease amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash flows from finance lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The maturities of the finance lease liability as of March 31, 2021 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_vdr1b3ZJ-EqxH6NTdQ3_pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into a finance lease in October 2019 in relation to equipment utilized in the commercial scale manufacturing of ADAIR ($ in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial lease right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term - finance lease (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from finance lease amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing cash flows from finance lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_UjHtOm-npkyfs-EgnkaHew_2_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">368000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_kxFe-qSY0kK_jZWPD-v3Pg_2_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">368000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_IqnuxUrtYEW0_SZjBtKe1w_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">107000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="-3"
      id="Tc_H_qrvBa2_0iJtkyAHB7IXQ_3_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">89000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      id="Tc_2T_tY441n0WUZUkpNLXDfg_4_3">P2Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      id="Tc__2rHPZujDECx0zS3EGhwGQ_4_6">P2Y9M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="4"
      id="Tc_n-hNp8yYsEOGztDe5645Uw_5_3"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.1350</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q"
      decimals="4"
      id="Tc_VsqfCdHV3EO40m4N70ZTCw_5_6"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.1350</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_6ruH5zRSlk6zFR2g26XzPQ_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_byttA8vdzEuaqxavHzRJnQ_3_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_waXUh2tHUkSFZiN84cqu5w_4_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">34000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w"
      decimals="-3"
      id="Tc_NYFwosuZyEya628hrvfMtA_4_6"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">29000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_t1kDe8VGjEihGNbc0SL3RA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The maturities of the finance lease liability as of March 31, 2021 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_HvfZEPLfNUOY91lUBpIxZw_1_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">95000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_-MV30wFL70O_ZKVEicE_Mw_2_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">114000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_1i5u8y3k_EKWYnvBfe-YEA_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">76000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_qGbdf_O0Rki_APkp-6meFA_4_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">285000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_0Kq2VCaKckW4ZjqGMIcaFA_5_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">44000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw"
      decimals="-3"
      id="Tc_Kuxla10tt0qHSd5wVyeJeQ_6_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">241000</us-gaap:FinanceLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_y6e2vxRVi0a8UfyyiD_7QA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;10 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(A)&#160;Employment Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 15, 2019, the Company entered into an employment agreement with David Baker, to serve as its President and Chief Executive Officer, which was subsequently superseded by a new employment agreement, effective as of April 20, 2021 (the &#x201c;Baker Agreement&#x201d;). The Baker Agreement provides for a base salary of $400,000 per year, effective as of April 20, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Under the Baker Agreement, in the event of an involuntary termination by the Company or termination by Mr. Baker for good reason, Mr. Baker will receive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;continued base salary for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;12 months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;six months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; during that year; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;12 months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event of a termination within 12 months after the occurrence of a change in control transaction, the President and Chief Executive Officer will receive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;continued base salary for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;18 months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;, plus a lump sum payment equal to 150% of his target bonus, without proration, for the fiscal year of termination;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;18 months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#x201c;target&#x201d; performance level, and any stock options remaining outstanding for their full term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In exchange for the severance benefits described above, Mr. Baker must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company. The description of the terms above are qualified in their entirety by reference to the Baker Agreement, a copy of which is filed by the Company as Exhibit 10.1 to this Quarterly Report on Form 10-Q.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(B)&#160;Clinical Trial Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2020, the Company entered into a service agreement, amended August 2020 and further amended January 2021, with a clinical research organization to provide clinical trial management services to the Company to assist the Company in its pivotal human abuse liability clinical trial of ADAIR, Study VAL-104. The agreement may be terminated by either party upon thirty days prior written notice. The total clinical trial cost is expected to be $3.1 million of which approximately $1.1 million and $49,000 was expensed during the three months ended March 31, 2021 and 2020, respectively. The Company has expensed $1.9 million cumulative from contract inception through the three months ended March 31, 2021 for Study VAL-104 and expects topline results from the study by the end of 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(C)&#160;Consulting Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective April 2, 2018, the Company entered into a consulting agreement with a consultant to serve as the Chief Medical Officer for the Company. Pursuant to the consulting agreement, the consultant is paid $10,000 per month for his services. In October 2018 and May 2020, the Company granted the consultant 15,625 and 6,250 options, respectively. For the three months ended March 31, 2021 and 2020, the Company has incurred consulting fees in the amount of approximately $30,000 and $30,000, respectively, under the agreement. The agreement may be terminated by either party with 30 days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(D)&#160;Manufacturing Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2019, the Company entered into an agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR. The total contract is estimated at $1.6 million of which approximately $79,000 and $79,000 was expensed under the agreement during the three months ended March 31, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company entered into an agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin&#xae;). The total contract is estimated at $232,000, of which $6,000 and $83,000 was expensed during the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(E)&#160;Pre-Clinical Agreement (included in research and development expense)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November 2019, the Company entered into an agreement with a clinical research organization for pre-clinical services. The total contract currently authorized is estimated at $1.5 million of which $245,000 and $175,000 was expensed during the three months ended March 31, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(F)&#160;COVID-19 Impact&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The global COVID-19 pandemic continues to rapidly evolve, and the Company continues to monitor the COVID-19 situation closely, including the worldwide vaccine rollout and the recent outbreaks of various strains of the virus. the full impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its future impact on the Company&#x2019;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom it does business, as well as its impact on regulatory authorities and the Company&#x2019;s key scientific and management personnel. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with many of its employees and consultants working remotely. The Company will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom the Company does business.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
      contextRef="As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ"
      decimals="0"
      id="Narr_oHrZ9OVs0kyv9jpFA4mcOQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">400000</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ"
      id="Narr_JbVDBeRIRUSmX4YSaP5w6Q">P12M</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ"
      id="Narr_8i5y-1DM3E69Pt9o87Xn-w">P6M</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <vlon:CobraHealthInsuranceCoveragePeriod
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_UelS--OXXEarmOG5j7yubQ"
      id="Narr_2FL1iGOyjkybrW49evdvdg">P12M</vlon:CobraHealthInsuranceCoveragePeriod>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA"
      id="Narr__y_j571jY0iuFsgeKPE04Q">P18M</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA"
      decimals="2"
      id="Narr_VhmnJep2JkO1qViW7_X-HQ"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">1.50</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <vlon:CobraHealthInsuranceCoveragePeriod
      contextRef="Duration_4_20_2021_To_4_20_2021_srt_StatementScenarioAxis_vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_1-w-MetATkCYP4XKh2I7TA"
      id="Narr_5Xz4m0FtOkWtC6QMvS-uSw">P18M</vlon:CobraHealthInsuranceCoveragePeriod>
    <vlon:TerminationPeriodUponPriorWrittenNotice
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_Tn38B5U-o02QABujfpad0A"
      id="Narr_XeiRZ_zEMUy5U_t0fy6TuA">P30D</vlon:TerminationPeriodUponPriorWrittenNotice>
    <vlon:ClinicalTrialCostExpectedAmount
      contextRef="As_Of_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_lVQgaSqrRkK1DTlNgKvOrA"
      decimals="-5"
      id="Narr_xDoRgWmEyUyJOo7BZQ6mWg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">3100000</vlon:ClinicalTrialCostExpectedAmount>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_PiKPhnXIVEe3otXkFQJSbg"
      decimals="-5"
      id="Narr_B92eaWS5g0yD1c2_dYDX6g"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_AY-YYGiTG0q7QQrpwLwsHg"
      decimals="0"
      id="Narr_pibCa7L6NUml21y09SBQag"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">49000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vlon_AdairStudyVal104Member_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_6XKRebR7BEWBtoFWLvbicQ"
      decimals="-5"
      id="Narr_YxIBoP6bTUaGoPefq-lhmQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1900000</us-gaap:ResearchAndDevelopmentExpense>
    <vlon:ProfessionalFeesPaidPerMonth
      contextRef="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A"
      decimals="0"
      id="Narr_1EELvVin0EiL9jPJ8IkguQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">10000</vlon:ProfessionalFeesPaidPerMonth>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_WGepaRPim0eFAsLrWHF3XQ"
      decimals="INF"
      id="Narr_mmqqdg6ym06xAuh-xXO7Dg"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">15625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_lmsSk0l7KkWPJE-KMU2SDw"
      decimals="INF"
      id="Narr_YC2-StoH20ab3fEB6QHcvQ"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_PeCqNyG65U-s5WHXh9lz0A"
      decimals="0"
      id="Narr_VxSvQvZ_60-MU93jYh1mgg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">30000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_hOnNiNgctkydAp6WTPWNzg"
      decimals="0"
      id="Narr_qnj4To1KzEWzNOgDBVxzhw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">30000</us-gaap:ProfessionalFees>
    <vlon:TerminationPeriodUponPriorWrittenNotice
      contextRef="Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A"
      id="Narr_zwYviDB9UUKTpyTOAa-v9Q">P30D</vlon:TerminationPeriodUponPriorWrittenNotice>
    <vlon:EstimatedContractCosts
      contextRef="As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g"
      decimals="-5"
      id="Narr_XjlQkwFwOUqjGrB-nwllZQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1600000</vlon:EstimatedContractCosts>
    <us-gaap:ManufacturingCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_aj1ck67-3kCcwaJeJiWVrg"
      decimals="0"
      id="Narr_Ugekvilo90WqtUu15WpLVg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">79000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_lCH-zADik0qKO3X2XzUZjw"
      decimals="0"
      id="Narr_THGRVrSKAUm4K8EL6TOdtQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">79000</us-gaap:ManufacturingCosts>
    <vlon:EstimatedContractCosts
      contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_z-8EZMohVECdXJnLeqPxEw"
      decimals="0"
      id="Narr_dDttVJmYrUqfq75xnKmNQQ"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">232000</vlon:EstimatedContractCosts>
    <us-gaap:ManufacturingCosts
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_IzAODsPw3UW6_K3qX2og7A"
      decimals="0"
      id="Narr_MQJZlaqsEUuca_xUL6vKGw"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">6000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember_BbC8XV5qlU2ceMNKytn5Qg"
      decimals="0"
      id="Narr_yhDAMmAra0qh4YTOrG_-ag"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">83000</us-gaap:ManufacturingCosts>
    <vlon:EstimatedContractCosts
      contextRef="As_Of_11_30_2019_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_SnkKNVvge0SVtghw5VA0qw"
      decimals="-5"
      id="Narr_7-qJnMQaVUWXN2xPHlVpOA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">1500000</vlon:EstimatedContractCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_6vvh1yU2_0mn3PPDkIvZWQ"
      decimals="0"
      id="Narr_1Rj7M0oYL0qZHvleSDa5_g"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_kkrPw5KwQkynmgre4Q1gJA"
      decimals="0"
      id="Narr_aFQUtK-HpkG8j5EM4NCRhA"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">175000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_z9PSXDPdPEGKwG_KeIS6eQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;11: FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $8 per share upon closing of the IPO. As such, an expense of $89,000 was recorded in the first quarter of 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the three months ended March 31, 2021 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions during the quarter ended March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transfer out of Level 3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA"
      decimals="INF"
      id="Narr_6rIYtBDvXkWwMbdZz0ya6A"
      unitRef="Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA">8</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="INF"
      id="Narr_jr9JRiK3Q06ncNR3voONwg"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">89000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_BKq6xbIm-0iKkn7-yr7X7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the three months ended March 31, 2021 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additions during the quarter ended March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transfer out of Level 3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_QFgD0fWl90Gi6-5_j7HNaQ_2_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      decimals="-3"
      id="Tc_gFgBG1bd7k2RORxOEk-2GA_3_3"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg"
      id="Tb_7XGkMaXjh0KiYEqadqccNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 12: SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On May 10, 2021, the Company appointed Leanne M. Kelly to serve as its Chief Financial Officer, and principal financial and accounting officer. In connection with Ms. Kelly&#x2019;s appointment, the Company entered into an employment agreement with Ms. Kelly (the &#x201c;Kelly Agreement&#x201d;), which provides for an initial base annual salary of $275,000 and a target bonus opportunity equal to 35%&lt;span style="white-space:pre-wrap;"&gt; of her base salary.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Kelly Agreement also provides that the Company will recommend that the Board approve a stock option grant covering 100,000&lt;span style="white-space:pre-wrap;"&gt; common shares of the Company (the &#x201c;Stock Option&#x201d;).  The Stock Option shall have an exercise price per share equal to the fair market value of a share of the Company&#x2019;s common stock on the date of grant and shall vest in installments and become exercisable as follows: (i) &lt;/span&gt;70% of the shares underlying the Stock Option shall vest as follows: (x) 17,500 option shares on the first anniversary of her start date, and (y) the remaining 52,500 option shares in equal installments on a quarterly basis for the next three years, in each case subject to continued employment, and (ii) 30% of the shares underlying the Stock Option shall vest as follows: (x) 15,000 option shares on the date the Company submits a New Drug Application (&#x201c;NDA&#x201d;) filing for ADAIR with the U.S. Food &amp;amp; Drug Administration, and (y) 15,000 option shares on the date when the U.S. Food &amp;amp; Drug Administration approves the NDA, provided that she is employed by the Company at the time the applicable performance objective is achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Kelly Agreement provides that if she is terminated by the Company other than for cause, or she resigns for good reason, in either case not in connection with a change in control, she will receive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;continued base salary for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided she was employed for at least &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;six months&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; during that year; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;If she is terminated by the Company other than for cause, or she resigns for good reason, in either case within the one-year period commencing on a change in control, she will receive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;continued base salary for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; months, plus a lump sum payment equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;100%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; of her target bonus, without proration, for the fiscal year of termination;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"&gt; months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;"&gt;accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#x201c;target&#x201d; performance level, and any stock options remaining outstanding for their full term.  &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In exchange for the severance benefits described above, Ms. Kelly must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company.  The description of the terms above are qualified in their entirety by reference to the Kelly Agreement, a copy of which is filed by the Company as Exhibit&#160;10.2 to this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See description of the Baker Agreement under Note 10 &#x2013; Employment Agreements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg"
      decimals="0"
      id="Narr_hBkuDYTmeUKD2YM8Ddts3Q"
      unitRef="Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg">275000</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_K8OayvzVWk6w7L3GnwtAdA"
      decimals="2"
      id="Narr_vaVbToZ7eEK4igaud0CtLQ"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.35</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_99MbGdLZZ06ZDQEAKCqSSg"
      decimals="0"
      id="Narr_yn-8_tLI80GqfhM6mPYKHg"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">100000</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7RrpN30090e56LLSpDLmkw"
      decimals="2"
      id="Narr_fqhacwp0TEyRbsg8Gj4rMA"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.70</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnFirstAnniversaryOfStartDateMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_XJA5MW80TUen-MTCbD2nKA"
      decimals="0"
      id="Narr_WbxtFkbTkEmxNvyZ0jvrQg"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">17500</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qHpeFWSKRU6tDNBCRoCPWA"
      decimals="0"
      id="Narr_vN4w1RKSsEGPkaveAdUfTA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">52500</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Nu0HlaQrV0STf4cE6gIghA"
      decimals="2"
      id="Narr_hvqUdhQL8kaB6vKzbbsOZg"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">0.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_GnqWo_CEXEeAcNENJ-Sk8A"
      decimals="0"
      id="Narr_Foimo3ERKkOO7rO3VttvDA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">15000</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardDateAxis_vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XY59mQ4yF0SnWeexPPyTCg"
      decimals="0"
      id="Narr_zelhPukZik6mbHwxVfvHPA"
      unitRef="Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg">15000</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw"
      id="Narr_x3oJfwgU_UOjPcfJoUNk3A">P9M</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw"
      id="Narr_ks_fxv6tx0uUQk4WY8h7Mg">P6M</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <vlon:CobraHealthInsuranceCoveragePeriod
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationNotInConnectionWithChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_geemwNspAkaJyaMUyt9Xxw"
      id="Narr_e48YLbQIQUKNkiSKqzHrmg">P9M</vlon:CobraHealthInsuranceCoveragePeriod>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q"
      id="Narr_BAsEqfSXSEyRCm_yxucMnw">P12M</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q"
      decimals="2"
      id="Narr_01brJRbFo0iAtrB0lf6StQ"
      unitRef="Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g">1</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <vlon:CobraHealthInsuranceCoveragePeriod
      contextRef="Duration_5_10_2021_To_5_10_2021_srt_StatementScenarioAxis_vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_VAq_zXY5uEaBntvOQKFp9Q"
      id="Narr_FSfC6HPeXkyLlBrmi90Exg">P12M</vlon:CobraHealthInsuranceCoveragePeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_FGbZdoNwW02Av2IEwUE_aA_3_2"
          xlink:label="Tc_FGbZdoNwW02Av2IEwUE_aA_3_2"
          xlink:type="locator"/>
        <link:footnote id="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" xlink:label="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:8pt;">The number of shares above give retroactive effect to the </xhtml:span><xhtml:span style="font-size:8pt;">one</xhtml:span><xhtml:span style="font-size:8pt;">-for-40 reverse stock split. See Note 1 to these financial statements.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_FGbZdoNwW02Av2IEwUE_aA_3_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2"
          xlink:label="Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_R_rA9qdPcE6VPWkT5C4MXQ_6_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__GHEDaYiVUGmBBtF5kMWvw_3_2"
          xlink:label="Tc__GHEDaYiVUGmBBtF5kMWvw_3_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__GHEDaYiVUGmBBtF5kMWvw_3_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2"
          xlink:label="Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ioPuGJqRRkqJwWg4O2IikQ_10_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2"
          xlink:label="Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Ua2u18Bo0UWGRYVGIwYaTg_4_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2"
          xlink:label="Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_4WE77vuAyUq84wJVmJ-RaQ_6_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2"
          xlink:label="Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_45G0PyX9Y06lgPuGKFUJ4A_5_2"
          xlink:to="_c9295d99_9c83_4cca_b3c0_96f29cc44e2e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653723816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VALLON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 N. 18th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">207-3606 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VLON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_TransitionReport', window );">Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_TransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the company has a shorter operating period because the period of inception of the company is later than the start of the reporting period, therefore, the Fiscal Period Focus is longer than the actual period of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_TransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653116504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,980<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,338<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset, net</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,573<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 6,812,836 and 4,506,216 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively, which gives retroactive effect to the one-for-40 reverse stock split. See Note 1 to these financial statements.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">27,264<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,237)<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">12,027<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653546584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet (parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652877624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,772<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Revaluation of derivative liability</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,638)<span></span>
</td>
<td class="num">$ (1,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding basic and diluted</a></td>
<td class="nump">5,710,270<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653768680">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,991<span></span>
</td>
<td class="num">$ (7,777)<span></span>
</td>
<td class="num">$ (3,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,026<span></span>
</td>
<td class="num">(8,937)<span></span>
</td>
<td class="num">(2,089)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,264<span></span>
</td>
<td class="num">$ (15,237)<span></span>
</td>
<td class="nump">$ 12,027<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:8pt;">The number of shares above give retroactive effect to the </span><span style="font-size:8pt;">one</span><span style="font-size:8pt;">-for-40 reverse stock split. See Note 1 to these financial statements.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652425928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statements of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654649582648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2,638,000)<span></span>
</td>
<td class="num">$ (1,160,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Revaluation of derivative liability</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Forgiveness of PPP note</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_NonCashInterestDepreciationAndOtherExpense', window );">Non-cash interest, depreciation and other expense</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">793,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">121,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,948,000)<span></span>
</td>
<td class="num">(766,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from common stock, net of offering expenses</a></td>
<td class="nump">15,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">15,819,000<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) increase in cash and cash equivalents</a></td>
<td class="nump">12,871,000<span></span>
</td>
<td class="num">(797,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">3,821,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">12,980,000<span></span>
</td>
<td class="nump">$ 3,024,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_NonCashInterestDepreciationAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest, depreciation and other income (expense) included in net income that results in no cash inflow (outflow).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_NonCashInterestDepreciationAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651015144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 1</b><b style="font-weight:bold;"> &#8211; NATURE</b><b style="font-weight:bold;"> OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vallon Pharmaceuticals, Inc. (&#8220;Vallon&#8221; or the &#8220;Company&#8221;), a Delaware corporation, is a biopharmaceutical company based in Philadelphia, PA, which is focused on the development and commercialization of proprietary biopharmaceutical products. The Company&#8217;s only clinical-stage product currently under development is ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of Attention-deficit/hyperactivity disorder, or ADHD, and Narcolepsy. The Company plans to develop other abuse-deterrent products which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company is conducting formulation development work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vallon Pharmaceuticals, Inc. was incorporated in Delaware on January 11, 2018, which is the date of inception. The Company&#8217;s fiscal-year ends on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immediately prior to the closing of the initial public offering of the Company&#8217;s common stock (the &#8220;IPO&#8221;) (Note 5), the Company effected a one-for-<span style="-sec-ix-hidden:Hidden_UIe2lbAF2kGKY5HDdycYJA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">40 </span></span>reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Formation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 15, 2017, before the Company&#8217;s formation, Amiservice Development Ltd., a BVI corporation (&#8220;Amiservice&#8221;) entered into an agreement for the purchase of the ADAIR product rights for a payment of $250,000. The Asset Purchase Agreement (&#8220;the APA&#8221;), by and between Amiservice and Arcturus Therapeutics Ltd. (&#8221;Arcturus&#8221;), was subject to several closing conditions. One of the key terms and conditions of the APA was that the purchasers provide funding of at least $2.75 million towards the development of ADAIR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 11, 2018, Ofir Levi, Chairman of the newly formed Vallon, purchased 196,875 common shares from the Company at par value for $788. On June 7, 2018, Vallon entered into a stock purchase agreement with several investors pursuant to which Vallon issued 1,771,881 common shares for $3.0 million (&#8220;Private Placement&#8221;). Subsequently, on June 22, 2018, the Company executed the amended APA, by and between Arcturus Therapeutics Ltd. Such APA was amended and restated from the initial agreement discussed above, dated as of November 15, 2017. In exchange for the ADAIR product rights, Vallon issued 843,750 common shares to Arcturus, valued at approximately $1.4 million based upon the price at which the common shares were issued and sold in the Private Placement, which comprised approximately 30% of the then-outstanding common stock of the Company, on a fully diluted basis. In addition, Amiservice signed a consent and release agreement to all rights to the APA in exchange for approximately $562,000 which represented a reimbursement for expenses Amiservice incurred on Vallon&#8217;s behalf in the amount of approximately $310,000, the repayment of two promissory notes totaling approximately $192,000 including interest, and approximately $60,000 of other operating expenses incurred. The assets acquired in the ADAIR acquisition are classified as in-process research and development (&#8220;IPR&amp;D&#8221;). Accounting for IPR&amp;D assets in an asset acquisition follows the guidance in Accounting Standards Codifications (&#8220;ASC&#8221;) 730, <i style="font-style:italic;">Research and Development</i>, which requires that both tangible and intangible identifiable research and development assets with no alternative future use be allocated a portion of the consideration transferred and charged to expense at the acquisition date. The Company recorded $1.7 million to research and development expense on June 22, 2018, the date of acquisition, which included $1.4 million of common shares issued for the acquisition, as well as, the original $250,000 exclusivity payment and approximately $60,000 in transaction fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern and Liquidity:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception, and has incurred $15.2 million in accumulated deficit through March 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (&#8220;PPP&#8221;) promissory note, as described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 11, 2021, the Company completed a $350,000 convertible note financing and on February 12, 2021, the Company completed the IPO, raising net proceeds of $15.5 million, as described in Note 5. On March&#160;31, 2021, the Company had cash and cash equivalents totaling approximately $13.0 million which management expects will provide funding for its ongoing business activities into the third quarter of 2022. However, the Company has based this estimate on assumptions that may prove to be wrong, and it could use capital resources sooner than it expects, therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that these financial statements are being issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company&#8217;s objective is to develop and commercialize biopharmaceutical products that treat central nervous system disorders, but there can be no assurances that the Company will be successful in this regard. Therefore, the Company intends to raise capital through additional issuances of common stock and /or short-term notes. Furthermore, the Company may not be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements. If the Company is unable to obtain sufficient cash resources to fund its operations, it may be forced to reduce or discontinue its operations entirely. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654650970264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s significant accounting policies are described in Note B, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 29, 2021. There have been no material changes to the significant accounting policies during the period ended March 31, 2021, except for items mentioned below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[A]&#160;&#160;Unaudited Interim Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments necessary for a fair presentation of the Company&#8217;s financial position at March 31, 2021 and the results of operations, stockholders&#8217; equity (deficit) and cash flows for the three months ended March 31, 2021 and 2020. All such adjustments are of a normal and recurring nature. Interim financial statements are prepared on a basis consistent with the Company&#8217;s annual financial statements. Results of operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is to the Accounting Standards Codification issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For further information, refer to the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[B]&#160;&#160;Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[C]&#160;&#160;Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <i style="font-style:italic;">Stock-Based Compensation</i>. ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised. The stock options granted, other than the 61,250 granted to Mr. Baker described in Note 10[A], as of March 31, 2021 vest primarily upon specified performance milestones. As Mr. Baker&#8217;s stock option grant was pursuant to milestones associated with an underwritten public offering or a listing on a national stock exchange, management determined that no expense should be recognized for this grant until such time that the milestone becomes probable. The options vested on February 12, 2021, concurrent with the closing of the IPO and thus the expense for such options was recognized in the three months ended March 31, 2021. The Company elected to use the expected term, rather than the contractual term, for both employee and consultant options issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[D]&#160;&#160;Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all Accounting Standards Updates (&#8220;ASUs&#8221;). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654650754152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3 &#8211; ACCRUED EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 342</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and preclinical trial and regulatory related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chemistry and manufacturing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Licensing related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 847</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654650969144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>PPP NOTE AND CONVERTIBLE NOTES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PPP NOTE AND CONVERTIBLE NOTES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4 &#8211; PPP NOTE AND CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, the Company had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments and in January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As the PPP note was forgiven, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61,000 included in other income on the accompanying Statements of Operations. The Company had accounted for the note under ASC 470. The note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a 1.5-year period beginning November 1, 2020 unless forgiven. The Company did not impute interest on the note as the rate was determined to be a below-market rate due to the scope exception in ASC 835-30-15-3(e) for government-mandated interest rates. Amounts due under the next twelve months are presented as notes payable &#8211; current on the Company&#8217;s balance sheet as of December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (&#8220;Salmon Pharma&#8221;), an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the &#8220;2021 Convertible Notes&#8221;), for cash proceeds of $350,000. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651024600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY FINANCING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EquityFinancingAbstract', window );"><strong>EQUITY FINANCING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EquityFinancingDisclosureTextBlock', window );">EQUITY FINANCING</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;5 &#8211; EQUITY FINANCING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February&#160;12, 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18.0 million. Underwriting discounts and expenses totaled $1.6 million and the Company incurred approximately $905,000 of additional expenses related to completing the IPO, of which $494,000 were incurred as of December 31, 2020 and included prepaids and other current assets on the Company&#8217;s balance sheet; thus aggregate net proceeds were approximately $15.5 million. Immediately prior to the closing of the IPO, the Company effected a one-for-<span style="-sec-ix-hidden:Hidden_RklKRiOmx06CoYYk0dhHnA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">40</span></span> reverse stock split of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the IPO, the Company granted the underwriters warrants (the &#8220;Underwriters' Warrants&#8221;) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share, which is 125% of the initial public offering price. The Underwriters&#8217; Warrants have a five-year term and are not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding at March 31, 2021. According to ASC 480-10-25-8 and ASC 480-10-25-14, a warrant is classified as a liability if the warrant obligates the issuer to repurchase its shares by transferring an asset. A warrant can also be classified as a liability if it (conditionally or unconditionally) obligates the issuer to settle the warrant by issuing a variable number of shares if the monetary value of the obligation is based on a predetermined fixed amount, variation in something other than the issuers stock price, or variations inversely related to the issuers stock price. Any other warrant would be classified as equity. Given that these warrants do not meet the criteria of debt classification, these warrants were classified as equity and the fair value of $399,000 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_EquityFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_EquityFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_EquityFinancingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_EquityFinancingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653561176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6&#8211; STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Equity Incentive Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. We have also granted certain stock options outside of the 2018 Equity Incentive Plan. As of March 31, 2021, all equity awards granted from the 2018 Equity Incentive Plan were in the form of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures equity-based awards granted to employees, and nonemployees based on their fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards the Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes stock option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the stock option, the risk-free interest rate for a period that approximates the expected term of the stock option, and the Company&#8217;s expected dividend yield. Expected volatility is calculated based on reported volatility data for a representative group of publicly traded companies for which historical information is available. The Company selects companies with comparable characteristics to it with historical share price information that approximates the expected term of the equity-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of its stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical exercise data. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of the options granted during the three months ended March 31, 2021 and 2020 was estimated by utilizing the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.63-0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of option on grant date</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.08-5.31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below represents the activity of stock options granted to employees and consultants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from December 31, 2020 through March 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">terms</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">000)</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.109</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 474</p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460</p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 320</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the deemed fair value of the Company&#8217;s common stock for those shares that had exercise prices lower than the deemed fair value of the Company&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2021, there was approximately $105,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to employees which is expected to be recognized over a weighted-average period of one year. As of March 31, 2021, there was approximately $118,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted to non-employees. That cost is expected to be recognized over a weighted-average period of 0.7 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651113720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; INCOME TAXES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended March 31, 2021 and 2020, respectively, no income tax expense or benefit was recognized. The Company&#8217;s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652819480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8 - RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 6, 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100,000 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 11, 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350,000. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651110488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE LEASE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>FINANCE LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">FINANCE LEASE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9 - FINANCE LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a finance lease in October 2019 in relation to equipment utilized in the commercial scale manufacturing of ADAIR ($ in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial lease right-of-use asset </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - finance lease (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from finance lease amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash flows from finance lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The maturities of the finance lease liability as of March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652485240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;10 &#8211; COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A)&#160;Employment Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 15, 2019, the Company entered into an employment agreement with David Baker, to serve as its President and Chief Executive Officer, which was subsequently superseded by a new employment agreement, effective as of April 20, 2021 (the &#8220;Baker Agreement&#8221;). The Baker Agreement provides for a base salary of $400,000 per year, effective as of April 20, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Baker Agreement, in the event of an involuntary termination by the Company or termination by Mr. Baker for good reason, Mr. Baker will receive:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continued base salary for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">six months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> during that year; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of a termination within 12 months after the occurrence of a change in control transaction, the President and Chief Executive Officer will receive:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continued base salary for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, plus a lump sum payment equal to 150% of his target bonus, without proration, for the fiscal year of termination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if he elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (or such earlier date that he obtains alternative coverage), such that he will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In exchange for the severance benefits described above, Mr. Baker must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company. The description of the terms above are qualified in their entirety by reference to the Baker Agreement, a copy of which is filed by the Company as Exhibit 10.1 to this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(B)&#160;Clinical Trial Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2020, the Company entered into a service agreement, amended August 2020 and further amended January 2021, with a clinical research organization to provide clinical trial management services to the Company to assist the Company in its pivotal human abuse liability clinical trial of ADAIR, Study VAL-104. The agreement may be terminated by either party upon thirty days prior written notice. The total clinical trial cost is expected to be $3.1 million of which approximately $1.1 million and $49,000 was expensed during the three months ended March 31, 2021 and 2020, respectively. The Company has expensed $1.9 million cumulative from contract inception through the three months ended March 31, 2021 for Study VAL-104 and expects topline results from the study by the end of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(C)&#160;Consulting Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective April 2, 2018, the Company entered into a consulting agreement with a consultant to serve as the Chief Medical Officer for the Company. Pursuant to the consulting agreement, the consultant is paid $10,000 per month for his services. In October 2018 and May 2020, the Company granted the consultant 15,625 and 6,250 options, respectively. For the three months ended March 31, 2021 and 2020, the Company has incurred consulting fees in the amount of approximately $30,000 and $30,000, respectively, under the agreement. The agreement may be terminated by either party with 30 days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(D)&#160;Manufacturing Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2019, the Company entered into an agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR. The total contract is estimated at $1.6 million of which approximately $79,000 and $79,000 was expensed under the agreement during the three months ended March 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered into an agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin&#174;). The total contract is estimated at $232,000, of which $6,000 and $83,000 was expensed during the three months ended March 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(E)&#160;Pre-Clinical Agreement (included in research and development expense)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company entered into an agreement with a clinical research organization for pre-clinical services. The total contract currently authorized is estimated at $1.5 million of which $245,000 and $175,000 was expensed during the three months ended March 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(F)&#160;COVID-19 Impact</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The global COVID-19 pandemic continues to rapidly evolve, and the Company continues to monitor the COVID-19 situation closely, including the worldwide vaccine rollout and the recent outbreaks of various strains of the virus. the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its future impact on the Company&#8217;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom it does business, as well as its impact on regulatory authorities and the Company&#8217;s key scientific and management personnel. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with many of its employees and consultants working remotely. The Company will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom the Company does business.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652390568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;11: FAIR VALUE MEASUREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $8 per share upon closing of the IPO. As such, an expense of $89,000 was recorded in the first quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the three months ended March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance at January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions during the quarter ended March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer out of Level 3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651051448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 12: SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 10, 2021, the Company appointed Leanne M. Kelly to serve as its Chief Financial Officer, and principal financial and accounting officer. In connection with Ms. Kelly&#8217;s appointment, the Company entered into an employment agreement with Ms. Kelly (the &#8220;Kelly Agreement&#8221;), which provides for an initial base annual salary of $275,000 and a target bonus opportunity equal to 35%<span style="white-space:pre-wrap;"> of her base salary.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Kelly Agreement also provides that the Company will recommend that the Board approve a stock option grant covering 100,000<span style="white-space:pre-wrap;"> common shares of the Company (the &#8220;Stock Option&#8221;).  The Stock Option shall have an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant and shall vest in installments and become exercisable as follows: (i) </span>70% of the shares underlying the Stock Option shall vest as follows: (x) 17,500 option shares on the first anniversary of her start date, and (y) the remaining 52,500 option shares in equal installments on a quarterly basis for the next three years, in each case subject to continued employment, and (ii) 30% of the shares underlying the Stock Option shall vest as follows: (x) 15,000 option shares on the date the Company submits a New Drug Application (&#8220;NDA&#8221;) filing for ADAIR with the U.S. Food &amp; Drug Administration, and (y) 15,000 option shares on the date when the U.S. Food &amp; Drug Administration approves the NDA, provided that she is employed by the Company at the time the applicable performance objective is achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Kelly Agreement provides that if she is terminated by the Company other than for cause, or she resigns for good reason, in either case not in connection with a change in control, she will receive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">continued base salary for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">9</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided she was employed for at least </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">six months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> during that year; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">9</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If she is terminated by the Company other than for cause, or she resigns for good reason, in either case within the one-year period commencing on a change in control, she will receive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">continued base salary for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">12</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months, plus a lump sum payment equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">100%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> of her target bonus, without proration, for the fiscal year of termination;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">if she elects to continue receiving group health insurance coverage pursuant to COBRA, subsidized premiums for COBRA continuation coverage for a period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">12</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> months (or such earlier date that she obtains alternative coverage), such that she will continue to pay the premium cost for active employees who receive the same type of coverage during that period; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;white-space:pre-wrap;">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.  </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In exchange for the severance benefits described above, Ms. Kelly must comply with certain confidentiality, non-competition and non-solicitation provisions, return all company property, and sign a release of claims in favor of the Company.  The description of the terms above are qualified in their entirety by reference to the Kelly Agreement, a copy of which is filed by the Company as Exhibit&#160;10.2 to this Quarterly Report on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See description of the Baker Agreement under Note 10 &#8211; Employment Agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654656312696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_UnauditedInterimFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[A]&#160;&#160;Unaudited Interim Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments necessary for a fair presentation of the Company&#8217;s financial position at March 31, 2021 and the results of operations, stockholders&#8217; equity (deficit) and cash flows for the three months ended March 31, 2021 and 2020. All such adjustments are of a normal and recurring nature. Interim financial statements are prepared on a basis consistent with the Company&#8217;s annual financial statements. Results of operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is to the Accounting Standards Codification issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For further information, refer to the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[B]&#160;&#160;Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[C]&#160;&#160;Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <i style="font-style:italic;">Stock-Based Compensation</i>. ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised. The stock options granted, other than the 61,250 granted to Mr. Baker described in Note 10[A], as of March 31, 2021 vest primarily upon specified performance milestones. As Mr. Baker&#8217;s stock option grant was pursuant to milestones associated with an underwritten public offering or a listing on a national stock exchange, management determined that no expense should be recognized for this grant until such time that the milestone becomes probable. The options vested on February 12, 2021, concurrent with the closing of the IPO and thus the expense for such options was recognized in the three months ended March 31, 2021. The Company elected to use the expected term, rather than the contractual term, for both employee and consultant options issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[D]&#160;&#160;Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all Accounting Standards Updates (&#8220;ASUs&#8221;). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_UnauditedInterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for unaudited interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_UnauditedInterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652379416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 342</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and preclinical trial and regulatory related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chemistry and manufacturing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Licensing related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 985</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 847</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654652385000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY FINANCING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EquityFinancingAbstract', window );"><strong>EQUITY FINANCING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of estimates used for fair value of the warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:83.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_EquityFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_EquityFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654669112104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair value of options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of the options granted during the three months ended March 31, 2021 and 2020 was estimated by utilizing the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.63-0.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of option on grant date</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.08-5.31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of activity of stock options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below represents the activity of stock options granted to employees and consultants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from December 31, 2020 through March 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">terms</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">000)</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">(1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.94</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.109</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 474</p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.060</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460</p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 320</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the deemed fair value of the Company&#8217;s common stock for those shares that had exercise prices lower than the deemed fair value of the Company&#8217;s common stock.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654651105400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE LEASE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>FINANCE LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of finance leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a finance lease in October 2019 in relation to equipment utilized in the commercial scale manufacturing of ADAIR ($ in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial lease right-of-use asset </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - finance lease (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from finance lease amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash flows from finance lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of finance lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The maturities of the finance lease liability as of March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654683130456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of liability measured at estimated fair value using unobservable inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the three months ended March 31, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance at January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions during the quarter ended March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer out of Level 3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:bottom;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654577587800">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 15, 2017 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,772,000<span></span>
</td>
<td class="nump">$ 883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,599,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vlon_AdairProductRightsAcquisitionMember', window );">ADAIR acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Exclusivity payment fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Stock purchase agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vlon_AmiserviceDevelopmentLtdMember', window );">Amiservice Development Ltd</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AssetPurchaseAgreementReimbursementOfExpenses', window );">Reimbursement for expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_NumberOfPromissoryNotes', window );">Number of promissory notes | item</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayment of Promissory notes due</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vlon_AmiserviceDevelopmentLtdMember', window );">Amiservice Development Ltd | Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vlon_ArcturusTherapeuticsLtdMember', window );">Arcturus Therapeutics Ltd | Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis', window );">Percentage of shares held on fully-diluted basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Ofir Levi, Chairman | Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=vlon_ArcturusTherapeuticsLtdMember', window );">Arcturus Therapeutics Ltd | Amiservice Development Ltd</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation', window );">Purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation', window );">Minimum funds for product development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:8pt;">The number of shares above give retroactive effect to the </span><span style="font-size:8pt;">one</span><span style="font-size:8pt;">-for-40 reverse stock split. See Note 1 to these financial statements.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount agreed for the purchase of product rights prior to business formation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AssetPurchaseAgreementReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reimbursement of expenses incurred under the asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AssetPurchaseAgreementReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount agreed under the asset purchase agreement for funding the development of product, as per the key terms and conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_NumberOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_NumberOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares then outstanding at the issuance on a diluted basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vlon_AdairProductRightsAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vlon_AdairProductRightsAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vlon_AmiserviceDevelopmentLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vlon_AmiserviceDevelopmentLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vlon_ArcturusTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vlon_ArcturusTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vlon_ArcturusTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vlon_ArcturusTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654649585704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">22,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">David Baker</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">61,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654649420584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Payroll and related</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent', window );">Clinical and preclinical trial and regulatory related</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AccruedChemistryAndManufacturingExpensesCurrent', window );">Chemistry and manufacturing</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Financing related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AccruedLicensingFeesCurrent', window );">Licensing related</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AccruedChemistryAndManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for chemistry and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AccruedChemistryAndManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for Clinical and preclinical trial and regulatory related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AccruedLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for licensing related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AccruedLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654649638696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Income from extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash proceeds</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vlon_PaycheckProtectionProgramLoanMember', window );">PPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Promissory note, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Income from extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash proceeds</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vlon_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vlon_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654647696200">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>EQUITY FINANCING (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="nump">$ 15,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants classified as additional paid in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_GrossProceedsFromInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses', window );">Underwriting discounts and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_SaleOfStockOtherOfferingCosts', window );">Additional expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vlon_UnderwritersWarrantsMember', window );">Underwriters' Warrants | IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable', window );">Percentage of public offering price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants classified as additional paid in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaids and other current assets | IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_SaleOfStockOtherOfferingCosts', window );">Additional expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:8pt;">The number of shares above give retroactive effect to the </span><span style="font-size:8pt;">one</span><span style="font-size:8pt;">-for-40 reverse stock split. See Note 1 to these financial statements.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_GrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds from initial public offering during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_GrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares on initial public offering price for warrants exercisable by underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other offering costs incurred in connection with the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting discounts and other expenses incurred and paid for underwriters to the public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vlon_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vlon_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654653555880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY FINANCING - Estimate the fair value of the warrants (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted average assumptions to estimate the fair value of warrants</a></td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted average assumptions to estimate the fair value of warrants</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted average assumptions to estimate the fair value of warrants</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted average assumptions to estimate the fair value of warrants</a></td>
<td class="nump">0.155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654656733240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654577458392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654647629304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of stock options granted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">266,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted during the period (in shares)</a></td>
<td class="nump">22,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">266,250<span></span>
</td>
<td class="nump">266,250<span></span>
</td>
<td class="nump">289,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">135,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted during the period (in dollars per share)</a></td>
<td class="nump">7.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">2.94<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual terms (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding balance of period (years)</a></td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="text">4 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period (years)</a></td>
<td class="text">3 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning of period (in dollars)</a></td>
<td class="nump">$ 474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period (in dollars)</a></td>
<td class="nump">$ 460,000<span></span>
</td>
<td class="nump">$ 474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period expected to be recognized (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Non-employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period expected to be recognized (in years)</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_WeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_WeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654650948216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654577569176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Jan. 06, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash proceeds from convertible loan</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vlon_MediceMember', window );">Medice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_RelatedPartyTransactionUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash proceeds from convertible loan</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Promissory Note | David Baker | Salmon Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash proceeds from convertible loan</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_RelatedPartyTransactionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment on milestone payments under the agreement with a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_RelatedPartyTransactionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vlon_MediceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vlon_MediceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654667864056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE LEASE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>FINANCE LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Initial lease right-of-use asset</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - finance lease (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Operating cash flows from finance lease amortization</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance lease payments</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654656372200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCE LEASE - Maturities of finance lease liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of finance lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654656043240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details) - David Baker - Baker Agreement<br></strong></div></th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount', window );">Base salary</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">In the event of an involuntary termination by the Company or termination</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Base salary period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">Minimum employment period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_CobraHealthInsuranceCoveragePeriod', window );">COBRA coverage period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">In the event of a termination within 12 months after the occurrence of a change in control transaction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Base salary period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_CobraHealthInsuranceCoveragePeriod', window );">COBRA coverage period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Percent of base salary</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment made to pay deferred cash remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_CobraHealthInsuranceCoveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of COBRA health insurance coverage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_CobraHealthInsuranceCoveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_NewEmploymentAgreementWithDavidBakerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_NewEmploymentAgreementWithDavidBakerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654738292328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,772,000<span></span>
</td>
<td class="nump">$ 883,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_ClinicalTrialAgreementsMember', window );">Clinical Trial Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_TerminationPeriodUponPriorWrittenNotice', window );">Termination period upon prior notice</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_ClinicalTrialCostExpectedAmount', window );">Total expected clinical trial cost</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vlon_AdairStudyVal104Member', window );">Study VAL-104 | Clinical Trial Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_ClinicalTrialCostExpectedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of clinical trial cost expected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_ClinicalTrialCostExpectedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_TerminationPeriodUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of termination upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_TerminationPeriodUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_ClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_ClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vlon_AdairStudyVal104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vlon_AdairStudyVal104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654647603096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_ConsultingAgreementsMember', window );">Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_ProfessionalFeesPaidPerMonth', window );">Consulting fees paid per month</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">15,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_TerminationPeriodUponPriorWrittenNotice', window );">Termination period upon prior notice</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_ProfessionalFeesPaidPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of professional fees paid per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_ProfessionalFeesPaidPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_TerminationPeriodUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of termination upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_TerminationPeriodUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654649514472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember', window );">Agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EstimatedContractCosts', window );">Estimated contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Manufacturing costs</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember', window );">Agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EstimatedContractCosts', window );">Estimated contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Manufacturing costs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_EstimatedContractCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated contract costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_EstimatedContractCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654656129272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Expenses incurred</a></td>
<td class="nump">$ 1,772,000<span></span>
</td>
<td class="nump">$ 883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember', window );">Pre-Clinical Agreement (included in research and development expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_EstimatedContractCosts', window );">Estimated contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Expenses incurred</a></td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_EstimatedContractCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated contract costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_EstimatedContractCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654683118824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Expense recognized on embedded derivative</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liability measured at estimated fair value using unobservable inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions during the quarter ended March 31, 2021</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer out of Level 3</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139654577397496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Kelly Agreement - SUBSEQUENT EVENTS - Leanne M. Kelly<br></strong></div></th>
<th class="th">
<div>May 10, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount', window );">Initial base annual salary | $</a></td>
<td class="nump">$ 275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Percent of base salary</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">If Termination not in Connection with change in Control</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Base salary period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">Minimum employment period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_CobraHealthInsuranceCoveragePeriod', window );">COBRA coverage period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">If Termination within One Year Period Commencing on Change in Control</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Percent of base salary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Base salary period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vlon_CobraHealthInsuranceCoveragePeriod', window );">COBRA coverage period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Stock option to be granted</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, one</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, one | Vest on First Anniversary of Start Date</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Stock option to be granted</a></td>
<td class="nump">17,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, one | Vest in Equal Installments on Quarterly Basis for Next Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Stock option to be granted</a></td>
<td class="nump">52,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, two | Vest on Date the Entity Submits New Drug Application ("NDA") Filing for ADAIR with U.S. Food &amp; Drug Administration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Stock option to be granted</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember', window );">Stock Option | Tranche, two | Vest on Date When U.S. Food &amp; Food Administration Approves New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Stock option to be granted</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment made to pay deferred cash remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vlon_CobraHealthInsuranceCoveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of COBRA health insurance coverage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vlon_CobraHealthInsuranceCoveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vlon_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vlon_EmploymentAgreementWithLeanneM.KellyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vlon_IfTerminationNotInConnectionWithChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vlon_IfTerminationNotInConnectionWithChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vlon_VestOnFirstAnniversaryOfStartDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vlon_VestOnFirstAnniversaryOfStartDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'/]^<45GZ-@,8ZMJAX-;?CZ*$UB$'T?!!6C_' .I"H6#N_R=="$G"U_&6*7
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MQH:0MLQ/QZG_>%<+6<S&=M97  80M-1.?X;;.[%Z#<X-[3,WDM1IW#Q"RV
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M"JK^*E-/C"S=AXT':8S,W3 %CN"M +[?2CSM^XG]5M)\&UO_ U!+ P04
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MP6RAUT>X6\9U%&]MH;[G2I=]VZSUQ0S"!.CO&\[5H6,F&*[ZXC]02P,$%
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M!R<K +^O)41=O5@']1W>_']02P,$%     @ 74JM4O*6%MHS"P  '1P  !@
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MI':T[<7\9++H^)<PER0US_>*D,S'(1AC3;W)Q&?&2/LFXK$Q 0I4172LP7F
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M??M:AD\^_?+PX0R-:J,1RURML74V.3TY" >C]H<W%7\ BHWWIN#+3$F4("W
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M'\E%XA7N1\YY*@+?H5CRNY3?4/2M%?)6(NIEE281E9Y<+- 3B=G(*9H))66
M2QWG50I4H>5<%[RS]%LVS+7/"NOK2$  1XDC\]L%8\6K6/"IKI_-S'.8J(V-
M?[BOQ',\Q9A%!IWH/O8[4AT>,HF4,J?>@H8T=U/!W,JB;K/A5TRQ52)[>DZ)
MS2G)W/(M"R$$MPI(YH6*I=47=](Y6KFHXJE;^AW=Z&][)[D5(P#RQ])E33GJ
MZB#O4RBIGF^5J<G7S&*1BT6.^>VHC]J@D+<IYYV1A[IV'%J$>6X=+@1,DI2&
MIFYC'I0H%*Z.F!8+NH=2L3=4BN:EAFJI[7%OM)76%[;M.W7/LP,?_8-:1#CC
M!(N]MJAI1J7DI0@_UK]U\B+@=0&/-??_' O.0@?&R"CF9 8)P>5ZG6J=28<J
M>!T':=J\ :*!ARX]^0KVP43?H7MTSE 0WAC2SD6DR<5O<"EE@..IP+]VC:$>
M&<;LM#_XCM:LJW7+$OM]$FT8<3K;W!&NL7)EXNUXOY]<.'[JPB\?OH+#,O7H
MKN.LP>>LLYDW?O(:0+M-'&I5A2M#[.HU^ZAQ##1"C%$\P^$W5<ZIWV"^\1L6
MIV\\^8A1:N^;NX2XH^L-M0#_1K9R3#8P(%TW4&0TUV/R2;I!ANZC'=!UAC[.
M\MT!DIJ6I :R2<7Y[!K;LOAD-/XIEB9-H&:" 3D_V1E/VGOEN4%NE;B6]^1P
MRLC>Z/4[7#-1"7JQ;HBK$RHJG*Y@"LZ@:P%W.);7*F7BH;B.XH'MSJD\2WM+
M#S-PDJ02YZM;<Q$A#>E.T&S_LN QTT*.6Y!$-/+$S(6W%#MG$<O.=I@BWY .
M)2IA_2_N':]HG,7[E>6<(H-QYVH!D5M9 >Z.,61R+],.%PD'@.A+LYS$#:&J
MYX"')<NC<#RMV2&-,@Y".DL;C&*6(#KG:T0<^"TQ<;&G13K]R,W*^X+UZHG
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MD-*,5(6^%=LO=%]/S_ EHE#V"]LZUH\=2"JE1;D'8P8EX_5(=OL^= !][Q5
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M 7.;.9X?4'-@.%#,B>9^ >#>8LJ+VAE,L9=A*"]>HTZ["8 F +%U^6#IS;,
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MOUOTWX/OY,M:.)P:];=,?7[7N>U BIFHE%^8W1_8^'/%>(E1+OS"KMX[N.E
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MZ;3=:SQO'Z%G\_8IITRNN33D2T'0B 8@:.=X)UA5^R=II2P]<'Y;TC\*U,Z
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M22KG%('-QY*)+'"'+M@$A_H8X HODT@K.O*[<LX?(__)5^0W55Y2)T-H<N9
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MG[*TFDXY^=GI^>SB%AYFE_<+N%K,EO>WBZO%]=UR'%H"=R9AV@+-&Z#X -
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M\9QK8^$W$;>$3\:.>:]150GJ3RZ&94X2ZG"&\C7>S[<.IR4U0;^Q4[?+BUE
M8SGU"5KLB5=[XK54B4&]]MA<5C4A;\%LH9%$;JH'7?4 W?VTZ"X_?/3\56V8
MS,RG$_CP;A1'@]/_CG-<<2E=_(0))DE=8OF#R>;/M>#OO7D_/H59EG'7*@UD
MM?92$+NM6B\2^S?@Z"O<:29-[N2MK9-X>Y]>,)WO2!W W7%K=UZJUG"O^Y6H
M5[['&[I9M;1-(^QVNV=DUG3/G7GS!A$-4LR P)Q<H]Z7XP!TT]>;A565[Z6)
MLM29_;2@IQ"U,Z#S7%$IM0L7H'M<IW\ 4$L#!!0    ( %U*K5+#_'!,D@8
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MH6FC-#.TW3T%7MO7M_2-NE,F56*"WIPI EQ%%S<V:\.>-DC1U(L&IA+'C4I
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MM\+8 )U94>> KBA(+IIY;!_+L!>G?J\UH31?;=K_9J!^A H!0"$K5% ;PS1
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MT4-#&@A2)M_)HFZCX9?,_57J0O2>,BZG[&,N:ND1$-PI>#(O5,SYOKB7SDE
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MN5I?P$.9_J+G;*QG=5"02,6C7!@01"S._LFW/!![ GZ3 ,X%\)$ MAL$G%S
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M#)FDG(' 1<\Y]4^&?F@ =L<MQ8W<&H-)9<;YG9F,YCW',XHPQ5@9"J+_UCC
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M. QGX(B&^C5W?6<\'^OF<?DO50X#&/E!N_\#[M/_A)+2W,F28]<U+2E[V:-
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MM /P_EIBYN6)=5!METW^!5!+ P04    " !=2JU2E69+I[<"   >"0  &0
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M- OP_E((?1R8!]0GIM&_4$L#!!0    ( %U*K5(@WSL'DP0  #X3   9
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MC;+8V7Y9XK\'M'/ \ZU2]F2X"[J_6?874$L#!!0    ( %U*K5(NKC3H$0,
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M>]?I5R0>VPR&]0I[I<)>H\)G4S8@;.$-<%4%5:'3I93059%?"3Q5=R4B%-,
MBL4+=6'> 7-Q61=)LT<O1Z(>2LVMJ3N@YS$,:QD.TM OT]#_7!I"(@*648FX
MVKQJ_'5!-_.[?KOK?*T+]?.X@P '98"#1J*?:Q67U-L:8!&C2#5#@2+.TLK.
M?G1*!\>GM'*/YHTF!^*'I?AAH_@;(_%C\6O\KOJUK"WAP^/;W:D(/S;QJK?+
MWNM#*?"5Z><"F:.2U_=RM7PR3$VGK*S/W*MYWOG_T^3O$%6]5X0*%5*D*)UV
M7UUZGO?V?"+9VG2[%R95[S3#6#V'@&L#]3UB3.XFVD'YP)K\ U!+ P04
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M0[W>I8Y=U%VU-A0O;&,*N=)MS@Y3_1"A,!OT>L*Y.AK&0?.T37\#4$L#!!0
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MIYH#JZ E%VL?[D%@IH32D;&%85-U(5(_>KCK>U SC4[)I=(NM\_@_TZ;QP^
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M>TN2),O""&!A!TF"(? VX@CF #Q@2)*X??!@/XHW^U2\_95K_!M02P,$%
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MU@2%K D*61,4LB8H9$W^DZSO6J_^^C=/N\:U*INC/^O^I<T_ 5!+ 0(4 Q0
M   ( %U*K5('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 74JM4I^T$L_O    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( %U*K5+\(Y3#FP(  /8'   8
M  " @2$3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !=
M2JU2&8QG0;D#  #;"P  &               @('R%0  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ 74JM4MG%I%DY!0  '18  !@
M         ("!X1D  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( %U*K5+\IGY9" (  ! %   8              " @5 ?  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !=2JU281]T "8%  #/$P
M&               @(&.(0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ 74JM4O*6%MHS"P  '1P  !@              ("!ZB8  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %U*K5+2;K+MH0@
M %D6   8              " @5,R  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !=2JU2M-ZH"+$"  "9!@  &0              @($J
M.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %U*K5+:
M#6H[[P4  .P-   9              " @1(^  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ 74JM4ABYXZ#$!0  9 T  !D
M     ("!.$0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %U*K5(:ORCIT H  , =   9              "
M@7)>  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 74JM
M4I[4'"4W P  : <  !D              ("!>6D  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !=2JU2P_QP3)(&  #]$   &0
M        @('G;   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( %U*K5)M4N>/7@@  "P6   9              " @;!S  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 74JM4D;21(>V @  A@8
M !D              ("!17P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !=2JU23C&J$4\"   C!0  &0              @($R?P
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %U*K5(>3 G3
M_P0  "X/   9              " @;B!  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ 74JM4@#6H9&  P  0PD  !D
M ("![H8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !=
M2JU2VBQ,&: "   K!@  &0              @(&EB@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %U*K5)IJ*XIG08  *H:   9
M          " @7R-  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#
M%     @ 74JM4M'"<)%F @  [P4  !D              ("!4)0  'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !=2JU22[K^3[8"  #W
M!P  &0              @('ME@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+ 0(4 Q0    ( %U*K5*)J^Q-[@(  %\)   9              " @=J9
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 74JM4IX6
MFMOL!   .A,  !D              ("!_YP  'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"% ,4    " !=2JU2E69+I[<"   >"0  &0
M    @($BH@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M %U*K5+=U5C>T0(  "<(   9              " @1"E  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ 74JM4CB< (5] P  /0T  !D
M             ("!&*@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !=2JU2(-\[!Y,$   ^$P  &0              @(',JP  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %U*K5(<.:Q4$ (
M -D$   9              " @9:P  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ 74JM4BZN-.@1 P  "PL  !D              ("!
MW;(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !=2JU2
M2A_ EP\#  !L"0  &0              @($EM@  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( %U*K5*_]HJ=8P(  #<&   9
M      " @6NY  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ 74JM4A0P;.T2 P  _ D  !D              ("!!;P  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !=2JU2JLO2#20#  !""@
M&0              @(%.OP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( %U*K5(P8!+,[P(  # )   9              " @:G"  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 74JM4GK ;4Q4
M P  [0D  !D              ("!S\4  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " !=2JU2NI>'G]\"    "   &0
M@(%:R0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %U*
MK5+DQ\3POP(  .8&   9              " @7#,  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ 74JM4MTI4BBV!   #10  !D
M         ("!9L\  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " !=2JU2 CXSXBH#  #R$@  #0              @ %3U   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( %U*K5*7BKL<P    !,"   +
M  "  :C7  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %U*K5*Q=C"<' 0  "(>
M   /              "  9'8  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !=2JU2N#;$W*D!   N&P  &@              @ ':W   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !=2JU24]DK*;(!  !3&P
M$P              @ &[W@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..-0 U &H.  ">X      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>260</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementBalanceSheet</Role>
      <ShortName>Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheet (parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical</Role>
      <ShortName>Balance Sheet (parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity</Role>
      <ShortName>NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - EQUITY FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureEquityFinancing</Role>
      <ShortName>EQUITY FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - FINANCE LEASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFinanceLease</Role>
      <ShortName>FINANCE LEASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - EQUITY FINANCING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables</Role>
      <ShortName>EQUITY FINANCING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureEquityFinancing</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - FINANCE LEASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables</Role>
      <ShortName>FINANCE LEASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureFinanceLease</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31103 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails</Role>
      <ShortName>NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40501 - Disclosure - EQUITY FINANCING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails</Role>
      <ShortName>EQUITY FINANCING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40502 - Disclosure - EQUITY FINANCING - Estimate the fair value of the warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails</Role>
      <ShortName>EQUITY FINANCING - Estimate the fair value of the warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40602 - Disclosure - STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40603 - Disclosure - STOCK-BASED COMPENSATION - Activity of stock options granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of stock options granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40701 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40901 - Disclosure - FINANCE LEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails</Role>
      <ShortName>FINANCE LEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40902 - Disclosure - FINANCE LEASE - Maturities of finance lease liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails</Role>
      <ShortName>FINANCE LEASE - Maturities of finance lease liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41002 - Disclosure - COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41003 - Disclosure - COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41004 - Disclosure - COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41005 - Disclosure - COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41101 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="vlon-20210331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41201 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vlon-20210331x10q.htm">vlon-20210331x10q.htm</File>
    <File>vlon-20210331.xsd</File>
    <File>vlon-20210331_cal.xml</File>
    <File>vlon-20210331_def.xml</File>
    <File>vlon-20210331_lab.xml</File>
    <File>vlon-20210331_pre.xml</File>
    <File>vlon-20210331xex10d1.htm</File>
    <File>vlon-20210331xex10d2.htm</File>
    <File>vlon-20210331xex31d1.htm</File>
    <File>vlon-20210331xex31d2.htm</File>
    <File>vlon-20210331xex32d1.htm</File>
    <File>vlon-20210331xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vlon-20210331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 100,
   "dts": {
    "calculationLink": {
     "local": [
      "vlon-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vlon-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vlon-20210331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vlon-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vlon-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vlon-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 341,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 12,
    "http://www.vallon-pharma.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 19
   },
   "keyCustom": 22,
   "keyStandard": 238,
   "memberCustom": 22,
   "memberStandard": 25,
   "nsprefix": "vlon",
   "nsuri": "http://www.vallon-pharma.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.vallon-pharma.com/role/DisclosureAccruedExpenses",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES",
     "role": "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vlon:EquityFinancingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - EQUITY FINANCING",
     "role": "http://www.vallon-pharma.com/role/DisclosureEquityFinancing",
     "shortName": "EQUITY FINANCING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vlon:EquityFinancingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - INCOME TAXES",
     "role": "http://www.vallon-pharma.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - FINANCE LEASE",
     "role": "http://www.vallon-pharma.com/role/DisclosureFinanceLease",
     "shortName": "FINANCE LEASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.vallon-pharma.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheet",
     "role": "http://www.vallon-pharma.com/role/StatementBalanceSheet",
     "shortName": "Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vlon:UnauditedInterimFinancialStatementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vlon:UnauditedInterimFinancialStatementsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - EQUITY FINANCING (Tables)",
     "role": "http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables",
     "shortName": "EQUITY FINANCING (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - STOCK-BASED COMPENSATION - (Tables)",
     "role": "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - FINANCE LEASE (Tables)",
     "role": "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables",
     "shortName": "FINANCE LEASE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
     "shortName": "NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_1_11_2021_B-c7BO4RP0aNIhbXZvMJhg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_JqpFDEggRkesYrNF0Z7d7A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_5_31_2020_us-gaap_DebtInstrumentAxis_vlon_PaycheckProtectionProgramLoanMember_ei25kWe8EU-JCt2bw1gHyA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheet (parenthetical)",
     "role": "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical",
     "shortName": "Balance Sheet (parenthetical)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_2_12_2021_To_2_12_2021_sWIiYTXmBUi928oT5lxyrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - EQUITY FINANCING (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
     "shortName": "EQUITY FINANCING (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "vlon:EquityFinancingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_2_12_2021_To_2_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_TF0TqswQu0mMkz-c3_4jwA",
      "decimals": "-5",
      "lang": null,
      "name": "vlon:GrossProceedsFromInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - EQUITY FINANCING - Estimate the fair value of the warrants (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails",
     "shortName": "EQUITY FINANCING - Estimate the fair value of the warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nITUBGIVy0uqt148t1aoog",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions to estimate fair value of options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_oid0NYl0SkaQgmg0xuB-9g",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2020_B_tq9M_D1kG0D9VaPXQx7Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - STOCK-BASED COMPENSATION - Activity of stock options granted (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of stock options granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_11_2021_To_1_11_2021_8qOoRPKb30yKP4fdaCxr0g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_6_2020_To_1_6_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vlon_MediceMember_NGprOuJ5l06TJqQZC_V8ig",
      "decimals": "0",
      "lang": null,
      "name": "vlon:RelatedPartyTransactionUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - FINANCE LEASE (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails",
     "shortName": "FINANCE LEASE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - FINANCE LEASE - Maturities of finance lease liability (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails",
     "shortName": "FINANCE LEASE - Maturities of finance lease liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_3_31_2021_NAfnTIaZ40OFLYUt1yJbKw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Employment Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_4_20_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_TypeOfArrangementAxis_vlon_NewEmploymentAgreementWithDavidBakerMember_XX-kEYqCYUKgJGHmRgLNSQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations",
     "role": "http://www.vallon-pharma.com/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_mdMeMVkvP0qihuv9cXKl0w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Clinical Trial Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_TypeOfArrangementAxis_vlon_ClinicalTrialAgreementsMember_Tn38B5U-o02QABujfpad0A",
      "decimals": null,
      "lang": "en-US",
      "name": "vlon:TerminationPeriodUponPriorWrittenNotice",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_UjyVKbMtFkeegF7gc7iuRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Consulting Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_4_2_2018_To_4_2_2018_us-gaap_TypeOfArrangementAxis_vlon_ConsultingAgreementsMember_DYse4xvQiEWZNo4dUdfW9A",
      "decimals": "0",
      "lang": null,
      "name": "vlon:ProfessionalFeesPaidPerMonth",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vlon:EstimatedContractCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Manufacturing Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_8_31_2019_us-gaap_TypeOfArrangementAxis_vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember_mlVWI3Mr3kS47dthfkoT8g",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "vlon:EstimatedContractCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Pre-Clinical Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_11_30_2019_us-gaap_TypeOfArrangementAxis_vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember_SnkKNVvge0SVtghw5VA0qw",
      "decimals": "-5",
      "lang": null,
      "name": "vlon:EstimatedContractCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_2_12_2021_fnYsyLXbgECpVpptBTg5xA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_mzH5tF0hG0yxsT05Y5DulA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_5_10_2021_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_vlon_EmploymentAgreementWithLeanneM.KellyMember_AbzZ4r3uTEenj-dMOQ1yWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Stockholders' Equity (Deficit)",
     "role": "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit",
     "shortName": "Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vCxHsxMRx0qhN-xfFdl_Xg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "role": "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_rHB0bwAWBkq2uAGKr0P7Jg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY",
     "role": "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity",
     "shortName": "NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vlon-20210331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_ri_unwq5E0SavGPPxXRNJg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r134",
      "r244",
      "r245",
      "r248",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Salmon Pharma"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors Chairman [Member]",
        "terseLabel": "Ofir Levi, Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "David Baker"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Leanne M. Kelly"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r36",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r136",
      "r139",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r136",
      "r139",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r133",
      "r136",
      "r139",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r133",
      "r136",
      "r139",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r115",
      "r137",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r105",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities - current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails",
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Payroll and related"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r171"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r141",
      "r144",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r117",
      "r122",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Underwriters Warrants",
        "verboseLabel": "Fair value of warrants classified as additional paid in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r144",
      "r165",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r59",
      "r91",
      "r94",
      "r100",
      "r107",
      "r198",
      "r202",
      "r218",
      "r275",
      "r285"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r35",
      "r59",
      "r107",
      "r198",
      "r202",
      "r218"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r145",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r145",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r135",
      "r138",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "verboseLabel": "Transaction fees"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "verboseLabel": "Exclusivity payment fees"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r54"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash held outside the Trust Account",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r54",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r219"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r129",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r114",
      "r279",
      "r289"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 6,812,836 and 4,506,216 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively, which gives retroactive effect to the one-for-40 reverse stock split. See Note 1 to these financial statements."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r10",
      "r276",
      "r284",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Promissory Note"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Shares converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r276",
      "r277",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Promissory note, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r63",
      "r123",
      "r124",
      "r125",
      "r126",
      "r227",
      "r228",
      "r229",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment made to pay deferred cash remuneration.",
        "label": "Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount",
        "terseLabel": "Initial base annual salary",
        "verboseLabel": "Base salary"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1": {
     "auth_ref": [
      "r132",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Maximum Contractual Term",
        "terseLabel": "Base salary period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualMaximumContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": {
     "auth_ref": [
      "r132",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period",
        "terseLabel": "Minimum employment period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.",
        "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance",
        "terseLabel": "Stock option to be granted"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Revaluation of derivative liability",
        "terseLabel": "Revaluation of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows",
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION."
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "verboseLabel": "Expense recognized on embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average period expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r80",
      "r108",
      "r122",
      "r127",
      "r168",
      "r169",
      "r170",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of estimates used for fair value of the warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability measured at estimated fair value using unobservable inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r213",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of liability measured at estimated fair value using unobservable inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "verboseLabel": "Transfer out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "verboseLabel": "Additions during the quarter ended March 31, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r231",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liability, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "verboseLabel": "Schedule of maturities of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseMaturitiesOfFinanceLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r233",
      "r235"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease liability",
        "verboseLabel": "Financing cash flows from finance lease payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use asset, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "verboseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r232",
      "r234",
      "r240"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance lease right-of-use asset",
        "verboseLabel": "Operating cash flows from finance lease amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "verboseLabel": "Initial lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r237",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term - finance lease (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r52",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Forgiveness of PPP note",
        "verboseLabel": "Income from extinguishment of loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r140",
      "r142",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r186",
      "r188",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r60",
      "r76",
      "r77",
      "r90",
      "r180",
      "r187",
      "r189",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "verboseLabel": "Financing related"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of finance leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCE LEASE"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "verboseLabel": "FINANCE LEASE"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureFinanceLease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r59",
      "r95",
      "r107",
      "r199",
      "r202",
      "r203",
      "r218"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r59",
      "r107",
      "r218",
      "r278",
      "r287"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r59",
      "r107",
      "r199",
      "r202",
      "r203",
      "r218"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, non-current"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManufacturingCosts": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred in the production of goods for sale.",
        "label": "Manufacturing Costs",
        "terseLabel": "Manufacturing costs"
       }
      }
     },
     "localname": "ManufacturingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r37",
      "r38",
      "r39",
      "r53",
      "r59",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r91",
      "r93",
      "r96",
      "r99",
      "r101",
      "r107",
      "r218",
      "r280",
      "r290"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r91",
      "r93",
      "r96",
      "r99",
      "r101"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "NATURE OF OPERATIONS, BUSINESS, GOING CONCERN AND LIQUIDITY"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "verboseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaids and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "netLabel": "Proceeds from convertible notes",
        "terseLabel": "Cash proceeds",
        "verboseLabel": "Cash proceeds from convertible loan"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from issuance initial public offering",
        "netLabel": "Net proceeds from initial public offering",
        "terseLabel": "Proceeds from common stock, net of offering expenses",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "verboseLabel": "Repayment of Promissory notes due"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Consulting fees incurred"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r37",
      "r38",
      "r48",
      "r59",
      "r69",
      "r76",
      "r77",
      "r91",
      "r93",
      "r96",
      "r99",
      "r101",
      "r107",
      "r197",
      "r200",
      "r201",
      "r204",
      "r205",
      "r218",
      "r282"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r109",
      "r288"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r134",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r134",
      "r244",
      "r248",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r245",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r177",
      "r303"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "netLabel": "Expenses incurred",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r127",
      "r171",
      "r286",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r108",
      "r168",
      "r169",
      "r170",
      "r184",
      "r185",
      "r294",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r88",
      "r89",
      "r92",
      "r97",
      "r98",
      "r102",
      "r103",
      "r104",
      "r130",
      "r131",
      "r262"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue-related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r144",
      "r164",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r144",
      "r164",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r61",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r145",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails",
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r151",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of activity of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of assumptions used to estimate fair value of options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails",
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted during the period (in shares)",
        "verboseLabel": "Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails",
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at end of period (in dollars)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r153",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "verboseLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "verboseLabel": "Outstanding at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted during the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Tranche, one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Tranche, two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r58",
      "r145",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r142",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r140",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Nonemployee [Member]",
        "terseLabel": "Non-employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Fair value of option on grant date"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r159",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationAssumptionsToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of period (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of period (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding balance of period (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Purchase price, per unit",
        "verboseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails",
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r80",
      "r108",
      "r122",
      "r127",
      "r168",
      "r169",
      "r170",
      "r184",
      "r185",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r80",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r33",
      "r122",
      "r123",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r122",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses (in shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r122",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r122",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "netLabel": "Shares issued",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r59",
      "r106",
      "r107",
      "r218"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails",
      "http://www.vallon-pharma.com/role/StatementBalanceSheetParenthetical",
      "http://www.vallon-pharma.com/role/StatementStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r226",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r226",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r226",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r226",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails",
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Weighted average assumptions to estimate the fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingEstimateFairValueOfWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vlon_AccruedChemistryAndManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for chemistry and manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Chemistry and Manufacturing Expenses, Current",
        "terseLabel": "Chemistry and manufacturing"
       }
      }
     },
     "localname": "AccruedChemistryAndManufacturingExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for Clinical and preclinical trial and regulatory related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical and Preclinical Trial and Regulatory Expenses, Current",
        "terseLabel": "Clinical and preclinical trial and regulatory related"
       }
      }
     },
     "localname": "AccruedClinicalAndPreclinicalTrialAndRegulatoryExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_AccruedLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for licensing related expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Licensing Fees, Current",
        "terseLabel": "Licensing related"
       }
      }
     },
     "localname": "AccruedLicensingFeesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_AdairProductRightsAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ADAIR product rights acquisition.",
        "label": "Adair Product Rights Acquisition [Member]",
        "terseLabel": "ADAIR acquisition"
       }
      }
     },
     "localname": "AdairProductRightsAcquisitionMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_AdairStudyVal104Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ADAIR, Study VAL-104.",
        "label": "Adair Study Val104 [Member]",
        "terseLabel": "Study VAL-104"
       }
      }
     },
     "localname": "AdairStudyVal104Member",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vlon_AgreementPurchasePriceProductRightsPriorToBusinessFormation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed for the purchase of product rights prior to business formation.",
        "label": "Agreement Purchase Price, Product Rights, Prior to Business Formation",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "AgreementPurchasePriceProductRightsPriorToBusinessFormation",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_AmiserviceDevelopmentLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amiservice Development Ltd.",
        "label": "Amiservice Development Ltd [Member]",
        "terseLabel": "Amiservice Development Ltd"
       }
      }
     },
     "localname": "AmiserviceDevelopmentLtdMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ArcturusTherapeuticsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Amiservice Development Ltd.",
        "label": "Arcturus Therapeutics Ltd [Member]",
        "terseLabel": "Arcturus Therapeutics Ltd"
       }
      }
     },
     "localname": "ArcturusTherapeuticsLtdMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_AssetPurchaseAgreementReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reimbursement of expenses incurred under the asset purchase agreement.",
        "label": "Asset Purchase Agreement, Reimbursement of Expenses",
        "terseLabel": "Reimbursement for expenses"
       }
      }
     },
     "localname": "AssetPurchaseAgreementReimbursementOfExpenses",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_ClinicalTrialAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Clinical Trial Agreements.",
        "label": "Clinical Trial Agreements [Member]",
        "terseLabel": "Clinical Trial Agreements"
       }
      }
     },
     "localname": "ClinicalTrialAgreementsMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ClinicalTrialCostExpectedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of clinical trial cost expected.",
        "label": "Clinical Trial Cost, Expected Amount",
        "terseLabel": "Total expected clinical trial cost"
       }
      }
     },
     "localname": "ClinicalTrialCostExpectedAmount",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_CobraHealthInsuranceCoveragePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of COBRA health insurance coverage.",
        "label": "COBRA, Health Insurance Coverage Period",
        "terseLabel": "COBRA coverage period"
       }
      }
     },
     "localname": "CobraHealthInsuranceCoveragePeriod",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vlon_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_EmploymentAgreementWithLeanneM.KellyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to employment agreement with Leanne M. Kelly.",
        "label": "Employment Agreement With Leanne M. Kelly [Member]",
        "terseLabel": "Kelly Agreement"
       }
      }
     },
     "localname": "EmploymentAgreementWithLeanneM.KellyMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_EquityFinancingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "EQUITY FINANCING"
       }
      }
     },
     "localname": "EquityFinancingAbstract",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "vlon_EquityFinancingDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of equity financing.",
        "label": "Equity Financing Disclosure [Text Block]",
        "terseLabel": "EQUITY FINANCING"
       }
      }
     },
     "localname": "EquityFinancingDisclosureTextBlock",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vlon_EstimatedContractCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated contract costs.",
        "label": "Estimated Contract Costs",
        "terseLabel": "Estimated contract costs"
       }
      }
     },
     "localname": "EstimatedContractCosts",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_GrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross proceeds from initial public offering during the period.",
        "label": "Gross Proceeds from Initial Public Offering",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_IfTerminationNotInConnectionWithChangeInControlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Termination not in Connection with change in Control [Member]",
        "label": "If Termination Not In Connection With Change In Control [Member]",
        "terseLabel": "If Termination not in Connection with change in Control"
       }
      }
     },
     "localname": "IfTerminationNotInConnectionWithChangeInControlMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Termination within One Year Period Commencing on Change in Control [Member]",
        "label": "If Termination Within One Year Period Commencing On Change In Control [Member]",
        "terseLabel": "If Termination within One Year Period Commencing on Change in Control"
       }
      }
     },
     "localname": "IfTerminationWithinOneYearPeriodCommencingOnChangeInControlMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of an involuntary termination by the Company or termination",
        "label": "In Event Of Involuntary Termination By Entity Or Termination For Good Reason [Member]",
        "terseLabel": "In the event of an involuntary termination by the Company or termination"
       }
      }
     },
     "localname": "InEventOfInvoluntaryTerminationByEntityOrTerminationForGoodReasonMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of a termination within 12 months after the occurrence of a change in control transaction",
        "label": "In Event Of Termination Within12 Months After Occurrence Of Change In Control [Member]",
        "terseLabel": "In the event of a termination within 12 months after the occurrence of a change in control transaction"
       }
      }
     },
     "localname": "InEventOfTerminationWithin12MonthsAfterOccurrenceOfChangeInControlMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR.",
        "label": "Manufacturing Agreement With Contract Manufacturer For Commercial Scale Up And Registration Batches For Adair [Member]",
        "terseLabel": "Agreement with a contract manufacturer for the commercial scale up and registration batches for ADAIR"
       }
      }
     },
     "localname": "ManufacturingAgreementWithContractManufacturerForCommercialScaleUpAndRegistrationBatchesForAdairMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin).",
        "label": "Manufacturing Agreement With Formulation Development Company For Formulation And Development For Abuse Deterrent Formulation Of Methylphenidate Ritalin [Member]",
        "terseLabel": "Agreement with a formulation development company for the formulation and development for an abuse-deterrent formulation of methylphenidate (Ritalin)"
       }
      }
     },
     "localname": "ManufacturingAgreementWithFormulationDevelopmentCompanyForFormulationAndDevelopmentForAbuseDeterrentFormulationOfMethylphenidateRitalinMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ManufacturingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to manufacturing agreements.",
        "label": "Manufacturing Agreements [Member]",
        "terseLabel": "Manufacturing Agreements [Member]"
       }
      }
     },
     "localname": "ManufacturingAgreementsMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesManufacturingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_MediceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Medice, a related party.",
        "label": "Medice [Member]",
        "terseLabel": "Medice"
       }
      }
     },
     "localname": "MediceMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount agreed under the asset purchase agreement for funding the development of product, as per the key terms and conditions.",
        "label": "Minimum Amount Agreed, Asset Purchase Agreement, Prior to Business Formation",
        "terseLabel": "Minimum funds for product development"
       }
      }
     },
     "localname": "MinimumAmountAgreedAssetPurchaseAgreementPriorToBusinessFormation",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_NewEmploymentAgreementWithDavidBakerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to New employment agreement with David Baker.",
        "label": "New Employment Agreement With David Baker [Member]",
        "terseLabel": "Baker Agreement"
       }
      }
     },
     "localname": "NewEmploymentAgreementWithDavidBakerMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_NonCashInterestDepreciationAndOtherExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash interest, depreciation and other income (expense) included in net income that results in no cash inflow (outflow).",
        "label": "Non-Cash Interest, Depreciation And Other Expense",
        "terseLabel": "Non-cash interest, depreciation and other expense"
       }
      }
     },
     "localname": "NonCashInterestDepreciationAndOtherExpense",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_NumberOfPromissoryNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of promissory notes.",
        "label": "Number Of Promissory Notes",
        "terseLabel": "Number of promissory notes"
       }
      }
     },
     "localname": "NumberOfPromissoryNotes",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vlon_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to paycheck protection program loan (PPP).",
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "PPP"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosurePppNoteAndConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares then outstanding at the issuance on a diluted basis.",
        "label": "Percentage of Shares of Outstanding at Issuance, on a Diluted Basis",
        "terseLabel": "Percentage of shares held on fully-diluted basis"
       }
      }
     },
     "localname": "PercentageOfSharesOfOutstandingAtIssuanceOnDilutedBasis",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureNatureOfOperationsBusinessGoingConcernAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vlon_PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares on initial public offering price for warrants exercisable by underwriters.",
        "label": "Percentage of Shares on Initial Public Offering Price Upon Warrants Exercisable",
        "terseLabel": "Percentage of public offering price"
       }
      }
     },
     "localname": "PercentageOfSharesOnInitialPublicOfferingPriceUponWarrantsExercisable",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vlon_PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to pre-clinical agreement (included in research and development expense).",
        "label": "Pre Clinical Agreement Included In Research And Development Expense [Member]",
        "terseLabel": "Pre-Clinical Agreement (included in research and development expense)"
       }
      }
     },
     "localname": "PreClinicalAgreementIncludedInResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesPreClinicalAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_ProfessionalFeesPaidPerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of professional fees paid per month.",
        "label": "Professional Fees, Paid per Month",
        "terseLabel": "Consulting fees paid per month"
       }
      }
     },
     "localname": "ProfessionalFeesPaidPerMonth",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_RelatedPartyTransactionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment on milestone payments under the agreement with a related party.",
        "label": "Related Party Transaction, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionUpfrontPayment",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_SaleOfStockOtherOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other offering costs incurred in connection with the initial public offering.",
        "label": "Sale of Stock, Other Offering Costs",
        "terseLabel": "Additional expenses"
       }
      }
     },
     "localname": "SaleOfStockOtherOfferingCosts",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_SaleOfStockUnderwritingDiscountsAndOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of underwriting discounts and other expenses incurred and paid for underwriters to the public offering.",
        "label": "Sale of Stock, Underwriting Discounts and Other Expenses",
        "terseLabel": "Underwriting discounts and expenses"
       }
      }
     },
     "localname": "SaleOfStockUnderwritingDiscountsAndOtherExpenses",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vlon_TerminationPeriodUponPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of termination upon prior written notice.",
        "label": "Termination Period Upon Prior Written Notice",
        "terseLabel": "Termination period upon prior notice"
       }
      }
     },
     "localname": "TerminationPeriodUponPriorWrittenNotice",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesClinicalTrialAgreementsDetails",
      "http://www.vallon-pharma.com/role/DisclosureCommitmentsAndContingenciesConsultingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vlon_TransitionReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the company has a shorter operating period because the period of inception of the company is later than the start of the reporting period, therefore, the Fiscal Period Focus is longer than the actual period of operations.",
        "label": "Transition Report"
       }
      }
     },
     "localname": "TransitionReport",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "vlon_UnauditedInterimFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for unaudited interim financial statements.",
        "label": "Unaudited Interim Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimFinancialStatementsPolicyTextBlock",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vlon_UnderwritersWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to underwriters' warrants.",
        "label": "Underwriters Warrants [Member]",
        "terseLabel": "Underwriters' Warrants"
       }
      }
     },
     "localname": "UnderwritersWarrantsMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest in Equal Installments on Quarterly Basis for Next Three Years [Member]",
        "label": "Vest In Equal Installments On Quarterly Basis For Next Three Years [Member]",
        "terseLabel": "Vest in Equal Installments on Quarterly Basis for Next Three Years"
       }
      }
     },
     "localname": "VestInEqualInstallmentsOnQuarterlyBasisForNextThreeYearsMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest on Date the Entity Submits New Drug Application (\"NDA\") Filing for ADAIR with U.S. Food &amp; Drug Administration [Member]",
        "label": "Vest On Date Entity Submits New Drug Application Nda Filing For Adair With U.s. Food Drug Administration [Member]",
        "terseLabel": "Vest on Date the Entity Submits New Drug Application (\"NDA\") Filing for ADAIR with U.S. Food &amp; Drug Administration"
       }
      }
     },
     "localname": "VestOnDateEntitySubmitsNewDrugApplicationNdaFilingForAdairWithU.s.FoodDrugAdministrationMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest on Date When U.S. Food &amp; Food Administration Approves New Drug Application [Member]",
        "label": "Vest On Date When U.s. Food Food Administration Approves New Drug Application [Member]",
        "terseLabel": "Vest on Date When U.S. Food &amp; Food Administration Approves New Drug Application"
       }
      }
     },
     "localname": "VestOnDateWhenU.s.FoodFoodAdministrationApprovesNewDrugApplicationMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_VestOnFirstAnniversaryOfStartDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest on First Anniversary of Start Date [Member]",
        "label": "Vest On First Anniversary Of Start Date [Member]",
        "terseLabel": "Vest on First Anniversary of Start Date"
       }
      }
     },
     "localname": "VestOnFirstAnniversaryOfStartDateMember",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vlon_WeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Weighted average remaining contractual terms (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.vallon-pharma.com/20210331",
     "presentation": [
      "http://www.vallon-pharma.com/role/DisclosureStockBasedCompensationActivityOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r304": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r305": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r306": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r307": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r308": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r309": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001104659-21-065584-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-065584-xbrl.zip
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M3+H_/*YID51)_:CM:A^(4-P%<BJ^![^,0*]O&<YSK7J6E*DWIB>(J46,K=C
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M%ZU4\N[8]U0\'LPA^L"X+1C?!._#!\OWB<4I>A,J\0+S[\,)/F,54"$VK&%
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M5Q5 \861&1RCZD5!4= /0/HMVR9A_P-$[*[;1@OB(\>(1$*=O:)R51"5!%X
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MW.*K[O=\U=VL?V]1$99*7@' .Z#DA1N6@8,L:5V,TY6N,(0Y*[V>1H'3<00
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M9/G4DQ*ZC V N(2;9I^1C:W*<>H%@C,QSKTY8<RC<O>J1$1;%,2=V!2RUS(
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M?"8VW:-9I?952S"_RT''FZ?FDI,B&&O <>Y5J@^QFP(F>0!88FGH,SJ/$NH
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MB7"V:$:CL0:$>.8\0]+(%#3,!%5=E_$1+70JFJA1/GPF#GTL_@%-=0<#61J
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MY;XG+G)%'&&J9[EUI>M^>ZV,9[EUO &8:>1UNX05]5:9&FR;YO9:VG7T%@,
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M[IQ!G>[D\RAB_!O<^:@1<L>M5DIVT7(+Q,ZH$+1SGL7)D5\R@D>%@GM1B(V
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MMCQJ-!7/?E ]9UEN,05??>CE><><'/F%$SPZUV_ \ZY=GR[9GZK%ILJ&4_'
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MY):S'*CX\[,5T]HGAL8T"A-_ Y.S8$UV*1=N!*HR L;<XV3XQ8\5[8W1+<=
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MD;1 9TOB9.DR!L0]*L8T9^.!PY<6Q>IE,62Q82_9BL]:SKM[8C(9;.W3J-6
MV@>'2:!HKXKV$=25, HRS0B7BJ1BS:1T5I(,)8BB,[(E&8RGKG&0)[,'*6R0
M-GN&))8ZN#!5'H1D<\[%H_?[SCC:FO $L;.;\9KPLAW5B6%D1^4&2RD%>Y9
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MKF+Z>\'G6MT1XC/(2T#@\DL&;P*@!_DM@.C9&@SFRJ7_#4,UO_Y39].LP13
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MJP3@-'=FI9W2.B.":6S%W!*+WQ(WWH.9 I\7I_[J*J<_#7VP@YN.RB60JNN
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M]L8H'_O0[8T8&SHHT?T$!"=(.$7C,U=9O=J):V7#"3FV>MIZW&HBCMK3G.[
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MF)$[11GS1S_:4=M=N]2IW)]I:HO9#9M4S%U1U1"K.S;*>[)+2J0-;=F,I.@
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M97.<J6V-'6[TA!\<=3(Q")>C.) 2C0P]PYI#J:5)(#*D<I_8%/A1XL7,E;2
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M^-:32AT)X<C<WVPT9X?0"%<6VO[H&EH&==WVT3IHK::VB0 )^"3/W[@0RM%
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M#<T] I:.O<EP*>K)9ARQ[1C ^>7#Y8>.[Z)QV(%=B,/[3LCM7WUDT@#'W,W
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M3V:,$<4>CXE=PLCD?H&6MC_<#@^FD[DH"\(XBAM0!ST5:8ZAI)B7-"=. O,
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M0+U^W*?2.I\#G,\!FMU17(F_DB_].<"5[%F*:CX'D  3)Q)IJ7, Z>$@P3F
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MRB1 =:V/L^<YV&)4K[46?6.8G4 YHY E;35-!;=(3D@:3ZBM[6(KP#1KPQ[
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MO610_Y6(FWJ(7I5.U[@\5G'0B<03TJX4)YZ?D_&%[%+4  %(#-T^701BK(G
M-O$.@9._LD$, D:2G;/!>)L ;UVC49QCPH@\32=U%C5UBI<ZG:-%D';%,I\L
MQ?F!C!1<%D]!%^4O4)6LX60@IZJK:0\P"^%5,1!=N)1J(ZHR,%.["<BF5^#5
M91\1:)@J!T[=+5RRTUTI9"7ADJ<RKFBRVA$@;FIXO/PRQ9N;/C>Y3!ZUX^TB
MI]SJ\ 4R()RB*G@V SQ-=W/*@K\\4;#=K'++/VPIT"GDJF -MBUDBW LXY.R
MB*[WT$'(CR="'()Q! 78VO1>W)\QV*5/>^72# +UBUE^A>G>=LJ18A/3*T'H
M[$1OI91CHB()[8@JQ_]S%E2>>V$6-]7,.5*%5AO)'V>-\*%&- ,#J/#:Z=ZI
M8GKC*-IGL/MD0=+M%$P'AKD,%\[D/&SB9)8G9<L-T<.2>%-'UIT9HDL3SFQ'
M[,^WNX)[Z:G.S%UZWXV)<W3&0!NA:8WU!6IN7".)(D)DX )S$U]RY F8(M$B
M.KI. 0M'1TFZLU@89;BCJ3U +1"<]M2=@($W+F4LTK1G2_ON5"+F,X0T&\T.
MK1*.R#OC(&O'D >V,]GC"G,,G<7VZ -+3HP_/*Z&I(6O0O/U/H]L2]<N$)Q^
M5>!H0Z0.= .AYK5<N5W>35$C_P)CH!S\^-;,TSC/KWLHLG\]5??;*_"+Z-D
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M@W6U"45![#,C!$#\L-=:?=5<)B&=ZJA=UJJ38S$&2PBO1P@K1G>+O6X&63_
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MK\A%<)4WB[2OYSYAXU]TG89?_G "L"U]\\!UUIPG>RZ=/YYA;",!^YZ896P
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M8XA+LP=T;=2&ANK?=SEB$2P3,VI03%D37BZ5INWT?2N7'R.+P"GA1[WRZJ.
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MT[=WGO[12U6I]:+5_JS=C/1[%:-1+$0T5(T:N>7>[1\=R*7+YV,%<NGC#L!
M+MU 2_I(O3B=+GJ-<KO9<.K99'UJ94U4MA[Y\GZG)?V-N>VV5RK+@BE.W)NE
M8>K)_0'M_#U$+8Y6Y=^0O4B9DJ_MD7<C-QQ_%R$<7W!LYDOIQ3R=HY7F>)-2
MY3QO.MKE+C@V>)--S*6:R#&=6E=I15.1<@_U<_CT!<=;H_K;"UR=<CI^/;>\
MGY1]!O_@30N!((GN_$ETUS[^LU/U2<_<39/U1:X?7,871T=-?5%EI*62Y;6^
MEJIH9)FY\/7$MNVDZ-5D3BB.5.DTLUF;;M674-.AZXG4$TD':NZ<"6_79IP+
MJ+EK]Y._VAVD,_N_%&K>6$78=(R#4]KD^W6KDI"^ZE(BGQP.BH-JF5:(##M/
MIM6"!L*H*1IR@L6?$N$/7DH,Y,#ON+0>0 Z<\CY].SFPJG&Q1$E5.EPQ3DNE
MY138MO-55Q'Y:E'6Q4Q^RLDI7HNT,LE4MH^; $9^_**?R'CB7:?3>3N[O\YV
MGVP;'F/B0X:2^$A<%/E(-!'EA1&9X)E$)!8;#JE$+.*W#=]V1+29^%RMCA:J
M(N?5<MHQNQ,GNSS57)6N]B?E=$X#RIQ<@XDZK':K7?94<U5I1#8'_=F05S2Q
MV'3HD9&I@]/-5<.-:#.3WLSE-N.D<V*N4^MEJ^S)YJKY,:T4(TZSQA&$&LYL
MY/#(F(Q/-5=UE,C&25-.O.TD.I%IO;X)&\3X5'-52^G48\:\E"=3*TKGY61/
M4%LGFZL*%:.R4+5HEFMJ(Y+,#LV*N#[=7+6=[?0'S5J[UR:F&7W1(A;S4>YT
M<]6>WBB9I%EB.":1F(\TLK/2U/&IYJJ1,&,"8L9I'#UO1EOC;$;HS.NGFJN&
MV_'(V%Z7^QP]B#!R);RTBP/V5'/5LIPO66I$CRI=74V3;*1@<;V3S547Z6%\
M8@Z,$M>LL\GT<I:@HM/QR>:J<J%-M3K=N<8)2[X[6DW:$DN=;J[:+T3:S8R9
M$,@L0^>2\8;6TMLGFZNFH]7<;+%9.$JS.0TWEDU;R\.'GFB9RBU*T?RPG+')
MN45%,PFV.$IVZU[N^.'06"M5KA6G\3@I;[CJ<.*4JF/U9'?5+B@O=-".:FU9
MZ91ZP'$6_<'R5,_4;"->772+6H'KEE8I*[X@DZ,RZ\7(#H<FY^WZK#BJ6PJQ
M'!=7XU4B4NF>;*^:GE#9<DIN-95U(EICPVEEF#*7IYJF2M-5FBN49+;MK,>I
M>:1'3ON)L8=.7I").5@Q87LV:3N+ID6NM5;=8ED^=OSZX8P)U\,6%5-2[>ZX
M5XFKS=(&C3QBO':J:(ETKK!6YL4Q&;::ZTY<12./)AI=))L,T6!Y<FTUG1R?
M3#']PA*./)[HQ)&;@]YB+'%,0Z'G46>ZJNIC/GX\T7JD75Q'&QU1T3J-4J)7
MG<Q'ZSH<>=Q^N6:!17U0,Y5L-\'R:Z<2R<&CCQ]/=&RUN&IW9DDD(*B9.1!2
MC6&2A2./)]I7=#+,9L-E12/"34+1&_4VW-'$B6Z]R<68["6ZHM*LYH>3$B<2
M[>$2CCR::%\C!_E,493;3KM 4*S$S+KL&(X\FNAT,%&Z8R*CDG([&S5213&9
MX=#;CT1^>#R.:6F'G2E,=6.-^7RN6Y6@R">/)]I<R/RZ/:^DR%1QEAQ,""%:
M,^IHZ)'8$:UPA^\)B:Q2[73S?'&TJ!7*^*E'4VV6-^.V06WR[6IW,*A:EM+*
MY%@T]$CPR(6N3?0,8T$R>GND)\1);1+%$SB6/%)YU6V6<AN;ZV9 :M+7E/2R
M@V=P]NZ^5VC=^Q;ZE^3%B<<;\)$CU5CZT,'_G4!H].?0! *4/' /_ID9%G:V
M_#2!*MCR KQXIH=2\8O]H<+0,E3'!B_6>9N-K^!:MO_^J1D6',0M',1[A2&"
M@_@ZCGC3,1$<Q)<=Q-O5-8*#^#+1]';-C^ @ M'TW0[B[3HIP4%\U4&\5[TE
M.(E -GVW@WB[O$IP$%]GT04<<0L'$8BFFSF(MVNS! ?Q10?Q7L68X" ^=Q"_
M<6_C=G)?\&_7:%_[0'NP;5T7^>UFEK'G"'5+E[@^W\P27]UPK]+@_)5[:6?X
M,J?\Y,J_@';^M!'J#=/&+OOY2LT-4=(UD=?OBB3OAP!Q_]5;)C]1=#0'8A$@
M!11P$0K G5=OF +V$RKQ=:?8/^^V.0T@W)4AW(7Z#/])@/Z.\9E[\?5:S86I
MO^]%\MYL=^OX<SAVUQ3(:H:C!UW.SP3W[Y@0O,N/ 26< W??,1UX'><#.C@'
M^KYC.G"O.%T+FGA4^/>[!L%OU]:^3HT>=_UI(.);IJ$P]11ZK4+/&2N87=\L
MNL]F[+?6&>Y2E8'\_HUG* U4+.1:]64YT>":*;L:"U/URH997JPT$)_-<6FA
M+W?:62V9M#-1I=Q=H(M@GRX-]% % ^^3W2[>N^^K.T#?35^^^R+^NZXY_C#D
M_>A=^OY0-;Y=7&B5IQ)"62ER2K6UT5;9,ID2NA<N+D361O'-NM#NDO.$F6LI
M4KF\6J'[U6YQ(2KRL6YZ]R4K[D4T7+C_WE=KONOVUOOGXIW.SU5F:%2+<5EZ
M,J<XD&PJ'2TBMAOAKZI10L4IMCD>Q.QV*I_,%<E!M5</XX(+J-8V_11-O%FD
M)! )ER^V_3 BX=H-\;Y$)"1Y>YXH\VE*R9+I1$>H]>JKV%<5#9/*LY35<F*Q
M=BK74V<Z9PK]/"JTXI:YCD0C9RYS_;74B5P R(46,D;P$)#; ;X"[@_:3G0J
M>+:H\()NV.!D"[M[])M];36TQ_=WO2Q13^V7J*?^V/M%9TL9D&FV1IP\S [:
M0T.OL4WV#[Q?Z-FN\PO.')Z$V\#2=8JE,-%;<#7546K' $T@PJ&V#*P3_K*V
M0#M4/&F0[6ZVT>]D\\N^T$)]+>D?OZ*1IP09%!@]9QWM;[7D._)WW23]WD,)
M[6]%T(_NX3JK,GS;W[7,SDIY<\ 9[6)6RO5R\V%.&/U^[Y=7]"+NYOQQM;C7
M[MFN#7O-*!57NLU6?6@890O,4>F_^(]?D?"Q%7PW,N6V^.G27J[;6_*U/6'W
MKA-OZC O[I*YO25?VVUS70UHRKRC+^=1CFP*BVRMMNHU*H4_],Z>46MI":''
M.='V@,OV)F(C;8Z2O3(RYI#'YVVU=;^95&_Z@?*UZE-(!S;ZH^P/!*L9T*W3
M/J&'2K*Z$<]UX$6Z)R\2W''\IU/>HD@T2];6O42?9-1QS<D6,^U"!!6:IE$-
M>SI*/I'D<?/$($+T(.E2=[07=^1[NB]6"'*M[IXW C?6/;JQCO7R7B:75B4+
M0K<44YIS:S7:.,JDA?4RRN2*/E'D<:CW_B71G3#; _BX'B4-[(7<>1B=?!^G
M_PC>LD?)?OHV;K2WM.9,G4_Z:F<J*'-CTRFT*P51MNNH;5+D VKSOA.DX-<7
MLACD105Y48_OT7(_SQAFTR/Z4YZM+A>++1QVW9['(\M"1RL0#:'.,\BS13W%
MJ(\!Z&^(#KZAC^IQ75$W2;]!&M2M+3GP']VA_^AU+;A#Q%4IJY+Y=J+%5<.U
MA*D5)J54!'7RC/_X%20]!4E/CY'T=&\*\*;.\A&\.(&SYC:=-1]14>RF0[:K
MT^*(U*RA7I^EY6)T@ PUY+1Y_ RGMBX!<VE"2C6M4%<P30$"CB"1Z7LF,@4!
MC""_)LBO>2Q6"/)K[IXW O_(K?I'6&GJ6#::D]4R7GFS!ZI>5!C< =!*TX:T
M(8T!)S?FM13H#31Y4^=CR$<2/E$@Y?Y%TIUPW0/X58)$FX 3@D2;(-'F1GTW
MYU"?DV$V$N>;@PJWYJ? "J_6UC*SA.H3^6_>UI\WGW&#?5O$4+  *ABOH5MF
M^'2"))M'2+()P@9!WL>#NDANDGZ#O(];6W+@U[ACOP;.A<38)+4'31H +L*"
M!^Z%W-QH7 .(QEC'3\&!N1,X;CE;$/E(9)PG'<#4\I1C=0?K.A_'5XZ8>) L
M$B2+!,DB ?G>OR<B<#C<ML/AS'HMV6BLE4*+7Y%5=53N)7ICJ3MFH5[#EX+>
M5&SWFV%2 79(-:P@D>1+$TENIQG@MXFNWP=YN,Z2*Y+''>V5ZV4)6.G1W3/G
M350)>.L3#I^ N0(]]89W(N"EC[LU;I>5_KE /YRS.E1?:9@UW[ ;+4ME$R1!
M<M765,S/Q ;[VQ8GM(3RNFAHH 3-H;>ZZZ3LY*K&$EQ.:=86TMAHQ3=4EN43
MN%<6_<2$CRW%H%76ER; !'+IX_ZJ0"Y=SHGU89&226E6/]Z)9TDF5TPT(XW!
M*)\8(Y$2^8!(N?GL&+_E?:@LF.+$;7P?II[<']#&WT.:S-&JW.F?+=WED!'#
MD!$EPT%=S*[/B5_5?/Y\56:ZG%6HK?+E+IF:%"-25QV-E4']8KWG9:/F9 OS
M1D.9%Y;=<:1*YV6ESE,D*B+#/,4I^BD>#OIIG3.AZ-KL<K E)_MEGL&===-2
MX-[BH_>0573MXS\[59]T)-TT65^D,^QE<HGZ&[V_R86+267=F+2H1I;1BLD_
MK"'S7NOXC4EK5;X3JY-9<9QQ8E9#,80Q4G5Q"%5C3S03%$P[9P;0M3GG GKN
MV!UV4P+A$G;GGTF!5QQ@G1QGS;5Q-M9N BYLRXGY4JQ]58]ICDLM2N.!DN&:
M1KR65IABO"POD1S +>.C3W0X]C$_6" )?L>K]0"2X)0#ZJ8DP1=#@PH[TEMY
M81 AJYE2OVU3Z\*P>&%UGJD.N7XC%JDJ556<]>MR)KG98'6.LY[H)Y(^9N,7
MKJ=_VP(\K\MSW@=Y3<!KXT?A.!.)1\/\,!X3^,@PD> %2:1Y2A*EX8AA$A&:
M@2_XM_"I;R"#_M/?"7O?.<\&>4Q J&!D_Z1>D##*FI-':_<C68>;9/\DJ$/V
MQ21-T5NZ?D.\_?CU%_6WZ^C:_]??;D@7(\.P=<,&H96F_E0%??R_/X!.M)LN
MA?%B@DY$);@K"3$>YB.B*/##L$CR"69$)T0Q$@$T>&<&K0D(04*'&@^507*=
M2B%A:"Q :"S#?TQ@FP:B3/@S&(V :(=L(V3#;_G3?.OI4-U^9!@!V8Z(D/!E
MJ#<?"+GUM*T9I,;G4!. 4 7M >6]&0X8R;J@B[*@PJ&>CK>>MV2ZMW$NT9[=
MQ!7A"X'Y@IODP^6AGW\B>T(6T1U&N I!1+<7!7T-"2R$9F>]LR*XQ_(Y5_".
MWET")**A9E&ECZI>CU%I9DA'(N20IX0$X".4..*%(0.%;SQ*#>.,Q(!XU&/3
M?TORXM?_P'_\5XLJ$$RDSB;>_+;:"LW3-W3)?UW$5W%XD'1DIY(\]HVZXAA/
M&O_[G_^Q/_GC<)&G5_=6-7&WE<;290R(H0D$A1!&\,4_!74IK"U?9<?WT/O/
MK6Y&^Q"*/L?C_PKM?D2[<;25FK B]C;L0):YW_(_PLK8_\RPL!G\TP2J@!@=
M/?O@J?A4;&/VDXX]AZ.(D.#OWK(@SHA>Z)Q>"-7P[E0@W4U,I.7_JU5-G2+E
MWWWE'NOJ" JH_^QSAO?1'OV@K452%.EH)$!3"('@TG$>CPB_]@CH-:H_/+53
MQ_$U$FSXJCCX\:LCJ"I$936H(30(-AV,1:VG4%X7H>0=[HN#K=UE&:.48$TR
MJK&T>(:.TW3\K,KZ3]:SFR0^-SC-$)[G=BW7G^)?CBXX$L3WTM^W-"M9ASK+
M<"P(R*US3^SH?>_-]#4EYK'JH49!L.R3FHUDHB*@A"@D7P A%CV"$)26*%Y*
MD$P$1(=1D(@=@%8(^ZV%K29Y1FRUYYER16,B]?R:&:.8^,N1Y4YOD9M7^]$V
M7=<DHI&VXUFY#D=&7XYLLEQVD!12;:7:TQOY,C^8+T9CGCY^9BW' ,7J%B)M
MIN48O7"NU5=4-/+HF2N2E"K<<!)6UNMXH^E$"T:[.(8VT]$S::LWLNE"F6ZO
MU>)FP3?G6I)>PI%'SQSH+<L>YI)Y;L[TQF4B.EZ7DBP?X<FCM3<R64V/Y9,D
M4R>+Q80SJ-J=,1\]'LE!:-2J:T6F72Q,F5*K3XQF8Z\]ZN%(N5SH4H-NG2*S
MW5E+)'/4.M5$(X_FN>92DV)5&$0YL!X3FV8IW5-&2YXY?KM@"YV!YK"U-FB*
MPKIL5A9%?LS'CD>FG0&Y%"/C(@F(25:99_1\'II[\>.1-)B7:LOQH$=FN6)C
M/AQH1'Q9YQ/'(_.]D<*0L4VW7<V5IM3$ >D1A9(7F*.=K_*3)+.>< HCR;%)
MNY.=-#3L,SIZZ$R1-B1$H0.R6TH)E&)T2SV114./GDJ&"Z74=-$:*LV$5*]H
MZY:>YB M4\=/E682UQR;M58[I;1 NFQK1+&\1$./GEIHYMOTLK8<*J#=E14C
M8O>U*GPJ??S43=0HYN*9;IC,-I-J/&98.;H(YQH^'IIIS<.383&ND?+:SBGC
M478FI>%33Q"?+L1M<I;82%RV4=K8%F7.UG7(>">HKT T(H;0EN$Y)")27DBW
MAW$53N $J31F1I];"<RT#<Q5HA$UZ_8L!Y]Z@@*H%55@BN7B@M3L3(Z)"HF)
M SF*.D$"(X85YK72+$,Z\G@<H<E\U^3PT/ 1IS"BI .EVU( B-0!V8K.)G '
MZ!,T8,[B!J$55A(GM.>=O@/F2J=<1T./GMI6M2J=H>:#-G!6BTBZ&6NT%#CT
MQ&DQZ;H1I3J%)"DTN:@ZJDY6T_F2IT^<%F=J=3J?IL1VRFP..5[0"C1@T= C
M<E%'4KB39]- $<3:(%I9-R92#@X]<; J*2=)?E#K*[+9;2Y (D]:2$Y&CI^:
M*TL-BLTS-LETL^*ZH/=3]12<ZPD:4+,$*>2S*;8-UA8MR1R1,N%IT2=HH)]N
MK8@((V8XII3KU0A+R )X6O0)&B@2]5DSO$INN.R8;^9BI!FSH 2D3]! *Z8Y
MFZQ63W)RM9)8S1;6,FE# 7SB8+/%YIQMAHNZ(C-F,QMN+*+RH(Z&'HE+L[B4
M\ASAY!6";A<V/9F(3LKXJ4?R<ME-QVEN4!ER34W-]BK%^6!.L<B[=C0!K32U
M![,N4V\[=+%?G2F.68_#IYX@E\6LEQ_US0'5UJ#9*TS:MCQ66#3T6 4)ZQ@Q
ML[/P<6%9K-929&].U='0(WHUETXQLD[&1UQ5[5?&DY:YS!/XJ4?+*FJER6:6
MS'(<F.:3?;+8JE@BGNL1N=CY!"M-G,Z %)9"1^Z,"T34@4-/D/8:DG)4+,6B
M2M89$\-&,IGE(6^%3]"K1+156NV:*Z6Y4LO-/C^UK>D2#3W: 4+K=LI&;)!5
MBN*XUBXP8:$KC-'0HV45(E&SWQ#D&5?M@9D.4I2]EO$$_&5AK^+6BG6]Q-""
M5869!7[Z/^RC,P9")\_D0P:+Z!HZ/L#")J;@V(;_@6M@XD\.S-!]'YL[YMC*
MMTU_8MX+*1?K?2P#+T8^T^&W8AA[5MC>\PWXS!$T 'Q0Z/].()_Z3]=F7\)]
M>M=<]K F?K$_5!A:ANK8X,)F\NON1NH3T92=K^./(ROA-X-)P4%\V4&\6>TB
M.(>O.@?J.1X+3N(63N(Y\F8%C> @ M'TO<XA$$WG/8E/WAMY%[5^R:K]QZ;@
M#(>F#!^3 ^H"H%FC1PJZ19Q,\_BB1)VWX>0C[1"TP-"'__N#_O$1ZJ'"SY$W
MN??<R3R?CAJT)B8 .%@P_)/]/'RHGR]Q]-3#867XT<1R!W.Z!*1MT.)C!/DA
MQ/"UF7&_&Z\/Z.OKZ2O0!($F"#3!CEO0-=50F'H*I/!W.=M  MZ=!#S*2?^3
M#?(UZ>NYKG_.%;=3:N'37.->TK]!87A,!&\MX_4S'@8'3+XK$7^KINDU1"7.
ME4-.'BLT,@TM9,P JONACT,X3URV96#]O&P=FNO"OVM7X;EJZ?(K+_X]-^6#
M+__*\/?:J_]JRC]48W=/UI])IOW,4=\ZOM_>Z6#P\]\JR_TM5-'-\]U9BF-\
M.4\]7HVUFFF,9/N] FOS8:Y(Y%H2JS"#8:I0RL^M/(.RKL.?*MGX+71AP'H/
MPWKD/NN1O":50;FC+&KD7)XXBX38*ZKD[U\P_QCKY>Q\(CD>E#B%WH!,I>&4
M"I,X8CWFQR_J"<*63Y8VO \C](4^WVMG@B[4F@">FBBK(*1[BAY]*B*KU4$M
M1&4],%F_!W!_+,A^2L;=U"'?HSX.2/QA2?QNK%)\+16J,<V L]M@C('N)+LE
M(4!(!8(%0GAK"&-$0!T6$BP+V('Y>JNL>84U7IU5'ZI!7L9EO1+BO 9::'74
MM@"+N&Z?2T\ <C5=!?'8F&"4E%1P0+W4JPXB=3Z&;&'J0NU;[U'O!CP<\/!E
M#>C?Y^%V7%5$JQ9ID\7DJM32*S,ZW$(\S+S#P_=O4'M0!%>W(W#WSY"XU_XS
M!%;H9Q"8RH]C1]S2XK^;!+PLBL%]%9(O6_B>$'A\:;0IKS)6DY.SBV:%68F*
M:J#FO.&/-YT/W @!^P?L?TL Z,/LSTAJMAP?92D2#-4QO8D!6>?KD/TAW@E'
M/X=W;AK6-,!"4)VM@T6"7U_@RX@A519<N@^<*@\LJ )Y=$TXDMZR6U:0=139
MK.J[SRK ?BO0V=924DO,42Q97$3*Z0F3+Y0 JI@&(4H\$?A5 C:^(S8^:N[T
M,(Z#C&&BLN$ZL'!9U5JMA@M=!_Z"P&!X2(/A_E/\D"ZVD#(&4!US*Y04X\C6
M!&735$=I,+1/*&.YE^E&IYNE0#KY0:4;KPYT=HKKAT)MS%!?W:'Y'O5TP/\/
MP?^_H]EO6H%7#)W J7(RNA\ +/L)"I:9"66':S9#618R[ DPWPH%? L-?O.,
M>K86RK?'9G>I<1>JH?^$_(7N3^8][DKO\1:K2U7$69S+6*?:PB4GAMY(J&$E
MQ4#^U!1N6%;KJ,(V<M0?Y_H&5G# FS>I N_3N$U-!'T,7N2/HWP""ZM%WX<<
MY)('@/=A >^-[<==:J> %;X]*]R/6>AV:*R98";(DF_T67MVH.B8)M!M3Q,&
MYN"M\NX#0<[[][KF==%$B:EIX/Y_7O<X+ U& /*3Y!F!ODV(TU:M$R9A3"@/
MYX6-V&W3$W'9( :<6=W@]DC0)(PEPL'5ZX!#'Y1#+YL]=38.70QG/3Y&,GDN
M-=Z4Z^2J2W<S8\2AS(]?\>/^WP]U0=N##ZPHPBE#.WDFK%'CH< \#FR"A[0)
M'L)1_;H(]/FXYK+Q*3Q2ZN9Y:MQ8<-FJ8[?:R4*F.%JB'HS(14T?QX8#]T @
M"@)1<']HZ'U1,$WWF7&)!$FEFZ@-J'2JH]1XW(Z50251WPI7W9M[!&Z&Z8"=
M>^0!O" 'CWV_Q//7F617K -\CUOFRL%K;]KMR,DK0"8D&DJ[X. )45DJS>92
M+CF-MIEIBH@;I>*R,\3MJ!%J.E% [P&<.#?)+8& "03,_0&Q]P5,1ETUIX!J
M1LAUJU++,& 920Q8)& 0%J.9ARYJ0$?P"U#9WW>K  :>J8N:H]<6$Q_TMY_9
M"KWVJA\ZE ;9&F54UDQC(4M 2J[;D+WS>M5G;G;+VV_=+ZQ7TU8JS<]3;488
MU;+QDAR1XE! ,FX1XT3D@T6, ]=5("L"67&KZ.D\LL(T@3P&6F:J-*E45#$R
MJ0@IUY&L@& JQAR#J;=#>K<)FCS/UK']L=_:R/T>H8*1C2?T&+W//F*%_4'7
MOWM)1[B%15_=BW\C^W +OIJ Y .2__0^W*WWX)_C1G>RO@!6T#4@B%]_B_CU
MC>U'8 ]_V\7?-2O<C<'G]M*I.:8X0?T&C%%H9B(/N;W&ESW W)%GJ"K( UAP
M02SQ:TMO77L7_N3V\MW:; &1!T3^,([;FK#&_=U:!BM"162"FJ>;:JJ@VZPN
M<;YZ.N&O;9CA'LEV6HSB<).>JF>&LUYTR5,)'/Q^[ L8K\6^3]FR@2G[?>)9
MM[0Y-R\_/P$2 GLWX)=OSR_WCS=>"13G?:WYL4 Q.=MD6Y5\<JX0G5)J(S3M
MF51EX81_!WC<%+ZXDK%QCQCBYEU]CW7MW%W-^=9TEWHXH+D;H+F[-1Y/A#[=
M7K1!Z/-AXSW?I)OT>]HA,-\"\KT[\KUU8^%EB-$TX E(GF81#4TS$-T:HO(4
MTH&-(H_&: 2?";7- UVH#I#<K3/80]U$]KDL YDL;UD.ZH6<A_.6!;7F#%59
MK'H\=L)OT9^6IFNAOJIRZZBM)VHRX.W&DJ=Q43DJ^A0EC^O*!;96P*'7=\3?
MK<WUCH[4\62'*L#MM()(W0-!UUM:_,TQ^,.HX-2.A5]IJD55Y'&4SC,HG)%J
M9YF-TBDNH=+%E=/"T8]U]PCLUT (/)P0N-^F6IXR=Y.7D&'K^E%!2$6U.X*N
MTT&Z89!N>(N:.^.R:0EQ:0T:R:(\@V:SEX-X0G>OPP.^:V?D'"G4*Y-558C0
M:Q;J;ER_*QP)BK '#!\P_"WG^WR6X6/SM2&K-;/#,=)X7IWFN 3'889'F3W'
M_>@?.J=XYF5)A8;KT%]>@O'?)T/&@=_B^V1,!A5S'LR=\4I.9,;G\X.<R)<"
M<S)N2H-ZJ3XG@5.N#B?U%K%@ZSS->"&%.'4L- ,'1R MOI.TN'\8]2D1\6K:
M-!>C9\/8G+/;\UYGS/5HB+-0VC3S6^#JIC!4D#<=Q%5OT.,:Y$T'-'<S-'>W
M!K)G$\M>B>[07Y)7I/OOW6>R[MK,J*0&_@'5U5A !:B?[IT:6,?W&=#[#@FI
M#V7=(MR*_N-V_-@ EFW*H@TD] =6EPX_V!M9@UMG2,>U^47502?"K<2)H(]!
M0[ !-QH!\53\?[WJEJAFNQ0ALUUCG9G*)7*CCWDZ[G9.>XK'@N9I@<2X;XEQ
M_Q;NEXN)5ZWD=+JI%R6]7V^#<*_#&9Q.S<MU)"]0%>K$9QO+WAJ22KV&DIY"
M@AT: CA21\$%5*<,;VM@*-^K[R\(J7XYMF(MOCKB*7HK)I.\/4^4^32E9,ET
MHB/4>O55K'X=,7GJ1H+<C27RT_9<H1-)HV4N5,)H0F&7P."(_%CLX%L H$ :
M!-+@SZ0!E> 3PC*JY0"95@BJETB5M40S=RW;ZH0T$$FJ5S0(9TAV+6LQ+1L9
MILMC:0"A3_@I_F:;Z7MV+[T-B@#\PYMP*' F/6;P]+^_=]ST2Z3CSO%484=Z
M*R\,(F0U4^JW;6I=&!:O9%&>$([=3)F.<:5*G)0SDX%#=[BPTQKS8=+S(R7B
MP5620%@$PN(KA 7)KVI<+%%2E0Y7C--2:3D%MNW<#I**IOO-PKQ77;6)K&H)
M#=$<1DHL$A8829'T<>[Z77F1FLYLI@*4Q2NH(4FV1-6P'!-7MQ=W)8YDW3T
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M19_C\7^%=C^BW3C:2DU8$7L;Y@EG0@4C^Z?[+?\C+%?]SPQ+QI%Q$Z@0X2P
M>O;!4_&IV,;L)QU[#D<16<'?O67%GYGHA<[I!7N%=Z<"Z6YB(E#V7ZUJZA1A
M_^XK]R2ECJ":>L 9WD=[](.V%LZGA?0-LJ=2"##BF[X>CPB_]@CH-:H_/+53
MQ_$U"F-X\)9]<?#C5T=050BB:Q,![H$('(P;K*=07A>A6ACNBX,*TB2VD?$U
M2'.K0/A8F(K2M"<*KK^HBJ_SMG,-[2:[7=7EYWFD/MZ:]%^.+C@2A&C2WR\W
MOMKB>)2_V&HW.+Y:XQIL*U^M-+W]=F%_!9H/IBR>P[8Y-%FJYEC0Y0U^$.0#
MG!"&?V%UJ69"3*';^-?JZ 1EI+>I.RTXJ:1JB(IGT SYK*B;<ZI4J9.IS)*:
MK F9+U">=2;K#I!8^XUQ/!H&[20 #:49G"ZTG\"E1!1%?NP(T4&%*'QZ;PUS
MX2WU3\@]T??'5S.AW:D_A9+M9K["->%/V6J^D@VEJI44UZB$V$HZ5,K7V_ET
MOM6_')F_#Y/>$BJAO]#J:?(?=Q#^!6Z%82* &O+^EG+QJ_?'OY]"0B@-Q>92
M, $D#W-FN'3]%)(M^*>A;,P.7A7R\&]H*'AMTVL3614DH,XFLO 4JK%/(6@-
MB1/T_9$AXMJ'<,)H!A)8 -7 +>G=C'U#@XR%J-KC 9RJ;QHS4P:V8*Y/O!W^
M57)$B*M#+?C O;50L7\L^!YU'1(AHL,6&D3A8^!_(R0ZI@E?# = Z ',@\G
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MD_4%\E(C%>28:+Y8X[E6JO=<&5/I)1F>X6-;LMC^_*<'N_V^,[1D:*::ZZ:
M2 R/.?@N5 L+^(Z:"NU[]"+O :5\*Z;)TPS@M.9HGEPNI2P;'U^%Y<55)]FT
MA%%*(:QFG!G6H]-\%!((]12+44_Q^'$AD)=,?TFVOM?C(Z)_S-DOWWT224Q)
M@NL)LU%2*:9+8J'3*/>=)#R]\/,Q"MX""1_O>F\(;5_AP]3G$-H:,'>P!_0)
MNYN06*!I7RX<>$960'209P1]"!>FHT8V+/+LOL3/KP/FI@.%@H]B_6>@[Z)K
M7]C]M=4MOLMG)W70K63'0LA!&$*K\PD[O^ O&!X?V:'/H;R./!*X4.#6$CQE
M^3U]I9BBZ3U"]W]Y!P>_B:'_E$M&D;$\R5'C' ?B56=0K-4J_+I^%1FE=R25
M*K&*0,[3<Q+N@#HM5""5QR/AI]B)?+L7$@IJ'7^KGEPL(B%D(LS@<:_@5+&7
M\8(B[ Z/]@SRZQ0RV1==9K$1MYG!A&UG[5$ZKX[#9I-%6//YN&+"5G2Y821G
MYH6(9B8VQNT]___AT2\A;/'9%XD3RU!]7V+H2/SY+G3D1S1E+$\.2.2#% +1
M#N -62(K?95L*D)]K(W)E9,D$@]%(O1';6C(YR@>+XR1BL7'4AU5'=M"^X4Z
MFMA;FM'3LHHT25*PY)TD(.@]JB%BXKJ43:^B7#'5(&L]JJR,*4@UX6,I\"_?
MW(3_Z82Q>^-A&. P5("5G1 :.:J*8FAX.HCJ9 OK#93=<^2F1!5F<6  'J[E
M1RO]Z-Y.32'HK*J^5]'S+2.=)[_01U\DF%[U-OZ1]^5/"0\D>HM))AV><T)D
MF&[D."(#>O7?-9I>43H=I 3>UCEKLT9JT9XJM%-BMCELC.Q&=S7^\2O*T"=]
MC)[L,,',S<3 !&$"61M"XV?G=0:K&8!$8NW3CZSC*"D.?.]B\=@O/@0301WY
M$LL-J& /WCV3R*(8'_=2U=:@W2R8TT$ZJD6-TOCW/,LGG7&-_6VOCCAOST^[
M/-*FTP!4),ME\U,K.5$TKNW4H4"A3ON2G[R0T%X\X(.[+T-^X$EKQ-7R\_Y*
M:29IB:]4NIJ3NK7M?PGL4&P3'<+2,"5(VP<G4,'1/&2N&/"UEF&N<<[7R;U6
MBDQ-JN4RJW9VNHFRY56&Z"Z@\+:7QC$_S;8/W&9.XX#_."#^T]"KX=,DU*_X
M#&K"&J5-G@ZA5 MR(UJ1,THVS]<+,[K:'TZ1V9]X1;S)?HUUY 3"U3C<\&IP
M&+O\/)0RDS(LF]4E3^9444H.RD Y>0CM^#)F#LW2F%OS"DB&ETJ8+,!#8$Z+
M'B1KW+0<PW_L3I_X2L2-=0E(+D)+6H3*U]R&SSTK%W_JYL"&<!Z7"H?+(]FU
MF66=F"&JLBQD? ,!RE9\T/LAA[^V:1.-_R-HLW_2.\\!*XKH-+RDF]!VA#\E
M.!,4BL6QN/V)C P55Q)#TQP[LH0 (1J\]SR?>BP(UB0X7U%P@V#;$' SM8W]
MQL+D4^CM"QJ-_=7MD0>Z@_&T5>=X [W(&LHF#L%)C/%U3O0UR O^K[*$LJ!&
M,LY4?G7GO%W CE(= 4)(MSK.0H:8TT:%U5#2TQ @J&B(KA\CA#(6O*PGU\31
M+?@V+P!NFX)NC0 &$#@Z""'V&'EC#)\X0EY0<'^[D8OD, /,!")*&).^W!+V
ML: ?.V-WT]QC9$F0S8.(\=XPCYL5HCC5>K82561-4R*=I)&?%7_?K/7I W+S
M'G5XC'W2I.TNNEG!#C<4CHX/%X0!8MP""]7GXUX2>V&]UZG%/\#3#C@_QVOO
M7+=98%A:7^$P;]MF_0*W1E5+<94E,VR159-;MR:2UL[-QN^X-?!%\7V_A>>R
M\+V3!R<L(+<&-"0%RR4# UJ4LBZHC\RXGU'#_G3@20UEW4V0W[VR@2Y]  FI
MZ=,@=="/4O55HMA0YG.:T"-#39P-WD@N<;/;+#?KUK<*+H^,W%2+"QR&SD5M
MQ4Y,:VV:B?&S>%))<J,_/HR]]Z"MKXY8#YJXB2$MI,3<C7G]9  ],#JYWHSC
MNK%N1BFI8R6>> ,NR9YR]#9\!(#EYDC\^^"BQMU=F8L%5^:"*W/7OS('F<B[
M(.0"T3<O$WF7A&XO<S9K(-,"[I$(@3B6VR492B8)7<R]9@IMZ_5L9WSK8H@B
MJC/DAS)W5V:PHWJ7!;AW%T((C0TOP1 M=!?J@+2AS9!*1.G2$(&,/1/3GL#A
MEN_M.KASXQN7*)X"/[1&GH"%?U*A^8,N-<O8(G63O3"!PC<AAQP:,_14PJ'Y
M,8&P1C?LT!CHP+WP@#Y%KG5LZ4&=BM*P=<=/,_),8&3_6;)K*WHW'5R_A&0
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MV;\\/_7?.X^/VPES6ZQK8@(0@O:*/;%."E[\1=3AU"N@@V[ [:]<<)ML"GX
MQ;U4@"(+V.$GN"&+_%N[C!ZQ'R(2O  13B"S[.V-W9.. U<#GJ:#QJG].EPZ
M@9?^MN9!\T-T[Q\R%$R0$"0,\1?;XA?[UI/[VJVO!1HYKJ=D+U?&KV6%OK!7
MRLI7L-<4B4-!Q=(,$CZR<_#^O9PBZ3J<D"R$9 >W8>_JXYLR%-OG\!_LLT'6
M_#8"]EMB!<G&#XB$:VTG1!Y0<&#/@.]V>+O&$Q31GM3WJD[9+I'YN:9;0+B[
MFO->YJF?I05W"XW?*>&3W\3%!K:J)\,VD]NDV6MM(MP=)(EQO'>/(IX@(8S
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MPBY")<,WBK9/N>YV'.RW+W&0?PIGD. GZ,:+;^[\J0>\MX]CO-,4_)JH@O=
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M.!ANR<&PY=$,>,M,T,I]*5:1:(XLUDVY2LM.="XO^1AR)@2)&]_8E_ 5?!Z
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M?2=:, 6AD:%(=&VHT6U5:$YF$WKM9"+IXP[UI^(AEEUQCC)0Q]ULW5[RB?C
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M$MSM:&DA2+&W0HMY+:GA3Y-0+%:.X,IA>&+B$HG*5/S&U:&WD2(7'Z'A-W\
M 4?U6WBOL"DG6"+T[GTP;LE<PF=V-VTYR.ZL37=Y[^AA0 8U4W[%CD2:X&WV
MAAF03&!XC;)"Z#XX(REHVE%X.Z<CK!^8@0!EO#B1R1AY4-J#W^G@+S5H>N]
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MN\F)37"-]* 8SP[X16J:SM3T:H[.-KU.!JESST(]N0%RR%!_G5A 7-13N+R
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MIPI:@J['K(<7)ULT\'E)[,;?'/:WB54H %\YFGT7]G@WRP%P3.!*^# $RP"
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M2D31,$=ETBJ2>:JB?E97ZW1JVE(CRZ*Q:'[[$8_=I>G$H1/G9ZR\)\V%>$Q
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MQJ/SE..S:_JY'>4+TU6AB5DR05@R&3_O0,@O;2A=O3TD*1;I0^+50^\90K>
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M4NJ)'[)[C%V8(6K26@GU;SAR#%H[.4?@39M<!A\&K\Y^(6T48+10W27PF(M
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M<JY:2?B$#G!(T*E]#YBBI+QGYJ97%<7N "(B4JH-U$N"'J>[68!4D9A58Z=
M2\O#>0DBG=(Q\,JRG"5@63QRT"RE& .AJ):,"&\_S^J[].-,!9:H=-8'DG=3
M4T*Y<LXH+&6!6RGUY VN<EBAIH.*I9)ME%S.;"?)4\$;>1R1W0/X+BWMK=62
M,CR\3 _308UY044.:O\: AR8Q805\N.:4_)A\JP3S/"VDFH:Y:^PT3F\__C+
M&0:;9W[L':!VOK3CS+%*0-1=+>$A4N$1?<F#<34#R03HX$46&$E7PMAA0OO,
M-VB["7F:D5' <>_HS4A<'U,N)G ]Q:H)I/T$.P 'RN&.I=TI?0$<#%E&HR+I
MP1@FL)<,"#=0P??<=8F2#;4*TI_FH+Q,5%(98;]NT8 V!]R:NE988!XE1JSG
M?1Q4MBDF%%$6 .96L.(VCS"3,9=4-ND(G?AITU"![HCK&EK212S45D8A-0-K
MR4JF-HB,C42J8D )41@!,6B^6I%@:Q5*VR#Y-9$>9@LTF+4AU(((<<FZ1V++
M7#FB<EPHXTO$)O(PYG'KF-:1I$DU^.Z":EMCGS>6'WS!Q H Y3FHY>DV:Q#.
M0N>]',>87>.T6URLTR@4;[-T$L2:&/%)Z@E,C]9Z'HW>L_*E8YTO7?H18%(4
M+U2;,*MD2()QG"IA>YY:DM;\\0[P^4J0'4@* PM5VABVOP6U\:#7(ATE)N,2
MY7""P+U#<K/Y-5]*GC1%6T\+Z<&%[A(F=;F@W@&2M]NO^X?.YX_.B4A0K7?P
MYCBW3_#LZ)5B()9GUD; PH"_EDZOM>Y%:[9%:?&8M0=&AB[S1^,O5/-(R^LT
MG4\1F!',$)#Y\]MH&?6*BIE>*_LUMM2:I2AK@!*SM8408K)M@HG94:#VMI])
M$Z,Z::).FGB621-?5[B YU.-JVX^3A48(LZMX97Z"Z73"#/"T@DSG4Y9S?A8
MC2\Q'R,7@F(.)V8JHW,AX)PWO3W6>$S?'7[8^"H6ILFG44G4J',_!47MJ-1F
M2#?MR764)#?E4&5- Z7$^[&C]\6Y%UQ/H]W75WZBFPC*=5Q?Y7Y+L ,\O" N
M\+E%E(BDH+'E-5#P.,U>5QM>,FQ7;D!<"C_0;L2QZGU4,%Z5VF! 2/45)P0P
M+(1"*,"^/V.B")V '*!\C 4GTW ]CS[4UO0WO%R6DV3$X67R7W-TE)&'TK;*
M<E!9&*RA%GHY\C<J2IYO[('C3-EW@%42JBD<5X*8@@OKBG=3W3U5.9S*Z7B&
M)<8(.)W$?OKY3.M:;SA)]PJI!IZP*LRVIR2#BF:Y?I7_&WV_D:T]=[3VS$&
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MI-[&R:*D*:ZFB]:8OO-76F/Z'=.B&^W^J,;TYZ2CU:H8JF*]S52Q_? 98IT
MC<?T0S>:5T9W:^NL3E;ZCI.5!NW:,U'C_O/$_>^MCKE.UMN^ZVW/2*""_>^!
M7ZTTG[EJ6.PS-\F^!^&T=S)H8^?!Z+#V'-1HND]RXG95Z1EA[7>B^.R;?O.G
MV.L^NZA.L36+3%*=P]9P0EG7E=:).,\Y$6=S9G"3JE433$TP-<&48O@UP=2Y
M:G6NVEU(9K"7'=(^R=0)HF1/,]*>W@!:D8==0%8ORL:!?#)L+8"@LD/A0PBN
M+1SL@;+/NGN>DU-C=8W5JYEF@XH6G#56WU45^QX0NTIGVBV\OF=6V7"U0H94
MJ+^D @ZV,UCYX.#[;Y:D_F19KF-M=ZHAR OAOU_[*:S@KHYER <6?.&!!>R\
M;[]QWF,EPA<UN. S#R[8ZM%^DXXG4QG/_1!VA(EXTO$31S@)8"R@\T+&DRB&
MU[K2B<:P*(=\K_QTYL0R64@W==+(B3),X+N,@DN)'?<<FLDBG?]&/OQAM>)S
MW&@^]]-42GPDEE,1>PDN@$]_E!Z S0D4[,0TEKP:-H%)9UE"3\$'/FSR1;O5
M:@"A.2(((A<Q%-8.$]]351[.E8!C) F  0^&;Q"PDNN"U435R%GH\\JQ=*-I
M".#S]+8G?IRDSN\9W(^,,;R- ^B:^X-]A4:([RSHGY@*[*TBW;I&C:9"')-!
M8RD2N)+QTA&+11Q=^W,@FF#IO!B-#NGBX4Y?@"1U8,,!7CA5^<"W7?H6L);N
M,J6!PO.(!@I+'"CL?*1WZ\&"&OMN>[#==+[.I-D9X^]MYT D7,2P]1B@ZGC
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M5NO'1W%,%"<:=7I6ARB^L4['VC7]]__^'WOWJW$NY5VQCC5C+.V0HV4J#\;
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M9Q!9&ND/F"_0)P7NT<I%J7HFY\[#P^;AX8\LV?76U"O;?-#-&A\-.LW^C5V
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MID\1QEG\0?=86N"$I!#X@!G7I<95N5F,$[B#)?VTP;.AX*1C==*$3BJLD]*
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ME2*STZ*.3B?W$_6U,3_LR<U@L()%P0.3:;1<"GME=5T9#B$;'#1R>)V506.
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M\>]X:&.-:U+R#EKU,3E79==KX2IG:7]#QT81=PY1<D\P?D>'#>X=#9T1RDL
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M=3/4B3SCPB!0(V8(F+Q E@C^P/!EE IFF]PD]04<.VU7/_UY'HUHV6#8=R"
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MX=HW'S0&\FVG@5'3MBX%Z( 3U2WX0N9U=ZG:X>XU6"LGD[],%G69XZ7W@=K
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M5CDP[J:E5 :7P?=89O%Z7C3)SV _3-51.PXBG4Q!I"F(](4'D0*A$,#+>%%
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MX=2+]+[@-YRS7C?]"J+^)J*Z1G&GHNU0?-H]R]%VH?[+\ZA@[#J64]ARG.=
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M:#K"+_L(J7'0=(A?\B%.#/9+/MAKP="Z+C.3'7B7SW2ZK'^]@YWLP,D.G.S
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MBG:JG7 !7S/N'EJLA&!F==6^8NMW9+0$O-0S*K1%)P^N?Y]S<U>38)^KSFS
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M"/&YQYX/],IB()B/=\HH$BB*YYI(RY#108LT/BLF6N*=5Z9O4W''H^L6=WS
MVT16^3N&7-L#.-]&>;2#J@YT&UU2ZK-QIYQI:A/WN:Z<_1/+(FZ9W2M+WRB"
M-U*DUD_2CP44SJ"JG;2"L:K=-[_^[O0O3KO%#F@WRQK,.-V^_O/C((EBB5 >
MJ!*0><JN>(1!2./427+@=0N@9Y< >W8H&?G->F5J)+HH>);M'.REV7R=;ZJ?
M84(9E0B<77<&8W,TPX-G/ 4/63E SR2="M4H C65=P\L<(:S+C4I%0%$ITUX
M0O^#X5LNI3E+]+HY-6MT :BVV&30E6YY!HPP$>RL> 2?']+<L>^=*VYWB4JN
M9CW>$_NH!5??I*"\":OP?>'L@3_?8$?1AV*RIIAP\#<KD4;@83IY/CYB4D[E
MQ&4$9?I3W4@.K@"FWSQH_=8WP^,&XMWH_SYH>M8_N$L!:B]!K+P5CM@]E]X!
MF^:&KM=@TE=QOJ#;ZFAB'#:1\(^,LO?>$"%='TC&(>+Y8C/+("=#N$+MBO&I
M&Z;<_H%[%G\8(!MC/\VCEA$S+)HHHS\=^A9VXS-D6RS.J4"7:( Z8*&4.0)#
MKRY5E5HX  $)D'UAY ")MK<-)>R&*2>Q41P:U9SY+VMW"-SQK"K*^,DC:-7*
MP.MSLEK?+JH"6'ORK,L1@OP]$%"5D8:'8O0,YG+ W6.C/6=,3WEQQ)8C?,!'
MH#M3J,PQ+K36@<](SL#N6?*VM\#!':V1:!XVWS8$:6H0Q9T [U*V$>W?]<\_
M]7CK2@0"ON]<7#WN^"]78?9VXUTLJHM2!=[ZB*R/^1P@QPZ 5IZ[3+3G-7<!
M>]?4K=S7=Z1.'E[+X'0(1&'"7K[5BZ7Y81AI'A,HFU7AAP%JW(X@ZA8E8133
M@8,TJ#N/W:_1=J-%2W@K83X[RPB[YH$"AQ<W9D'I)1C_RB6X]P!37>;;M_3-
MXX.IZP)PE?SMI9N.,O10 .]M]KMHLSO/XY<8Z[;8E&&65D,3?6AO$[77:U--
M4H>0[3 G@ H(>EL")F/Y*80:Q?&7[VWOC=:W9-H1X+WWY=+4MV]:'QAWW*&,
M@ QA\OL(^TXC[(_V$?8[&&&_;EEF_U[?5-] L8"X5(9RN8>0;:D?-GHUN15]
M')A3\*WAZM BN0@1^Q_8E^?LM8\0ABRR_WN-F+0Z-NZL:O*M-'0(\H#8]P;F
MW'F=K7,!DFY!!M-N>+)=PW7Q=Z3DC[;QP"9"(2 46'?M(8HD-NW"[20_G'/
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MW BD=QUN/0..,'SQ6R5'L++I"SRL.R3T(%IGB !!.K!1U#7"1HRF7[I(,>P
M*=IO?'X8%A):QDQ)%>0?M1/ &L(@]##&@O#*NV4(W5'LS0XQ[8&+7CT(I3V*
M.L<K 0HNX4(2^:BF8:QAFW85;4) C;1\[F:'N:A=Q=VBBH9+HZF4O6DQX[*0
M7,Z%:F$HJFDD/*!A%'TW;/3,3_<GF.XVE>-#9STIK0RY9.-2X> AU"C7<_9[
M>S)LJ<8@U-("PH,AGW6""9^@2^+R[G]7&_'V7GCEIM?8(N!=B45NEB@?9G
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MR3QW+778^19UTNGQH+'>HD2;CBOF.CFX<?,]?/5VG0\P6J8_<R=TU'@D:H>
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MU (X #Y405]A* ;0.@\$QYY(&U'3L"*-H-6!P(.?X&_H+V)3%TU=S5 P.H:
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MRO!D3DQ*3;A-8S=T+!@92Q4S]:$1-,!3(:I=:WFM"QI5UU!#P6^\Z*;:G8[
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M##G7K4<34"8AG4H>5^M\=-3J'"QITI4%-G;<EY?LMZ%._@M02P,$%     @
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M#R0RDO <8AUALXSM.L 0S.&V6KG/\P2HA6(" I\C4<;0)N!G)9#K@#V.=%1
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M(TBV;CV:@"0)Z43RN%KGHZ-&ZV#!CZXLL+'COKEDOPIU\E]02P,$%     @
M74JM4D$I@+54!0  &QD  !@   !V;&]N+3(P,C$P,S,Q>&5X,S)D,2YH=&WM
M66UOVCH4_BOG4MVME<@;M!4+K!*%5$-J"X.PNWTTB4.LFCAS3"GWU]]C)[3
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M2P$"% ,4    " !=2JU2*RQ6[$4)  !*<P  %0              @ %=#P
M=FQO;BTR,#(Q,#,S,5]C86PN>&UL4$L! A0#%     @ 74JM4L^'N"4F(0
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M2P$"% ,4    " !=2JU2Z]CI,2E2  "C% ( &               @ %P<0(
M=FQO;BTR,#(Q,#,S,7AE>#$P9#(N:'1M4$L! A0#%     @ 74JM4JOPU&3'
M"   X34  !@              ( !S\," '9L;VXM,C R,3 S,S%X97@S,60Q
M+FAT;5!+ 0(4 Q0    ( %U*K5)7LN+:P0@  -XU   8              "
M <S, @!V;&]N+3(P,C$P,S,Q>&5X,S%D,BYH=&U02P$"% ,4    " !=2JU2
M02F M50%   ;&0  &               @ '#U0( =FQO;BTR,#(Q,#,S,7AE
M>#,R9#$N:'1M4$L! A0#%     @ 74JM4IC3<7-*!0  "QD  !@
M     ( !3=L" '9L;VXM,C R,3 S,S%X97@S,F0R+FAT;5!+!08     #  ,
+ #(#  #-X (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
